-- MySQL dump 10.13  Distrib 5.7.12, for osx10.9 (x86_64)
--
-- Host: 127.0.0.1    Database: puru
-- ------------------------------------------------------
-- Server version	5.7.14

/*!40101 SET @OLD_CHARACTER_SET_CLIENT=@@CHARACTER_SET_CLIENT */;
/*!40101 SET @OLD_CHARACTER_SET_RESULTS=@@CHARACTER_SET_RESULTS */;
/*!40101 SET @OLD_COLLATION_CONNECTION=@@COLLATION_CONNECTION */;
/*!40101 SET NAMES utf8 */;
/*!40103 SET @OLD_TIME_ZONE=@@TIME_ZONE */;
/*!40103 SET TIME_ZONE='+00:00' */;
/*!40014 SET @OLD_UNIQUE_CHECKS=@@UNIQUE_CHECKS, UNIQUE_CHECKS=0 */;
/*!40014 SET @OLD_FOREIGN_KEY_CHECKS=@@FOREIGN_KEY_CHECKS, FOREIGN_KEY_CHECKS=0 */;
/*!40101 SET @OLD_SQL_MODE=@@SQL_MODE, SQL_MODE='NO_AUTO_VALUE_ON_ZERO' */;
/*!40111 SET @OLD_SQL_NOTES=@@SQL_NOTES, SQL_NOTES=0 */;

--
-- Table structure for table `master`
--

DROP TABLE IF EXISTS `master`;
/*!40101 SET @saved_cs_client     = @@character_set_client */;
/*!40101 SET character_set_client = utf8 */;
CREATE TABLE `master` (
  `FDA_Drug_Name` varchar(400) NOT NULL,
  `FDA_Org_ID` varchar(200) NOT NULL,
  `Pubmed_epub_date` date DEFAULT NULL,
  `FDA_Drug_Approval_Date` date DEFAULT NULL,
  `FDA_Alt_ID` varchar(200) DEFAULT NULL,
  `FDA_Phase` int(11) DEFAULT NULL,
  `FDA_Type` varchar(400) DEFAULT NULL,
  `FDA_Study_Population` varchar(200) DEFAULT NULL,
  `FDA_Participants` int(220) DEFAULT NULL,
  `FDA_Countries` varchar(200) DEFAULT NULL,
  `FDA_Review_Page` varchar(45) DEFAULT NULL,
  `FDA_Dosage` varchar(45) DEFAULT NULL,
  `FDA_Sponsor_Country` varchar(45) DEFAULT NULL,
  `CT_NCT` varchar(45) DEFAULT NULL,
  `CT_Brief_Title` varchar(400) DEFAULT NULL,
  `CT_Conditions` varchar(400) DEFAULT NULL,
  `CT_Status` varchar(45) DEFAULT NULL,
  `CT_Interventions` varchar(400) DEFAULT NULL,
  `CT_Acronym` varchar(45) DEFAULT NULL,
  `CT_Agency` varchar(200) DEFAULT NULL,
  `CT_Study_Type` varchar(400) DEFAULT NULL,
  `CT_Enrollment` varchar(45) DEFAULT NULL,
  `CT_Agency_Class` varchar(45) DEFAULT NULL,
  `CT_Phase` int(11) DEFAULT NULL,
  `CT_Study_Design` varchar(400) DEFAULT NULL,
  `CT_Secondary_ID` varchar(400) DEFAULT NULL,
  `CT_First_Received_Date` date DEFAULT NULL,
  `CT_Start_Date` date DEFAULT NULL,
  `CT_Completion_Date` date DEFAULT NULL,
  `CT_Last_Changed_Date` date DEFAULT NULL,
  `CT_Verification_Date` date DEFAULT NULL,
  `Derived_CT_Is_Result` varchar(45) DEFAULT NULL,
  `CT_First_Received_Results_Date` date DEFAULT NULL,
  `Derived_CT_Is_Certificate` varchar(45) DEFAULT NULL,
  `CT_PCD` date DEFAULT NULL,
  `CT_Countries` varchar(600) DEFAULT NULL,
  `CT_CSR_Summary` varchar(400) DEFAULT NULL,
  `CT_Study_Arms` varchar(45) DEFAULT NULL,
  `CT_Is_FDA_Regulated` varchar(45) DEFAULT NULL,
  `CT_Is_Section_801` varchar(45) DEFAULT NULL,
  `Pubmed_Link` varchar(500) DEFAULT NULL,
  `Pubmed_Published_Date` date DEFAULT NULL,
  `Pubmed_Abstract` varchar(1000) DEFAULT NULL,
  `Pubmed_NCT` varchar(45) DEFAULT NULL,
  `Pubmed_Type_Design` varchar(800) DEFAULT NULL,
  `Pubmed_Enrollment` varchar(45) DEFAULT NULL,
  `Pubmed_Phase` int(20) DEFAULT NULL,
  `Pubmed_Conditions` varchar(400) DEFAULT NULL,
  `Pubmed_Location` varchar(400) DEFAULT NULL,
  `Derived_Ethics_2_Applicable` varchar(45) DEFAULT NULL,
  `Derived_CT_Results_Within_30_Days` varchar(45) DEFAULT NULL,
  `Derived_Is_Reported` varchar(45) DEFAULT NULL,
  `Derived_Is_Published` varchar(45) DEFAULT NULL,
  `Derived_Is_Available` varchar(45) DEFAULT NULL,
  `Derived_Is_Registered` varchar(45) DEFAULT NULL,
  `Derived_Has_US_Site` varchar(45) DEFAULT NULL,
  `Derived_Is_DataSharing_Applicable` varchar(45) DEFAULT NULL,
  `Derived_Results_Within_1_Year` varchar(45) DEFAULT NULL,
  `Derived_FDAAA_Timely_Registration` varchar(45) DEFAULT NULL,
  `Derived_Is_FDA_Compliant` varchar(45) DEFAULT NULL,
  `Derived_Is_FDA_Compliant_Certificate` varchar(45) DEFAULT NULL,
  `Derived_Ethics_Applicable` varchar(45) DEFAULT NULL,
  `Derived_Is_Published_Cutoff` varchar(45) DEFAULT NULL,
  `Derived_Certificate_Validation` varchar(45) DEFAULT NULL,
  `Derived_Certificate_Expression_Date` varchar(45) DEFAULT NULL,
  `Derived_FDAAA_2017_Compliant` varchar(45) DEFAULT NULL,
  `CT_Has_CSR_summary` varchar(100) DEFAULT NULL,
  `FDA_Drug_Sponsor` varchar(400) DEFAULT NULL,
  `Derived_Timely_Reported` varchar(45) DEFAULT NULL,
  `Derived_FDA_Applicable` varchar(45) DEFAULT NULL,
  `Derived_Timely_Reported_Cert` varchar(45) DEFAULT NULL,
  `CT_Certificate_Of_Delay` date DEFAULT NULL,
  `Derived_Ethics21` varchar(45) DEFAULT NULL,
  `Derived_in_patients` varchar(45) DEFAULT NULL,
  `Derived_Reg_Ethics2` varchar(45) DEFAULT NULL,
  `Derived_Rep_Ethics2` varchar(45) DEFAULT NULL,
  `Derived_Pub_Ehtics2` varchar(45) DEFAULT NULL,
  `Derived_Avail_Ethics2` varchar(45) DEFAULT NULL,
  `Derived_Rep_Ethics1` varchar(45) DEFAULT NULL,
  `Derived_Pub_Ethics1` varchar(45) DEFAULT NULL,
  `Derived_Avail_Ethics1` varchar(45) DEFAULT NULL,
  `Derived_epub_cutoff` varchar(45) DEFAULT NULL,
  `Derived_final_published_cutoff` varchar(45) DEFAULT NULL,
  `Derived_study_check` varchar(45) DEFAULT NULL,
  `Derived_published_3months` varchar(45) DEFAULT NULL,
  `Derived_published_6months` varchar(45) DEFAULT NULL,
  `Derived_results_6months` varchar(45) DEFAULT NULL,
  `Derived_results_3months` varchar(45) DEFAULT NULL,
  `Derived_available_3months` varchar(45) DEFAULT NULL,
  `Derived_available_6months` varchar(45) DEFAULT NULL,
  `Derived_result_approval` varchar(45) DEFAULT NULL,
  `published_at_approval` varchar(45) DEFAULT NULL,
  `available_at_approval` varchar(45) DEFAULT NULL,
  PRIMARY KEY (`FDA_Drug_Name`,`FDA_Org_ID`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;
/*!40101 SET character_set_client = @saved_cs_client */;

--
-- Dumping data for table `master`
--

LOCK TABLES `master` WRITE;
/*!40000 ALTER TABLE `master` DISABLE KEYS */;
INSERT INTO `master` VALUES ('Addyi','511.1',NULL,'2015-08-18',NULL,1,'','Healthy  ',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.105',NULL,'2015-08-18',NULL,1,'','HSDD',67,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'67',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.106',NULL,'2015-08-18',NULL,NULL,'','HSDD, FSAD and no FDS',261,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'261',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.11',NULL,'2015-08-18',NULL,2,'','male and female',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.111',NULL,'2015-08-18',NULL,1,'','Healthy',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.114',NULL,'2015-08-18','511.114U11-3247-01',3,'','HSDD',111,NULL,NULL,NULL,NULL,'NCT01040208','12 Week Safety Trial of Flibanserin in Depressed Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire and Distress','Sexual Dysfunctions, Psychological|Depression',NULL,NULL,NULL,'Sprout Pharmaceuticals, Inc','Interventional','111',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2009-12-28','2010-01-01',NULL,NULL,NULL,'','2013-06-13','N','2011-01-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Addyi','511.117',NULL,'2015-08-18',NULL,NULL,'','Japanese healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.118',NULL,'2015-08-18',NULL,3,'','Flibanserin subjects from 511.77 ',480,NULL,NULL,NULL,NULL,'NCT00601367','Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder','Sexual Dysfunctions, Psychological',NULL,NULL,NULL,'Sprout Pharmaceuticals, Inc','Interventional','480',NULL,NULL,'Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2008-01-15','2008-01-01',NULL,NULL,NULL,'','2014-04-22','N','2009-10-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Addyi','511.12',NULL,'2015-08-18',NULL,2,'','male and female',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.121',NULL,'2015-08-18',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.13',NULL,'2015-08-18','511.130U11-3281-01',3,'','Postmenopausal women with HSDD',949,NULL,NULL,NULL,NULL,'NCT00996372','Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women','Sexual Dysfunctions, Psychological',NULL,NULL,NULL,'Sprout Pharmaceuticals, Inc','Interventional','949',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2009-10-15','2009-10-01',NULL,NULL,NULL,'','2014-02-26','N','2011-03-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/24281236','2014-06-24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Addyi','511.133',NULL,'2015-08-18',NULL,3,'','HSDD',596,NULL,NULL,NULL,NULL,'NCT01103362','A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder','Sexual Dysfunctions, Psychological',NULL,NULL,NULL,'Sprout Pharmaceuticals, Inc','Interventional','596',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-04-13','2010-04-01',NULL,NULL,NULL,'','2014-04-11','N','2011-01-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Addyi','511.14',NULL,'2015-08-18',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.144',NULL,'2015-08-18',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.146',NULL,'2015-08-18','511.146U11-3112-01',1,'',NULL,40,NULL,NULL,NULL,NULL,'NCT01188603','Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)','Sexual Dysfunctions, Psychological',NULL,NULL,NULL,'Sprout Pharmaceuticals, Inc','Interventional','40',NULL,NULL,'Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-08-24','2010-07-01',NULL,NULL,NULL,'','2011-05-04','N','2010-10-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Addyi','511.147','2013-05-14','2015-08-18','511.147U11-3190-01',3,'','HSDD',1090,NULL,NULL,NULL,NULL,'NCT00996164','Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder','Sexual Dysfunctions, Psychological',NULL,NULL,NULL,'Sprout Pharmaceuticals, Inc','Interventional','1090',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2009-10-15','2009-10-01',NULL,NULL,NULL,'','2014-03-11','N','2010-12-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/23672269','2013-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Addyi','511.15',NULL,'2015-08-18',NULL,1,'','Healthy male  ',8,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'8',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.151',NULL,'2015-08-18',NULL,NULL,'','HSDD',63,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'63',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.156',NULL,'2015-08-18','511.156U11-3244-01',3,'','Postmenopausal women with HSDD',748,NULL,NULL,NULL,NULL,'NCT01057901','Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America','Sexual Dysfunctions, Psychological',NULL,NULL,NULL,'Sprout Pharmaceuticals, Inc','Interventional','748',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2010-01-25','2010-01-01',NULL,NULL,NULL,'','2014-04-14','N','2011-01-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Addyi','511.158',NULL,'2015-08-18','511.158U11-1029-01',1,'','Healthy male and female',24,NULL,NULL,NULL,NULL,'NCT01134965','to Evaluate Effect of Multi Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 mg, Healthy Volunteers','Healthy',NULL,NULL,NULL,'Boehringer Ingelheim','Interventional','24',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-06-01','2010-06-01',NULL,NULL,NULL,'',NULL,'N','2010-07-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.2',NULL,'2015-08-18',NULL,1,'','Healthy male and female',81,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'81',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.21',NULL,'2015-08-18',' maybe typo',1,'','HSDD',25,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'25',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.26',NULL,'2015-08-18',NULL,1,'','Fasted healthy male',64,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'64',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.3',NULL,'2015-08-18',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.37',NULL,'2015-08-18',NULL,1,'','Healthy male and female',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.44',NULL,'2015-08-18',' maybe typo',1,'','HSDD',15,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'15',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.67',NULL,'2015-08-18',NULL,1,'','Healthy male and female',28,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'28',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.68',NULL,'2015-08-18',NULL,2,'','HSDD',152,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'152',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.69',NULL,'2015-08-18',NULL,2,'','HSDD',151,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'151',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.7',NULL,'2015-08-18',NULL,3,'','HSDD',1392,NULL,NULL,NULL,NULL,'NCT00360243','6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA','Sexual Dysfunctions, Psychological',NULL,NULL,NULL,'Sprout Pharmaceuticals, Inc','Interventional','1392',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2006-08-03','2006-07-01',NULL,NULL,NULL,'','2014-04-25','N','2008-04-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Addyi','511.71','2012-01-16','2015-08-18',NULL,3,'','HSDD',880,NULL,NULL,NULL,NULL,'NCT00360529','24-Week Placebo-Controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder','Sexual Dysfunctions, Psychological',NULL,NULL,NULL,'Boehringer Ingelheim','Interventional','880',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment',NULL,'2006-08-03','2006-07-01',NULL,NULL,NULL,'','2012-03-14','N','2008-04-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/22248038','2012-04-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Addyi','511.73',NULL,'2015-08-18',NULL,NULL,'','HSDD, FSAD and no FDS',223,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'223',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.74 (Part 1)','2011-09-20','2015-08-18',NULL,3,'','HSDD',749,NULL,NULL,NULL,NULL,'NCT00277914','Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women','Sexual Dysfunctions, Psychological',NULL,NULL,NULL,'Sprout Pharmaceuticals, Inc','Interventional','749',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2006-01-16','2006-01-01',NULL,NULL,NULL,'',NULL,'N','2007-07-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/21933348','2017-11-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.74 (Part 2)','2011-09-20','2015-08-18',NULL,3,'','HSDD',333,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'333',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/21933348','2011-11-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.75','2012-01-12','2015-08-18',NULL,3,'','HSDD',1584,NULL,NULL,NULL,NULL,'NCT00360555','A Twenty Four Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder','Sexual Dysfunctions, Psychological',NULL,NULL,NULL,'Sprout Pharmaceuticals, Inc','Interventional','1584',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2006-08-03','2006-07-01',NULL,NULL,NULL,'','2014-03-27','N','2008-03-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/22239862','2012-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Addyi','511.77',NULL,'2015-08-18',NULL,3,'','HSDD',949,NULL,NULL,NULL,NULL,'NCT00491829','Flibanserin Versus Placebo in Premenopausal Women With HSDD','Sexual Dysfunctions, Psychological',NULL,NULL,NULL,'Sprout Pharmaceuticals, Inc','Interventional','949',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2007-06-25','2007-06-01',NULL,NULL,NULL,'','2014-04-02','N','2009-03-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N ',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Addyi','511.84','2012-10-11','2015-08-18',NULL,3,'','Flibanserin subjects from 511.70, 511.71, 511.75',1723,NULL,NULL,NULL,NULL,'NCT00441558','A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).','Sexual Dysfunctions, Psychological',NULL,NULL,NULL,'Sprout Pharmaceuticals, Inc','Interventional','1723',NULL,NULL,'Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-02-28','2007-02-01',NULL,NULL,NULL,'','2014-05-14','N','2009-08-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/23057791','2012-12-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Addyi','511.85',NULL,'2015-08-18',NULL,NULL,'','HSDD and no FSD',254,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'254',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.86',NULL,'2015-08-18',NULL,1,'','Healthy',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.87',NULL,'2015-08-18',NULL,1,'','Healthy male and female',27,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'27',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.88',NULL,'2015-08-18',NULL,1,'','Healthy',22,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'22',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.93',NULL,'2015-08-18',NULL,1,'','Healthy',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.96',NULL,'2015-08-18',NULL,1,'','Healthy male and female',35,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'35',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.97',NULL,'2015-08-18',NULL,1,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','511.9O',NULL,'2015-08-18',NULL,1,'','Healthy male and female',56,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'56',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','SPR-12-01',NULL,'2015-08-18',NULL,1,'','Healthy',26,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','SPR-12-02',NULL,'2015-08-18',NULL,1,'','Healthy',30,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','SPR-12-03',NULL,'2015-08-18',NULL,1,'','Healthy male and female',25,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'25',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','SPR-12-04',NULL,'2015-08-18',NULL,1,'','Healthy',20,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','SPR-12-05',NULL,'2015-08-18',NULL,1,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','SPR-14-01',NULL,'2015-08-18',NULL,1,'','Healthy',83,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'83',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','SPR-14-06',NULL,'2015-08-18',NULL,1,'','Healthy',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','SPR14-06',NULL,'2015-08-18','med 29',1,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Addyi','U10-2254-01',NULL,'2015-08-18',NULL,NULL,'',NULL,114,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'114',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Sprout Pharms/ Valeant',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Alecensa','AF-001JP','2013-04-30','2015-12-11',NULL,2,'','ALK-positive NSCLC treatment na?ve and platinum-based chemo',70,NULL,NULL,NULL,NULL,'JPRN-JapicCTI-101264','(NOT found on ICTRP!!!)',NULL,NULL,NULL,NULL,NULL,NULL,'70',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23639470','2013-06-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Hoffmann-La Roche',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Alecensa','AF-002JG','2014-08-18','2015-12-11','NP28761',1,'','ALK-positive NSCLC',47,NULL,NULL,NULL,NULL,'NCT01588028','A Clinical Study Testing The Safety and Efficacy of CH5424802/RO5424802 in Patients With ALK Positive Non-Small Cell Lung Cancer','ALK-Rearranged Non-Small Cell Lung Cancer',NULL,NULL,NULL,'Hoffmann-La Roche','Interventional','47',NULL,NULL,'Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-04-26','2012-04-01',NULL,NULL,NULL,'',NULL,'N','2015-09-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25153538','2017-09-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Hoffmann-La Roche',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Alecensa','BO28984',NULL,'2015-12-11',NULL,3,'','ALK-positive NSCLC treatment na?ve and platinum-based chemo',303,NULL,NULL,NULL,NULL,'NCT02075840','ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants','Non-Small Cell Lung Cancer',NULL,NULL,NULL,'Hoffmann-La Roche','Interventional','303',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2014-02-27','2014-08-01',NULL,NULL,NULL,'',NULL,'N','2017-03-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Hoffmann-La Roche',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Alecensa','NP28673',NULL,'2015-12-11',NULL,2,'','ALK-positive NSCLC',154,NULL,NULL,NULL,NULL,'NCT01801111','A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment','Non-Squamous Non-Small Cell Lung Cancer',NULL,NULL,NULL,'Hoffmann-La Roche','Interventional','154',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-02-20','2013-06-01',NULL,NULL,NULL,'',NULL,'N','2016-01-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Hoffmann-La Roche',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Alecensa','NP28761','2015-12-19','2015-12-11',NULL,2,'','ALK-positive NSCLC',134,NULL,NULL,NULL,NULL,'NCT01871805','A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer','Non-Small Cell Lung Cancer',NULL,NULL,NULL,'Hoffmann-La Roche','Interventional','134',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-05-28','2013-09-01',NULL,NULL,NULL,'','2016-01-14','N','2014-10-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26708155','2017-02-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Hoffmann-La Roche',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Alecensa','NP28989',NULL,'2015-12-11',NULL,1,'','Healthy',6,NULL,NULL,NULL,NULL,'NCT01981005','A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802','Healthy Volunteer',NULL,NULL,NULL,'Hoffmann-La Roche','Interventional','6',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-11-05','2013-11-01',NULL,NULL,NULL,'',NULL,'N','2013-12-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/27180975','2016-05-16',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Hoffmann-La Roche',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Alecensa','NP28990',NULL,'2015-12-11',NULL,1,'','Healthy',23,NULL,NULL,NULL,NULL,'NCT01984229','A Study of the Effects of Posaconazole on RO5424802 Pharmacokinetics in Healthy Volunteers','Healthy Volunteer',NULL,NULL,NULL,'Hoffmann-La Roche','Interventional','23',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-11-07','2013-12-01',NULL,NULL,NULL,'',NULL,'N','2014-02-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Hoffmann-La Roche',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Alecensa','NP28991',NULL,'2015-12-11',NULL,1,'','Healthy',42,NULL,NULL,NULL,NULL,'NCT02023125','A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of RO5424802 in Healthy Volunteers.','Healthy Volunteer',NULL,NULL,NULL,'Hoffmann-La Roche','Interventional','42',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-12-23','2014-01-01',NULL,NULL,NULL,'',NULL,'N','2014-02-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Hoffmann-La Roche',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Alecensa','NP29040',NULL,'2015-12-11',NULL,1,'','Healthy',97,NULL,NULL,NULL,NULL,'NCT02074553','A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers','Healthy Volunteer',NULL,NULL,NULL,'Hoffmann-La Roche','Interventional','97',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2014-02-26','2014-02-01',NULL,NULL,NULL,'',NULL,'N','2014-09-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Hoffmann-La Roche',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Alecensa','NP29042',NULL,'2015-12-11',NULL,1,'','Healthy',24,NULL,NULL,NULL,NULL,'NCT01940510','A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802','Healthy Volunteer',NULL,NULL,NULL,'Hoffmann-La Roche','Interventional','24',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Masking: Open Label',NULL,'2013-09-09','2013-10-01',NULL,NULL,NULL,'',NULL,'N','2013-10-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Hoffmann-La Roche',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Aubagio',' HWA486-1024',NULL,'2012-09-12',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','1001',NULL,'2012-09-12',NULL,1,'PK/PD/initial tolerability; ascending dose','healthy',16,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','1002',NULL,'2012-09-12',NULL,1,'PK/PD/initial tolerability','healthy',16,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','1024',NULL,'2012-09-12',NULL,1,'Pilot, single dose study [1]','healthy',6,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','1932',NULL,'2012-09-12',NULL,1,'Extrinsic Factor; PK interactions [p 158]','healthy',20,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','2001',NULL,'2012-09-12',NULL,2,'Rand, double-blind; 36wks [MR p.8]','Patients',179,NULL,NULL,NULL,NULL,'NCT01487096',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2011-12-05','2001-04-01',NULL,NULL,NULL,'N',NULL,'N','2003-03-01','Canada,France',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/16567708','2006-03-28',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','ALI6504',NULL,'2012-09-12',NULL,1,'Food effect; OL randomized [p.132]','healthy',30,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','BDR6639',NULL,'2012-09-12',NULL,1,'Relative BA','healthy',27,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','BEQ10169',NULL,'2012-09-12',NULL,1,'Relative BA','healthy',94,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','BEX6038',NULL,'2012-09-12',NULL,1,'PK; Mass balance and metab; See [CBPR p. 123]','healthy',6,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','EFC10531','2014-01-23','2012-09-12','TOWER',3,NULL,'Patients w/ relapsing MS',1096,NULL,NULL,NULL,NULL,'NCT00751881',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-05-07','2008-08-01',NULL,NULL,NULL,'Y','2013-04-14','N','2012-04-01','United States, Australia, Austria, Belarus (UM), Belgium,Canada, Chile, China (UM), Czech Republic,Estonia, France, Germany, Greece,Mexico (UM), Netherlands, Philippines (LM), Poland, Romania (UM), Slovakia, Spain, Sweden, Thailand (UM), Tunisia (UM), Turkey (UM), Ukraine (LM), United Kingdom',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24461574','2014-01-23',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','Y','Y','Y','N',NULL,'N','Y','N','N','N','Y',NULL,'Sanofi Aventis US','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','EFC10891','2013-10-14','2012-09-12','TENERE',3,'Teriflunomide 7 mg/day and 14 mg/day against active control','patients',324,NULL,NULL,NULL,NULL,'NCT00883337',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-04-16','2009-04-01',NULL,NULL,NULL,'Y','2012-10-03','N','2011-09-01','Belgium,  Canada,  Czech Republic,  France,  Germany,  Greece,  Hungary (UM),  Italy,  Poland,  Spain,  Switzerland,  Tunisia (UM),  United Kingdom',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24126064','2013-10-14',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Aubagio','EFC6049','2012-06-21','2012-09-12','TEMSO',3,NULL,'Patients w/ relapsing MS',1088,NULL,NULL,NULL,NULL,'NCT00134563',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2005-08-23','2004-09-01',NULL,NULL,NULL,'Y','2012-10-03','Y','2010-07-01','United States,   Portugal,   Norway,   Chile,   Netherlands,   Italy,   Russian Federation,   Sweden,   Estonia,   Czech Republic,   Ukraine,   Austria,   Denmark,   Germany,   Finland,   France,   Poland,   Switzerland,   Turkey,   United Kingdom,   Canada',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22723573\r\nhttp://www.ncbi.nlm.nih.gov/pubmed/21991951','2012-06-21',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N','2011-08-08','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Aubagio','EFC6058',NULL,'2012-09-12','TERACLES',3,'Ongoing placebo controlled study adjunctive study of teriflunomide 7 mg/day and 14 mg/day or placebo in patients on a stable dose of IFN-?.',NULL,1455,NULL,NULL,NULL,NULL,'NCT01252355',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2010-11-30','2011-01-01',NULL,NULL,NULL,'N',NULL,'N','2013-04-01','Argentina,   Australia,   Austria,   Belgium,   Brazil,   Canada,   Chile,   Colombia,   Denmark,   Estonia,   Finland,   France,   Germany,   Greece,   Hungary,   Italy,   Korea, Republic of,   Lithuania,   Netherlands,   Norway,   Portugal,   Russian Federation,   Slovakia,   Spain,   Sweden,   Tunisia,   United Kingdom,   United States',NULL,NULL,NULL,NULL,'terminated',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','EFC6260',NULL,'2012-09-12','TOPIC',3,'Ongoing placebo controlled study evaluating patients with clinically isolated syndrome','patients',618,NULL,NULL,NULL,NULL,'NCT00622700',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-02-14','2008-02-01',NULL,NULL,NULL,'N',NULL,'Y','2012-11-01','Australia,   Austria,   Bulgaria,   Canada,   Chile,   Czech Republic,   Denmark,   Estonia,   Finland,   France,   Germany,   Hungary,   Lithuania,   Mexico,   Poland,   Romania,   Russian Federation,   Turkey,   Ukraine,   United Kingdom,   United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N','2013-12-16','Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','INT 10564',NULL,'2012-09-12',NULL,1,'p.1 76; OL 2-period crossover (all male)','healthy',36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','INT10563',NULL,'2012-09-12',NULL,1,'PK interaction (midazolam) [p. 169]','healthy',26,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','INT10564',NULL,'2012-09-12',NULL,1,'PK interaction, contraceptives) p. 172 (all female)','healthy',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','INT11697',NULL,'2012-09-12',NULL,1,'Drug interaction (repaglinide)',NULL,20,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','INT11720',NULL,'2012-09-12',NULL,1,'Drug interaction (cocktail)',NULL,36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','INT11932',NULL,'2012-09-12',NULL,1,'OL, nonrandomized, interaction study (Bupriopion); see [1: p. 161]','healthy',17,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','INT6039',NULL,'2012-09-12',NULL,1,'Extrinsic Factors [p.155]','healthy',20,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','INT6040',NULL,'2012-09-12',NULL,1,'PD and PK interaction (warfarin) [1: p. 161]','healthy',14,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','LTS6047',NULL,'2012-09-12',NULL,2,'Extension (Adjunct w/ IFN-beta and GA)','patients',182,NULL,NULL,NULL,NULL,'NCT00811395',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-12-18','2007-10-01',NULL,NULL,NULL,'Y','2012-10-03','Y','2010-04-01','United States,  Austria,  Canada,  Germany,  Italy,  Spain,  United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N','2011-05-24','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Aubagio','LTS6048','2012-02-03','2012-09-12',NULL,2,'Uncontrolled extension study','Patients w/ relapsing MS',180,NULL,NULL,NULL,NULL,'NCT00228163',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2005-09-26','2002-01-01',NULL,NULL,NULL,'N',NULL,'N','2014-08-01','Canada, France',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22307384','2012-02-03',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Aubagio','LTS6050 ',NULL,'2012-09-12',NULL,2,'Uncontrolled extension study','Patients w/ relapsing MS',1080,NULL,NULL,NULL,NULL,'NCT00803049',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-12-01','2006-10-01',NULL,NULL,NULL,'N',NULL,'N','2015-11-01','United States,  Austria,  Canada,  Chile,  Czech Republic,  Denmark,  Estonia,  Finland,  France,  Germany,  Italy,  Netherlands,  Norway,  Poland,  Portugal,  Russian Federation,  Sweden,  Switzerland,  Turkey (UM),  Ukraine (LM),  United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','N',NULL,'N','N','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','PDY11684',NULL,'2012-09-12',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','PDY6045 ','2012-05-23','2012-09-12',NULL,2,'Adjunct w/ IFN-beta (see CPBR, p. 10)','Patients',116,NULL,NULL,NULL,NULL,'NCT00489489',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2007-06-20','2007-05-01',NULL,NULL,NULL,'Y','2012-10-03','Y','2009-06-01','United States,   Canada,   Germany,   Italy,   Spain',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22622860','2012-05-23',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N','2010-09-30','N','N','N','N','N','N','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Aubagio','PDY6046',NULL,'2012-09-12',NULL,2,'Adjunct w/ GA','Patients',123,NULL,NULL,NULL,NULL,'NCT00475865',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2007-05-18','2007-04-01',NULL,NULL,NULL,'Y','2012-10-03','Y','2009-10-01','United States,  Austria,  Canada,  Germany,  Italy,  United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N','2011-02-25','N','N','N','N','N','N','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Aubagio','PHM0086',NULL,'2012-09-12',NULL,NULL,'impact of enzyme on drug exposure',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','PMH0091',NULL,'2012-09-12',NULL,NULL,'impact of enzyme on drug exposure',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','POH0290',NULL,'2012-09-12',NULL,1,'Intrinsic factors (age/gender); pop PK in safety/efficacy study',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','POH0295',NULL,'2012-09-12',NULL,1,'Pop PK/PD in safety/efficacy studies',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','POP11432 ',NULL,'2012-09-12',NULL,1,'See [1: p. 180]; OL PK and initial tolerability; 8 patients and 8 healthy','Patients (renal impairment)',16,NULL,NULL,NULL,NULL,'NCT01239459',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2010-11-09','2010-11-01',NULL,NULL,NULL,'N',NULL,'N','2011-02-01','Germany',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','POP6505',NULL,'2012-09-12',NULL,1,'PK and tolerability; in mild, moderate and no hepatic impairment','Patients (mild and moderate hepatic impairment) and healthy',25,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','POP6507',NULL,'2012-09-12',NULL,1,'Intrinsic facors: mild/moderate impaitment','healthy',8,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','SIM0041',NULL,'2012-09-12',NULL,NULL,'Pop PK in safety/efficacy study',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','TDR10892',NULL,'2012-09-12',NULL,1,'PK/PD; randomized, double-blinded [p. 129]','healthy',13,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Aubagio','TES10852',NULL,'2012-09-12',NULL,1,NULL,NULL,61,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis US','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Avycaz','CXL-PK-01','2013-01-07','2015-02-25',NULL,1,'','healthy adults',60,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'60',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/23295928','2013-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','CXL-PK-03',NULL,'2015-02-25',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','CXL-PK-04',NULL,'2015-02-25',NULL,1,'','renal impairment/healthy',24,NULL,NULL,NULL,NULL,'NCT01624246','Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance','Augmented Renal Clearance (ARC)|Systemic Inflammatory Response Syndrome (SIRS)',NULL,NULL,NULL,'Forest Laboratories','Interventional','24',NULL,NULL,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-06-14','2012-05-01',NULL,NULL,NULL,'',NULL,'N','2013-03-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','CXL-PK-06',NULL,'2015-02-25',NULL,NULL,'',NULL,40,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'40',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','D4280C00001','2016-03-08','2015-02-25','RECLAIM',3,'',NULL,1149,NULL,NULL,NULL,NULL,'NCT01499290','Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections','Complicated Intra-Abdominal Infection',NULL,NULL,NULL,'AstraZeneca|Forest Laboratories','Interventional','1149',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2011-12-19','2012-03-01',NULL,NULL,NULL,'','2015-11-06','N','2014-04-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/?term=26962078','2016-06-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','D4280C00002',NULL,'2015-02-25','D4280C0001/5',3,'',NULL,598,NULL,NULL,NULL,NULL,'NCT01595438','Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)','Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis',NULL,NULL,NULL,'AstraZeneca|Forest Laboratories','Interventional','598',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2012-04-27','2012-10-01',NULL,NULL,NULL,'','2015-10-28','N','2014-08-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','D4280C00004',NULL,'2015-02-25','RECLAIM 1',3,'',NULL,641,NULL,NULL,NULL,NULL,'NCT01599806','Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)','Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis',NULL,NULL,NULL,'AstraZeneca|Forest Laboratories','Interventional','641',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2012-05-15','2012-10-01',NULL,NULL,NULL,'','2015-11-04','N','2014-08-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','D4280C00005','2016-03-08','2015-02-25','D4280C0002/4',3,'',NULL,1064,NULL,NULL,NULL,NULL,'NCT01500239','A Study Comparing Ceftazidime-Avibactam+Metronidazole Versus Meropenem in Adults With Complicated Intra-abdominal Infections','Complicated Intra-Abdominal Infection',NULL,NULL,NULL,'AstraZeneca|Forest Laboratories','Interventional','1064',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2011-12-22','2012-04-01',NULL,NULL,NULL,'','2015-11-09','N','2014-04-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/?term=26962078','2016-06-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','D4280C00006','2016-06-01','2015-02-25','Phase 3 cUTI',3,'','(hospitalized) patients with ceftazidime-resistant organisms , adults with cIAI and cUTI',345,NULL,NULL,NULL,NULL,'NCT01644643','Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens','Complicated Urinary Tract Infection,|Complicated Intra-abdominal Infection',NULL,NULL,NULL,'AstraZeneca|Forest Laboratories','Interventional','345',NULL,NULL,'Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-06-28','2013-01-01',NULL,NULL,NULL,'','2015-09-28','N','2014-09-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/?term=27107460','2016-04-20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','D4280C00007','2013-10-22','2015-02-25','D4280C0002/4',1,'','healthy adults',54,NULL,NULL,NULL,NULL,'NCT01290900','A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox??) as a Positive Control, in Healthy Male Volunteers','Healthy Male Volunteers',NULL,NULL,NULL,'AstraZeneca','Interventional','54',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2011-02-04','2011-02-01',NULL,NULL,NULL,'',NULL,'N','2011-05-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/24150927','2014-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','D4280C00008','2014-03-10','2015-02-25','Phase 3 cUTI',1,'','healthy adults',6,NULL,NULL,NULL,NULL,'NCT01448395','Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]NXL104','Healthy',NULL,NULL,NULL,'AstraZeneca','Interventional','6',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2011-09-30','2011-10-01',NULL,NULL,NULL,'',NULL,'N','2011-11-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/24616266','2014-05-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','D4280C00009','2015-07-01','2015-02-25','D4280C0001/5',1,'','healthy adults',45,NULL,NULL,NULL,NULL,'NCT01395420','Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma','Healthy',NULL,NULL,NULL,'AstraZeneca','Interventional','45',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2011-07-14','2011-08-01',NULL,NULL,NULL,'',NULL,'N','2012-07-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/?term=26133566','2015-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','D4280C00010','2015-04-28','2015-02-25','Phase 3 cIAI',1,'','japanese healthy adults',16,NULL,NULL,NULL,NULL,'NCT01291602','A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects','Healthy Male and Female Japanese Volunteers',NULL,NULL,NULL,'AstraZeneca','Interventional','16',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)',NULL,'2011-02-06','2011-02-01',NULL,NULL,NULL,'',NULL,'N','2011-04-01','','1',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/?term=26076867','2015-08-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','D4280C00011','2015-08-25','2015-02-25','RECLAIM 2',1,'','healthy adults',43,NULL,NULL,NULL,NULL,'NCT01430910','A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately','Healthy',NULL,NULL,NULL,'AstraZeneca','Interventional','43',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2011-09-07','2011-09-01',NULL,NULL,NULL,'',NULL,'N','2012-10-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/?term=26516584','2015-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','D4280C00012','2015-08-25','2015-02-25','Resistant Pathogen Study',1,'','healthy adults',28,NULL,NULL,NULL,NULL,'NCT01534247','A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and Separately','Healthy',NULL,NULL,NULL,'AstraZeneca|Forest Laboratories','Interventional','28',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2012-02-09','2012-02-01',NULL,NULL,NULL,'',NULL,'N','2012-07-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/?term=26516584','2015-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','D4280C00014',NULL,'2015-02-25',NULL,1,'','infected pediatric patients',35,NULL,NULL,NULL,NULL,'NCT01893346','Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections','Systemic Infections',NULL,NULL,NULL,'AstraZeneca|Forest Laboratories','Interventional','35',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2013-06-26','2013-07-01',NULL,NULL,NULL,'','2015-04-09','N','2014-10-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Avycaz','D4280C00018',NULL,'2015-02-25',NULL,3,'',NULL,486,NULL,NULL,NULL,NULL,'NCT01726023','Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections','Complicated Intra-abdominal Infection',NULL,NULL,NULL,'AstraZeneca','Interventional','486',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2012-11-05','2013-01-01',NULL,NULL,NULL,'','2016-02-01','N','2015-03-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','D4280C00020','2015-12-09','2015-02-25',NULL,1,'','healthy adults',42,NULL,NULL,NULL,NULL,'NCT01920399','A Phase I Study to Assess the Safety, Tolerability and PK of Ceftazidime-Avibactam in Healthy Chinese Subjects','Healthy Volunteers',NULL,NULL,NULL,'AstraZeneca','Interventional','42',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)',NULL,'2013-07-25','2013-10-01',NULL,NULL,NULL,'',NULL,'N','2013-11-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/?term=26649741','2016-02-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','D4280C00023','2015-05-18','2015-02-25',NULL,1,'','healthy adults',48,NULL,NULL,NULL,NULL,'NCT01789528','A Study to Investigate the Effect of Administration of Ceftazidime-avibactam (CAZ-AVI) and Ceftaroline Fosamil -Avibactam (CXL) on the Intestinal Flora of Healthy Volunteers','Pharmacokinetics,|Open Label,|CAZ-AVI,|CXL,|Effect on Intestinal Flora,|Safety.',NULL,NULL,NULL,'AstraZeneca','Interventional','48',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2013-02-04','2013-08-01',NULL,NULL,NULL,'',NULL,'N','2014-03-01','','1',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25987638','2015-08-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','D4281C00001',NULL,'2015-02-25',NULL,3,'',NULL,969,NULL,NULL,NULL,NULL,'NCT01808092','A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia','Nosocomial Pneumonia (NP),|Ventilator-associated Pneumonia (VAP)',NULL,NULL,NULL,'AstraZeneca','Interventional','969',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2013-02-28','2013-04-01',NULL,NULL,NULL,'',NULL,'N','2016-01-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','NXL104/1001','2015-03-27','2015-02-25',NULL,1,'','healthy adults',70,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'70',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/?term=25813217','2015-05-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','NXL104/1002','2015-03-27','2015-02-25',NULL,1,'','healthy adults',49,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'49',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/?term=25813217','2015-05-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','NXL104/1003',NULL,'2015-02-25','cIAI in Asia',1,'','renal impairment/healthy adults',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','NXL104/1004','2015-03-10','2015-02-25',NULL,1,'','age and gender/healthy adults',36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'36',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25769615','2015-04-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','NXL104/2001','2012-11-21','2015-02-25',NULL,2,'','adults with cUTI',135,NULL,NULL,NULL,NULL,'NCT00690378','Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections','Complicated Urinary Tract Infection',NULL,NULL,NULL,'AstraZeneca','Interventional','135',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator)',NULL,'2008-05-29','2008-11-01',NULL,NULL,NULL,'',NULL,'N','2010-06-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/23145859','2012-12-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Avycaz','NXL104/2002','2013-02-07','2015-02-25','HABP/VABP  ',2,'','adults with cIAI',203,NULL,NULL,NULL,NULL,'NCT00752219','Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections','Complicated Intra-Abdominal Infections',NULL,NULL,NULL,'Novexel Inc','Interventional','203',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2008-09-11','2009-03-01',NULL,NULL,NULL,'',NULL,'N','2009-11-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/23391714','2013-05-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Cerexa Inc/ Allergan',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Belsomra','P001',NULL,'2014-08-13',NULL,1,'PK and Initial Tolerability','healthy',40,NULL,'Medical Review (p. 142)',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P002',NULL,'2014-08-13',NULL,1,'PK and PK/PD','healthy',22,NULL,'clinpharm 149',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/23372274','2013-02-01',NULL,NULL,'Randomized, double-blind, placebo-controlled, 4-period crossover PSG study, followed by an additional 5(th) period to assess pharmacokinetics.','22',1,'healthy young men','United kingdom',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P003',NULL,'2014-08-13',NULL,1,'PK and Initial Tolerability','healthy',40,NULL,'Medical Review (p. 142)',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P004',NULL,'2014-08-13',NULL,1,'Intrinsic Factors PK','healthy elderly subjects',20,NULL,'Medical Review (p. 142)',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P005',NULL,'2014-08-13',NULL,1,'Intrinsic Factors','healthy',32,NULL,'Medical Review (p. 142)',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P006','2012-11-28','2014-08-13',NULL,2,'dose finding','patients--primary insomnia non-elderly',254,'United States, Japan','clinpharm 175',NULL,'Europe','NCT00792298','Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)','Primary Insomnia',NULL,'Drug: Suvorexant|Drug: Dose-matched Placebo to Suvorexant','null','Merck Sharp & Dohme Corp.','Interventional','254','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','4305-006|2008_583','2008-11-10','2008-11-01','2009-12-01','2015-02-23','2015-02-01','Y','2014-08-19','N','2009-12-01','Japan,   United States','N',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/23197752','2012-12-04',NULL,NULL,'randomized, double-blind, placebo-controlled, 2-period (4 weeks per period) crossover polysomnography','254',2,'patients','Japan, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Belsomra','P007',NULL,'2014-08-13',NULL,1,'Comparative BA/BE -- biopharmaceutics',NULL,18,NULL,'Medical Review, 220',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P008',NULL,'2014-08-13',NULL,1,'Extrinsic Factors PK','healthy',10,NULL,'Medical Review (p. 142)',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P009','2014-03-27','2014-08-13',NULL,3,'safety','patients--primary insomnia',781,'United States, Australia, Belgium,\nCanada, Colombia, Denmark, Finland, France, Germany, Hungary, Mexico, South Africa, Spain, Sweden, and United Kingdom',NULL,NULL,'Europe','NCT01021813','A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)','Insomnia',NULL,'Drug: Suvorexant|Drug: Dose-matched Placebo to Suvorexant','null','Merck Sharp & Dohme Corp.','Interventional','781','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','4305-009|2009_696','2009-11-25','2009-12-01','2011-08-01','2015-08-14','2015-08-01','Y','2014-08-19','N','2011-05-01','Australia,   Belgium,   Canada,   Colombia,   Denmark,   Finland,   France,   Germany,   Hungary,   South Africa,   Spain,   Sweden,   United Kingdom,   United States','Y',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/24680372','2014-05-01',NULL,NULL,'randomised, placebo-controlled, parallel-group','781',3,'primary insomnia','Australia, Belgium, Canada, Colombia, Denmark, Finland, France, Germany, Hungary, Mexico, South Aftrica, Spain, Sweden, United Kingdom, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'1','Merck, Sharp & Dohme Corp.','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Belsomra','P010','2015-10-13','2014-08-13',NULL,1,'Extrinsic Factors PK','healthy',31,NULL,'Medical Review (p. 143)',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26464455','2015-11-01',NULL,NULL,'double-blind crossover','31',1,'healthy volunteers',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P011',NULL,'2014-08-13',NULL,1,'PK and Initial Tolerability','healthy',17,NULL,'Medical Review (p. 142)',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P012',NULL,'2014-08-13',NULL,1,'PK and Initial Tolerability','healthy',6,NULL,'Medical Review (p. 142)',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P013',NULL,'2014-08-13',NULL,1,'Extrinsic Factors','healthy',20,NULL,'Medical Review (p. 142)',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P015',NULL,'2014-08-13',NULL,1,'Extrinsic Factors PK','healthy',12,NULL,'Medical Review (p. 142)',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P016',NULL,'2014-08-13',NULL,1,'Extrinsic Factors PK','healthy',20,NULL,'Medical Review (p. 142)',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P017',NULL,'2014-08-13',NULL,1,'Intrinsic Factors','8 moderate hepatic insufficiency, 8 healthy',16,NULL,'Medical Review (p. 142)',NULL,'Europe','NCT01043926','Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)','Insomnia|Hepatic Insufficiency',NULL,'Drug: Suvorexant','null','Merck Sharp & Dohme Corp.','Interventional','16','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','4305-017|2010_500','2010-01-05','2010-02-01','2010-04-01','2015-04-07','2015-04-01','Y','2014-08-19','N','2010-04-01','United States','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'1','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Belsomra','P018',NULL,'2014-08-13',NULL,1,'PK and Initial Tolerability','healthy',32,NULL,'Medical Review (p. 142)',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P020',NULL,'2014-08-13',NULL,1,'Bioavailability','healthy',14,NULL,'clinpharm 188',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P021',NULL,'2014-08-13',NULL,1,'PK and PK/PD','healthy',12,NULL,'clinpharm 159',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P022',NULL,'2014-08-13',NULL,1,'PK and PK/PD--QT','healthy',53,NULL,'Medical Review (p. 143)',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P023',NULL,'2014-08-13',NULL,1,'Intrinsic Factors','8 severe renal impairment, 8 healthy',16,NULL,'Medical Review (p. 142)',NULL,'Europe','NCT01059851','Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)','Insomnia',NULL,'Drug: Suvorexant','null','Merck Sharp & Dohme Corp.','Interventional','16','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','4305-023|2010_505','2010-01-28','2010-05-01','2010-07-01','2015-08-04','2015-08-01','Y','2014-08-19','N','2010-07-01','United States','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'1','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Belsomra','P024',NULL,'2014-08-13',NULL,1,'Extrinsic Factors PK','healthy',14,NULL,'Medical Review (p. 142)',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P025',NULL,'2014-08-13',NULL,1,'PK and PK/PD','healthy',73,NULL,'clinpharm 160',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P026',NULL,'2014-08-13',NULL,1,'Extrinsic Factors','healthy',24,NULL,'Medical Review (p. 142)',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P027',NULL,'2014-08-13',NULL,1,'Intrinsic Factors','healthy elderly subjects',75,NULL,'Medical Review (p. 142)',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P028','2014-10-23','2014-08-13',NULL,3,'safety, efficacy','patients--primary insomnia',1022,'United States, Australia, Brazil, Canada, Denmark, Finland, France, Germany, Japan, Peru, Russian Federation, South Africa, Spain, Taiwan, Sweden, and United Kingdom ',NULL,NULL,'Europe','NCT01097616','Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)','Primary Insomnia',NULL,'Drug: Suvorexant High Dose (HD)|Drug: Suvorexant Low Dose (LD)|Drug: Comparator: Placebo','null','Merck Sharp & Dohme Corp.','Interventional','1023','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','4305-028|2010_520','2010-03-26','2010-05-01','2011-12-01','2016-02-25','2016-02-01','Y','2014-08-19','N','2011-09-01','Australia,   Brazil,   Canada,   Denmark,   Finland,   France,   Germany,   Japan,   Peru,   Russian Federation,   South Africa,   Spain,   Sweden,   Taiwan,   United Kingdom,   United States','Y',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25526970?dopt=Abstract','2016-01-15',NULL,NULL,'Two randomized, double-blind, placebo-controlled, parallel-group','1021',3,'patients','Brazil, Canada, Denmark, Finland, France, Germany, Japan, Peru, South Africa, Spain, Sweden, Taiwan, United Kingdom, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'1','Merck, Sharp & Dohme Corp.','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','N','N'),('Belsomra','P029','2014-10-23','2014-08-13',NULL,3,'safety, efficacy','patients--primary insomnia',1019,'United States, Australia, Brazil, Canada, Denmark, Finland, France, Germany,India, Italy, Mexico, Peru, Poland, Republic of Korea, Russian Federation, South Africa, Spain, Sweden, and United Kingdom ',NULL,NULL,'Europe','NCT01097629','Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)','Primary Insomnia',NULL,'Drug: Suvorexant High Dose (HD)|Drug: Suvorexant Low Dose (LD)|Drug: Comparator: Placebo','null','Merck Sharp & Dohme Corp.','Interventional','1020','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','4305-029|2010_521|CTRI/2010/091/001177','2010-03-26','2010-05-01','2011-11-01','2016-02-26','2016-02-01','Y','2014-08-19','N','2011-11-01','Australia,   Brazil,   Canada,   Denmark,   Finland,   France,   Germany,   India,   Italy,   Korea, Republic of,   Mexico,   Peru,   Poland,   Russian Federation,   South Africa,   Spain,   Sweden,   United Kingdom,   United States','Y',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25526970?dopt=Abstract','2016-01-15',NULL,NULL,'Two randomized, double-blind, placebo-controlled, parallel-group','1019',3,'patients','Australia, Canada, Denmark, Finland, France, Germany, India, Italy, Mexico, Peru, Poland, Korea, Russain Federation, South Africa, Spain, Sweden, United Kingdom, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'1','Merck, Sharp & Dohme Corp.','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','N','N'),('Belsomra','P032','2015-01-05','2014-08-13',NULL,1,'PD and PK/PD','patient',25,NULL,'Medical Review (p. 143)',NULL,'Europe','NCT01293006','Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)','Insomnia',NULL,'Drug: suvorexant|Drug: Placebo','null','Merck Sharp & Dohme Corp.','Interventional','25','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','4305-032','2011-02-08','2011-03-01','2012-02-01','2016-01-22','2016-01-01','Y','2014-08-19','N','2012-01-01','United States','Y',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25661282','2015-03-01',NULL,NULL,' randomized, double-blind, placebo-controlled, 2-period, cross-over','25',1,'COPD patients','United States',NULL,'Y','Y','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y','N','N','N'),('Belsomra','P035',NULL,'2014-08-13',NULL,1,'PK and PK/PD','healthy 21-64',28,NULL,'clinpharm 162',NULL,'Europe','NCT01311882','A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)','Insomnia',NULL,'Drug: MK-4305 40 mg|Drug: MK-4305 20 mg|Drug: Zopiclone|Drug: Grossly Matching Placebo for Zopiclone|Drug: Matching Placebo for MK-4305','null','Merck Sharp & Dohme Corp.','Interventional','28','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','4305-035','2011-03-08','2011-04-01','2011-11-01','2016-02-19','2016-02-01','N',NULL,'N','2011-11-01','Netherlands','N',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26039969?dopt=Abstract','2015-11-01',NULL,NULL,'Double-blind, placebo-controlled, 4-period crossover','28',1,'healthy','Netherlands',NULL,'N','N','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P036',NULL,'2014-08-13',NULL,1,'PD and PK/PD','patient-mild to moderate',26,NULL,'Medical Review (p. 143)',NULL,'Europe','NCT01300455','Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036)','Sleep Apnea',NULL,'Drug: Suvorexant|Drug: Matching Placebo','null','Merck Sharp & Dohme Corp.','Interventional','26','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','4305-036','2011-02-17','2011-03-01','2011-08-01','2016-03-10','2016-03-01','Y','2014-08-19','N','2011-08-01','United States','Y',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26194728','2016-01-15',NULL,NULL,'randomized, double-blind, placebo-controlled, 2-period (4 days per period), crossover','26',1,'mild to moderate',NULL,NULL,'Y','Y','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Belsomra','P038',NULL,'2014-08-13',NULL,1,'Extrinsic Factors PK','healtht',10,NULL,'clinpharm 144',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P039',NULL,'2014-08-13',NULL,1,'PK and PK/PD','healthy elderly subjects',24,NULL,'clinpharm 168',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P040','2015-06-03','2014-08-13',NULL,1,'PK and PK/PD','healthy',12,NULL,'clinpharm 171',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/?term=25903940','2015-10-01',NULL,NULL,'randomized, double-blind, 3-period crossover','12',1,'healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P041',NULL,'2014-08-13',NULL,1,'Comparative BA/BE ','healthy',12,NULL,'clinpharm 190',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P042',NULL,'2014-08-13',NULL,1,'bioavailability','healthy',12,NULL,'clinpharm 193',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P055',NULL,'2014-08-13',NULL,1,'pk','healthy',24,NULL,'ClinPharm',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck, Sharp & Dohme Corp.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Belsomra','P056',NULL,'2014-08-13',NULL,1,'pk','healthy',36,NULL,'clinPharm',NULL,'Europe',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0',NULL,'N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Bosulif','3160A1-100-US','2011-12-16','2012-09-04',NULL,1,'Dose escalation study w/ expansion cohort.','Patients (advanced malignant tumors)',151,NULL,NULL,NULL,NULL,'NCT00195260',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'151',NULL,NULL,NULL,NULL,'2005-09-12','2004-10-01',NULL,NULL,NULL,'N',NULL,'N','2007-11-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22179664','2011-12-16',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Wyeth Pharms INC','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Bosulif','3160A1-102-JA',NULL,'2012-09-04',NULL,1,'Dose-escalation study','Patients (advanced malignant tumors)',25,NULL,NULL,NULL,NULL,'NCT01001936',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'28',NULL,NULL,NULL,NULL,'2009-10-26','2006-02-01',NULL,NULL,NULL,'N',NULL,'N','2008-12-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Wyeth Pharms INC','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Bosulif','3160A1-103-EU','2011-06-21','2012-09-04',NULL,1,'Single dose PK; preliminary food effect','Healthy',41,NULL,NULL,NULL,NULL,'NCT00406406',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-11-29','2006-11-01',NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21691746','2011-06-21',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Wyeth Pharms INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Bosulif','3160A4-104-US','2010-12-08','2012-09-04',NULL,1,'Ketoconazole DDI (CYP3A4 Inhibitor) ','Healthy',24,NULL,NULL,NULL,NULL,'NCT00434486',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,'2007-02-09','2007-03-01',NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21148045','2010-12-08',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Wyeth Pharms INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Bosulif','3160A4-105-US','2011-12-14','2012-09-04',NULL,1,'QT study; placebo-controlled (p. 34)','Healthy',60,NULL,NULL,NULL,NULL,'NCT00914121',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'60',NULL,NULL,NULL,NULL,'2009-05-28','2009-06-01',NULL,NULL,NULL,'N',NULL,'N','2009-08-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22065400','2011-12-14',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Wyeth Pharms INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Bosulif','3160A4-1106-US',NULL,'2012-09-04',NULL,1,'Rifampin DDI (CYP3A4 Induction) ','Healthy',24,NULL,NULL,NULL,NULL,'NCT00725426',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,'2008-07-24','2008-07-01',NULL,NULL,NULL,'N',NULL,'N','2008-08-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Wyeth Pharms INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Bosulif','3160A4-1108-US',NULL,'2012-09-04',NULL,1,'Lansoprazole DDI','Healthy',24,NULL,NULL,NULL,NULL,'NCT00952913',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,'2009-08-03','2009-08-01',NULL,NULL,NULL,'N',NULL,'N','2009-10-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23839484','2013-08-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Wyeth Pharms INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Bosulif','3160A4-1109-US',NULL,'2012-09-04',NULL,1,'Relative BA of 3 new formulation tablets and a reference capsule','Healthy',40,NULL,NULL,NULL,NULL,'NCT00499538',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'40',NULL,NULL,NULL,NULL,'2007-07-09','2007-07-01',NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Wyeth Pharms INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Bosulif','3160A4-1110-US',NULL,'2012-09-04',NULL,1,'Food effect','Healthy',24,NULL,NULL,NULL,NULL,'NCT00721474',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,'2008-07-22','2008-09-01',NULL,NULL,NULL,'N',NULL,'N','2008-09-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Wyeth Pharms INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Bosulif','3160A4-1111-EU',NULL,'2012-09-04',NULL,1,'Hepatic impairment study','Healthy (Some participants have varying levels of liver disease (to measure hepatic impairment). Table 2 of the CPBR describes the population as \"healthy\")',27,NULL,NULL,NULL,NULL,'NCT00759837',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'27',NULL,NULL,NULL,NULL,'2008-09-23','2008-10-01',NULL,NULL,NULL,'N',NULL,'N','2009-05-01',NULL,NULL,NULL,NULL,NULL,NULL,'2012-09-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Wyeth Pharms INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Bosulif','3160A4-1112-US',NULL,'2012-09-04',NULL,1,'Mass balance','Healthy',6,NULL,NULL,NULL,NULL,'NCT00757341',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'6',NULL,NULL,NULL,NULL,'2008-09-19','2008-12-01',NULL,NULL,NULL,'N',NULL,'N','2008-12-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Wyeth Pharms INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Bosulif','3160A4-1114-EU','2012-08-09','2012-09-04',NULL,1,'Ketoconazole DDI (CYP3A4 inhibition)','Healthy',48,NULL,NULL,NULL,NULL,'NCT00777530',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'48',NULL,NULL,NULL,NULL,'2008-10-20','2008-04-01',NULL,NULL,NULL,'N',NULL,'N','2008-08-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22884766','2012-08-09',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Wyeth Pharms INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Bosulif','3160A4-1115-US',NULL,'2012-09-04',NULL,1,'Relative BE under fasting conditions','Healthy',30,NULL,NULL,NULL,NULL,'NCT00934674',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'30',NULL,NULL,NULL,NULL,'2009-07-02','2009-07-01',NULL,NULL,NULL,'N',NULL,'N','2009-08-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Wyeth Pharms INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Bosulif','3160A4-1120-US',NULL,'2012-09-04',NULL,1,'Relative BE','Healthy',31,NULL,NULL,NULL,NULL,'NCT01080365',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'31',NULL,NULL,NULL,NULL,'2010-03-02','2010-02-01',NULL,NULL,NULL,'N',NULL,'N','2010-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Wyeth Pharms INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Bosulif','3160A4-200-WW','2011-08-24','2012-09-04',NULL,2,'Part 1: dose escalation; Part II: efficacy','Patients (ph+ leukemia)',588,NULL,NULL,NULL,NULL,'NCT00261846',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'571',NULL,NULL,NULL,NULL,'2005-12-02','2006-01-01',NULL,NULL,NULL,'N',NULL,'Y','2009-09-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22371878 \r\nhttp://www.ncbi.nlm.nih.gov/pubmed/21865346\r\nhttp://www.ncbi.nlm.nih.gov/pubmed/24345751','2012-02-27',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Wyeth Pharms INC','N','N','N','2011-11-15','Y','Y','Y','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Bosulif','3160A4-2203',NULL,'2012-09-04',NULL,2,'Single arm trial in Japan','Patients (CML)',58,NULL,NULL,NULL,NULL,'NCT00811070',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'62',NULL,NULL,NULL,NULL,'2008-12-17','2007-12-01',NULL,NULL,NULL,'N',NULL,'N','2013-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Wyeth Pharms INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Bosulif','3160A4-3000-WW','2012-09-04','2012-09-04',NULL,3,'Randomized, OL; compare safety and efficacy with imatinib','Patients (CP CML)',499,NULL,NULL,NULL,NULL,'NCT00574873',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'502',NULL,NULL,NULL,NULL,'2007-12-13','2008-02-01',NULL,NULL,NULL,'N',NULL,'Y','2010-08-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22949154',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Wyeth Pharms INC','N','N','N','2011-09-07','Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Bosulif','3160A6-2207 ',NULL,'2012-09-04',NULL,NULL,'breast cancer, safety only for NDA',NULL,16,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N','2010-05-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,NULL,'N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Bridion','19.4.101 part 1',NULL,'2015-12-15','P05775',1,'',NULL,29,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'29',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/16192761','2017-10-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.101 part 2',NULL,'2015-12-15',NULL,1,'',NULL,29,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'29',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/16192761','2017-10-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.102',NULL,'2015-12-15',NULL,1,'',NULL,28,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'28',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.105',NULL,'2015-12-15',NULL,1,'',NULL,62,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'62',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22735462','2017-08-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.106',NULL,'2015-12-15',NULL,1,'',NULL,19,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'19',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.107',NULL,'2015-12-15','P05700',1,'',NULL,6,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'6',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.108','2008-01-31','2015-12-15',NULL,1,'',NULL,16,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'16',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/18238834','2017-03-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.109 groups A&F',NULL,'2015-12-15',NULL,1,'',NULL,84,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'84',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20568829','1905-07-02',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.109 groups C, D, & E',NULL,'2015-12-15',NULL,1,'',NULL,84,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'84',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20568829','1905-07-02',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.110',NULL,'2015-12-15','P105-02',1,'','volunteers not previously exposed to sugammadex',23,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'23',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.112',NULL,'2015-12-15','Study 301',NULL,'',NULL,24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22201295','2012-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.113',NULL,'2015-12-15','Study 302',NULL,'',NULL,22,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'22',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.114',NULL,'2015-12-15','Study 310',1,'','male and female Chinese volunteers',12,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'12',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25907172','2017-06-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.115',NULL,'2015-12-15','Study 303',1,'',NULL,8,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'8',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24447651','2017-03-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.116',NULL,'2015-12-15','P076',NULL,'','healthy volunteers',132,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'132',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23824662','2017-08-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.201',NULL,'2015-12-15',NULL,2,'',NULL,27,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'27',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/16571960','2017-04-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.202',NULL,'2015-12-15',NULL,2,'',NULL,98,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'98',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/17457124','2017-05-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.203',NULL,'2015-12-15',NULL,2,'',NULL,28,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'28',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.204',NULL,'2015-12-15',NULL,2,'',NULL,36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'36',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.205',NULL,'2015-12-15',NULL,2,'',NULL,45,NULL,NULL,NULL,NULL,'NCT00379613','Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron?? (19.4.205)(P05942)','Anesthesia, General',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','45',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2006-09-21','2003-11-01',NULL,NULL,NULL,'',NULL,'N','2004-07-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/17667567','2017-08-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.206',NULL,'2015-12-15',NULL,2,'',NULL,176,NULL,NULL,NULL,NULL,'NCT00535743','Dose-Finding Trial With Sugammadex at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Subjects of ASA Class 1-3 (19.4.206)(P05944)','Anesthesia, General',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','176',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-09-25','2004-03-01',NULL,NULL,NULL,'',NULL,'N','2004-07-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/18648227','2017-08-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.207',NULL,'2015-12-15',NULL,2,'',NULL,106,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'106',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.208A',NULL,'2015-12-15',NULL,2,'',NULL,191,NULL,NULL,NULL,NULL,'NCT00591409','A Bridging Trial Comparing Org 25969 at Reappearance of T2 in Japanese and Caucasian Subjects. Part A: Japanese Subjects (19.4.208A)(P05956)','Anesthesia, General',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','191',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-12-27','2006-01-01',NULL,NULL,NULL,'',NULL,'N','2006-09-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.208B',NULL,'2015-12-15',NULL,2,'',NULL,100,NULL,NULL,NULL,NULL,'NCT00552617','A Bridging Trial Comparing Org 25969 at Reappearance of T2 in Japanese and Caucasian Subjects. Part B: Caucasian Subjects (19.4.208B)(P05971)','Anesthesia, General',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','100',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)',NULL,'2007-10-31','2005-09-01',NULL,NULL,NULL,'',NULL,'N','2006-08-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/?term=20876699',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.209A',NULL,'2015-12-15',NULL,2,'',NULL,199,NULL,NULL,NULL,NULL,'NCT00591786','A Bridging Trial Comparing Org 25969 at 1-2 PTC in Japanese and Caucasian Subjects. Part A: Japanese Subjects (19.4.209A)(P05957)(COMPLETED)','Anesthesia, General',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','199',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-12-27','2005-12-01',NULL,NULL,NULL,'',NULL,'N','2006-08-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.209B',NULL,'2015-12-15',NULL,2,'',NULL,100,NULL,NULL,NULL,NULL,'NCT00552929','A Bridging Trial Comparing Org 25969 at 1-2 PTC in Japanese and Caucasian Subjects. Part B: Caucasian Subjects (19.4.209B)(P05974)','Anesthesia, General',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','100',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)',NULL,'2007-10-31','2005-10-01',NULL,NULL,NULL,'',NULL,'N','2006-09-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.210',NULL,'2015-12-15',NULL,2,'',NULL,42,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'42',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/17312209','2017-03-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.301','2009-08-27','2015-12-15','19.4.117',3,'','\"shallow\" neuromuscular block',198,NULL,NULL,NULL,NULL,'NCT00451217','Comparison of Org 25969 With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (19.4.301)(P05960)','Anesthesia, General',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','198',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-03-22','2005-11-01',NULL,NULL,NULL,'',NULL,'N','2006-03-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19713265','2010-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.302',NULL,'2015-12-15',NULL,3,'','\"profound\" neuromuscular block',182,NULL,NULL,NULL,NULL,'NCT00473694','Comparison of Sugammadex With Neostigmine Administered at 1-2 PTCs After Administration of Rocuronium or Vecuronium (19.4.302)(P05945)','Anesthesia, General',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','182',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-05-14','2005-11-01',NULL,NULL,NULL,'',NULL,'N','2006-11-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/18946293','2017-11-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.303',NULL,'2015-12-15','P05774, Study 194334',3,'','\"immediate\" reversal (defined as 3 min following rocuronium administration)',115,NULL,NULL,NULL,NULL,'NCT00474253','Comparison of Recovery From Rocuronium 1.2 mg/kg Followed By Org 25969 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)','Anesthesia, General',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','115',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-05-15','2006-02-01',NULL,NULL,NULL,'',NULL,'N','2006-08-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19387176','2017-05-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.304','2008-07-23','2015-12-15',NULL,3,'',NULL,30,NULL,NULL,NULL,NULL,'NCT00482599','Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED)','Anesthesia, General',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','30',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-06-04','2005-06-01',NULL,NULL,NULL,'',NULL,'N','2006-04-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/18653492','2017-10-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.305',NULL,'2015-12-15',NULL,3,'','elderly vs adult patients',162,NULL,NULL,NULL,NULL,'NCT00474617','Comparison of Org 25969 in Elderly Subjects With Adult Subjects (19.4.305)(P05950)','Anesthesia, General',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','162',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-05-15','2005-12-01',NULL,NULL,NULL,'',NULL,'N','2006-10-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21239968','2017-02-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.306',NULL,'2015-12-15',NULL,3,'','pediatric subjects w rocuronium induced moderate NMB',120,NULL,NULL,NULL,NULL,'NCT00421148','Dose-Finding Pediatric Trial With Sugammadex (19.4.306)(P05961)(COMPLETED)','Anesthesia',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','120',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-01-08','2005-05-01',NULL,NULL,NULL,'',NULL,'N','2006-05-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.308',NULL,'2015-12-15',NULL,3,'','pax w pulmonary disease',77,NULL,NULL,NULL,NULL,'NCT00475215','Evaluation of Safety and Efficacy of Org 25969 in Subjects With or Having a Past History of Pulmonary Disease (19.4.308)(P05932)','Anesthesia, General',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','77',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-05-17','2005-10-01',NULL,NULL,NULL,'',NULL,'N','2006-08-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22608583','2017-06-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.309',NULL,'2015-12-15',NULL,3,'','pax w cardiac disease',120,NULL,NULL,NULL,NULL,'NCT00420680','Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934)','Anesthesia',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','120',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-01-10','2005-11-01',NULL,NULL,NULL,'',NULL,'N','2006-08-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19455040','2017-10-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.310','2008-04-02','2015-12-15','Study 306',3,'','shallow neuromuscular block',84,NULL,NULL,NULL,NULL,'NCT00451100','Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)','Anesthesia, General',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','84',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-03-22','2005-11-01',NULL,NULL,NULL,'',NULL,'N','2006-05-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/18385265','2017-05-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.311',NULL,'2015-12-15',NULL,3,'',NULL,224,NULL,NULL,NULL,NULL,'NCT00298831','Use of Sugammadex at the End of Case in Routine Anesthesia (19.4.311)(P05943)','Anesthesia, General',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','224',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2006-03-01','2005-10-01',NULL,NULL,NULL,'',NULL,'N','2006-05-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25157214','2017-08-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.312',NULL,'2015-12-15',NULL,3,'',NULL,52,NULL,NULL,NULL,NULL,'NCT00559468','Org 25969 After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (19.4.312)(P05949)','Anesthesia, General',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','52',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)',NULL,'2007-11-14','2006-12-01',NULL,NULL,NULL,'',NULL,'N','2007-03-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19512873','2017-07-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.313',NULL,'2015-12-15','P05854',3,'',NULL,91,NULL,NULL,NULL,NULL,'NCT00535496','Relation Between TOF-Watch?? SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)','Neuromuscular Blockade',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','91',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-09-25','2007-09-01',NULL,NULL,NULL,'','2013-05-01','N','2008-01-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20523215','2017-10-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.316','2015-07-01','2015-12-15','P05860',3,'',NULL,140,NULL,NULL,NULL,NULL,'NCT00758485','Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767)','Anesthesia|Neuromuscular Blockade',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','140',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)',NULL,'2008-09-23','2008-10-01',NULL,NULL,NULL,'','2013-03-11','N','2009-05-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/?term=26126940','2017-07-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.318','2012-06-14','2015-12-15','P05861',3,'','adult ASA-PS 1-3 subjects scheduled to undergo laparoscopic cholecystectomy or appendectomy',140,NULL,NULL,NULL,NULL,'NCT00724932','Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)','Anesthesia, General',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','140',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)',NULL,'2008-07-28','2008-07-01',NULL,NULL,NULL,'','2013-03-14','N','2009-04-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/?term=22698066%5Buid%5D','2017-09-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.319','2014-04-08','2015-12-15','P05773',3,'',NULL,161,NULL,NULL,NULL,NULL,'NCT00751179','Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)','Neuromuscular Blockade',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','161',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)',NULL,'2008-09-10','2008-11-01',NULL,NULL,NULL,'','2012-02-23','N','2009-12-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24710957','2017-05-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.324',NULL,'2015-12-15','P05997',3,'',NULL,308,NULL,NULL,NULL,NULL,'NCT00825812','Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)','Anesthesia, General|Neuromuscular Blockade',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','308',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)',NULL,'2009-01-15','2010-01-01',NULL,NULL,NULL,'','2011-07-22','N','2010-09-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25187755','2014-07-12',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.328','2015-03-31','2015-12-15','P06315',3,'','subjects w normal or severely impaired renal function',69,NULL,NULL,NULL,NULL,'NCT00702715','Comparison of 4.0 mg/kg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769)','Anesthesia',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','69',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2008-06-19','2008-09-01',NULL,NULL,NULL,'','2011-03-15','N','2010-03-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25829395','2017-05-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.333','2012-06-24','2015-12-15','P05698',3,'','subjects w renal impairment',6,NULL,NULL,NULL,NULL,'NCT00656799','Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)','Neuromuscular Blockade',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','6',NULL,NULL,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2008-04-07','2008-04-01',NULL,NULL,NULL,'','2013-05-21','N','2009-07-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22732111','2017-09-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.334',NULL,'2015-12-15',NULL,3,'',NULL,100,NULL,NULL,NULL,NULL,'NCT00675792','Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)','Anesthesia',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','100',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)',NULL,'2008-05-07','2008-05-01',NULL,NULL,NULL,'','2013-05-21','5/4/09','2008-09-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'Y',NULL,'2009-05-04','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Bridion','19.4.335',NULL,'2015-12-15','P05767',3,'','Caucasian & Chinese subjects',164,NULL,NULL,NULL,NULL,'NCT00826176','Efficacy and Safety of 4.0 mg/kg Sugammadex at 1-2 PTC in Chinese and European Subjects (Study 19.4.335)(P05775AM1)(COMPLETED)','Anesthesia, General|Neuromuscular Blockade',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','164',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2009-01-15','2010-01-01',NULL,NULL,NULL,'','2011-08-09','N','2010-08-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Bridion','INT00103441',NULL,'2015-12-15','P05769',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','P06042',NULL,'2015-12-15','NXL104-1001',1,'','Koreans and Caucasians',448,NULL,NULL,NULL,NULL,'NCT00988065','Sugammadex Hypersensitivity Study (Study P06042)','Hypersensitivity',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','448',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2009-09-30','2009-09-01',NULL,NULL,NULL,'','2011-04-13','N','2010-04-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Bridion','P06101','2013-12-28','2015-12-15','P05810',3,'','Korean and Caucasians subjects',128,NULL,NULL,NULL,NULL,'NCT01050543','Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101)','Neuromuscular Blockade',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','128',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)',NULL,'2010-01-14','2010-02-01',NULL,NULL,NULL,'','2012-02-13','N','2010-08-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24427455','2017-12-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Bridion','P07025',NULL,'2015-12-15','P05699',1,'',NULL,26,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24120718','2017-12-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','P07038',NULL,'2015-12-15','19.4.326',3,'',NULL,1198,NULL,NULL,NULL,NULL,'NCT01422304','Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)','Neuromuscular Blockade|Arthroplasty, Replacement, Hip|Arthroplasty, Replacement, Knee|Blood Coagulation|Antithrombotic Agents',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','1198',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)',NULL,'2011-08-22','2011-10-01',NULL,NULL,NULL,'','2013-08-19','N','2012-09-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25208233','2017-11-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Bridion','P07044',NULL,'2015-12-15','P05768',1,'',NULL,51,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'51',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Bridion','P07981','2015-05-02','2015-12-15','Trial 2001',3,'',NULL,154,NULL,NULL,NULL,NULL,'NCT01479764','Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)','Surgical Procedures, Elective',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','154',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-11-22','2011-12-01',NULL,NULL,NULL,'','2013-08-26','N','2012-10-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25935840','2017-11-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Bridion','P07982',NULL,'2015-12-15',NULL,3,'','pax undergoing laparoscopic cholecystectomy',127,NULL,NULL,NULL,NULL,'NCT01728584','A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982)','Gallbladder Disease',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','127',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)',NULL,'2012-10-16','2012-11-01',NULL,NULL,NULL,'','2015-03-12','N','2014-04-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Bridion','P101',NULL,'2015-12-15',NULL,1,'','healthy subjects',382,NULL,NULL,NULL,NULL,'NCT02028065','A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)','Hypersensitivity|Anaphylaxis',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','382',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)',NULL,'2014-01-03','2014-01-01',NULL,NULL,NULL,'','2015-09-01','N','2014-07-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Bridion','P105',NULL,'2015-12-15','Trial 2002',1,'','pax w severe or moderate renal impairment, matched healthy control',42,NULL,NULL,NULL,NULL,'NCT02011490','Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)','Renal Insufficiency|Renal Impairment',NULL,NULL,NULL,'Merck Sharp & Dohme Corp.','Interventional','42',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-12-10','2013-12-01',NULL,NULL,NULL,'','2015-01-29','N','2014-06-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Organon Sub Merck',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Cerdelga','GZGD00103',NULL,'2014-08-19','Single dose tolerability study ',1,'Single ascending dose',NULL,74,NULL,NULL,NULL,'France',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20864621','2011-05-01',NULL,NULL,'single ascending dose','99',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Genzyme Corp/Sanofi','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Cerdelga','GZGD00204',NULL,'2014-08-19','Repeated dose tolerability study ',1,'Multiple ascending dose',NULL,24,NULL,NULL,NULL,'France',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20864621','2011-05-01',NULL,NULL,'multiple ascending dose','36',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Genzyme Corp/Sanofi','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Cerdelga','GZGD00304',NULL,'2014-08-19','GZGD03310 (biomarker sub-study)\nPhase 2 [GZGD03310 (biomarker sub-study)] Phase 2 2 year extension\nPhase 2 4-year extension\nPhase 2 4-year extension \nPhase 2 4-year extension bone \n',2,'LT ongoing Hemoglobin, platelets, and spleen','Gaucher type 1 patients 18-65 years old who did not receive miglustat or ERT within 12 months prior',26,NULL,NULL,NULL,'France','NCT00358150','A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients','Gaucher Disease, Type 1|Cerebroside Lipidosis Syndrome|Glucocerebrosidase Deficiency Disease|Glucosylceramide Beta-Glucosidase Deficiency Disease|Gaucher Disease, Non-Neuronopathic Form',NULL,'Drug: Eliglustat tartrate','null','Genzyme, a Sanofi Company|Sanofi','Interventional','26','Industry',2,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','GZGD00304|2005-004732-42','2006-07-27','2006-06-01','2015-12-01','2015-10-16','2015-10-01','Y','2014-08-22','Y','2009-08-01','United States,   Argentina,   Israel,   Italy,   Mexico,   Russian Federation',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20439622','2010-08-12',NULL,NULL,'multinational, open-label, single-arm phase 2 study','26',2,'Gaucher disease type 1',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Genzyme Corp/Sanofi','Y','Y','Y','2011-12-16','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Cerdelga','GZGD00404',NULL,'2014-08-19','Food effect ',1,'Food effect',NULL,24,NULL,NULL,NULL,'France',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20864621','2011-05-01',NULL,NULL,'food effect','24',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Genzyme Corp/Sanofi','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Cerdelga','GZGD01707',NULL,'2014-08-19','TQT',1,'Thorough QT/QTc',NULL,47,NULL,NULL,NULL,'France',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genzyme Corp/Sanofi','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Cerdelga','GZGD01807',NULL,'2014-08-19','Ketoconazole DDI ',1,'Ketoconazole (strong CYP3A and P-gp inhibitor)',NULL,36,NULL,NULL,NULL,'France',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genzyme Corp/Sanofi','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Cerdelga','GZGD01907',NULL,'2014-08-19','Antacids DDI',1,'Antacids and pantoprazole',NULL,24,NULL,NULL,NULL,'France',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genzyme Corp/Sanofi','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Cerdelga','GZGD02007',NULL,'2014-08-19','Paroxetine DDI ',1,'Paroxetine (strong CYP2D6 inhibitor)',NULL,36,NULL,NULL,NULL,'France',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genzyme Corp/Sanofi','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Cerdelga','GZGD02107',NULL,'2014-08-19','Radiolabelled [DMPK09-049];\nDMPK09-049',1,'Absolute bioavailiability, PK, mass balance, excretion, and metabolism',NULL,10,NULL,NULL,NULL,'France',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genzyme Corp/Sanofi','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Cerdelga','GZGD02407',NULL,'2014-08-19','Rifampin DDI ',1,'Rifampin (strong CYP and P-gp inducer)',NULL,25,NULL,NULL,NULL,'France',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genzyme Corp/Sanofi','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Cerdelga','GZGD02507',NULL,'2014-08-19','ENGAGE\nENGAGE 18 month extension \nENGAGE 18 month extension bone ',3,'LT ongoing % change in spleen volume','Gaucher type 1 patients 16 years old or older',40,'Latin America, US, Canada, Middle East, Northern Africa, India, Europe',NULL,NULL,'France','NCT00891202','A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)','Gaucher Disease, Type 1',NULL,'Drug: Eliglustat tartrate|Drug: Placebo','null','Genzyme, a Sanofi Company|Sanofi','Interventional','40','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','GZGD02507|2008-005222-37|EFC12813','2008-10-10','2009-11-01','2015-11-01','2015-10-16','2015-10-01','Y','2014-08-22','Y','2012-07-01','United States,   Bulgaria,   Canada,   Colombia,   India,   Israel,   Jordan,   Lebanon,   Mexico,   Netherlands,   Russian Federation,   Serbia,   Tunisia,   United Kingdom',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25688781','2015-02-17',NULL,NULL,NULL,'40',3,'Gaucher disease type 1','Bulgaria, Canada, Colombia, India, Israel, Lebanon, Mexico, Russia, Serbia, Tunisia, United Kingdom, United States',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Genzyme Corp/Sanofi','Y','Y','Y','2012-10-12','Y','Y','N','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Cerdelga','GZGD02607',NULL,'2014-08-19','ENCORE\nENCORE 2 year extension \nENCORE final 4 year ENCORE final 4 year ',3,'LT ongoing % patients who remain stable in Hgb levels, platelet counts and organ vol','Gaucher type 1 patients 18 years old or older',160,'US, Canada, Australia, Middle East, Europe',NULL,NULL,'France','NCT00943111','A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)','Gaucher Disease, Type 1',NULL,'Drug: Eliglustat tartrate|Drug: Imiglucerase','ENCORE','Genzyme, a Sanofi Company|Sanofi','Interventional','160','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','GZGD02607|2008-005223-28|EFC12812','2009-07-20','2009-09-01','2015-05-01','2014-08-22','2014-08-01','Y','2014-08-22','Y','2012-11-01','United States,   Argentina,   Australia,   Brazil,   Canada,   Egypt,   France,   Germany,   Italy,   Russian Federation,   Spain,   United Kingdom',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25819691','2015-06-13',NULL,NULL,NULL,'160',3,'Gaucher disease type 1','Australia, Argentina, Brazil, Canada, Egypt, Germany, Italy, Russian Federation  Spain, United Kingdom, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Genzyme Corp/Sanofi','Y','Y','Y','2014-03-07','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Cerdelga','GZGD02707',NULL,'2014-08-19','OC DDI ',1,'Norethindrone / ethinyl estradiol (oral contraceptives, Ortho- Novum 1/35)',NULL,29,NULL,NULL,NULL,'France',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genzyme Corp/Sanofi','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Cerdelga','GZGD03109',NULL,'2014-08-19','EDGE\nEDGE interim lead in ',3,'LT ongoing % paties who remain stable through R- Week 52','Gaucher type 1 patients 18 years or older who demonstrate stability on BID dosing',170,NULL,NULL,NULL,'France','NCT01074944','A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)','Gaucher Disease',NULL,'Drug: eliglustat tartrate','null','Genzyme, a Sanofi Company|Sanofi','Interventional','171','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','GZGD03109|2009-015811-42','2010-02-23','2010-06-01','2015-09-01','2015-12-09','2015-12-01','N',NULL,'N','2015-09-01','United States,   Australia,   Austria,   Brazil,   Canada,   China,   Croatia,   France,   Greece,   India,   Japan,   Netherlands,   Portugal,   Romania,   Russian Federation,   Serbia,   Sweden',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Genzyme Corp/Sanofi','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Cerdelga','GZGD03610',NULL,'2014-08-19','DMPK11-R084;\nDigoxin DDI [DMPK11-R084] ',1,'Digoxin (P-gp substrate)',NULL,28,NULL,NULL,NULL,'France','NCT01357811','A Phase 1 Study Evaluating Eliglustat\'s Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults','Healthy Volunteer',NULL,'Drug: eliglustat; digoxin|Drug: digoxin','null','Genzyme, a Sanofi Company|Sanofi','Interventional','28','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label','GZGD03610','2011-05-19','2011-08-01','2011-11-01','2015-03-19','2015-03-01','N',NULL,'N','2011-11-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genzyme Corp/Sanofi','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Cerdelga','GZGD03811',NULL,'2014-08-19','BE',1,'Relative bioavailability of Phase 3 and common blend capsules',NULL,22,NULL,NULL,NULL,'France','NCT01452542','A Phase I Study of the Pharmacokinetic Variability and Relative Bioavailability of the Phase 3 and Common Blend Formulations of Eliglustat in Healthy Adult Subjects','Healthy Volunteer',NULL,'Drug: Eliglustat, common blend proposed commercial formulation|Drug: Eliglustat, Phase 3 capsule formulation','null','Genzyme, a Sanofi Company|Sanofi','Interventional','22','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label','GZGD03811','2011-10-12','2011-10-01','2011-11-01','2015-03-19','2015-03-01','N',NULL,'N','2011-11-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genzyme Corp/Sanofi','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Cerdelga','GZGD04112',NULL,'2014-08-19','Metoprolol DDI ',1,'Metroprolol (CYP2D6 substrate)',NULL,14,NULL,NULL,NULL,'France','NCT01659944','Study to Evaluate the Effect of Eliglustat on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adults','Healthy',NULL,'Drug: Eliglustat|Drug: Metoprolol','null','Genzyme, a Sanofi Company|Sanofi','Interventional','14','Industry',1,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label','GZGD04112','2012-08-06','2012-05-01','2012-07-01','2015-03-19','2015-03-01','N',NULL,'N','2012-06-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genzyme Corp/Sanofi','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Corlanor','CL1-001',NULL,'2015-04-15',NULL,1,'','healthy volunteers',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-002',NULL,'2015-04-15',NULL,1,'','healthy volunteers',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-003',NULL,'2015-04-15',NULL,NULL,'','Healthy ',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-004',NULL,'2015-04-15',NULL,NULL,'','Healthy ',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-005',NULL,'2015-04-15',NULL,NULL,'','healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-007',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-008',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-024',NULL,'2015-04-15','MAD Study',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-027',NULL,'2015-04-15','CL1-16257-002',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-029',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-033',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-036',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-038',NULL,'2015-04-15',NULL,NULL,'','Asthmatics',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-039',NULL,'2015-04-15',NULL,1,'','healthy volunteers',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-040',NULL,'2015-04-15',NULL,1,'','healthy volunteers',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-041',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-042',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-043',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-048',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-049',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL1-055',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-002',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-006',NULL,'2015-04-15',NULL,NULL,'','patients',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-009',NULL,'2015-04-15',NULL,2,'','stable angina pectoris',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-010',NULL,'2015-04-15',NULL,NULL,'','Patients',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-011',NULL,'2015-04-15',NULL,NULL,'','LVdx',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-012',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-013',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-014',NULL,'2015-04-15','typo for CL1-002?',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-015',NULL,'2015-04-15','sAP',NULL,'','H',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-026',NULL,'2015-04-15','NP07497',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-028',NULL,'2015-04-15','CL2-16257-009',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-030',NULL,'2015-04-15',NULL,NULL,'','HF & CAD',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-044',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-045',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-047',NULL,'2015-04-15',NULL,NULL,'','patients w/ proven coronary artery disease',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-050',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-052',NULL,'2015-04-15',NULL,NULL,'','Electrophys',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-054',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-061',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-062',NULL,'2015-04-15',NULL,2,'','chronic heart failure',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-073',NULL,'2015-04-15',NULL,NULL,'','(HF, OL)',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL2-16257-053',NULL,'2015-04-15',NULL,2,'',NULL,12,NULL,NULL,NULL,NULL,'NCT00202579','Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure','Heart Failure, Congestive',NULL,NULL,NULL,'Institut de Recherches Internationales Servier|Servier','Interventional','12',NULL,NULL,'Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label',NULL,'2005-09-12','2004-09-01',NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL3-017 ',NULL,'2015-04-15','CL2-16257-047',2,'','HF',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL3-018',NULL,'2015-04-15',NULL,NULL,'','stable angina pectoris',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL3-019',NULL,'2015-04-15',NULL,2,'','stable angina pectoris',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL3-021',NULL,'2015-04-15',NULL,NULL,'','angina',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL3-022',NULL,'2015-04-15','Can\'t locate',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL3-023',NULL,'2015-04-15','CL2-16257-062',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL3-044',NULL,'2015-04-15','NP26408',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL3-064',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL3-068',NULL,'2015-04-15','CL2-053',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL3-078',NULL,'2015-04-15','CL3-16257-017',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL3-16257-056','2008-08-29','2015-04-15','NP15194',3,'',NULL,10917,NULL,NULL,NULL,NULL,'NCT00143507','The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction','Coronary Disease|Ventricular Dysfunction, Left',NULL,NULL,NULL,'Institut de Recherches Internationales Servier|Servier','Interventional','10,917',NULL,NULL,'Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2005-08-31','2004-12-01',NULL,NULL,NULL,'','2015-05-13','N','2008-02-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/18757088','2008-09-06',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL3-16257-063','2010-08-29','2015-04-15','CL3-16257-018 ',3,'','Support',6558,NULL,NULL,NULL,NULL,'NCT02441218','Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study','Chronic Heart Failure',NULL,NULL,NULL,'Servier','Interventional','6558',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2015-05-05','2006-09-01',NULL,NULL,NULL,'','2015-05-12','N','2010-04-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/20801500','2010-09-11',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL3-16257-067',NULL,'2015-04-15','NP15390',NULL,'','Patients with Ischemic Heart Disease (IHD)',NULL,NULL,NULL,NULL,NULL,'EUCTR2006-005475-17-IE',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-01-04',NULL,NULL,NULL,'','2016-03-02','N','2015-02-12','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','CL3-16257-083','2014-08-31','2015-04-15',NULL,3,'','Pivotal',102,NULL,NULL,NULL,NULL,'NCT02446990','Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure','Coronary Artery Disease.',NULL,NULL,NULL,'Servier','Interventional','102',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2015-05-05','2009-09-01',NULL,NULL,NULL,'','2015-05-20','N','2014-01-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25176136','2014-09-18',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Corlanor','NP15364',NULL,'2015-04-15',NULL,NULL,'','Patients with Heart Failure (HF)',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','PKH-001',NULL,'2015-04-15','CL3-16257-023 ',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','PKH-002',NULL,'2015-04-15',NULL,NULL,'','IHD patients without systlic dysfunction (HF)',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','PKH-003',NULL,'2015-04-15',NULL,NULL,'','Renal Impairment: dialysis',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','PKH-004',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','PKH-005',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','PKH-006',NULL,'2015-04-15','NP27426',NULL,'','patients',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','PKH-007',NULL,'2015-04-15','BEAUTIFUL',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','PKH-008',NULL,'2015-04-15','CL3-056',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','PKH-009',NULL,'2015-04-15','CL3-063',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','PKH-010',NULL,'2015-04-15','NP29800',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','PKH-012',NULL,'2015-04-15','CL-3-063',NULL,'','Hepatic impairment',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','PKH-013',NULL,'2015-04-15','SHIFT',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','PKH-014',NULL,'2015-04-15','SHIFT-HF',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','PKH-015',NULL,'2015-04-15',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Corlanor','PKH-017',NULL,'2015-04-15','CL3-083',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Amgen Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Cotellic','GO28141','2014-09-29','2015-11-10','NP33386',3,'',NULL,495,NULL,NULL,NULL,NULL,'NCT01689519','A Phase III Study Comparing Vemurafenib vs Vemurafenib Plus Cobimetinib (GDC-0973) in Patients With Metastatic Melanoma','Malignant Melanoma',NULL,NULL,NULL,'Hoffmann-La Roche','Interventional','495',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)',NULL,'2012-09-18','2013-01-01',NULL,NULL,NULL,'','2015-07-01','N','2017-12-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25265494','2014-11-13',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','N',NULL,NULL,NULL,NULL,NULL,'Genentech Inc',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Cotellic','GP28369',NULL,'2015-11-10',NULL,1,'',NULL,6,NULL,NULL,NULL,NULL,'NCT01711762','A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers','Healthy Volunteer',NULL,NULL,NULL,'Genentech, Inc.','Interventional','6',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label',NULL,'2012-10-18','2012-09-01',NULL,NULL,NULL,'',NULL,'N','2012-09-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Genentech Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Cotellic','GP28370',NULL,'2015-11-10',NULL,1,'','patients with BRAFV600E mutation-positive melanoma',28,NULL,NULL,NULL,NULL,'NCT02136524','A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation','Healthy Volunteer',NULL,NULL,NULL,'Genentech, Inc.','Interventional','28',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Crossover Assignment|Masking: Open Label',NULL,'2014-05-09','2014-04-01',NULL,NULL,NULL,'',NULL,'N','2014-05-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Genentech Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Cotellic','GP28620',NULL,'2015-11-10',NULL,1,'','pax w solid tumors',16,NULL,NULL,NULL,NULL,'NCT01929876','A Study to Evaluate of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Volunteers','Healthy Volunteer',NULL,NULL,NULL,'Genentech, Inc.','Interventional','16',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label',NULL,'2013-08-22','2013-08-01',NULL,NULL,NULL,'',NULL,'N','2013-09-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Genentech Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Cotellic','GPO14821',NULL,'2015-11-10','SIGNIFY',NULL,'','Renal impairment (Severe RI)',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Genentech Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Cotellic','MEK4592g','2015-09-13','2015-11-10',NULL,1,'','previously untreated BRAF V600 mutation-positive unresectable or metastatic melanoma',120,NULL,NULL,NULL,NULL,'NCT00467779','Study of GDC-0973/XL518 in Patients With Solid Tumors','Solid Tumour',NULL,NULL,NULL,'Genentech, Inc.','Interventional','120',NULL,NULL,'Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-04-18','2009-04-01',NULL,NULL,NULL,'',NULL,'N','2015-05-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26365290','2017-11-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Genentech Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Cotellic','MEK4952g',NULL,'2015-11-10',NULL,1,'','healthy subjects',13,NULL,NULL,NULL,NULL,'NCT01249118','An Absolute Bioavailability Study in Healthy Subjects Comparing Oral to Intravenous Administration of GDC-0973','Healthy Volunteers',NULL,NULL,NULL,'Genentech, Inc.','Interventional','13',NULL,NULL,'Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2010-11-24','2010-11-01',NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24010577','2013-09-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Genentech Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Cotellic','MEK4953g',NULL,'2015-11-10',NULL,1,'','healthy subjects',19,NULL,NULL,NULL,NULL,'NCT01249131','A Study of Relative Bioavailability and Food Effect Study of GDC-0973 in Healthy Subjects','Healthy Volunteers',NULL,NULL,NULL,'Genentech, Inc.','Interventional','19',NULL,NULL,'Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2010-11-24','2010-11-01',NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24010577','2013-09-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Genentech Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Cotellic','MEK4954g',NULL,'2015-11-10',NULL,1,'','healthy subjects',20,NULL,NULL,NULL,NULL,'NCT01277718','A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of GDC 0973 in Healthy Subjects','Healthy Volunteer',NULL,NULL,NULL,'Genentech, Inc.','Interventional','20',NULL,NULL,'Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-01-07','2011-01-01',NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24010577','2013-09-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Genentech Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Cotellic','NO25395','2014-07-15','2015-11-10','NP15364',1,'','patients',131,NULL,NULL,NULL,NULL,'NCT01271803','A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma','Malignant Melanoma',NULL,NULL,NULL,'Hoffmann-La Roche','Interventional','131',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-01-05','2011-02-01',NULL,NULL,NULL,'','2016-05-11','N','2016-12-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25037139','2017-08-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Genentech Inc',NULL,'N',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI443014','2017-02-17','2015-07-24',NULL,2,'','healthy subjects',320,NULL,NULL,NULL,NULL,'NCT01455090','Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications','Chronic Hepatitis C',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','320',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment',NULL,'2011-10-18','2011-11-01',NULL,NULL,NULL,'',NULL,'9/23/15','2014-03-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24184132','2013-10-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,'2015-09-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI443102',NULL,'2015-07-24',NULL,3,'','healthy subjects',416,NULL,NULL,NULL,NULL,'NCT01979939','UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects','Hepatitis C',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','416',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment',NULL,'2013-11-04','2013-12-01',NULL,NULL,NULL,'',NULL,'9/23/15','2014-08-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25942723','2015-05-05',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,'2015-09-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444004',NULL,'2015-07-24',NULL,2,'',NULL,167,NULL,NULL,NULL,NULL,'NCT00663208','A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects','Chronic Hepatitis C',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','167',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment',NULL,'2008-04-18','2008-05-01',NULL,NULL,NULL,'','2015-08-14','N','2009-06-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21837752','2017-12-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444005',NULL,'2015-07-24',NULL,NULL,'',NULL,14,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'14',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444006',NULL,'2015-07-24',NULL,NULL,'','male and female; 18 y/o +; patients w/ HCV genotype 3 infection (treatment-na?ve OR treatment-experienced)',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444008',NULL,'2015-07-24','PKH-15',NULL,'','subjects infected w/ hepatitis C virus genotype 1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444009',NULL,'2015-07-24',NULL,1,'','healthy subjects',18,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'18',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444010','2017-06-17','2015-07-24',NULL,2,'','healthy male subjects',558,NULL,NULL,NULL,NULL,'NCT01125189','Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- na??ve Patients','Hepatitis C Virus',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','558',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment',NULL,'2010-05-17','2010-07-01',NULL,NULL,NULL,'','2015-08-13','N','2012-04-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25080450','2014-07-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444011',NULL,'2015-07-24',NULL,2,'','healthy subjects',512,NULL,NULL,NULL,NULL,'NCT01170962','Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment','Hepatitis C Virus',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','512',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment',NULL,'2010-07-16','2010-08-01',NULL,NULL,NULL,'','2015-08-10','N','2012-06-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444012',NULL,'2015-07-24','BRIM7',NULL,'','healthy subjects',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444013',NULL,'2015-07-24','MIK4592g',1,'','genotype 1 and 4 treatment-na?ve',46,NULL,NULL,NULL,NULL,'NCT00859053','Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment','Hepatic Insufficiency',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','46',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label',NULL,'2009-03-06','2009-03-01',NULL,NULL,NULL,'','2015-08-10','N','2009-09-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444014','2017-09-17','2015-07-24',NULL,2,'','genotype 1 null or partial responders',74,NULL,NULL,NULL,NULL,'NCT00874770','Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)','Hepatitis C Infection',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','74',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment',NULL,'2009-04-02','2009-06-01',NULL,NULL,NULL,'','2015-08-06','N','2009-11-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22714001','2012-06-18',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444020','1905-07-06','2015-07-24',NULL,1,'','healthy subjects',20,NULL,NULL,NULL,NULL,'NCT00983957','Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen?? in Healthy Female Subjects','Chronic Hepatitis C',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','20',NULL,NULL,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label',NULL,'2009-09-23','2009-10-01',NULL,NULL,NULL,'','2015-08-18','N','2010-02-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24343001','2013-12-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444021','1905-07-06','2015-07-24',NULL,2,'','subjects w/ heaptic impairment compared to healthy subjects',51,NULL,NULL,NULL,NULL,'NCT01016912','Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients','Hepatitis C Infection',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','51',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment',NULL,'2009-11-19','2009-12-01',NULL,NULL,NULL,'','2015-08-17','N','2010-09-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24451122','2014-01-22',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444022','1905-07-06','2015-07-24',NULL,2,'','genotype 1 treatment-na?ve',55,NULL,NULL,NULL,NULL,'NCT01017575','Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)','Hepatitis C Infection',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','55',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment',NULL,'2009-11-19','2009-12-01',NULL,NULL,NULL,'','2015-08-13','N','2011-10-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24451151','2014-01-22',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444024',NULL,'2015-07-24',NULL,1,'','healthy female subjects',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444026',NULL,'2015-07-24',NULL,2,'','genotype 1 patients',276,NULL,NULL,NULL,NULL,'NCT01428063','Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials','Hepatitis C Virus Infection',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','276',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment',NULL,'2011-09-01','2011-09-01',NULL,NULL,NULL,'','2015-08-19','N','2014-09-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444027',NULL,'2015-07-24',NULL,1,'','genotype 1 patients',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444031','2017-02-17','2015-07-24','UNITY-1',2,'','healthy subjects',196,NULL,NULL,NULL,NULL,'NCT01257204','Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection','Hepatitis C Virus',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','196',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment',NULL,'2010-12-01','2010-12-01',NULL,NULL,NULL,'','2015-08-05','N','2012-05-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25311593','2014-10-13',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444032','1905-07-05','2015-07-24','ALLY-3',1,'',NULL,14,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'14',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23963204','2013-08-20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444033','1905-07-05','2015-07-24',NULL,1,'','healthy subjects',21,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'21',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23963204','2013-08-20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444034','1905-07-05','2015-07-24',NULL,1,'','genotype 2 and 3 treatment-na?ve',17,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23963204','2013-08-20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444039',NULL,'2015-07-24',NULL,1,'','healthy subjects',23,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'23',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444040',NULL,'2015-07-24',NULL,2,'','healthy subjects',211,NULL,NULL,NULL,NULL,'NCT01359644','Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care','Chronic Hepatitis C',NULL,NULL,NULL,'Bristol-Myers Squibb|Pharmasset','Interventional','211',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment',NULL,'2011-05-23','2011-06-01',NULL,NULL,NULL,'','2015-08-21','N','2013-01-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24428467','2014-01-16',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444042',NULL,'2015-07-24',NULL,3,'','healthy subjects',152,NULL,NULL,NULL,NULL,'NCT01448044','Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C','Hepatitis C',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','152',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment',NULL,'2011-10-05','2011-12-01',NULL,NULL,NULL,'','2015-08-07','N','2013-10-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26313445','2015-08-27',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444044',NULL,'2015-07-24',NULL,NULL,'','healthy subjects',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444046',NULL,'2015-07-24',NULL,NULL,'','genotype 1, 2, and 3 treatment-na?ve or telaprevir or boceprevir treatment failure',1850,NULL,NULL,NULL,NULL,'NCT01492504','Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial','Hepatitis C',NULL,NULL,NULL,'Bristol-Myers Squibb','Observational','1850',NULL,NULL,'Observational Model: Cohort|Time Perspective: Prospective',NULL,'2011-11-30','2012-02-01',NULL,NULL,NULL,'',NULL,'N','2021-02-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444052',NULL,'2015-07-24',NULL,3,'','treatment-na?ve subjects w/ chronic hepatitis C genotype 4',605,NULL,NULL,NULL,NULL,'NCT01492426','Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection','Hepatitis C',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','605',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment',NULL,'2011-12-13','2012-01-01',NULL,NULL,NULL,'','2015-08-17','N','2013-12-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444054',NULL,'2015-07-24',NULL,1,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444063',NULL,'2015-07-24',NULL,1,'',NULL,58,NULL,NULL,NULL,NULL,'NCT01830205','Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment','Hepatitis C',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','58',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment',NULL,'2013-04-10','2012-09-01',NULL,NULL,NULL,'','2015-08-19','N','2013-06-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25654812','2015-02-05',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444064','2017-09-17','2015-07-24',NULL,1,'',NULL,38,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'38',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26124175','2015-06-29',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444065',NULL,'2015-07-24',NULL,1,'','healthy subjects',28,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'28',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444084',NULL,'2015-07-24',NULL,1,'','subjects w/ renal function impairment',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444099',NULL,'2015-07-24',NULL,NULL,'','healthy subjects',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444215',NULL,'2015-07-24',NULL,3,'',NULL,116,NULL,NULL,NULL,NULL,'NCT02032875','Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant','Hepatitis C',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','116',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment',NULL,'2014-01-09','2014-03-01',NULL,NULL,NULL,'','2015-08-18','N','2014-11-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444216','2015-08-20','2015-07-24',NULL,3,'','patients w/ advanced liver disease',203,NULL,NULL,NULL,NULL,'NCT02032888','A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.','Hepatitis C',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','203',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment',NULL,'2014-01-09','2014-02-01',NULL,NULL,NULL,'','2015-08-21','N','2014-10-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26196502','2015-07-21',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444218','2017-04-17','2015-07-24',NULL,3,'','healthy subjects',152,NULL,NULL,NULL,NULL,'NCT02032901','Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV','Hepatitis C',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','152',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment',NULL,'2014-01-09','2014-01-01',NULL,NULL,NULL,'','2015-08-12','N','2014-09-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25614962','2015-03-10',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444237',NULL,'2015-07-24',NULL,NULL,'','healthy subjects',NULL,NULL,NULL,NULL,NULL,'NCT02097966','EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C','Chronic Hepatitis C',NULL,NULL,NULL,'Bristol-Myers Squibb','Expanded Access',NULL,NULL,NULL,'0',NULL,'2014-03-25',NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI444258',NULL,'2015-07-24',NULL,NULL,'','healthy subjects',4111,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'4111',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI446026',NULL,'2015-07-24',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI446028',NULL,'2015-07-24',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI446029',NULL,'2015-07-24',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI447007',NULL,'2015-07-24',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI447009','2017-09-17','2015-07-24','COMMAND-4',1,'',NULL,28,NULL,NULL,NULL,NULL,'NCT00904059','Drug-Drug Interaction Study in Healthy Subjects','Hepatitis C',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','28',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label',NULL,'2009-04-21','2009-05-01',NULL,NULL,NULL,'',NULL,'N','2009-07-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25117173','2014-08-13',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI447011','2017-03-17','2015-07-24',NULL,2,'',NULL,215,NULL,NULL,NULL,NULL,'NCT01012895','Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care','Chronic Hepatitis C',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','215',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment',NULL,'2009-11-12','2009-12-01',NULL,NULL,NULL,'',NULL,'9/23/15','2012-10-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24444658','2013-10-26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,'2015-09-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI447016','2017-12-17','2015-07-24',NULL,2,'',NULL,285,NULL,NULL,NULL,NULL,'NCT01030432','Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin','Hepatitis C Virus',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','285',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment',NULL,'2009-12-10','2017-02-17',NULL,NULL,NULL,'',NULL,'9/23/15','2017-10-17','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25038486','2014-07-16',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,'2015-09-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI447017','2017-04-17','2015-07-24',NULL,2,'','healthy subjects',43,NULL,NULL,NULL,NULL,'NCT01051414','An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject','Hepatitis C Infection',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','43',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment',NULL,'2010-01-15','2010-04-01',NULL,NULL,NULL,'',NULL,'9/23/15','2011-09-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23178977','2012-11-22',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,'2015-09-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI447026','2017-06-17','2015-07-24',NULL,3,'','genotype 1 null responders',224,NULL,NULL,NULL,NULL,'NCT01497834','A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients','Hepatitis C',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','224',NULL,NULL,'Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment',NULL,'2011-12-02','2012-01-01',NULL,NULL,NULL,'',NULL,'9/23/15','2013-04-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24604476','2014-04-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,'2015-09-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI447027',NULL,'2015-07-24',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI447028','2017-11-17','2015-07-24',NULL,3,'','genotype 1 null responders, IFN therapy ineligible na?ve/intolerant',747,NULL,NULL,NULL,NULL,'NCT01581203','Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)','Hepatitis C Virus',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','747',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment',NULL,'2012-04-18','2012-05-01',NULL,NULL,NULL,'',NULL,'9/23/15','2013-10-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25078304','2014-07-28',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,'2015-09-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI447029','2017-07-17','2015-07-24',NULL,3,'','genotype 1b subjects, Japanese',398,NULL,NULL,NULL,NULL,'NCT01573351','Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)','Hepatitis C Virus',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','398',NULL,NULL,'Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment',NULL,'2012-04-05','2012-05-01',NULL,NULL,NULL,'',NULL,'9/23/15','2013-09-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25703086','2015-02-19',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,'2015-09-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI447030',NULL,'2015-07-24',NULL,NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI447031',NULL,'2015-07-24',NULL,3,'','genotype 1b subjects',258,NULL,NULL,NULL,NULL,'NCT01718145','A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects','Hepatitis C Virus Infection',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','258',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment',NULL,'2012-10-29','2012-11-01',NULL,NULL,NULL,'',NULL,'9/23/15','2013-12-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,'2015-09-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI447034',NULL,'2015-07-24','ATU',NULL,'','genotype 1a, 1b and 4 subjects',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI447040',NULL,'2015-07-24','CUP',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI447043',NULL,'2015-07-24','ALLY-1',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','AI452017',NULL,'2015-07-24','ALLY-2',3,'',NULL,880,NULL,NULL,NULL,NULL,'NCT01616524','Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3','Hepatitis C Virus (HCV)',NULL,NULL,NULL,'Bristol-Myers Squibb','Interventional','880',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment',NULL,'2012-06-07','2012-07-01',NULL,NULL,NULL,'',NULL,'9/23/15','2014-06-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'Y',NULL,'2015-09-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Daklinza','TMC435HPC1005',NULL,'2015-07-24',NULL,1,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Bristol-Myers-Squibb',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Dalvance','A8841004',NULL,'2014-05-23',NULL,1,'Safety PK','Adolescents aged 12-17',10,NULL,NULL,NULL,'United States','NCT00678106','Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections','Bacterial Infections',NULL,'Drug: Dalbavancin','null','Pfizer','Interventional','10','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label','A8841004','2008-05-09','2008-09-01','2009-07-01','2009-10-09','2009-10-01','N',NULL,'N','2009-07-01','United States','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25551831','2015-07-01',NULL,NULL,'Open-label, Multicenter, Single-Dose, PK study','10',1,'Healthy',NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Dalvance','DUR001-101',NULL,'2014-05-23',NULL,1,'PK following a supratherapeutic dose ','Healthy subjects',8,'USA',NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Dalvance','DUR001-102','2015-01-22','2014-05-23',NULL,1,'QT Study, prolongation','Healthy subjects',200,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25681068','2015-01-22',NULL,NULL,'QT study','200',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','N','N','N','N','N','N','N','N','N'),('Dalvance','DUR001-103',NULL,'2014-05-23',NULL,1,'PK and safety of a single 1000 mg dose of dalbavancin in healthy Japanese subjects ','Healthy Japanese',18,'Japan',NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26458939','2015-12-01',NULL,NULL,'double-blind, placebo-controlled','18',1,'Healthy','Japan',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Dalvance','DUR001-104','2015-01-05','2014-05-23',NULL,1,'Safety PK','Healthy subjects',18,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25561338','2015-01-05',NULL,NULL,'Extended-Duration Dosing Study','18',1,'Healthy','United States',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','N','N','N','N','N','N','N','N','N'),('Dalvance','DUR001-301',NULL,'2014-05-23',NULL,3,'Acute bacterial skin and skin structure infections ',NULL,573,'Ukraine',NULL,NULL,'United States','NCT01339091','Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections','Abscess|Wound Infection|Surgical Site Infection|Cellulitis',NULL,'Drug: Dalbavancin|Drug: Vancomycin / Linezolid','null','Durata Therapeutics Inc., an affiliate of Allergan plc','Interventional','573','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','DUR001-301','2011-04-18','2011-03-01','2012-11-01','2013-12-26','2013-12-01','Y','2013-11-07','N','2012-09-01','United States,   Canada,   Croatia,   Georgia,   Germany,   Poland,   Russian Federation,   Ukraine','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24897082','2014-06-05',NULL,NULL,'double-blind, double-dummy, international, multicenter, randomized non-inferiority trial','659',3,'Skin Infection',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Dalvance','DUR001-302',NULL,'2014-05-23',NULL,3,'Acute bacterial skin and skin structure infections ',NULL,739,NULL,NULL,NULL,'United States','NCT01431339','Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections','Abscess|Wound Infection|Surgical Site Infection|Cellulitis',NULL,'Drug: IV Dalbavancin|Drug: Vancomycin/Linezolid','null','Durata Therapeutics Inc., an affiliate of Allergan plc','Interventional','739','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','DUR001-302','2011-09-08','2011-07-01','2012-12-01','2013-12-27','2013-12-01','Y','2013-12-27','N','2012-11-01','United States,   Bulgaria,   Estonia,   Hungary,   Israel,   Korea, Republic of,   Latvia,   Lithuania,   Romania,   Russian Federation,   Slovakia,   South Africa,   Taiwan,   Ukraine','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24897082','2014-06-05',NULL,NULL,'double-blind, double-dummy, international, multicenter, randomized non-inferiority trial','653',3,'Skin Infection',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','N','N','N','Y','Y',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Dalvance','VER001-06',NULL,'2014-05-23',NULL,1,'Renal Impairment',NULL,NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Dalvance','VER001-1',NULL,'2014-05-23',NULL,1,'PK, and detection of dose- limiting toxicity ','Healthy adults, ages 18-60 ',23,'UK',NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Dalvance','VER001-10',NULL,'2014-05-23',NULL,1,'Assessment of skin concentration, calculation of extent of renal clearance ','Adults ages 18-65',6,'USA',NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Dalvance','VER001-11',NULL,'2014-05-23',NULL,1,'Safety, PK, and tolerability Subjects with severe renal impairment or ESRD versus age ','Adults, ages 18-80',22,'USA',NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19318696','2009-04-01',NULL,NULL,'open-label, safety, tolerability, and PK study in patients w/ various degrees of renal insufficiency','22',1,'Severe Renal Impairment and ESRD',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Dalvance','VER001-12',NULL,'2014-05-23',NULL,1,'Safety, PK, and tolerability in subjects with hepatic impairment ','Adults, ages 18- 80, mild, moderate, or severe hepatic impairment, or healthy subjects ',27,'USA',NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19318696','2009-04-01',NULL,NULL,'open-label, safety, tolerability, and PK study in patients w/ various degrees of hepatic insufficiency','27',1,'Mild, Moderate and Severe Hepatic Impairment',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Dalvance','VER001-13',NULL,'2014-05-23',NULL,1,'Safety, PK, and tolerability in subjects with mild to moderate renal impairment versus ag ','Adults, ages 18- 80 years, with varying degrees of renal function ',21,'USA',NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19318696','2009-04-01',NULL,NULL,'open-label, safety, tolerability, and PK study in patients w/ various degrees of renal insufficiency','21',1,'Mild to Moderate Renal Impairment',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Dalvance','VER001-15','2006-07-12','2014-05-23',NULL,1,'Intestinal flora','Healthy subjects',12,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/16840427','2006-07-12',NULL,NULL,NULL,'12',1,'Healthy','Sweden',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Dalvance','VER001-16',NULL,'2014-05-23',NULL,3,'Complicated or uncomplicated skin and skin structure infections in patients with suspected or confirmed MRSA ',NULL,156,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Dalvance','VER001-19','2007-07-12','2014-05-23',NULL,1,'Safety, excretion, and skin blister concentration','Adults, ages 19- 65 years',9,'USA',NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/17631507','2007-07-12',NULL,NULL,'Single-dose, Open-label, Single-Center, PK, skin penetration study','9',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Dalvance','VER001-2',NULL,'2014-05-23',NULL,1,'Assess tissue penetration ','Healthy adults, ages 18-55 ',52,'USA',NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/14982787','2004-03-01',NULL,NULL,'randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study','52',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Dalvance','VER001-3',NULL,'2014-05-23',NULL,1,'PK in subjects with mild to moderate renal impairment ','Adults ages 18-75',5,'USA',NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Dalvance','VER001-4','2005-01-07','2014-05-23',NULL,2,'Catheter-related bloodstream Infections ',NULL,74,NULL,NULL,NULL,'United States','NCT00057369','Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections','Bacteremia',NULL,'Drug: dalbavancin','null','Vicuron Pharmaceuticals','Interventional','88','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','VER001-4','2003-03-31','2001-02-01','2003-06-01','2005-06-23','2003-06-01','N',NULL,'N',NULL,'United States','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/15668859','2005-01-07',NULL,NULL,'open-label, randomized, controlled, multicenter study (comparison of dalbavancin w. vancomycin)','75',2,'Bacteremia','United States',NULL,'N','N','Y','Y','Y','Y','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','N','Y','Y'),('Dalvance','VER001-5','2003-10-17','2014-05-23',NULL,2,'Complicated skin and soft tissue infections ',NULL,62,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/14583862','2003-10-17',NULL,NULL,'randomized, controlled, open-label, phase 2 proof-of-concept trial','62',2,'Skin and Soft-Tissue Infections','United States',NULL,'N','N','Y','Y','N','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'Y','Y','N','N','Y','Y','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Dalvance','VER001-8',NULL,'2014-05-23',NULL,3,'Uncomplicated skin and soft tissue infections ',NULL,553,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Dalvance','VER001-9','2005-10-06','2014-05-23',NULL,3,'Complicated skin and soft tissue infections ',NULL,854,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/16231250','2005-10-06',NULL,NULL,'randomized, double-blind','854',3,'Complicated SSSI','United States, Latvia, Lithuania, Canada, United Kingdom, Estonia, Germany',NULL,'N','N','Y','Y','N','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Durata Therapeutics Inc/ Allergan (Actavis)','N','N','N',NULL,'Y','Y','N','N','Y','Y','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Elelyso','P-01-2005','2009-03-11','2012-05-01',NULL,1,'Safety','Healthy',6,NULL,NULL,NULL,NULL,'NCT00258778',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2005-11-23','2005-11-01',NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19277123','2009-03-11',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Elelyso','PB-06-001','2011-09-06','2012-05-01',NULL,3,'R/DB/Safety/Efficacy','Patients',33,NULL,NULL,NULL,NULL,'NCT00376168',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-09-12','2007-08-01',NULL,NULL,NULL,'Y','2012-05-11','N','2009-09-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21900191 \nhttp://www.ncbi.nlm.nih.gov/pubmed/23199589','2011-09-06',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Elelyso','PB-06-002',NULL,'2012-05-01',NULL,3,'OL/Safety/Efficacy','Patients',30,NULL,NULL,NULL,NULL,'NCT00712348',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-07-07','2008-12-01',NULL,NULL,NULL,'N',NULL,'N','2013-04-01',NULL,NULL,NULL,NULL,NULL,NULL,'2014-06-18',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Elelyso','PB-06-003',NULL,'2012-05-01',NULL,3,'OL/Safety/Efficacy','Patients',60,NULL,NULL,NULL,NULL,'NCT00705939',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-06-25','2008-06-01',NULL,NULL,NULL,'N',NULL,'N','2012-05-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Elelyso','PB-06-004',NULL,'2012-05-01',NULL,3,'Expanded Access',NULL,NULL,NULL,NULL,NULL,NULL,'NCT00962260',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-08-18',NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Elelyso','PB-06-005',NULL,'2012-05-01',NULL,3,'Pediatric Trial','patients',11,NULL,NULL,NULL,NULL,'NCT01132690',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2010-05-26','2010-08-01',NULL,NULL,NULL,'N',NULL,'Y','2012-05-01',NULL,NULL,NULL,NULL,NULL,NULL,'2014-11-07',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,NULL,'N','N','N','2014-04-25','Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185001',NULL,'2012-12-28',NULL,NULL,'safety, PK, PD [1]','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22759198','2013-02-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185002a',NULL,'2012-12-28',NULL,1,'safety, PK, PD [1]','Healthy',36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'company says these are same study part A','2014-09-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185002b',NULL,'2012-12-28',NULL,NULL,'safety, tolerability, aspirin interaction [1]','Healthy',16,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185005',NULL,'2012-12-28',NULL,NULL,'safety when coadministered with Plavix [1]','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185006',NULL,'2012-12-28',NULL,NULL,'PK & metabolism [1]','Healthy',10,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185007',NULL,'2012-12-28',NULL,NULL,'regional gastrointestinal absorption [1]','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'from company: Frost CF, Wang X, Nepal S, Schuster A, Shenker A. Assessment of the Sites of Gastrointestinal Absorption of Apixaban in Healthy Subjects. American College of Clinical Pharmacology - 42nd Annual Meeting. 2013;','2013-09-22',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185008',NULL,'2012-12-28',NULL,NULL,'food effect on PK [1]','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22759198','2013-02-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185010','2007-09-15','2012-12-28',NULL,2,'venous thromboembolism prevention (VTEp) [1]','patients',1238,NULL,NULL,NULL,NULL,'NCT00097357',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2004-11-22','2004-10-01',NULL,NULL,NULL,'N',NULL,'Y','2005-12-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/17868430','2007-09-15',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N','2010-02-27','Y','Y','Y','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Eliquis','CV185013 ',NULL,'2012-12-28',NULL,1,'PK in Japanese and Caucasian subj [1]',NULL,24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185015',NULL,'2012-12-28',NULL,NULL,'safety when co-administered with Clopidogrel and Aspirin [1]','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185017','2008-06-06','2012-12-28',NULL,2,'deep vein thrombosis (DVT) [1]',NULL,520,NULL,NULL,NULL,NULL,'NCT00252005',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2005-11-09','2005-11-01',NULL,NULL,NULL,'N',NULL,'Y','2007-02-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/18541000 ','2008-06-06',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N','2010-02-27','Y','Y','Y','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Eliquis','CV185018',NULL,'2012-12-28',NULL,1,'renal impairment and PK [1]','Healthy & Renal Impaired [1]',523,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185019',NULL,'2012-12-28',NULL,NULL,'bioequivalence study [1]','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185020',NULL,'2012-12-28',NULL,NULL,'intravenous study - PK, PD [1]','Healthy',8,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185022',NULL,'2012-12-28',NULL,1,'effect og age/gender [1]','Healthy',79,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185023','2010-08-30','2012-12-28',NULL,2,'indication: safe for people in angina or heart attack','patients',1715,NULL,NULL,NULL,NULL,'NCT00313300',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-04-10','2006-05-01',NULL,NULL,NULL,'N',NULL,'N','2008-05-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19470889\nhttp://www.ncbi.nlm.nih.gov/pubmed/20806117','2009-05-26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Eliquis','CV185024',NULL,'2012-12-28',NULL,NULL,'relative bioavailability assessment [1]','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185025',NULL,'2012-12-28',NULL,NULL,'hepatitic impairment study [1]',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185026',NULL,'2012-12-28',NULL,NULL,'effect of ketoconazole on PK [1]','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2014-11-06',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185028',NULL,'2012-12-28',NULL,NULL,'effect of apixaban on PK of digoxin [1]','Healthy',24,NULL,NULL,NULL,NULL,'NCT02262520',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2014-10-09','2006-01-01',NULL,NULL,NULL,'N',NULL,'N','2006-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185030','2012-05-08','2012-12-28','ARISTOTLE ',3,NULL,'subjects with risk for stroke',18201,NULL,NULL,NULL,NULL,'NCT00412984',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-12-18','2006-12-01',NULL,NULL,NULL,'Y','2013-01-25','N','2011-06-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24226808\nhttp://www.ncbi.nlm.nih.gov/pubmed/24055845\nhttp://www.ncbi.nlm.nih.gov/pubmed/24016506\nhttp://www.ncbi.nlm.nih.gov/pubmed/23640971\nhttp://www.ncbi.nlm.nih.gov/pubmed/23575255\nhttp://www.ncbi.nlm.nih.gov/pubmed/23563134\nhttp://www.ncbi.nlm.nih.gov/pubmed/21870978\nhttp://www.ncbi.nlm.nih.gov/pubmed/22572202','2013-05-02',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Eliquis','CV185031',NULL,'2012-12-28',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2015-01-14',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'0','0','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185032',NULL,'2012-12-28',NULL,NULL,'effect of diltiazem on PK [1]','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2015-05-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185033',NULL,'2012-12-28',NULL,1,'Interaction of Apixaban and Atenolol [1]','Healthy',15,NULL,NULL,NULL,NULL,'NCT02262533',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2014-10-09','2007-06-01',NULL,NULL,NULL,'N',NULL,'N','2007-06-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185036',NULL,'2012-12-28',NULL,3,NULL,'patients [4]',6524,NULL,NULL,NULL,NULL,'NCT00457002',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2007-04-04','2007-06-01',NULL,NULL,NULL,'N',NULL,'N','2011-05-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22077144','2011-11-13',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185045',NULL,'2012-12-28',NULL,NULL,'effect of rifampin on PK [1]','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185046 ',NULL,'2012-12-28',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2014-09-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185048','2011-02-10','2012-12-28','AVERROES ',3,'indication: prevention of strokes in patients','patients',6421,NULL,NULL,NULL,NULL,'NCT00496769',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2007-07-02','2007-09-01',NULL,NULL,NULL,'Y','2013-08-01','Y','2010-11-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23892201\nhttp://www.ncbi.nlm.nih.gov/pubmed/23033347\nhttp://www.ncbi.nlm.nih.gov/pubmed/22305462\nhttp://www.ncbi.nlm.nih.gov/pubmed/21309657','2012-10-02',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N','2012-02-23','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Eliquis','CV185054',NULL,'2012-12-28',NULL,NULL,'naproxen and apixiban coadministered [1]','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2014-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185055',NULL,'2012-12-28',NULL,NULL,'PK & PD Interactions Between Apixaban and Enoxaparin [1]','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22398784','2012-03-08',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185056',NULL,'2012-12-28',NULL,NULL,NULL,'patients [4]',891,NULL,NULL,NULL,NULL,'NCT00643201',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-03-20','2008-07-01',NULL,NULL,NULL,'N',NULL,'N','2013-03-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23808982','2013-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185057',NULL,'2012-12-28',NULL,3,NULL,'patients [4]',2711,NULL,NULL,NULL,NULL,'NCT00633893',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-03-05','2008-05-01',NULL,NULL,NULL,'Y','2013-08-19','N','2012-08-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23216615','2012-12-08',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','N','Y','Y','N',NULL,'N','Y','N','N','N','Y',NULL,'Bristol Myers Squibb','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185058',NULL,'2012-12-28',NULL,1,'PK in healthy Chinese subj','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2013-12-06',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185059',NULL,'2012-12-28',NULL,1,'PK [1]','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2013-12-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185060',NULL,'2012-12-28',NULL,NULL,'Effect of Famotidine on Apixaban PK [1]','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2011-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185061',NULL,'2012-12-28',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185067',NULL,'2012-12-28',NULL,2,'Atrial Fibrillation - different indication',NULL,139,NULL,NULL,NULL,NULL,'NCT00787150',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-11-05','2008-06-01',NULL,NULL,NULL,'Y','2013-01-29','N','2009-09-01',NULL,NULL,NULL,NULL,NULL,NULL,'2011-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Eliquis','CV185068',NULL,'2012-12-28','APPRAISE-2',3,'indication: accute coronary syndrome','Patients',10848,NULL,NULL,NULL,NULL,'NCT00831441',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-01-28','2009-03-01',NULL,NULL,NULL,'N',NULL,'N','2011-11-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21780946','2011-07-24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185070',NULL,'2012-12-28',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2013-08-23',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185074',NULL,'2012-12-28','EMA= ph I',2,'multi dose PK & PD of apixaban and rivaroxaban [1]','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2014-11-13',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bristol Myers Squibb','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Eliquis','CV185104',NULL,'2012-12-28',NULL,NULL,'effect of activated charcoal on PK [1]','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,NULL,'N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Entresto','CLCZ696A1101',NULL,'2015-07-07',NULL,NULL,'','pax w essential hypertension',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A1305','2015-09-24','2015-07-07','A2102',3,'','obese hypertensive',35,NULL,NULL,NULL,NULL,'NCT01646671','Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients','Severe Hypertension',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','35',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-07-18','2012-07-01',NULL,NULL,NULL,'','2015-07-08','N','2013-02-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26402918','2017-04-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A1306',NULL,'2015-07-07',NULL,3,'','essential HTN',1161,NULL,NULL,NULL,NULL,'NCT01599104','Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension','Essential Hypertension',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','1161',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2012-05-13','2012-06-01',NULL,NULL,NULL,'','2015-07-11','N','2013-04-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2101',NULL,'2015-07-07',NULL,NULL,'','elderly subjects w essential HTN',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2102',NULL,'2015-07-07',NULL,NULL,'','essential HTN',8,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'8',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2103',NULL,'2015-07-07','B2116',NULL,'','Age/gender',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2109',NULL,'2015-07-07','A1305',NULL,'','elderly pax w essential hypertension',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2114',NULL,'2015-07-07','B2128',NULL,'',NULL,84,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'84',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2117',NULL,'2015-07-07','PARADIGM-HF; B2314',2,'',NULL,30,NULL,NULL,NULL,NULL,'NCT00913653','Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart Failure','Heart Failure',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','30',NULL,NULL,'Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2009-06-02','2009-05-01',NULL,NULL,NULL,'',NULL,'N','2009-07-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26990595','2016-03-14',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2119 ',NULL,'2015-07-07','B2115',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2120 ',NULL,'2015-07-07','B2203',NULL,'','Japanese hypertensive w renal dysfunction',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2124 ',NULL,'2015-07-07','B2105',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2126','2016-03-08','2015-07-07','B2111',1,'',NULL,39,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'39',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834603/','2017-05-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2201','2010-03-16','2015-07-07',NULL,2,'','NYHA class II to IV chronic heart failure and an LVEF',1328,NULL,NULL,NULL,NULL,'NCT00549770','Efficacy and Safety of LCZ696A in Patients With Essential Hypertension','Hypertension',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','1328',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2007-10-05','2007-09-01',NULL,NULL,NULL,'','2012-08-10','N','2008-07-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20236700','2010-04-10',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2204',NULL,'2015-07-07','A2223',1,'',NULL,32,NULL,NULL,NULL,NULL,'NCT01569815','Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function','Mild and Moderate Renal Impairment',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','32',NULL,NULL,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2012-03-30','2009-02-01',NULL,NULL,NULL,'','2015-07-30','N','2014-08-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2205',NULL,'2015-07-07','A1306',2,'',NULL,12,NULL,NULL,NULL,NULL,'NCT01569828','Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment vs. Matched Healthy Subjects With Normal Renal Function','Pharmacokinetics|Renal Impaired|Healthy Volunteer',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','12',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-03-30','2009-03-01',NULL,NULL,NULL,'','2015-07-30','N','2009-09-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2216',NULL,'2015-07-07','B2207',2,'',NULL,454,NULL,NULL,NULL,NULL,'NCT01692301','Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension','Hypertension',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','454',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2012-09-20','2012-12-01',NULL,NULL,NULL,'','2016-03-31','N','2015-04-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24496699','2017-02-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2219','2014-01-20','2015-07-07',NULL,2,'','HFrEF',389,NULL,NULL,NULL,NULL,'NCT01193101','Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension','Hypertension',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','389',NULL,NULL,'Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2010-08-26','2010-08-01',NULL,NULL,NULL,'','2015-07-23','N','2011-04-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24446062','2017-04-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2219E1',NULL,'2015-07-07','A2101',2,'',NULL,341,NULL,NULL,NULL,NULL,'NCT01256411','A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension','Essential Hypertension',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','341',NULL,NULL,'Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-12-07','2010-11-01',NULL,NULL,NULL,'','2015-07-21','N','2012-04-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2222',NULL,'2015-07-07','A2315',2,'','pax w severe renal impairment',72,NULL,NULL,NULL,NULL,'NCT01681576','Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension','Salt-sensitive Hypertension',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','72',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2012-08-30','2012-08-01',NULL,NULL,NULL,'','2015-07-10','N','2013-10-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26102721','2017-06-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2223',NULL,'2015-07-07',NULL,2,'','HFpEF',910,NULL,NULL,NULL,NULL,'NCT01281306','An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension','Systolic Hypertension',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','910',NULL,NULL,'Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2011-01-20','2011-01-01',NULL,NULL,NULL,'','2015-07-21','1/2/13','2011-12-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,'2013-01-02','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2224',NULL,'2015-07-07',NULL,2,'','pax w chronic HF and reduced ejection fraction from PARADIGM-HF',124,NULL,NULL,NULL,NULL,'NCT01870739','A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension','Hypertension',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','124',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2013-06-03','2013-10-01',NULL,NULL,NULL,'',NULL,'N','2015-06-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2315',NULL,'2015-07-07','HALLMARK-DUAL',3,'','Japanese pax w essential HTN',1438,NULL,NULL,NULL,NULL,'NCT01785472','Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension','Essential Hypertension',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','1438',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-02-05','2013-04-01',NULL,NULL,NULL,'','2015-08-06','N','2014-08-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2316',NULL,'2015-07-07',NULL,3,'','essential HTN',588,NULL,NULL,NULL,NULL,'NCT01615198','Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension','Essential Hypertension',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','588',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2012-06-06','2012-08-01',NULL,NULL,NULL,'','2015-07-20','N','2013-07-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2318',NULL,'2015-07-07','A2222',3,'','HF patients',376,NULL,NULL,NULL,NULL,'NCT01876368','Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan','Hypertension',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','376',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-06-09','2013-09-01',NULL,NULL,NULL,'','2015-07-29','N','2014-08-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696A2319',NULL,'2015-07-07',NULL,3,'','mild-moderate systolic HTN',266,NULL,NULL,NULL,NULL,'NCT01663233','Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine','Essential Hypertension',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','266',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)',NULL,'2012-08-08','2012-08-01',NULL,NULL,NULL,'','2015-07-21','N','2013-05-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2105',NULL,'2015-07-07',NULL,NULL,'','mild/moderate hepatic impairment w matching healthy subjects',4,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'4',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2107',NULL,'2015-07-07','A2204',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2109 ',NULL,'2015-07-07','A2117',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2111',NULL,'2015-07-07','TITRATION; B2228',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2112 ',NULL,'2015-07-07','PARAMOUNT; B2214',NULL,'','healthy male subjects',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2113 ',NULL,'2015-07-07','B2126',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2115',NULL,'2015-07-07',NULL,NULL,'',NULL,10,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'10',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2116',NULL,'2015-07-07','A2201',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2122 ',NULL,'2015-07-07','A1101',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2123',NULL,'2015-07-07','B2112',1,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2125',NULL,'2015-07-07','B2223',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2126',NULL,'2015-07-07',NULL,NULL,'',NULL,40,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'40',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2128 ',NULL,'2015-07-07','A2219',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2203',NULL,'2015-07-07',NULL,2,'',NULL,32,NULL,NULL,NULL,NULL,'NCT01621633','A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers','Hepatic Impairment',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','32',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label',NULL,'2012-06-14','2012-09-01',NULL,NULL,NULL,'','2015-07-11','N','2013-01-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2207',NULL,'2015-07-07','A2319',2,'','pax w mild/moderate renal impairment',98,NULL,NULL,NULL,NULL,'NCT01631864','Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects','Hypertension|Concurrent Obesity',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','98',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2012-06-27','2012-10-01',NULL,NULL,NULL,'','2015-07-11','N','2013-07-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2214','2012-08-26','2015-07-07',NULL,2,'','healthy subjects',307,NULL,NULL,NULL,NULL,'NCT00887588','LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction','Chronic Heart Failure',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','307',NULL,NULL,'Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2009-04-22','2009-11-01',NULL,NULL,NULL,'','2015-07-16','1/2/13','2011-12-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22932717','2012-10-20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,'2013-01-02','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2223',NULL,'2015-07-07',NULL,2,'',NULL,32,NULL,NULL,NULL,NULL,'NCT01353508','Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers','Hypertension',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','32',NULL,NULL,'Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2011-03-16','2011-03-01',NULL,NULL,NULL,'','2015-07-15','1/21/14','2012-08-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,'2014-01-21','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2225',NULL,'2015-07-07','A2316',2,'',NULL,28,NULL,NULL,NULL,NULL,'NCT01601470','Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension','Mild to Moderate Hypertension',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','28',NULL,NULL,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label',NULL,'2012-05-16','2012-09-01',NULL,NULL,NULL,'','2015-07-11','N','2013-01-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2228',NULL,'2015-07-07',NULL,2,'',NULL,498,NULL,NULL,NULL,NULL,'NCT01922089','Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients','Heart Failure With Reduced Ejection Fraction',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','498',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2013-08-12','2013-11-01',NULL,NULL,NULL,'','2015-07-16','N','2014-08-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/27170530','2016-05-12',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2314','2013-04-05','2015-07-07',NULL,3,'',NULL,8442,NULL,NULL,NULL,NULL,'NCT01035255','This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure','Heart Failure With Reduced Ejection Fraction',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','8442',NULL,NULL,'Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2009-12-16','2009-12-01',NULL,NULL,NULL,'','2015-08-06','N','2014-05-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23563576','2013-09-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696B2317',NULL,'2015-07-07','B2225',3,'',NULL,3714,NULL,NULL,NULL,NULL,'NCT02226120','Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction','Chronic Heart Failure With Reduced Ejection Fraction.',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','3714',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2014-08-25','2014-10-01',NULL,NULL,NULL,'',NULL,'N','2018-05-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Entresto','CLCZ696D2301',NULL,'2015-07-07','A2205',3,'',NULL,4300,NULL,NULL,NULL,NULL,'NCT01920711','Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction','Heart Failure With Preserved Ejection Fraction',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','4300',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-08-08','2014-07-01',NULL,NULL,NULL,'',NULL,'N','2019-05-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Erivedge','SHH3925g',NULL,'2012-01-30',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'68',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-09-02',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Erivedge','SHH4318g',NULL,'2012-01-30',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Erivedge','SHH4429g',NULL,'2012-01-30',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'199',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','2012-02-14','N','2010-12-01',NULL,NULL,NULL,NULL,NULL,NULL,'2012-10-18',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'Y','Y','N','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Erivedge','SHH4433g',NULL,'2012-01-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Erivedge','SHH4437g [!]',NULL,'2012-01-30',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'19',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N','2013-12-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'N','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Erivedge','SHH4476g*',NULL,'2012-01-30',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'104',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','2012-02-23','N','2010-11-01',NULL,NULL,NULL,NULL,NULL,NULL,'2012-06-07',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'Y','Y','N','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Erivedge','SHH4489g',NULL,'2012-01-30',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'104',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','2012-02-10','N','2010-11-01',NULL,NULL,NULL,NULL,NULL,NULL,'2012-10-02',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'Y','Y','N','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Erivedge','SHH4593g',NULL,'2012-01-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'53',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N','2012-03-01',NULL,NULL,NULL,NULL,NULL,NULL,'2012-10-11',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'0','0','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Erivedge','SHH4610g',NULL,'2012-01-30',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'67',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2011-07-13',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Erivedge','SHH4683g',NULL,'2012-01-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N','2010-07-01',NULL,NULL,NULL,NULL,NULL,NULL,'2012-11-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Erivedge','SHH4811g',NULL,'2012-01-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2013-11-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Erivedge','SHH4871g',NULL,'2012-01-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'61',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2013-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Erivedge','SHH4893s',NULL,'2012-01-30','NCI-CTEP 8395',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2013-04-03',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Erivedge','SHH8395g',NULL,'2012-01-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,NULL,'N','N','N',NULL,'0','0','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Esbriet','97-HG-0085','2011-03-21','2014-10-15',NULL,2,NULL,'Patients with Hermansky-Pudlak syndrome and IPF',20,NULL,NULL,NULL,'Switzerland','NCT00001596','Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome','Albinism|Inborn Errors of Metabolism|Oculocutaneous Albinism|Platelet Storage Pool Deficiency|Pulmonary Fibrosis',NULL,'Drug: Pirfenidone|Drug: Placebo','null','William Gahl, M.D.|National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)','Interventional','35','NIH',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'1999-11-03','2005-09-01','2020-09-01','2015-10-05','2015-10-01','Y','2011-12-12','N','2009-09-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21420888','2011-06-01',NULL,NULL,'randomized, placebo-controlled','35',NULL,'Hermansky-Pudlak syndrome','United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Esbriet','IPP/Exception',NULL,'2014-10-15',NULL,2,'Safety (Expanded access: company feedback) ','Patients with a diagnosis IPF/PF',34,NULL,NULL,NULL,'Switzerland',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Observational',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','N','N',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','N','N','N',NULL,'N','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Esbriet','Marnac Study 96-06',NULL,'2014-10-15',NULL,2,NULL,'Patients with a diagnosis IPF',57,NULL,NULL,NULL,'Switzerland',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Esbriet','PIPF-001',NULL,'2014-10-15','Marnac Study PF-1999',2,'safety and efficacy, RDBAC','Patients with a diagnosis IPF',56,NULL,NULL,NULL,'Switzerland',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Esbriet','PIPF-002',NULL,'2014-10-15',NULL,2,'Safety and Efficacy','Patients with a diagnosis IPF/PF',83,NULL,NULL,NULL,'Switzerland','NCT00080223','Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis','Idiopathic Pulmonary Fibrosis|Pulmonary Fibrosis',NULL,'Drug: Pirfenidone','null','Genentech, Inc.','Interventional','83','Industry',2,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label',NULL,'2004-03-24','2003-08-01','2015-04-01','2015-06-05','2015-06-01','N',NULL,'N','2015-04-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','N','N','N','N','N',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Esbriet','PIPF-003',NULL,'2014-10-15',NULL,2,'Safety and Efficacy','Patients with a diagnosis IPF/PF',52,NULL,NULL,NULL,'Switzerland',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Esbriet','PIPF-004','2011-05-13','2014-10-15','CAPACITY 004, Study 2, GA29974*',3,'Safety and Efficacy','Age 40 - 80 with a diagnosis IPF',435,'US, Poland, France, Italy, Canada, Mexico, Australia',NULL,NULL,'Switzerland','NCT00287716','Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis','Idiopathic Pulmonary Fibrosis',NULL,'Drug: Pirfenidone|Drug: Placebo','null','InterMune','Interventional','435','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2006-02-06','2006-06-01','2008-11-01','2011-05-12','2011-05-01','Y','2010-06-02','Y','2008-11-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21571362','2011-05-21',NULL,NULL,'double-blind, placebo-controlled','435',3,'Idiopathic pulmonary fibrosis','Australia, Belgium, Canada, France, Germany, Ireland, Italy, Mexico, Poland, Spain, Switzerland, United Kingdom, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','Y','Y','Y','2009-08-25','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Esbriet','PIPF-005','2009-03-27','2014-10-15',NULL,1,'PK','Healthy',41,NULL,NULL,NULL,'Switzerland',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19328861','2009-08-01',NULL,NULL,'randomized, open-label, single-dose, four-way crossover study','16',1,'healthy','USA',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Esbriet','PIPF-006','2011-05-13','2014-10-15','CAPACITY 006, Study 3',3,'Safety and Efficacy','Age 40 - 80 with a diagnosis IPF',344,'US, Belgium, Germany, Ireland, Spain, Switzerland',NULL,NULL,'Switzerland','NCT00287729','Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis','Idiopathic Pulmonary Fibrosis',NULL,'Drug: Pirfenidone|Drug: Placebo','null','InterMune','Interventional','344','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2006-02-06','2006-04-01','2008-11-01','2011-05-12','2011-05-01','Y','2010-06-02','Y','2008-11-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21571362','2011-05-21',NULL,NULL,'double-blind-placebo-controlled','344',3,'Idiopathic pulmonary fibrosis','Australia, Belgium, Canada, France, Germany, Ireland, Italy, Mexico, Poland, Spain, Switzerland, United Kingdom, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','Y','Y','Y','2009-08-25','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Esbriet','PIPF-007',NULL,'2014-10-15',NULL,1,'Thorough QTc ','Healthy',162,NULL,NULL,NULL,'Switzerland',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Esbriet','PIPF-008',NULL,'2014-10-15',NULL,1,'MTD/Safety','Healthy young adults',20,NULL,NULL,NULL,'Switzerland',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Esbriet','PIPF-009',NULL,'2014-10-15',NULL,1,'Renal Impairment','Renal or Heathy',26,NULL,NULL,NULL,'Switzerland',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Esbriet','PIPF-010',NULL,'2014-10-15',NULL,1,'DDI/PK','Healthy',54,NULL,NULL,NULL,'Switzerland',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Esbriet','PIPF-011',NULL,'2014-10-15',NULL,1,'Hepatic Impairment','Hepatic or healthy',24,NULL,NULL,NULL,'Switzerland',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Esbriet','PIPF-012',NULL,'2014-10-15',NULL,3,'Safety  ','Patients with a diagnosis IPF',3000,NULL,NULL,NULL,'Switzerland','NCT00662038','Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)','Idiopathic Pulmonary Fibrosis',NULL,'Drug: pirfenidone','PIPF-012','Genentech, Inc.','Interventional','3000','Industry',3,'Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2008-04-17','2008-08-01','2015-12-01','2012-01-30','2012-01-01','N',NULL,'N','2016-02-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26835133','2016-01-12',NULL,NULL,NULL,NULL,3,'Hermansky-Pudlak syndrome',NULL,NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','N','Y',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N','N'),('Esbriet','PIPF-016','2014-05-18','2014-10-15','ASCEND, Study 1',3,'Safety and Efficacy',NULL,555,'US, Australia, Brazil, Coatia, Isreal, Mexico, New Zealand, Peru, Singapore',NULL,NULL,'Switzerland','NCT01366209','Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)','Idiopathic Pulmonary Fibrosis',NULL,'Drug: Pirfenidone|Drug: Placebo','ASCEND','Genentech, Inc.','Interventional','555','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2011-06-02','2011-06-01','2014-02-01','2015-05-07','2015-05-01','Y','2015-02-27','N','2014-02-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24836312','2014-05-29',NULL,NULL,NULL,'555',3,'Idiopathic pulmonary fibrosis','Australia, Brazil, Croatia, Israel, Mexico, New Zealand Peru, Singapore, United States',NULL,'N','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y'),('Esbriet','PIPF-017',NULL,'2014-10-15',NULL,1,'PK and Safety','Healthy',27,NULL,NULL,NULL,'Switzerland',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Esbriet','Raghu',NULL,'2014-10-15',NULL,2,NULL,'Patients with a diagnosis IPF',54,NULL,NULL,NULL,'Switzerland',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/10194146','1999-04-01',NULL,NULL,'open-label, compassionate use','54',2,'Idiopathic pumonary fibrosis','United States',NULL,'N','N','Y','Y','N','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','N','N','N',NULL,'Y','Y','N','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Esbriet','SP2','2005-01-21','2014-10-15','Japan study',2,'Safety and Efficacy','Patients with a diagnosis IPF',109,NULL,NULL,NULL,'Switzerland',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/15665326','2005-05-01',NULL,NULL,'double-blind, randomized, placebo-controlled trial','109',2,'Idiopathic pulmonary fibrosis','Japan',NULL,'N','N','Y','Y','N','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','N','N','N',NULL,'Y','Y','N','N','Y','Y','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Esbriet','SP3','2009-12-08','2014-10-15',NULL,3,'Efficacy','Age 20 - 75 with a diagnosis IPF',275,'Japan',NULL,NULL,'Switzerland',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19996196','2010-04-01',NULL,NULL,'multicentre, double-blind, placebo-controlled, randomised','275',3,'Idiopathic pulmonary fibrosis','Japan',NULL,'N','N','Y','Y','N','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Genentech / Roche Holding AG','N','N','N',NULL,'Y','Y','N','N','Y','Y','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Esbriet','Study 031',NULL,'2014-10-15',NULL,NULL,NULL,'Expanded Access',NULL,NULL,NULL,NULL,'Switzerland','NCT02141087','Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone','Idiopathic Pulmonary Fibrosis',NULL,'Drug: Pirfenidone','null','Genentech, Inc.','Expanded Access',NULL,'Industry',NULL,NULL,NULL,'2014-05-15',NULL,NULL,'2015-07-09','2015-07-01','N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','N','N',NULL,NULL,NULL,'0',NULL,'N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Farxiga','D1690C00001',NULL,'2014-01-08',NULL,1,'QTc interval','Healthy',50,NULL,NULL,NULL,'UK','NCT00688493','Effects of Single Oral Dose Dapagliflozin QT Study','Healthy',NULL,'Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Moxifloxacin|Drug: Placebo to match moxifloxacin and dapagliflozin','null','AstraZeneca|Bristol-Myers Squibb','Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)','36','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)','D1690C00001','2008-05-30','2007-07-01','2008-04-01','2012-03-20','2012-03-01','N',NULL,'N',NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'1','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','Y','N','Y','N','N','N','N','N','N','N','N','N','N','N','N'),('Farxiga','D1690C00004','2011-08-04','2014-01-08','D1690C00004/D_004/MB102022',3,'Add-on to metformin IR','T2DM on metformin',814,NULL,NULL,NULL,'UK','NCT00660907','Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients','Type 2 Diabetes',NULL,'Drug: dapagliflozin|Drug: glipizide|Drug: metformin hydrochloride','null','AstraZeneca|Bristol-Myers Squibb','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','1217','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1690C00004','2008-04-15','2008-03-01','2013-01-01','2015-03-10','2015-03-01','Y','2013-01-21','N','2009-12-01','Argentina,   France,   Germany,   Italy,   Mexico,   Netherlands,   South Africa,   Spain,   Sweden,   United Kingdom',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21816980, http://www.ncbi.nlm.nih.gov/pubmed/23529570, http://www.ncbi.nlm.nih.gov/pubmed/24919526, *http://www.ncbi.nlm.nih.gov/pubmed/25735400','2011-09-01',NULL,NULL,NULL,'814',3,'Type 2 Diabetes','Argentina, France, germany, United Kingdom, Italy, Mexioc, Ntherlands, South Africa, Spain, Sweden',NULL,'Y','Y','Y','Y','Y','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Farxiga','D1690C00005',NULL,'2014-01-08','MB102028/D_005/DC1960C0/C00004/',3,'Add-onto SU ','T2DM on sulfonylurea',596,NULL,NULL,NULL,'UK','NCT00680745','Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients','Type 2 Diabetes',NULL,'Drug: dapagliflozin|Drug: Glimepiride|Drug: metformin hydrochloride|Drug: pioglitazone hydrochloride|Drug: Rosiglitazone','null','AstraZeneca|Bristol-Myers Squibb','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','597','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1690C00005','2008-05-16','2008-04-01','2010-05-01','2013-08-09','2013-08-01','Y','2011-04-13','N','2009-11-01','Czech Republic,   Hungary,   Korea, Republic of,   Philippines,   Poland,   Thailand,   Ukraine',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23529567, http://www.ncbi.nlm.nih.gov/pubmed/21672123','2011-10-01',NULL,NULL,NULL,'597',3,'Type 2 Diabetes','Czech Republic, Hungary, Republic of Korea, Philippines, Poland, Thailand, Ukriane',NULL,'Y','Y','Y','Y','Y','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Farxiga','D1690C00006',NULL,'2014-01-08','MB102033/D_006',3,'Add-on to insulin','Insulin-dependent T2DM',807,NULL,NULL,NULL,'UK','NCT00673231','Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Placebo|Drug: Dapagliflozin|Drug: Dapagliflozin','null','AstraZeneca|Bristol-Myers Squibb','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','1240','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1690C00006','2008-05-06','2008-04-01','2011-01-01','2013-09-25','2013-09-01','Y','2013-01-21','N','2009-05-01','United States,   Austria,   Bulgaria,   Canada,   Finland,   Germany,   Hungary,   Netherlands,   Romania,   Russian Federation,   Slovakia,   Spain,   United Kingdom',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23911013, http://www.ncbi.nlm.nih.gov/pubmed/23529568, http://www.ncbi.nlm.nih.gov/pubmed/22431673','2012-03-20',NULL,NULL,NULL,'808',3,'Type 2 Diabetes','Austria, Bulgaria, Canada, Finland, United Kingdom, Hungary, Ntherlands, Romania, Russian Federation, Slovakia, Spain, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Farxiga','D1690C00010','2013-10-21','2014-01-08','D1690C00010/MB102061',3,NULL,'Inadequate glycemic control',451,NULL,NULL,NULL,'UK','NCT00984867','Dapagliflozin DPPIV Inhibitor add-on Study','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Placebo','null','AstraZeneca|Bristol-Myers Squibb','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','833','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1690C00010','2009-09-23','2009-10-01','2011-09-01','2014-06-09','2014-06-01','Y','2013-01-21','N','2011-03-01','United States,   Argentina,   Germany,   Mexico,   Poland,   United Kingdom',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24144654','1905-07-06',NULL,NULL,NULL,'432',3,'Type 2 Diabetes',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Farxiga','D1690C00012','2012-01-11','2014-01-08','MB102047/C00012/',3,'Add-on to metformin','T2DM on metformin',182,NULL,NULL,NULL,'UK','NCT00855166','Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes','Type 2 Diabetes Mellitus',NULL,'Drug: Dapagliflozin|Drug: Metformin|Drug: Sitagliptin|Drug: Placebo','null','AstraZeneca|Bristol-Myers Squibb','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','182','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','D1690C00012','2009-03-03','2009-02-01','2011-12-01','2013-08-09','2013-08-01','Y','2013-01-21','N','2010-06-01','Bulgaria,   Czech Republic,   Hungary,   Poland,   Sweden',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22238392, http://www.ncbi.nlm.nih.gov/pubmed/23906445, http://www.ncbi.nlm.nih.gov/pubmed/22651373','2012-03-01',NULL,NULL,NULL,'182',3,'Type 2 Diabetes','Bulgaria, Czech Republic, Hungary, Poland, Sweden',NULL,'Y','Y','Y','Y','Y','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Farxiga','D1690C00016',NULL,'2014-01-08',NULL,1,NULL,'pediatric',NULL,NULL,NULL,NULL,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','D1690C00017',NULL,'2014-01-08','planned enrollment in 2016',3,NULL,NULL,NULL,NULL,NULL,NULL,'UK','NCT02725593','Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Dapagliflozin placebo','null','AstraZeneca|Parexel|Q2 solutions|PRA Health Sciences|Covance Laboratories, Inc','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','54','Industry|Other',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','D1690C00017|2015-005041-31','2016-03-29','2016-05-01','2019-07-01','2016-03-29','2016-03-01','N',NULL,'N','2019-07-01','United States,   Hungary,   Israel,   Mexico,   Romania,   Russian Federation,   Spain,   United Kingdom','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Farxiga','D1690C00018','2015-04-07','2014-01-08','D1690C00018/D_018/MB102067',3,NULL,'Patients with cardiovascular disease and hypertension',922,NULL,NULL,NULL,'UK','NCT01031680','Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension','Type 2 Diabetes Mellitus|Cardiovascular Disease|Hypertension|Inadequate Glycaemic Control',NULL,'Drug: Dapagliflozin|Drug: Placebo','null','AstraZeneca|Bristol-Myers Squibb','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','922','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1690C00018','2009-12-10','2010-02-01','2012-12-01','2013-09-24','2013-09-01','Y','2013-01-21','N','2011-05-01','United States,   Argentina,   Canada,   Germany,   Romania,   Slovakia,   Spain,   Taiwan,   Vietnam',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25852208','2015-07-01',NULL,NULL,NULL,'922',3,'Type 2 Diabetes',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y','Y','N','Y'),('Farxiga','D1690C00019','2014-06-02','2014-01-08','D1690C00019/D_019/MB102080',3,NULL,'Patients with cardiovascular disease  ',965,NULL,NULL,NULL,'UK','NCT01042977','Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease','Type 2 Diabetes Mellitus|Cardiovascular Disease|Inadequate Glycaemic Control',NULL,'Drug: Dapagliflozin|Drug: Placebo','null','AstraZeneca|Bristol-Myers Squibb','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','964','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1690C00019','2010-01-05','2010-03-01','2012-12-01','2013-12-18','2013-12-01','Y','2013-01-21','N','2011-05-01','United States,   Argentina,   Australia,   Austria,   Bulgaria,   Canada,   Chile,   Germany,   Hungary,   Poland',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24890683','2014-07-01',NULL,NULL,NULL,'964',3,'Type 2 Diabetes','United States, Canada, Australia, Chile, Argentina, 5 Centers in Europe',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Farxiga','D1691C00003','2014-10-16','2014-01-08',NULL,3,'Dosing',NULL,400,NULL,NULL,NULL,'UK','NCT01217892','Evaluation of Dapagliflozin Taken Twice-daily','Type 2 Diabetes',NULL,'Drug: dapagliflozin|Drug: dapagliflozin|Drug: dapagliflozin|Drug: metformin|Drug: placebo','null','AstraZeneca|Bristol-Myers Squibb','Allocation: Randomized|Endpoint Classification: Safety Study| Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','400','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1691C00003','2010-10-07','2010-11-01','2011-08-01','2014-10-16','2014-10-01','Y','2013-01-21','N','2011-08-01','Germany,   Hungary,   Romania,   Slovakia,   South Africa,   Switzerland,   Ukraine',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25200570','2015-01-01',NULL,NULL,NULL,'400',3,'Type 2 Diabetes',NULL,NULL,'Y','Y','Y','Y','Y','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Farxiga','D1692C00002',NULL,'2014-01-08',NULL,1,'Interaction, voglibose','T2DM',22,'Japan',NULL,NULL,'UK','NCT01055652','Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients','Type 2 Diabetes Mellitus',NULL,'Drug: Dapagliflozin','null','AstraZeneca|Bristol-Myers Squibb','Endpoint Classification: Pharmacokinetics Study| Intervention Model: Single Group Assignment|Masking: Open Label','28','Industry',1,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label','D1692C00002','2010-01-22','2010-01-01','2010-04-01','2011-10-14','2010-10-01','N',NULL,'N','2010-04-01','Japan',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'1','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','D1692C00005','2013-01-25','2014-01-08','MB102064',2,'Monotherapy v placebo','T2DM, Japanese',220,'Japan',NULL,NULL,'UK','NCT00972244','Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients','Type 2 Diabetes Mellitus',NULL,'Drug: Dapagliflozin|Drug: Placebo','null','AstraZeneca|Bristol-Myers Squibb','Allocation: Randomized|Endpoint Classification: Efficacy Study | Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','417','Industry',2,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','D1692C00005','2009-08-31','2009-08-01','2010-05-01','2013-08-09','2013-08-01','Y','2013-01-21','N','2010-05-01','Japan',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23194084','2013-05-01',NULL,NULL,NULL,'279',2,'Type 2 Diabetes','Japan',NULL,'Y','Y','Y','Y','Y','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Farxiga','D1692C00006','2014-07-08','2014-01-08','D1692C00006/C00006/MB102106',3,NULL,'Japanese drug-naive',261,'Japan',NULL,NULL,'UK','NCT01294423','Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus','Type 2 Diabetes|High Blood Sugar',NULL,'Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Placebo','null','AstraZeneca|Bristol-Myers Squibb','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study | Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','261','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1692C00006','2011-02-10','2011-02-01','2012-03-01','2014-07-17','2014-07-01','Y','2013-01-30','Y','2012-03-01','Japan',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24909293','2014-11-01',NULL,NULL,NULL,'261',3,'Type 2 Diabetes','Japan',NULL,'Y','Y','Y','Y','Y','N','Y','Y','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','N','N','N','2011-05-09','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Farxiga','D1692C00012',NULL,'2014-01-08',NULL,3,NULL,'Japanese with or without OAD',728,'Japan',NULL,NULL,'UK','NCT01294436','Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus','Type2 Diabetes|High Blood Sugar',NULL,'Drug: Dapagliflozin','null','AstraZeneca|Bristol-Myers Squibb','Endpoint Classification: Safety/Efficacy Study | Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','728','Industry',3,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','D1692C00012','2011-02-10','2011-02-01','2012-09-01','2013-11-22','2013-11-01','Y','2013-07-10','N','2012-09-01','Japan',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','Y','N',NULL,'N','Y','N',NULL,NULL,NULL,'1','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Farxiga','D1693C00001 ',NULL,'2014-01-08','DECLARE/TIMI-58',3,NULL,'T2DM',17150,NULL,NULL,NULL,'UK','NCT01730534','Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events','Diabetes Mellitus, Non-Insulin-Dependent|High Risk for Cardiovascular Event',NULL,'Drug: Dapagliflozin 10 mg|Drug: Placebo tablet','DECLARE-TIMI58','AstraZeneca|Bristol-Myers Squibb|The TIMI Study Group|Hadassah Medical Organization','Allocation: Randomized|Endpoint Classification: Safety Study| Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','17276','Industry|Other',3,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1693C00001','2012-11-15','2013-04-01','2019-04-01','2015-12-10','2015-12-01','N',NULL,'N','2019-04-01','United States,   Argentina,   Australia,   Belgium,   Brazil,   Bulgaria,   Canada,   China,   Czech Republic,   France,   Germany,   Hong Kong,   Hungary,   India,   Israel,   Italy,   Japan,   Korea, Republic of,   Mexico,   Netherlands,   Philippines,   Poland,   Romania,   Russian Federation,   Slovakia,   South Africa,   Spain,   Sweden,   Taiwan,   Thailand,   Turkey,   Ukraine,   United Kingdom,   Vietnam','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Farxiga','D1693C00002',NULL,'2014-01-08',NULL,3,NULL,NULL,NULL,NULL,NULL,NULL,'UK','NCT01257412','Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: placebo','null','AstraZeneca|Bristol-Myers Squibb','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study| Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','375','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1693C00002','2010-12-08','2012-01-01','2013-06-01','2012-02-29','2012-02-01','N',NULL,'N','2013-06-01','India','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','D1693C00005','2015-01-15','2014-01-08',NULL,3,NULL,'pediatric',NULL,NULL,NULL,NULL,'UK','NCT01392677','Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea','Type 2 Diabetes Mellitus|High HbA1c Level|Inadequate Glycaemic Control',NULL,'Drug: dapagliflozin|Drug: placebo','null','AstraZeneca|Bristol-Myers Squibb','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','311','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1693C00005','2011-07-11','2011-10-01','2013-08-01','2014-02-11','2014-02-01','Y','2013-11-05','N','2013-01-01','Canada,   Czech Republic,   Germany,   Poland,   Slovakia,   Spain',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25592197','2015-03-01',NULL,NULL,NULL,'219',3,'Type 2 Diabetes','Canada, Czech Republic, Germany, Poland, Slovak Republic, Spain',NULL,'Y','Y','Y','Y','Y','N','Y','Y','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y'),('Farxiga','MB102001','2009-01-07','2014-01-08',NULL,1,'Safety/PK ','Healthy',64,NULL,NULL,NULL,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19129748','2009-05-01',NULL,NULL,NULL,'64',1,'Healthy','United States',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102002','2009-01-07','2014-01-08',NULL,1,'Safety/PK ','Healthy',40,NULL,NULL,NULL,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19129748','2009-05-01',NULL,NULL,NULL,'40',1,'Healthy','United States',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102003','2009-01-07','2014-01-08',NULL,1,'Safety/PK ','T2DM',47,NULL,NULL,NULL,'UK','NCT00162305','A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects','Diabetes Mellitus, Type 2',NULL,'Drug: BMS-512148|Drug: BMS-512148|Drug: BMS-512148|Drug: Placebo','null','AstraZeneca','Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','47','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','MB102-003','2005-09-09','2005-04-01','2005-08-01','2015-03-20','2015-03-01','N',NULL,'N','2005-08-01','United States','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19129749','2009-05-01',NULL,NULL,NULL,'47',1,'Healthy','United States',NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102004',NULL,'2014-01-08',NULL,1,'Co-prescribed, Hydrochlorothiazide','Healthy',18,NULL,NULL,NULL,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102005',NULL,'2014-01-08',NULL,1,'Relative bioavailability','Healthy',14,NULL,NULL,NULL,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102006','2009-12-08','2014-01-08',NULL,1,'C-ADME and Mass Balance','Healthy',6,NULL,NULL,NULL,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19996149','2010-03-01',NULL,NULL,NULL,'6',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102007',NULL,'2014-01-08',NULL,1,'Safety/PK ','Healthy and Renal impairment',40,NULL,NULL,NULL,'UK','NCT00554450','Renal Impairment in Type 2 Diabetic Subjects','Diabetes Mellitus, Type 2',NULL,'Drug: Dapagliflozin','null','AstraZeneca','Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','40','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','MB102-007','2007-11-05','2006-03-01','2008-10-01','2015-03-20','2015-03-01','N',NULL,'N','2008-10-01','United States','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23210765','2013-09-01',NULL,NULL,NULL,'40',1,'Healthy and Renal Impairment',NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102008','2008-12-29','2014-01-08',NULL,2,'Monotherapy v placebo','T2DM Tx naive',389,NULL,NULL,NULL,'UK','NCT00263276','A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus','Type 2 Diabetes',NULL,'Drug: dapagliflozin|Drug: dapagliflozin|Drug: dapagliflozin|Drug: dapagliflozin|Drug: dapagliflozin|Drug: placebo|Drug: metformin','null','AstraZeneca','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','385','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','MB102-008','2005-12-07','2005-12-01','2007-02-01','2015-03-20','2015-03-01','N',NULL,'N','2007-02-01','United States,   Canada,   Mexico,   Puerto Rico','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19114612','2009-04-01',NULL,NULL,NULL,'389',2,'Type 2 Diabetes','United States, Canada, Mexico, Puerto Rico',NULL,'N','N','Y','Y','Y','Y','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102009','2009-06-15','2014-01-08',NULL,2,'Add-on to insulin','Insulin-dependent T2DM',71,NULL,NULL,NULL,'UK','NCT00357370','A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Placebo','null','AstraZeneca','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','67','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','MB102-009','2006-07-26','2006-10-01','2008-03-01','2015-03-20','2015-03-01','N',NULL,'N','2008-03-01','United States,   Canada','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19528367','2009-09-01',NULL,NULL,NULL,'75',3,'Type 2 Diabetes','United States, Canada  ',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','Y','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102010',NULL,'2014-01-08','MB_010',1,NULL,'Healthy, Japanese',32,'Japan',NULL,NULL,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21226818','2011-04-01',NULL,NULL,NULL,'32',1,'Type 2 diabetes','Japan',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102013','2010-06-21','2014-01-08','MB_013 / 2013',3,'Monotherapy v placebo','T2DM Tx naive',485,NULL,NULL,NULL,'UK','NCT00528372','A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Dapagliflozin placebo|Drug: Metformin','null','AstraZeneca|Bristol-Myers Squibb','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','1067','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','MB102-013 LT','2007-09-11','2007-09-01','2010-07-01','2015-09-30','2015-09-01','Y','2014-02-06','N','2009-02-01','United States,   Canada,   Mexico,   Russian Federation','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20566676','2010-10-01',NULL,NULL,NULL,'485',3,'Type 2 Diabetes','United States, Canada, Mexico, Russia',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Farxiga','MB102014',NULL,'2014-01-08','MB_014 /2014',3,'Add-on to metformin','T2DM on metformin',546,NULL,NULL,NULL,'UK','NCT00528879','A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Placebo|Drug: Metformin','null','AstraZeneca|Bristol-Myers Squibb','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','915','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','MB102-014 LT|MB102-014','2007-09-11','2007-09-01','2010-05-01','2015-09-30','2015-09-01','Y','2014-02-06','N','2008-11-01','United States,   Argentina,   Brazil,   Canada,   Mexico',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23425012, http://www.ncbi.nlm.nih.gov/pubmed/20609968','2010-06-26',NULL,NULL,NULL,'534',3,'Type 2 Diabetes','United States, Canada, Argentina, Mexico, Brazil',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Farxiga','MB102016',NULL,'2014-01-08',NULL,1,'Safety/PK ','Healthy',11,'Argentina',NULL,NULL,'UK','NCT00562250','Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects','Diabetes Mellitus, Type 2',NULL,'Drug: Dapagliflozin|Drug: Glimepiride|Drug: Dapagliflozin + Glimepiride','null','AstraZeneca','Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label','11','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label','MB102-016','2007-11-21','2008-05-01','2008-08-01','2015-03-20','2015-03-01','N',NULL,'N','2008-08-01','Argentina','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102017',NULL,'2014-01-08',NULL,1,'Interaction, pioglitazone','T2DM',24,NULL,NULL,NULL,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21114603','2011-01-01',NULL,NULL,NULL,'24',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'Y','Y','N','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102019',NULL,'2014-01-08','M_019',1,'Food effect','Healthy',14,NULL,NULL,NULL,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21435141','2011-08-01',NULL,NULL,NULL,'14',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102020',NULL,'2014-01-08',NULL,1,'Safety/PK ','T2DM',1,NULL,NULL,NULL,'UK','NCT00726505','Renal Mechanism of Action/Splay vs. TmG','Diabetes, NOS',NULL,'Drug: Dapagliflozin','MOA','AstraZeneca','Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label','1','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label','MB102-020','2008-07-30','2009-06-01','2009-08-01','2015-03-20','2015-03-01','N',NULL,'N','2009-08-01','United States','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','N','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102021','2012-03-13','2014-01-08','M_021 / 2021',3,NULL,'Baseline HbA1c 7.5 to 12 ',598,NULL,NULL,NULL,'UK','NCT00643851','An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Metformin XR','null','AstraZeneca','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','600','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','MB102-021','2008-03-20','2008-06-01','2009-08-01','2015-03-20','2015-03-01','N',NULL,'N','2009-08-01','United States,   Korea, Republic of,   Mexico,   Philippines,   Puerto Rico,   Russian Federation,   Ukraine','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22413962','2012-05-01',NULL,NULL,NULL,'591',3,'Type 2 Diabetes',NULL,NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','Y','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102025',NULL,'2014-01-08',NULL,1,NULL,'T2DM, Japanese',36,'Japan',NULL,NULL,'UK','NCT00538174','Phase I Multiple-Ascending Dose (Japan)','Diabetes Mellitus, Type 2',NULL,'Drug: Dapagliflozin|Drug: placebo','MAD','AstraZeneca','Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','36','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','MB102-025','2007-10-01','2007-11-01','2008-05-01','2015-03-20','2015-03-01','N',NULL,'N','2008-05-01','Japan','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21226818','2011-04-01',NULL,NULL,NULL,'36',1,'Type 2 diabetes','Japan',NULL,'N','N','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102026','2011-01-01','2014-01-08',NULL,1,'Interaction, metformin','T2DM',18,NULL,NULL,NULL,'UK','NCT00546741','Drug Interaction With Metformin','Diabetes',NULL,'Drug: Dapagliflozin|Drug: Metformin|Drug: Dapagliflozin + Metformin','null','AstraZeneca','Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label','18','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label','MB102-026','2007-10-18','2007-11-01','2008-02-01','2015-03-24','2015-03-01','N',NULL,'N','2008-02-01','United States','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21114603','2011-01-01','',NULL,NULL,'18',1,'Healthy',NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102027','2011-10-26','2014-01-08',NULL,1,'Safety/PK ','Hepatic impairment',24,NULL,NULL,NULL,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22030444','2011-11-01',NULL,NULL,NULL,'24',1,'Healthy and Hepatic Impairment','United States, Argentina, Poland',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102029','2013-09-25','2014-01-08','M_029',3,'Monotherapy v placebo','T2DM Moderate renal impairment',252,NULL,NULL,NULL,'UK','NCT00663260','Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment','Diabetes Mellitus, Type 2',NULL,'Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Placebo','null','AstraZeneca','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','202','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','MB102-029','2008-04-18','2008-06-01','2011-06-01','2015-03-20','2015-03-01','N',NULL,'N','2009-12-01','United States,   Argentina,   Australia,   Canada,   Denmark,   France,   India,   Italy,   Mexico,   Peru,   Puerto Rico,   Singapore,   Spain','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24067431','2014-04-01',NULL,NULL,NULL,'252',3,'Type 2 Diabetes','United States, Argentina, Canada, India, Mexico, Peru, Italy, Australia, France, Spain, Denmark, Puerto Rico, Singapore',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','Y','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102030','2012-03-23','2014-01-08','MB_030',3,'Add-on to TZD','T2DM on pioglitazone',420,NULL,NULL,NULL,'UK','NCT00683878','Add-on to Thiazolidinedione (TZD) Failures','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Placebo matching Dapagliflozin|Drug: Thiazolidinedione (Pioglitazone)','null','AstraZeneca','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','420','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','MB102-030','2008-05-22','2008-07-01','2010-06-01','2015-03-24','2015-03-01','N',NULL,'Y','2010-01-01','United States,   Argentina,   Canada,   India,   Mexico,   Peru,   Philippines,   Puerto Rico,   Taiwan','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22446170','2012-07-01',NULL,NULL,NULL,'480',3,'Type 2 Diabetes','Argentina, Canada, India, Mexico, Peru, Philippines, Taiwan, United States',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','Y','N','2011-06-21','Y','Y','Y','N','Y','Y','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102032','2012-07-24','2014-01-08','MB_032 /2032',3,'Low dose monotherapy v placebo','T2DM Tx naive',210,NULL,NULL,NULL,'UK','NCT00736879','Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes','Type 2 Diabetes Mellitus',NULL,'Drug: Dapagliflozin|Drug: Placebo','null','AstraZeneca|Bristol-Myers Squibb','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','497','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','MB102-032','2008-08-15','2008-09-01','2009-12-01','2015-09-23','2015-09-01','Y','2014-02-05','N','2009-12-01','United States,   Canada,   India,   Mexico,   Puerto Rico,   Russian Federation,   South Africa',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22776824, http://www.ncbi.nlm.nih.gov/pubmed/25381876','2012-10-01',NULL,NULL,NULL,'282',3,'Type 2 Diabetes','United States, Canada, Russia, India, South Africa, Puerto Rico',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Farxiga','MB102034','2012-03-13','2014-01-08','M_034 / 2034',3,'Combo with metformin XR','Baseline HbA1c 7.5 to 12 ',1093,NULL,NULL,NULL,'UK','NCT00859898','Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes','Type 2 Diabetes Mellitus',NULL,'Drug: Dapagliflozin|Drug: Metformin XR|Drug: Metformin XR|Drug: dapagliflozin matching Placebo|Drug: metformin HCl Modified Release matching Placebo','null','Bristol-Myers Squibb|AstraZeneca','Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','1093','Industry',3,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','MB102-034|Eudract #: 2008-007548-33','2009-03-10','2009-04-01','2010-05-01','2014-02-04','2014-02-01','Y','2014-02-04','N','2010-05-01','United States,   India,   Korea, Republic of,   Mexico,   Puerto Rico,   Russian Federation','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22413962','2012-05-01',NULL,NULL,NULL,'638',3,'Type 2 Diabetes',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Farxiga','MB102035','2013-06-05','2014-01-08',NULL,2,NULL,'T2DM on metformin',75,NULL,NULL,NULL,'UK','NCT00976495','Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes','Type 2 Diabetes Mellitus',NULL,'Drug: Dapagliflozin|Drug: Placebo|Drug: Hydrochlorothiazide','null','AstraZeneca','Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Caregiver)','75','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Caregiver)','MB102-035|EUDRACT #: 2009-010221-39','2009-09-11','2009-10-01','2010-11-01','2015-03-24','2015-03-01','N',NULL,'Y','2010-11-01','United States,   Canada,   Netherlands','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23668478','2013-09-01',NULL,NULL,NULL,'75',2,'Type 2 Diabetes','Canada, Netherlands, United States',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','Y','N','2012-03-24','Y','Y','Y','N','Y','Y','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102036','2012-01-19','2014-01-08',NULL,1,'Co-prescribed, valsartan and simvastatin','Healthy',24,NULL,NULL,NULL,'UK','NCT00839683','Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects','Type 2 Diabetes Mellitus',NULL,'Drug: simvastatin|Drug: Dapagliflozin|Drug: simvastatin|Drug: valsartan','null','AstraZeneca','Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label','24','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label','MB102-036','2009-02-05','2009-02-01','2009-03-01','2015-03-20','2015-03-01','N',NULL,'N','2009-03-01','United States','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22271159','2012-02-01',NULL,NULL,NULL,'24',1,'Healthy',NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102037',NULL,'2014-01-08',NULL,1,'Interaction, glimepiride and sitagliptin','T2DM',18,NULL,NULL,NULL,'UK','NCT00842556','Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects','Type 2 Diabetes Mellitus',NULL,'Drug: Dapagliflozin|Drug: Glimepiride|Drug: Sitagliptin','null','AstraZeneca','Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label','18','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label','MB102-037','2009-02-11','2009-03-01','2009-05-01','2015-03-20','2015-03-01','N',NULL,'N','2009-05-01','United States','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21114603','2011-01-01',NULL,NULL,NULL,'18',1,'Healthy',NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102045','2013-11-15','2014-01-08',NULL,2,NULL,NULL,44,NULL,NULL,NULL,'UK','NCT00831779','Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes','Type 2 Diabetes Mellitus',NULL,'Drug: Dapagliflozin|Drug: Placebo','null','AstraZeneca','Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','44','Industry',2,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','MB102-045','2009-01-28','2009-04-01','2010-08-01','2015-03-20','2015-03-01','N',NULL,'Y','2010-08-01','United States','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24237386','2014-03-01',NULL,NULL,NULL,'44',2,'Type 2 Diabetes',NULL,NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','Y','N','2012-03-24','Y','Y','Y','N','Y','Y','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102049',NULL,'2014-01-08',NULL,1,NULL,'pax w T2DM',NULL,NULL,NULL,NULL,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Observational',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102054','2013-12-28','2014-01-08',NULL,3,NULL,'Asian drug-naive',393,NULL,NULL,NULL,'UK','NCT01095653','A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Metformin|Drug: Dapagliflozin Placebo','null','AstraZeneca','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','393','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','MB102-054','2010-03-26','2010-06-01','2012-03-01','2015-03-20','2015-03-01','N',NULL,'N','2012-03-01','China,   India,   Korea, Republic of,   Taiwan','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24378206','2014-01-01',NULL,NULL,NULL,'378',3,'Type 2 Diabetes','China, Korea, Taiwan, India',NULL,'N','N','Y','Y','Y','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102055',NULL,'2014-01-08',NULL,3,'dapa as add-on therapy to metformin','Asian patients',444,NULL,NULL,NULL,'UK','NCT01095666','A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Metformin|Drug: Dapagliflozin Placebo|Drug: Pioglitazone','null','AstraZeneca','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','445','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','MB102-055','2010-03-26','2010-06-01','2013-03-01','2015-03-20','2015-03-01','N',NULL,'N','2013-03-01',NULL,'N',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26589253',NULL,NULL,NULL,NULL,'444',3,'Type 2 Diabetes','China, South Korea',NULL,'N','N','Y','Y','Y','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102057',NULL,'2014-01-08',NULL,1,'Co-prescribed, bumetanide','Healthy',42,NULL,NULL,NULL,'UK','NCT00930865','Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects','Type 2 Diabetes Mellitus',NULL,'Drug: Bumetanide|Drug: Dapagliflozin','null','AstraZeneca','Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','42','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','MB102-057','2009-06-30','2009-07-01','2009-09-01','2015-03-20','2015-03-01','N',NULL,'N','2009-09-01','United States','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102058','2012-01-19','2014-01-08',NULL,1,'Co-prescribed, dioxin and warfarin','Healthy',30,NULL,NULL,NULL,'UK','NCT00904176','Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects','Type 2 Diabetes Mellitus',NULL,'Drug: Dapagliflozin|Drug: Warfarin|Drug: Digoxin','null','AstraZeneca','Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label','30','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label','MB102-058','2009-05-18','2009-06-01','2009-08-01','2015-03-20','2015-03-01','N',NULL,'N','2009-08-01',NULL,'N',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/22271159','2012-02-01',NULL,NULL,NULL,'30',1,'Healthy',NULL,NULL,'N','N','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102059',NULL,'2014-01-08',NULL,1,'Absolute Oral Bioavailability','Healthy',7,NULL,NULL,NULL,'UK','NCT00908271','Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects','Type 2 Diabetes Mellitus',NULL,'Drug: Dapagliflozin','null','AstraZeneca','Endpoint Classification: Bio-availability Study|Intervention Model: Single Group Assignment|Masking: Open Label','7','Industry',1,'Endpoint Classification: Bio-availability Study|Intervention Model: Single Group Assignment|Masking: Open Label','MB102-059','2009-05-22','2009-07-01','2009-08-01','2015-03-20','2015-03-01','N',NULL,'N','2009-08-01','United States','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22823746','2013-03-01',NULL,NULL,NULL,'7',1,'Healthy','United States',NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102062',NULL,'2014-01-08',NULL,1,'Bioequivalence in tables','Healthy',29,NULL,NULL,NULL,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102066','2013-06-04','2014-01-08',NULL,1,'Safety/PK ','Healthy and T2DM',20,NULL,NULL,NULL,'UK','NCT01165268','Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)','Type 2 Diabetes Mellitus',NULL,'Drug: Dapagliflozin','null','AstraZeneca','Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label','65','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label','MB102-066','2010-07-16','2010-08-01','2010-12-01','2015-03-20','2015-03-01','N',NULL,'N','2010-12-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23735727','2013-10-01',NULL,NULL,NULL,'24',1,'Healthy and Type 2 Diabetes',NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102072','2014-09-30','2014-01-08',NULL,2,NULL,'T1DM',70,NULL,NULL,NULL,'UK','NCT01498185','BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes','Type 1 Diabetes Mellitus',NULL,'Drug: Dapagliflozin|Drug: Placebo matching Dapagliflozin','null','AstraZeneca','Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','70','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','MB102-072','2011-12-21','2012-02-01','2012-10-01','2015-03-20','2015-03-01','N',NULL,'N','2012-10-01','United States','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25271207','2015-03-01',NULL,NULL,NULL,'62',2,'Type 1 Diabetes','United States',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','Y','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','Y','Y','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102073',NULL,'2014-01-08','M_073',3,NULL,'Hypertension on OAD and/or insulin',613,NULL,NULL,NULL,'UK','NCT01137474','A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Placebo-matching dapagliflozin|Drug: Oral antidiabetic agent|Drug: Angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB)|Drug: With or without insulin','null','Bristol-Myers Squibb|AstraZeneca','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','2996','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','MB102-073 ST|2010-019797-32','2010-06-03','2010-07-01','2013-02-01','2014-04-01','2014-04-01','Y','2014-02-07','N','2013-02-01','United States,   Canada,   Colombia,   Czech Republic,   Denmark,   Finland,   Germany,   Hungary,   India,   Mexico,   Peru,   Poland,   Puerto Rico,   Romania,   Russian Federation,   Spain','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','Y','Y','Y','Y','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','Y','Y','Y',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Farxiga','MB102074','2012-11-19','2014-01-08',NULL,1,'Inducer, rifampin','Healthy',14,NULL,NULL,NULL,'UK','NCT01068756','Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects','Type 2 Diabetes Mellitus',NULL,'Drug: Dapagliflozin|Drug: Rifampin','null','AstraZeneca','Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label','14','Industry',1,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label','MB102-074','2010-02-12','2010-03-01','2010-04-01','2015-03-20','2015-03-01','N',NULL,'N','2010-04-01','United States','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23061428','2013-03-01',NULL,NULL,NULL,'14',1,'Healthy',NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102077',NULL,'2014-01-08','M_077',3,NULL,'Hypertension on OAD and/or insulin',449,NULL,NULL,NULL,'UK','NCT01195662','A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Placebo matching Dapagliflozin','null','AstraZeneca|Bristol-Myers Squibb','Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','2245','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','MB102-077 ST|2010-019798-13','2010-09-03','2010-10-01','2013-02-01','2015-12-02','2015-12-01','Y','2014-02-07','N','2013-02-01','United States,   Australia,   Canada,   Colombia,   Czech Republic,   Denmark,   Finland,   Germany,   Hungary,   India,   Ireland,   Mexico,   Poland,   Puerto Rico,   Romania,   United Kingdom','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26620248',NULL,NULL,NULL,NULL,'1213',3,'Type 2 Diabetes','Australia, Canada, Colombia, Czech Republic, Denmark, Finland, germany, Hungary, India, Ireland, Mexico, Poland, Puerto Rico, Romania, United Kingdom, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Farxiga','MB102088','2013-07-11','2014-01-08',NULL,1,'Safety/PK ','Healthy',35,NULL,NULL,NULL,'UK','NCT01135446','Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects','Type 2 Diabetes',NULL,'Drug: dapagliflozin|Drug: dapagliflozin|Drug: dapagliflozin|Drug: dapagliflozin|Drug: dapagliflozin|Drug: dapagliflozin','ULDS','AstraZeneca','Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label','35','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label','MB102-088','2010-05-27','2010-05-01','2010-06-01','2015-03-20','2015-03-01','N',NULL,'N','2010-06-01','United States','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23851069','2013-10-01',NULL,NULL,NULL,'36',1,'Healthy',NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102090',NULL,'2014-01-08',NULL,1,'Bioequivalence and food effect in tablets','Healthy',28,NULL,NULL,NULL,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102091',NULL,'2014-01-08','ongoing',1,NULL,'pediatric w T2DM',4,NULL,NULL,NULL,'UK','NCT01525238','PK Study of Dapagliflozin in Pediatric Subjects With T2DM','Type 2 Diabetes Mellitus',NULL,'Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Dapagliflozin','null','Bristol-Myers Squibb|AstraZeneca','Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label','24','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label','MB102-091|2011-005225-40','2012-01-31','2012-07-01','2014-09-01','2015-02-06','2014-11-01','N',NULL,'N','2014-09-01','United States,   Mexico',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Farxiga','MB102093','2012-11-19','2014-01-08',NULL,1,'Mefenamic acid','Healthy',16,NULL,NULL,NULL,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23061428','2013-03-01',NULL,NULL,NULL,'16',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Farxiga','MB102104',NULL,'2014-01-08',NULL,1,'risk of hepatic and renal failure','pax w T2DM',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Observational',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0',NULL,'N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Farydak','CLBH589A2101','2015-05-05','2015-02-23','A2114',1,'','relapsed multiple myeloma',15,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'15',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25939707','2015-06-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589A2102','2015-05-05','2015-02-23','B2107',1,'','chronic myeloid leukemia in accerlerated or blast phase',76,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'76',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25939707','2015-06-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589B1101','2011-04-12','2015-02-23','D2301; PARAGON',1,'','relapsed multiple myeloma',26,NULL,NULL,NULL,NULL,'NCT00412997','LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma','Tumors|Cutaneous T-Cell Lymphoma',NULL,NULL,NULL,'Novartis','Interventional','26',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2006-12-18','2006-11-01',NULL,NULL,NULL,'',NULL,'N','2008-05-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21484248','2012-06-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589B1201','2015-05-05','2015-02-23','B2317',2,'','adult pax w advanced solid tumors, Hodgkin\'s lymphoma, or non-Hodgkin\'s lymphoma',4,NULL,NULL,NULL,NULL,'NCT00699296','Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma','Cutaneous T-Cell Lymphoma|Leukemia-Lymphoma, Adult T-Cell',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','4',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2008-06-13','2008-05-01',NULL,NULL,NULL,'',NULL,'N','2008-12-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25939707','2015-06-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589B2007',NULL,'2015-02-23','A2103',1,'','relapsed chronic myeloid leukemia',47,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'47',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589B2101','2015-05-05','2015-02-23','A2216',1,'','adult pax w advanced hematologic malignancies',95,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'95',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25939707','2015-06-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589B2102','2013-02-06','2015-02-23','A2318',1,'','Japanese adult pax w advanced solid tumors or Cutaneous T-cell lymphoma',308,NULL,NULL,NULL,NULL,'NCT00621244','A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies','Lymphoma|Leukemia|Multiple Myeloma',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','308',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2008-02-12','2006-03-01',NULL,NULL,NULL,'',NULL,'5/1/12','2009-08-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23385375','2013-08-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,'2012-05-01','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589B2105',NULL,'2015-02-23','E2214',1,'','pax w advanced solid tumors',16,NULL,NULL,NULL,NULL,'NCT00493766','Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone','Hormone Refractory Prostate Cancer',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','16',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-06-26','2006-05-01',NULL,NULL,NULL,'',NULL,'N','2008-07-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589B2108',NULL,'2015-02-23','A2224',1,'','cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma',4,NULL,NULL,NULL,NULL,'NCT00472368','A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589','Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','4',NULL,NULL,'Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-05-10','2007-05-01',NULL,NULL,NULL,'',NULL,'N','2008-06-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589B2109','2013-09-08','2015-02-23','A2109',1,'','adult pax w advanced solid tumors or non-Hodgkin\'s lymphoma',18,NULL,NULL,NULL,NULL,'NCT00535951','Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma','Carcinoma, Non-Small-Cell Lung|Mesothelioma',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','18',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-09-26','2007-11-01',NULL,NULL,NULL,'',NULL,'N','2009-01-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24013574','2013-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589B2110','2011-06-26','2015-02-23','D2308',1,'','adult pax w hematological malignancies',14,NULL,NULL,NULL,NULL,'NCT00503451','A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors','Non-Hodgkin Lymphoma|Neoplasms',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','14',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-07-17','2007-09-01',NULL,NULL,NULL,'',NULL,'N','2010-04-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21706316','2011-09-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589B2111','2011-11-06','2015-02-23','B2207',1,'','advanced cancer patients',36,NULL,NULL,NULL,NULL,'NCT00570284','A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors','Cancer',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','36',NULL,NULL,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-12-07','2007-11-01',NULL,NULL,NULL,'',NULL,'N','2011-02-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22057852','2012-02-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589B2201','2012-09-13','2015-02-23','A2124',2,'','relapsed and bortezzomib-refractory multiple myeloma',139,NULL,NULL,NULL,NULL,'NCT00425555','Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma','Cutaneous T-Cell Lymphoma',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','139',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-01-22','2007-01-01',NULL,NULL,NULL,'',NULL,'N','2013-06-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22981498','2013-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589B2202','2015-05-05','2015-02-23','B2109',2,'','adult pax w relapsed/refractory multiple myeloma who have received at least two prior lines of therapy',29,NULL,NULL,NULL,NULL,'NCT00451035','Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase','Chronic Myeloid Leukemia in Chronic Phase',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','29',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-03-20','2007-01-01',NULL,NULL,NULL,'',NULL,'N','2008-09-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25939707','2015-06-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589B2203','2012-03-01','2015-02-23','B2113',2,'','relapsed multiple myeloma',38,NULL,NULL,NULL,NULL,'NCT00445068','Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma','Multiple Myeloma',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','38',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-03-07','2007-04-01',NULL,NULL,NULL,'',NULL,'N','2009-12-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22288662','2012-09-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589B2206',NULL,'2015-02-23','A2126',1,'','chronic myeloid leukemia in accelerated or blast phase',46,NULL,NULL,NULL,NULL,'NCT00532675','Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.','Multiple Myeloma',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','46',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-09-18','2008-04-01',NULL,NULL,NULL,'',NULL,'N','2016-12-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589B2207',NULL,'2015-02-23','A2119',1,'','pax w essential hypertension',62,NULL,NULL,NULL,NULL,'NCT00532389','Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma','Multiple Myeloma',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','62',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-09-18','2007-10-01',NULL,NULL,NULL,'',NULL,'N','2013-10-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589B2211','2015-05-05','2015-02-23','B2123',2,'','refractory cutaneous T-cell lymphoma',29,NULL,NULL,NULL,NULL,'NCT00449761','Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)','Leukemia, Myeloid, Chronic',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','29',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-03-20','2007-02-01',NULL,NULL,NULL,'',NULL,'N','2008-08-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25939707','2015-06-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589D2308','2014-09-18','2015-02-23','B2122',3,'','pax w essential hypertension',768,NULL,NULL,NULL,NULL,'NCT01023308','Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma','Multiple Myeloma',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','768',NULL,NULL,'Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2009-11-30','2009-12-01',NULL,NULL,NULL,'','2015-03-23','N','2013-03-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25242045','2014-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589DUS71','2013-08-15','2015-02-23','A2120',2,'',NULL,55,NULL,NULL,NULL,NULL,'NCT01083602','Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma','Relapsed and Bortezomib Refractory Multiple Myeloma|Refractory Multiple Myeloma|Multiple Myeloma in Relapse',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','55',NULL,NULL,'Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-03-08','2010-06-01',NULL,NULL,NULL,'','2015-02-23','N','2014-02-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23950178','2013-10-03',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589E2214','2012-04-30','2015-02-23','B2125',2,'','pax had received at least one prior treatment for mutliple myeloma',129,NULL,NULL,NULL,NULL,'NCT00742027','Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkin\'s Lymphoma','Classical Hodgkin\'s Lymphoma (i.e. Nodular Sclerosing, Mixed-cellularity, Lymphocyte-rich, Lymphocyte-depleted)',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','129',NULL,NULL,'Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2008-08-25','2008-09-01',NULL,NULL,NULL,'',NULL,'N','2013-08-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22547596','2012-06-20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589X2101','2014-09-25','2015-02-23','DUS71',1,'','pax w advanced solid tumors',25,NULL,NULL,NULL,NULL,'NCT01007968','Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function','Advanced Solid Tumors',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','25',NULL,NULL,'Intervention Model: Single Group Assignment|Masking: Open Label',NULL,'2009-10-28','2010-03-01',NULL,NULL,NULL,'',NULL,'N','2012-11-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25253045','2014-11-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Farydak','CLBH589X2105','2014-11-07','2015-02-23','B2203',1,'','pax w advanced solid tumors',37,NULL,NULL,NULL,NULL,'NCT00997399','Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function','Advanced Solid Tumors',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','37',NULL,NULL,'Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label',NULL,'2009-10-15','2010-03-01',NULL,NULL,NULL,'',NULL,'N','2014-06-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25377157','2015-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','FTCB-101',NULL,'2015-11-05',NULL,1,'','healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-99-903',NULL,'2015-11-05','B2201',3,'','pax w advanced solid tumors and various degrees of hepatic funtion',180,NULL,NULL,NULL,NULL,'NCT00158821','Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.','HIV Infections',NULL,NULL,NULL,'Gilead Sciences','Interventional','180',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2005-09-07','2000-03-01',NULL,NULL,NULL,'',NULL,'N','2001-12-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/18042503','2007-11-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-104-0321',NULL,'2015-11-05','B2202',3,'','pax w advanced solid tumors and various degrees of renal funtion',87,NULL,NULL,NULL,NULL,'NCT00352053','Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy','HIV Infections',NULL,NULL,NULL,'Gilead Sciences','Interventional','87',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2006-07-13','2006-06-01',NULL,NULL,NULL,'','2010-03-05','N','2008-09-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25599284','2015-04-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-120-0104',NULL,'2015-11-05','B2206',1,'','renal impairment trial',40,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'40',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23807155','2013-08-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-120-0108',NULL,'2015-11-05','B2211',NULL,'','Tx-na?ve adults',27,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'27',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/27216057','2016-05-23',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-120-0109',NULL,'2015-11-05','B2007',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-120-0114',NULL,'2015-11-05','A2101',NULL,'','PK and antiviral activity (Viread?)',40,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'40',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-183-0128',NULL,'2015-11-05','A2102',NULL,'','HIV-/HBV- with severe renal impairment',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-216-0105',NULL,'2015-11-05','B1101',2,'','healthy',85,NULL,NULL,NULL,NULL,'NCT00892437','Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults','HIV-1 Infection',NULL,NULL,NULL,'Gilead Sciences','Interventional','85',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)',NULL,'2009-04-30','2009-05-01',NULL,NULL,NULL,'','2014-10-23','8/23/11','2009-12-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/21811136','2011-09-24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'Y',NULL,'2011-08-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-216-0107',NULL,'2015-11-05','B1201',NULL,'','mild/mod hepatic impariment v. healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-216-0113',NULL,'2015-11-05','B2101',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-216-0114','2013-03-26','2015-11-05','B2102',3,'',NULL,698,NULL,NULL,NULL,NULL,'NCT01108510','Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults','HIV|HIV Infections',NULL,NULL,NULL,'Gilead Sciences','Interventional','698',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)',NULL,'2010-04-20','2010-04-01',NULL,NULL,NULL,'','2014-10-23','8/23/11','2011-11-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23532097','2013-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'Y',NULL,'2011-08-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-216-0137',NULL,'2015-11-05','B2108',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-236-0102',NULL,'2015-11-05','B2109',3,'',NULL,707,NULL,NULL,NULL,NULL,'NCT01095796','Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults','HIV|HIV Infections',NULL,NULL,NULL,'Gilead Sciences','Interventional','707',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2010-03-17','2010-03-01',NULL,NULL,NULL,'','2012-09-20','8/23/11','2011-08-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22748591','2012-06-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'Y',NULL,'2011-08-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-236-0103',NULL,'2015-11-05','B2110',3,'',NULL,708,NULL,NULL,NULL,NULL,'NCT01106586','Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults','HIV|HIV Infections',NULL,NULL,NULL,'Gilead Sciences','Interventional','708',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2010-04-14','2010-04-01',NULL,NULL,NULL,'','2012-09-20','8/23/11','2011-09-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22748590','2012-06-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'Y',NULL,'2011-08-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-236-0104',NULL,'2015-11-05','B2111',2,'','healthy adults',71,NULL,NULL,NULL,NULL,'NCT00869557','Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults','HIV|HIV Infections',NULL,NULL,NULL,'Gilead Sciences','Interventional','71',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2009-03-24','2009-04-01',NULL,NULL,NULL,'','2012-09-20','8/23/11','2009-11-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'Y',NULL,'2011-08-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-236-0112',NULL,'2015-11-05','X2101',3,'',NULL,50,NULL,NULL,NULL,NULL,'NCT01721109','Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents','Acquired Immunodeficiency Syndrome|HIV Infections',NULL,NULL,NULL,'Gilead Sciences','Interventional','50',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-11-01','2012-12-01',NULL,NULL,NULL,'',NULL,'N','2015-10-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-236-0114',NULL,'2015-11-05','X2105',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-236-0118',NULL,'2015-11-05','B2105',3,'',NULL,106,NULL,NULL,NULL,NULL,'NCT01363011','Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment','Acquired Immunodeficiency Syndrome|HIV Infections',NULL,NULL,NULL,'Gilead Sciences','Interventional','106',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-05-11','2011-05-01',NULL,NULL,NULL,'','2014-10-27','1/10/14','2013-01-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'Y',NULL,'2014-01-10','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-264-0110',NULL,'2015-11-05',NULL,3,'','renal impairment',799,NULL,NULL,NULL,NULL,'NCT01309243','Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults','HIV-1 Infection',NULL,NULL,NULL,'Gilead Sciences','Interventional','799',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-03-03','2011-02-01',NULL,NULL,NULL,'','2013-09-25','N','2012-09-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26684822','2016-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-292-0102',NULL,'2015-11-05',NULL,2,'',NULL,279,NULL,NULL,NULL,NULL,'NCT01497899','Safety and Efficacy of E/C/F/TAF (Genvoya??) Versus E/C/F/TDF (Stribild??) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults','Acquired Immunodeficiency Syndrome|HIV Infections',NULL,NULL,NULL,'Gilead Sciences','Interventional','279',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2011-12-14','2011-12-01',NULL,NULL,NULL,'','2015-12-04','10/21/13','2012-10-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24872136','2014-09-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'Y',NULL,'2013-10-21','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-292-0103',NULL,'2015-11-05',NULL,1,'',NULL,34,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'34',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-292-0104','2015-04-15','2015-11-05',NULL,3,'',NULL,867,NULL,NULL,NULL,NULL,'NCT01780506','Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya??) Versus E/C/F/TDF (Stribild??) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults','HIV|HIV Infections',NULL,NULL,NULL,'Gilead Sciences','Interventional','867',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-01-16','2012-12-01',NULL,NULL,NULL,'','2015-12-04','6/24/14','2014-08-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25890673','2015-06-27',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'Y',NULL,'2014-06-24','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-292-0106',NULL,'2015-11-05',NULL,3,'','Tx-na?ve adults',73,NULL,NULL,NULL,NULL,'NCT01854775','Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children','Acquired Immune Deficiency Syndrome (AIDS)|HIV Infections',NULL,NULL,NULL,'Gilead Sciences','Interventional','73',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-05-03','2013-05-01',NULL,NULL,NULL,'',NULL,'N','2016-04-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-292-0108',NULL,'2015-11-05',NULL,1,'','healthy volunteers',20,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-292-0109','2015-11-02','2015-11-05',NULL,3,'','Tx-na?ve adults',1443,NULL,NULL,NULL,NULL,'NCT01815736','Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants','HIV|HIV Infections',NULL,NULL,NULL,'Gilead Sciences','Interventional','1443',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-03-19','2013-03-01',NULL,NULL,NULL,'','2016-03-15','10/30/14','2015-03-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26538525','2016-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'Y',NULL,'2014-10-30','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-292-0110',NULL,'2015-11-05',NULL,1,'','adolescents',43,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'43',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-292-0111','2015-04-15','2015-11-05',NULL,3,'','Healthy Japanese and Caucasian ',866,NULL,NULL,NULL,NULL,'NCT01797445','Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya??) Versus E/C/F/TDF (Stribild??) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults','HIV|HIV Infections',NULL,NULL,NULL,'Gilead Sciences','Interventional','866',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-02-20','2013-01-01',NULL,NULL,NULL,'','2015-12-04','7/28/15','2014-09-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25890673','2015-06-27',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'Y',NULL,'2015-07-28','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-292-0112',NULL,'2015-11-05',NULL,3,'','vir suppressed adults',252,NULL,NULL,NULL,NULL,'NCT01818596','Open-label Safety Study of E/C/F/TAF (Genvoya??) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment','HIV|HIV Infections',NULL,NULL,NULL,'Gilead Sciences','Interventional','252',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-03-22','2013-04-01',NULL,NULL,NULL,'','2015-12-04','9/16/14','2014-07-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26627107','2016-04-15',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'Y',NULL,'2014-09-16','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-292-1249',NULL,'2015-11-05',NULL,3,'','healthy',79,NULL,NULL,NULL,NULL,'NCT02071082','Efficacy and Safety of E/C/F/TAF (Genvoya??) in HIV-1/Hepatitis B Co-infected Adults','HIV|HBV',NULL,NULL,NULL,'Gilead Sciences','Interventional','79',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2014-02-21','2014-03-01',NULL,NULL,NULL,'','2016-01-21','N','2015-01-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-292-1316',NULL,'2015-11-05',NULL,NULL,'','Tx-na?ve adults',20,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-299-0102',NULL,'2015-11-05',NULL,2,'','HIV+ adults with mild/mod renal impairment',153,NULL,NULL,NULL,NULL,'NCT01565850','D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults','Acquired Immunodeficiency Syndrome|HIV Infections',NULL,NULL,NULL,'Gilead Sciences','Interventional','153',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2012-03-27','2012-04-01',NULL,NULL,NULL,'','2016-03-11','11/25/13','2013-01-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25867913','2015-08-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'Y',NULL,'2013-11-25','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,NULL,NULL),('Genvoya','GS-US-311-0101',NULL,'2015-11-05',NULL,NULL,'','HBV and HIV',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Gilead Sciences Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Harvoni','BP-US-337-1115',NULL,'2014-10-10',NULL,1,'Bioavailability',NULL,NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','CO-US-337-0116',NULL,'2014-10-10','ERADICATE, Study IND 117444',2,NULL,NULL,NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','CO-US-337-0117',NULL,'2014-10-10','SYNERGY, Study IND 116585',2,NULL,NULL,NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','CO-US-337-1116',NULL,'2014-10-10',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-169-015',NULL,'2014-10-10',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-248-0102',NULL,'2014-10-10',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-248-0104',NULL,'2014-10-10',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-248-0117',NULL,'2014-10-10',NULL,1,NULL,'Hepatic impairment',NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-248-0120',NULL,'2014-10-10',NULL,2,'SVR12 rate','HCV-Infected',46,NULL,NULL,NULL,'United States','NCT01353248','GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection','Hepatitis C, Chronic',NULL,'Drug: GS-5885|Drug: Tegobuvir|Drug: GS-9451|Drug: ribavirin tablet|Drug: GS-5885','null','Gilead Sciences','Interventional','141','Industry',2,'Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-248-0120','2011-04-22','2011-05-01','2013-03-01','2013-11-26','2013-11-01','N',NULL,'Y','2012-10-01','United States,   Puerto Rico',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24501005','2014-07-01',NULL,NULL,NULL,'140',2,'Genotype 1 HCV','United States, France, Germany',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N','2013-11-26','Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-248-0121',NULL,'2014-10-10',NULL,2,'SVR12 rate','HCV-Infected',94,NULL,NULL,NULL,'United States','NCT01384383','GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Nave Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype','Chronic Hepatitis C',NULL,'Drug: GS-5885|Drug: GS-9451|Drug: RBV|Drug: PEG','null','Gilead Sciences','Interventional','248','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-248-0121','2011-06-22','2011-08-01','2013-06-01','2014-01-02','2014-01-01','N',NULL,'Y','2013-06-01','United States,   Australia,   Canada,   New Zealand',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N','2013-11-26','Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-248-0122',NULL,'2014-10-10',NULL,4,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01457755','Gilead Sustained Virologic Response (SVR) Registry','Hepatitis C, Chronic',NULL,'0','null','Gilead Sciences','Observational','7000','Industry',NULL,'Observational Model: Cohort|Time Perspective: Prospective','GS-US-248-0122|2011-000945-19','2011-10-04','2012-04-01','2019-07-01','2016-01-21','2016-01-01','N',NULL,'N','2019-07-01','United States,   Australia,   Austria,   Belgium,   Canada,   Czech Republic,   Estonia,   France,   Germany,   Italy,   Netherlands,   New Zealand,   Poland,   Puerto Rico,   Spain,   Sweden,   United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','N',NULL,'N','N','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-248-0123',NULL,'2014-10-10',NULL,4,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01457768','A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response','Hepatitis C, Chronic',NULL,'0','null','Gilead Sciences','Observational','650','Industry',NULL,'Observational Model: Cohort|Time Perspective: Prospective','GS-US-248-0123|2011-000946-39','2011-10-04','2011-12-01','2019-07-01','2016-01-21','2016-01-01','N',NULL,'N','2019-07-01','United States,   Australia,   Austria,   Canada,   Czech Republic,   Estonia,   France,   Germany,   Italy,   Netherlands,   New Zealand,   Poland,   Puerto Rico,   Spain,   Sweden,   United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','N',NULL,'N','N','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-248-0124',NULL,'2014-10-10',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-248-0125',NULL,'2014-10-10',NULL,1,NULL,'Healthy',NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-248-0131',NULL,'2014-10-10',NULL,2,'SVR12 rate','HCV-Infected',169,NULL,NULL,NULL,'United States','NCT01435226','GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection','Hepatitis C, Chronic',NULL,'Drug: GS-5885|Drug: GS-9451|Drug: tegobuvir|Drug: placebo to match tegobuvir|Drug: placebo to match RBV|Drug: Ribavirin','null','Gilead Sciences','Interventional','170','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','GS-US-248-0131','2011-09-13','2011-09-01','2013-07-01','2013-11-22','2013-11-01','N',NULL,'Y','2013-01-01','United States,   Germany',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N','2013-11-22','Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-248-0132',NULL,'2014-10-10',NULL,2,'SVR12 rate','HCV-Infected',160,NULL,NULL,NULL,'United States','NCT01434498','GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection','Chronic Genotype 1a or 1b HCV Infection',NULL,'Drug: GS-5885 tablet|Drug: GS-9451 tablet|Drug: tegobuvir capsule|Drug: ribavirin tablet|Drug: placebo matching ribavirin tablet|Device: placebo matching tegobuvir capsule','null','Gilead Sciences','Interventional','163','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','GS-US-248-0132','2011-09-09','2011-09-01','2013-01-01','2013-11-26','2013-11-01','N',NULL,'Y','2013-01-01','United States,   Canada,   Puerto Rico',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N','2013-11-26','Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-256-0101',NULL,'2014-10-10',NULL,1,NULL,'Fasted Healthy',61,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-256-0102',NULL,'2014-10-10',NULL,1,NULL,'HCV-Infected',72,NULL,NULL,NULL,'United States','NCT01193478','A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C','HCV Infection',NULL,'Drug: GS-5885|Drug: Placebo|Drug: GS-5885|Drug: Placebo|Drug: GS-5885|Drug: Placebo|Drug: GS-5885|Drug: Placebo|Drug: GS-5885|Drug: Placebo|Drug: GS-5885|Drug: Placebo','null','Gilead Sciences','Interventional','71','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','GS-US-256-0102','2010-08-31','2010-08-01','2011-12-01','2013-01-18','2013-01-01','N',NULL,'N','2011-01-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22314425','2012-07-01',NULL,NULL,NULL,'72',1,'Genotype 1 HCV','United States',NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-256-0108',NULL,'2014-10-10','Leslie',1,NULL,'Healthy',8,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-256-0110',NULL,'2014-10-10',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-256-0124',NULL,'2014-10-10',NULL,2,'SVR12 rate','HCV-Infected',163,NULL,NULL,NULL,'United States','NCT01371578','Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection','Hepatitis C, Chronic',NULL,'Drug: GS-5885 tablet|Drug: GS-9451 tablet|Biological: peginterferon alfa-2a|Drug: ribavirin tablet','null','Gilead Sciences','Interventional','163','Industry',2,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-256-0124','2011-06-09','2011-07-01','2013-03-01','2014-01-14','2014-01-01','N',NULL,'Y','2013-03-01','United States,   Puerto Rico',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N','2014-01-14','Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-256-0129',NULL,'2014-10-10','Leslie',1,NULL,NULL,NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-256-0148',NULL,'2014-10-10',NULL,2,'SVR12 rate','HCV-Infected',348,NULL,NULL,NULL,'United States','NCT01356160','GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus','Hepatitis C, Chronic',NULL,'Drug: GS-5885|Drug: GS-9451|Biological: peginterferon alfa-2a|Drug: ribavirin tablet|Drug: GS-9451 Placebo','null','Gilead Sciences','Interventional','351','Industry',2,'Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','GS-US-256-0148','2011-05-02','2011-07-01','2013-06-01','2014-01-02','2014-01-01','N',NULL,'Y','2013-06-01','United States,   Australia,   Puerto Rico',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N','2013-11-26','Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-334-0101',NULL,'2014-10-10','Leslie',1,NULL,'Healthy',17,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-334-0107',NULL,'2014-10-10','POSITRON',3,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01542788','Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon','Chronic Hepatitis C',NULL,'Drug: SOF|Drug: RBV|Drug: Placebo to match SOF|Drug: Placebo to match RBV','POSITRON','Gilead Sciences','Interventional','278','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','GS-US-334-0107','2012-02-17','2012-03-01','2013-02-01','2014-05-08','2014-05-01','Y','2014-01-06','N','2012-11-01','United States,   Australia,   Canada,   New Zealand,   Puerto Rico',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23607593','2013-05-16',NULL,NULL,NULL,'280',3,'Genotype 2 or 3 HCV','United States, Canada, Australia, New Zealand',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Harvoni','GS-US-334-0108',NULL,'2014-10-10','FUSION',3,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01604850','Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)','Chronic Hepatitis C',NULL,'Drug: SOF|Drug: RBV|Drug: Placebo to match SOF|Drug: Placebo to match RBV','FUSION','Gilead Sciences','Interventional','202','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','GS-US-334-0108','2012-05-21','2012-06-01','2013-05-01','2014-05-09','2014-05-01','Y','2014-03-31','N','2013-02-01','United States,   Canada,   New Zealand,   Puerto Rico',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23607593','2013-05-16',NULL,NULL,NULL,'202',3,'Genotype 2 or 3 HCV','United States, Canada, New Zealand',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Harvoni','GS-US-334-0110',NULL,'2014-10-10','NEUTRINO',3,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01641640','Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection','Chronic Hepatitis C',NULL,'Drug: Sofosbuvir|Drug: RBV|Drug: PEG','NEUTRINO','Gilead Sciences','Interventional','328','Industry',3,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-334-0110','2012-07-09','2012-06-01','2013-04-01','2014-04-08','2014-04-01','Y','2014-02-25','N','2013-01-01','United States,   Puerto Rico',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23607594','2013-05-16',NULL,NULL,NULL,'327',2,'Genotype 1, 4, 5, or 6 HCV','United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Harvoni','GS-US-334-0111',NULL,'2014-10-10',NULL,1,NULL,'Healthy',64,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-334-0124',NULL,'2014-10-10',NULL,3,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01783678','A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults','Chronic Hepatitis C|Human Immunodeficiency Virus',NULL,'Drug: Sofosbuvir|Drug: RBV','null','Gilead Sciences','Interventional','275','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-334-0124','2013-01-31','2013-01-01','2014-07-01','2015-04-15','2015-04-01','Y','2015-04-15','N','2014-04-01','Australia,   France,   Germany,   Italy,   Spain,   United Kingdom',NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25659285','2015-03-21',NULL,NULL,NULL,'275',3,'HCV and HIV','Europe and Australia',NULL,'N','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-334-0126',NULL,'2014-10-10',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01687270','Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant','Recurrent Chronic Hepatitis C Virus|Post Liver Transplant',NULL,'Drug: Sofosbuvir|Drug: RBV','null','Gilead Sciences','Interventional','40','Industry',2,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-334-0126|2012-002417-19','2012-09-12','2012-11-01','2014-08-01','2014-12-11','2014-12-01','Y','2014-12-11','N','2013-12-01','United States,   France,   Germany,   New Zealand,   Spain',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25304641','2015-01-01',NULL,NULL,NULL,'40',NULL,'Genotype 1 HCV','United States, Germany, France, New Zealand, Spain',NULL,'N','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Harvoni','GS-US-334-0146',NULL,'2014-10-10','Leslie',1,NULL,'Healthy female',21,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-337-0101',NULL,'2014-10-10',NULL,1,NULL,'Healthy',NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-337-0102',NULL,'2014-10-10','ION-1',3,'SVR12 rate','HCV-Infected and compensated cirrhosis',865,NULL,NULL,NULL,'United States','NCT01701401','Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV','Chronic Hepatitis C Virus',NULL,'Drug: LDV/SOF|Drug: RBV','null','Gilead Sciences','Interventional','870','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-337-0102|2012-003387-43','2012-10-02','2012-09-01','2014-04-01','2015-03-17','2015-03-01','Y','2015-03-17','N','2014-03-01','United States,   France,   Germany,   Italy,   Puerto Rico,   Spain,   United Kingdom',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24725239','2014-05-15',NULL,NULL,NULL,'865',3,'Genotype 1 HCV','France, Germany, Italy, Puerto Rico, Spain, United Kingdom, United States',NULL,'N','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','N','N','Y','N','N','N'),('Harvoni','GS-US-337-0108',NULL,'2014-10-10','ION-3',3,'SVR12 rate','HCV-Infected',647,NULL,NULL,NULL,'United States','NCT01851330','Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination  Ribavirin for the Treatment of HCV (ION-3)','Chronic Hepatitis C Virus',NULL,'Drug: LDV/SOF|Drug: RBV','null','Gilead Sciences','Interventional','647','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-337-0108','2013-05-03','2013-05-01','2014-03-01','2014-12-18','2014-12-01','Y','2014-12-18','N','2013-12-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24720702','2014-05-15',NULL,NULL,NULL,'647',3,'Genotype 1 HCV','United States',NULL,'N','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Harvoni','GS-US-337-0109',NULL,'2014-10-10','ION-2',3,'SVR12 rate >25%','HCV-Infected and compensated cirrhosis',440,' ',NULL,NULL,'United States','NCT01768286','Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination  Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection','Chronic Hepatitis C Virus',NULL,'Drug: LDV/SOF|Drug: RBV','ION-2','Gilead Sciences','Interventional','441','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-337-0109','2013-01-10','2013-01-01','2014-02-01','2014-11-21','2014-11-01','Y','2014-11-21','N','2013-11-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24725238','2014-04-17',NULL,NULL,NULL,'440',3,'Genotype 1 HCV','United States',NULL,'N','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Harvoni','GS-US-337-0113',NULL,'2014-10-10',NULL,3,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01975675','Efficacy and Safety of Sofosbuvir/Ledipasvir  Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection','Chronic HCV Infection',NULL,'Drug: LDV/SOF|Drug: RBV','null','Gilead Sciences','Interventional','341','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-337-0113','2013-10-29','2013-10-01','2014-08-01','2015-06-04','2015-06-01','Y','2015-06-04','N','2014-06-01','Japan',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25863559','2015-06-01',NULL,NULL,NULL,'341',3,'Genotype 1 HCV','Japan',NULL,'N','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-337-0115',NULL,'2014-10-10',NULL,3,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT02073656','Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection','Hepatitis C Virus|HIV',NULL,'Drug: LDV/SOF|Drug: RBV','null','Gilead Sciences','Interventional','335','Industry',3,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-337-0115','2014-02-25','2014-02-01','2015-12-01','2015-12-08','2015-12-01','N',NULL,'N','2015-09-01','United States,   Canada,   New Zealand,   Puerto Rico',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26196665','2015-08-20',NULL,NULL,NULL,'335',3,'HCV and HIV-1','United States, Puerto Rico, Canada, New Zealand',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','N','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-337-0118',NULL,'2014-10-10','LONESTAR',2,'SVR12 rate','HCV-Infected',100,NULL,NULL,NULL,'United States','NCT01726517','Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC)  Ribavirin in HCV Genotype 1 Subjects','Chronic Hepatitis C Virus',NULL,'Drug: LDV/SOF|Drug: RBV','null','Gilead Sciences','Interventional','100','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-337-0118','2012-11-10','2012-10-01','2014-01-01','2014-11-07','2014-11-01','Y','2014-11-07','Y','2013-07-01','United States',NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/24209977','2014-02-08',NULL,NULL,'Open label','100',2,'HCV and HIV-1','United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y','2014-03-17','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Harvoni','GS-US-337-0121',NULL,'2014-10-10','SIRIUS',2,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01965535','Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination  Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection','HCV Infection',NULL,'Drug: LDV/SOF|Drug: RBV|Drug: Placebo to match LDV/SOF|Drug: Placebo to match RBV','null','Gilead Sciences','Interventional','155','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','GS-US-337-0121|2013-002296-17','2013-10-16','2013-10-01','2014-11-01','2015-08-27','2015-08-01','Y','2015-08-27','N','2014-08-01','France',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25773757','2015-04-01',NULL,NULL,NULL,'172',2,'Genotype 1 HCV','France',NULL,'N','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-337-0122',NULL,'2014-10-10','ELECTRON-2',2,'SVR12 rate','HCV-Infected',51,'New Zealand',NULL,NULL,'United States','NCT01826981','Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Subjects With Chronic Genotype 1, 2, 3, or 6 HCV Infection','Chronic Hepatitis C',NULL,'Drug: LDV/SOF FDC|Drug: SOF|Drug: RBV|Drug: PEG|Drug: GS-9669|Drug: GS-5816','null','Gilead Sciences','Interventional','362','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-337-0122','2013-04-01','2013-04-01','2015-05-01','2015-06-03','2015-06-01','N',NULL,'Y','2015-03-01','New Zealand',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26261007','2015-11-01',NULL,NULL,NULL,'126',2,'Genotype 3 or 6 HCV','New Zealand',NULL,'N','N','Y','Y','Y','N','Y','N','N',NULL,'N','N','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N','2016-01-22','N','Y','Y','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-337-0123',NULL,'2014-10-10','SOLAR',2,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01938430','Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant','Chronic HCV Infection',NULL,'Drug: LDV/SOF|Drug: RBV','null','Gilead Sciences','Interventional','339','Industry',2,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-337-0123','2013-09-05','2013-09-01','2015-03-01','2015-11-04','2015-11-01','N',NULL,'Y','2015-01-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25985734','2015-09-01',NULL,NULL,NULL,'337',2,'Genotype 1 or 4 HCV','United States  ',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N','2015-11-04','Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-337-0124',NULL,'2014-10-10',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT02010255','Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant','Chronic HCV Infection',NULL,'Drug: LDV/SOF|Drug: RBV','null','Gilead Sciences','Interventional','334','Industry',2,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-337-0124|2013-002802-30','2013-12-09','2014-01-01','2015-08-01','2015-09-09','2015-09-01','N',NULL,'N','2015-05-01','Australia,   Austria,   Belgium,   Canada,   France,   Germany,   Italy,   Netherlands,   New Zealand,   Spain,   Switzerland,   United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-337-0125',NULL,'2014-10-10',NULL,2,'Safety data','HCV-Infected',5,NULL,NULL,NULL,'United States','NCT01924949','Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection','Hepatitis C',NULL,'Drug: LDV/SOF','null','Gilead Sciences','Interventional','5','Industry',2,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-337-0125','2013-08-14','2013-07-01','2014-08-01','2015-05-13','2015-05-01','Y','2015-05-13','N','2014-05-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','Y','Y','Y','Y','Y','Y','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-337-0127',NULL,'2014-10-10',NULL,1,NULL,'Healthy',92,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-337-0128',NULL,'2014-10-10',NULL,1,NULL,'Healthy',35,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-337-0131',NULL,'2014-10-10',NULL,3,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT02021656','Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection','Chronic HCV Infection',NULL,'Drug: LDV/SOF','null','Gilead Sciences','Interventional','360','Industry',3,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-337-0131','2013-12-20','2013-12-01','2017-04-01','2015-10-26','2015-10-01','N',NULL,'N','2017-02-01','Republic of Korea, Taiwan',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','N','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-337-0133',NULL,'2014-10-10','LONESTAR-3',3,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01984294','Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection','Chronic HCV Infection',NULL,'Drug: LDV/SOF|Drug: RBV|Drug: GS-9669','null','Gilead Sciences','Interventional','101','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-337-0133','2013-11-08','2013-10-01','2014-07-01','2015-04-30','2015-04-01','Y','2015-04-30','N','2014-04-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','Y','Y','Y','Y','Y','Y','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-337-1116',NULL,'2014-10-10',NULL,2,'Open-label','HCV pediatric',NULL,NULL,NULL,NULL,'United States','NCT02249182','Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/-Ribavirin in Adolescents and Children With Chronic HCV-Infection','Hepatitis C Virus Infection',NULL,'Drug: LDV/SOF|Drug: Placebo to match LDV/SOF|Drug: RBV','null','Gilead Sciences','Interventional','200','Industry',2,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-337-1116','2014-09-23','2014-11-01','2017-10-01','2016-01-13','2016-01-01','N',NULL,'N','2017-07-01','United States,  Australia,  New Zealand,  United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-337-1118',NULL,'2014-10-10',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01987453','Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination  Ribavirin in Subjects With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study','HCV Infection',NULL,'Drug: LDV/SOF|Drug: RBV','null','Gilead Sciences','Interventional','100','Industry',2,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-337-1118|2014-001245-24','2013-11-12','2013-11-01','2015-11-01','2015-12-10','2015-12-01','N',NULL,'N','2015-11-01','United States,   Australia,   France,   Puerto Rico,   Spain',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-344-0101',NULL,'2014-10-10',NULL,1,'Food effect','Healthy',NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-344-0102',NULL,'2014-10-10',NULL,1,NULL,'Healthy',168,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-344-0108',NULL,'2014-10-10',NULL,1,NULL,'Healthy',NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','GS-US-344-0109',NULL,'2014-10-10',NULL,1,NULL,'Healthy',60,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','NIAID-13-I-0159',NULL,'2014-10-10',NULL,2,'Safety efficacy fixed dose',NULL,NULL,NULL,NULL,NULL,'United States','NCT01878799','Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV','Hepatitis C|HIV',NULL,'Drug: GS-7977/GS- 5885 FDC','null','National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)','Interventional','63','NIH',2,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','130159|13-I-0159','2013-06-14','2013-06-01','2014-09-01','2015-09-24','2014-09-01','N',NULL,'N','2014-09-01','United States',NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25706232','2015-03-24',NULL,NULL,NULL,'50',2,'HCV G1 HIV','United States',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','P2938-0212',NULL,'2014-10-10','NUCLEAR',1,NULL,'Healthy',NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24010644','2013-10-01',NULL,NULL,NULL,'40',1,NULL,'United States, Puerto Rico',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','P2938-0515',NULL,'2014-10-10',NULL,1,NULL,'HCV-Infected with CPT',NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','P7977-0111',NULL,'2014-10-10',NULL,1,NULL,'Fasted Healthy',NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','P7977-0221',NULL,'2014-10-10',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01054729','Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Nave GT 1 HCV Patients','Hepatitis C',NULL,'Drug: Sofosbuvir|Drug: Placebo|Drug: PEG|Drug: RBV','null','Gilead Sciences','Interventional','64','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','P7977-0221','2010-01-21','2010-01-01','2011-08-01','2014-03-31','2014-03-01','Y','2014-01-06','Y','2010-04-01','United States,   Puerto Rico',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23183528','2013-04-01',NULL,NULL,NULL,'64',NULL,'Genotype 1 HCV','United States, Puerto Rico',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y','2012-05-24','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Harvoni','P7977-0312',NULL,'2014-10-10',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','P7977-0422',NULL,'2014-10-10','PROTON',2,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01188772','Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients','Hepatitis C Virus',NULL,'Drug: Sofosbuvir|Drug: Placebo to match sofosbuvir|Drug: PEG|Drug: RBV','null','Gilead Sciences','Interventional','147','Industry',2,'Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','P7977-0422','2010-08-23','2010-08-01','2012-05-01','2014-04-02','2014-04-01','Y','2014-01-06','Y','2011-04-01','United States,   Puerto Rico',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23499158','2013-05-01',NULL,NULL,NULL,'122',2,'Genotype 1,2 and 3 HCV','United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y','2012-05-16','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Harvoni','P7977-0523',NULL,'2014-10-10','ELECTRON/FUSION',2,'SVR12 rate','HCV-Infected',92,'New Zealand',NULL,NULL,'United States','NCT01260350','Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Nave Patients With HCV GT2 or GT3','Chronic Hepatitis C Infection',NULL,'Drug: SOF|Drug: RBV|Drug: PEG|Drug: LDV|Drug: GS-9669|Drug: LDV/SOF','null','Gilead Sciences','Interventional','292','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','P7977-0523|Medsafe','2010-12-13','2010-12-01','2013-12-01','2014-11-07','2014-11-01','Y','2014-11-07','Y','2013-10-01','New Zealand',NULL,NULL,NULL,NULL,' http://www.ncbi.nlm.nih.gov/pubmed/23281974','2013-01-03',NULL,NULL,NULL,'113/40',2,'Genotype 1, 2 or 3 HCV','New Zealand',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y','2014-05-28','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Harvoni','P7977-0613',NULL,'2014-10-10',NULL,1,NULL,'Fasted Healthy',NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','P7977-0724',NULL,'2014-10-10',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01329978','Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6','Hepatitis C, Chronic',NULL,'Drug: Sofosbuvir|Drug: RBV|Drug: PEG','ATOMIC','Gilead Sciences','Interventional','332','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','P7977-0724','2011-03-30','2011-03-01','2012-08-01','2014-04-24','2014-04-01','Y','2014-01-06','Y','2012-08-01','United States,   Puerto Rico',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23499440','2013-06-15',NULL,NULL,NULL,'316',2,'Genotype 1 HCV','United States and Puerto Rico',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y','2013-08-27','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Harvoni','P7977-0915',NULL,'2014-10-10',NULL,1,NULL,'Renal impairment',NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','P7977-1231',NULL,'2014-10-10','FISSION',2,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01497366','Phase 3 Study of Sofosbuvir and Ribavirin','Hepatitis C',NULL,'Drug: Sofosbuvir|Drug: PEG|Drug: RBV','FISSION','Gilead Sciences','Interventional','527','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','P7977-1231','2011-12-19','2011-12-01','2013-04-01','2014-03-04','2014-03-01','Y','2014-01-15','Y','2013-01-01','United States,   Australia,   Canada,   Italy,   Netherlands,   New Zealand,   Puerto Rico,   Sweden',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23607594','2013-05-16',NULL,NULL,NULL,'527',2,'Genotype 1, 4, 5, or 6 HCV','United States, Australia, New Zealand, Italy, Sweden, Netherlands',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y','2013-11-20','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Harvoni','P7977-1318',NULL,'2014-10-10',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','P7977-1819',NULL,'2014-10-10',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Harvoni','P7977-2025',NULL,'2014-10-10',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01559844','Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant','Hepatitis C|Hepatocellular Carcinoma',NULL,'Drug: Sofosbuvir|Drug: Ribavirin','null','Gilead Sciences','Interventional','61','Industry',2,'Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','P7977-2025','2012-03-05','2012-03-01','2014-10-01','2015-06-02','2015-06-01','Y','2015-05-12','N','2014-05-01','United States,   New Zealand,   Spain',NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25261839','2015-01-01',NULL,NULL,'Open label','61',2,'HCV ','United States, New Zealand, Spain',NULL,'N','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0',NULL,'Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Ibrance','A5481001','2012-01-15','2015-02-03',NULL,1,'',NULL,74,NULL,NULL,NULL,NULL,'NCT00141297','A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer','Neoplasms|Lymphoma, Non-Hodgkin',NULL,NULL,NULL,'Pfizer','Interventional','74',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2005-08-30','2004-09-01',NULL,NULL,NULL,'','2015-03-04','N','2008-07-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/22090362','2011-11-16',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481002','2012-05-17','2015-02-03',NULL,1,'','healthy',17,NULL,NULL,NULL,NULL,'NCT00420056','An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.','Lymphoma, Mantle-Cell',NULL,NULL,NULL,'Pfizer','Interventional','17',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-01-05','2007-05-01',NULL,NULL,NULL,'','2015-03-04','N','2010-03-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/22383795','2012-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481003','2015-01-16','2015-02-03',NULL,2,'','chronic HBV',177,NULL,NULL,NULL,NULL,'NCT00721409','Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer','Breast Cancer',NULL,NULL,NULL,'Pfizer','Interventional','177',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2008-07-22','2008-09-01',NULL,NULL,NULL,'','2015-03-04','12/5/14','2013-11-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25524798','2014-12-16',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'Y',NULL,'2014-12-05','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481004',NULL,'2015-02-03',NULL,2,'',NULL,53,NULL,NULL,NULL,NULL,'NCT00555906','An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.','Multiple Myeloma',NULL,NULL,NULL,'Pfizer','Interventional','53',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-11-08','2008-01-01',NULL,NULL,NULL,'','2015-03-04','9/12/13','2012-08-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'Y',NULL,'2013-09-12','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481008',NULL,'2015-02-03',NULL,3,'',NULL,650,NULL,NULL,NULL,NULL,'NCT01740427','A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)','Breast Neoplasms',NULL,NULL,NULL,'Pfizer','Interventional','650',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2012-11-26','2013-02-01',NULL,NULL,NULL,'',NULL,'N','2016-02-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481009',NULL,'2015-02-03',NULL,1,'','post-menopausal women with advanced ER-positive, HER2-negative breast cancer',24,NULL,NULL,NULL,NULL,'NCT01602887','Relative Bioavailability Study','Healthy',NULL,NULL,NULL,'Pfizer','Interventional','24',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2012-05-17','2012-05-01',NULL,NULL,NULL,'',NULL,'N','2012-11-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481010','2016-03-15','2015-02-03','104',1,'',NULL,18,NULL,NULL,NULL,NULL,'NCT01684215','A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer','Neoplasms|Breast Neoplasms',NULL,NULL,NULL,'Pfizer','Interventional','18',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-09-10','2012-10-01',NULL,NULL,NULL,'',NULL,'N','2016-03-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26991823',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481011',NULL,'2015-02-03','106',1,'',NULL,6,NULL,NULL,NULL,NULL,'NCT01756768','A Single-Radiolabeled Dose Mass Balance Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] Palbociclib (PD-0332991) In Healthy Male Volunteers','Healthy',NULL,NULL,NULL,'Pfizer','Interventional','6',NULL,NULL,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2012-12-20','2013-01-01',NULL,NULL,NULL,'',NULL,'N','2013-03-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481012',NULL,'2015-02-03',NULL,1,'',NULL,26,NULL,NULL,NULL,NULL,'NCT01756781','A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.','Healthy',NULL,NULL,NULL,'Pfizer','Interventional','26',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2012-12-20','2013-05-01',NULL,NULL,NULL,'',NULL,'N','2013-07-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481013',NULL,'2015-02-03','109',1,'',NULL,28,NULL,NULL,NULL,NULL,'NCT02334800','A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib','Healthy, Hepatic Insufficiency',NULL,NULL,NULL,'Pfizer','Interventional','28',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2015-01-06','2015-03-01',NULL,NULL,NULL,'',NULL,'N','2017-04-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481014',NULL,'2015-02-03','GS-US-242-0109 (Med: 113)',1,'',NULL,28,NULL,NULL,NULL,NULL,'NCT02085538','Study Of Palbociclib (PD-0332991) In Renal Impairment','Renal Impairment',NULL,NULL,NULL,'Pfizer','Interventional','28',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2014-03-11','2014-05-01',NULL,NULL,NULL,'',NULL,'N','2016-05-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481015',NULL,'2015-02-03',NULL,1,'',NULL,14,NULL,NULL,NULL,NULL,'NCT01802476','A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991)','Healthy',NULL,NULL,NULL,'Pfizer','Interventional','14',NULL,NULL,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2013-02-27','2013-05-01',NULL,NULL,NULL,'',NULL,'N','2013-06-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481016',NULL,'2015-02-03','111',1,'','impaired hepatic function',12,NULL,NULL,NULL,NULL,'NCT02131298','Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib','Healthy',NULL,NULL,NULL,'Pfizer','Interventional','12',NULL,NULL,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2014-05-02','2014-05-01',NULL,NULL,NULL,'',NULL,'N','2014-06-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481017',NULL,'2015-02-03','112',1,'','normal renal function and pre-existing renal impairment',15,NULL,NULL,NULL,NULL,'NCT01953731','A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)','Healthy',NULL,NULL,NULL,'Pfizer','Interventional','15',NULL,NULL,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2013-09-26','2013-10-01',NULL,NULL,NULL,'',NULL,'N','2014-01-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481018',NULL,'2015-02-03',NULL,1,'',NULL,26,NULL,NULL,NULL,NULL,'NCT01918176','Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)','Healthy',NULL,NULL,NULL,'Pfizer','Interventional','26',NULL,NULL,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2013-08-05','2013-09-01',NULL,NULL,NULL,'',NULL,'N','2013-12-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481020',NULL,'2015-02-03',NULL,1,'',NULL,73,NULL,NULL,NULL,NULL,'NCT01906125','A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market Product','Healthy',NULL,NULL,NULL,'Pfizer','Interventional','73',NULL,NULL,'Endpoint Classification: Bio-equivalence Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2013-07-16','2013-09-01',NULL,NULL,NULL,'',NULL,'N','2014-01-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481021',NULL,'2015-02-03',NULL,1,'',NULL,28,NULL,NULL,NULL,NULL,'NCT01904747','Characterization Of The Effect Of Food On Palbociclib (PD-0332991) Absorption','Healthy',NULL,NULL,NULL,'Pfizer','Interventional','28',NULL,NULL,'Endpoint Classification: Bio-availability Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2013-07-01','2013-07-01',NULL,NULL,NULL,'',NULL,'N','2013-10-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481022',NULL,'2015-02-03',NULL,1,'',NULL,24,NULL,NULL,NULL,NULL,'NCT01844323','A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract','Healthy',NULL,NULL,NULL,'Pfizer','Interventional','24',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2013-04-16','2013-06-01',NULL,NULL,NULL,'',NULL,'N','2013-08-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481023','2015-07-16','2015-02-03','FOR HBV???',3,'',NULL,521,NULL,NULL,NULL,NULL,'NCT01942135','Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)','Metastatic Breast Cancer',NULL,NULL,NULL,'Pfizer|AstraZeneca','Interventional','521',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)',NULL,'2013-09-10','2013-09-01',NULL,NULL,NULL,'',NULL,'N','2014-12-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26030518','2015-06-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481026',NULL,'2015-02-03','1001',1,'',NULL,25,NULL,NULL,NULL,NULL,'NCT01821066','A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers','Healthy',NULL,NULL,NULL,'Pfizer','Interventional','25',NULL,NULL,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2013-03-26','2013-04-01',NULL,NULL,NULL,'',NULL,'N','2013-08-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481036',NULL,'2015-02-03','1002',1,'',NULL,36,NULL,NULL,NULL,NULL,'NCT02041273','Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted Conditions','Healthy',NULL,NULL,NULL,'Pfizer','Interventional','36',NULL,NULL,'Endpoint Classification: Bio-equivalence Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2014-01-14','2014-01-01',NULL,NULL,NULL,'',NULL,'N','2014-03-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481038',NULL,'2015-02-03','PALOMA-1, 1003',1,'',NULL,27,NULL,NULL,NULL,NULL,'NCT02097329','Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food','Healthy',NULL,NULL,NULL,'Pfizer','Interventional','27',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2014-03-24','2014-04-01',NULL,NULL,NULL,'',NULL,'N','2014-06-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481039',NULL,'2015-02-03','1004',1,'',NULL,14,NULL,NULL,NULL,NULL,'NCT02222441','Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)','Healthy',NULL,NULL,NULL,'Pfizer','Interventional','14',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2014-08-19','2014-10-01',NULL,NULL,NULL,'',NULL,'N','2014-12-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Ibrance','A5481040',NULL,'2015-02-03','PALOMA-2',1,'',NULL,30,NULL,NULL,NULL,NULL,'NCT02083640','Relative Bioavailability For Palbociclib Formulations','Healthy',NULL,NULL,NULL,'Pfizer','Interventional','30',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2014-03-07','2014-03-01',NULL,NULL,NULL,'',NULL,'N','2014-05-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Pfizer Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Inlyta','A4060010','2005-07-18','2012-01-27',NULL,1,'plasma PK of single oral doses of axitinib [1]','Patients',36,NULL,NULL,NULL,NULL,'NCT01469052',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2011-11-02','2002-11-01',NULL,NULL,NULL,'Y','2012-02-25','N','2004-07-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/16027439','2005-07-18',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Inlyta','A4060019',NULL,'2012-01-27',NULL,1,'MTD of axitinib in combination with other drugs [1]','Patients',35,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.nature.com/bjc/journal/v107/n8/full/bjc2012407a.html','2012-09-20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Inlyta','A4061003',NULL,'2012-01-27',NULL,1,'mass balance study of C labeled axitinib [1]','Healthy',8,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Inlyta','A4061004','2010-08-26','2012-01-27',NULL,1,'axitinib coadministered with ketoconazole [1]','Healthy',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20740300','2010-08-26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Inlyta','A4061006','2012-05-27','2012-01-27',NULL,1,'Effect of meal vs. fasting [1]','Healthy',42,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22644797','2012-05-27',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','Y','N','N','N','Y','N','N','N'),('Inlyta','A4061007',NULL,'2012-01-27',NULL,1,'Bioavailability [1]','Healthy',16,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Inlyta','A4061011','2009-07-13','2012-01-27',NULL,2,'NSCLC [1]','Patients',32,NULL,NULL,NULL,NULL,'NCT00094094',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2004-10-11','2005-02-01',NULL,NULL,NULL,'Y','2012-02-25','N','2007-07-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19597027','2009-07-13',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Inlyta','A4061012','2007-10-23','2012-01-27',NULL,2,'activity of axitinib in patients who have received 1 prior cytokine-based therapy [1]','Patients',52,NULL,NULL,NULL,NULL,'NCT00076011',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2004-01-12','2003-10-01',NULL,NULL,NULL,'Y','2012-02-25','N','2007-02-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/17959415','2007-10-23',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Inlyta','A4061014','2008-06-09','2012-01-27',NULL,2,'thyroid [1]','Patients',60,NULL,NULL,NULL,NULL,'NCT00094055',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2004-10-08','2004-09-01',NULL,NULL,NULL,'Y','2012-02-25','Y','2009-01-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/18541897','2008-06-09',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N','2009-03-20','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Inlyta','A4061015','2011-10-05','2012-01-27',NULL,2,'melanoma [1]','Patients',32,NULL,NULL,NULL,NULL,'NCT00094107',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2004-10-11','2004-12-01',NULL,NULL,NULL,'Y','2012-02-25','Y','2008-04-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21976544','2011-10-05',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N','2009-03-20','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Inlyta','A4061018',NULL,'2012-01-27',NULL,1,NULL,'Healthy',40,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Inlyta','A4061019','2012-09-18','2012-01-27',NULL,NULL,'dose proprtionality [1]','Patients',102,NULL,NULL,NULL,NULL,'NCT00454649',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2007-03-29','2005-12-01',NULL,NULL,NULL,'Y','2012-02-25','N','2009-08-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22990652','2012-09-18',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Inlyta','A4061021',NULL,'2012-01-27',NULL,1,'Comparative Bioavailability [1]','Healthy',40,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Inlyta','A4061022','2009-12-09','2012-01-27',NULL,2,'solid tumor [1]','Patients',12,NULL,NULL,NULL,NULL,'NCT00447005',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2007-03-12','2007-02-01',NULL,NULL,NULL,'Y','2012-02-25','N','2009-08-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20180805','2009-12-09',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Inlyta','A4061023','2009-08-03','2012-01-27',NULL,2,'activity of axitinib in patients with advanced and refractory RCC [1]','Patients',62,NULL,NULL,NULL,NULL,'NCT00282048',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-01-23','2006-03-01',NULL,NULL,NULL,'Y','2012-02-25','Y','2009-02-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19652060\nhttp://www.ncbi.nlm.nih.gov/pubmed/21476015','2009-08-03',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N','2009-05-20','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Inlyta','A4061026','2009-07-15','2012-01-27',NULL,1,'potential for PK interaction with rifampin','Healthy',40,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19603168','2009-07-15',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Inlyta','A4061032*','2013-04-16','2012-01-27',NULL,3,'compare PFS of patients receiving axitinib vs other [1]','Patients',723,NULL,NULL,NULL,NULL,'NCT00678392',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-05-12','2008-09-01',NULL,NULL,NULL,'Y','2012-02-25','Y','2010-08-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23598172\nhttp://www.ncbi.nlm.nih.gov/pubmed/23630366',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N','2010-10-02','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Inlyta','A4061033',NULL,'2012-01-27',NULL,1,'Comparative Bioavailability [1]','Healthy',56,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Inlyta','A4061035 ','2011-08-31','2012-01-27',NULL,2,'objective tumor response of axitinib [1]','Patients ',64,NULL,NULL,NULL,NULL,'NCT00569946',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2007-12-07','2007-12-01',NULL,NULL,NULL,'Y','2012-02-25','N','2010-02-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21889330','2011-08-31',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Inlyta','A4061036','2010-07-02','2012-01-27',NULL,1,'effects of hepatitic impairment on PK [1]','Healthy',24,NULL,NULL,NULL,NULL,'NCT00692341',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-06-04','2008-05-01',NULL,NULL,NULL,'Y','2012-02-25','N','2008-10-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20596748','2010-07-02',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Inlyta','A4061037',NULL,'2012-01-27',NULL,1,NULL,'Healthy',20,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Inlyta','A4061044','2011-02-08','2012-01-27',NULL,1,'plasma PK of axitinib [1]','Patients',6,NULL,NULL,NULL,NULL,'NCT00726752',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-07-30','2008-07-01',NULL,NULL,NULL,'Y','2012-02-25','N','2010-04-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21301929','2011-02-08',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Inlyta','A4061045',NULL,'2012-01-27',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'0','0','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Inlyta','A4061046','2013-10-18','2012-01-27',NULL,2,'compare ORR in patients with or without dose titration','Patients',213,NULL,NULL,NULL,NULL,'NCT00835978',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-02-02','2009-08-01',NULL,NULL,NULL,'Y','2013-10-11','N','2012-10-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24140184','2013-10-18',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','N','Y','Y','N',NULL,'N','Y','N','N','N','Y',NULL,'Pfizer','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Inlyta','A4061047',NULL,'2012-01-27',NULL,1,NULL,'Healthy ',68,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Inlyta','A4061050',NULL,'2012-01-27',NULL,1,'Human PK Study [1]','Healthy',14,NULL,NULL,NULL,NULL,'NCT00919204',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-06-11','2009-08-01',NULL,NULL,NULL,'N',NULL,'N','2009-08-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22011693','2011-11-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Inlyta','A4061052',NULL,'2012-01-27',NULL,1,'Bioequivalence [1]','Healthy',60,NULL,NULL,NULL,NULL,'NCT00905814',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-05-20','2009-07-01',NULL,NULL,NULL,'N',NULL,'N','2009-09-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Inlyta','A4061053','2012-05-27','2012-01-27',NULL,1,'Effect of food vs. fasting [1]','Healthy',30,NULL,NULL,NULL,NULL,'NCT00918632',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-06-08','2009-06-01',NULL,NULL,NULL,'N',NULL,'N','2009-07-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22644797','2012-05-27',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','Y','N','N','N','Y','N','N','N'),('Inlyta','A4061063',NULL,'2012-01-27',NULL,1,'Bioequivalence [1]','Healthy',42,NULL,NULL,NULL,NULL,'NCT01020136',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-11-23','2010-01-01',NULL,NULL,NULL,'N',NULL,'N','2010-02-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,NULL,'N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Invokamet','DIA1001',NULL,'2014-08-08',NULL,1,'PK Study',NULL,NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Invokamet','DIA1002',NULL,'2014-08-08',NULL,1,'PK Study',NULL,NULL,NULL,NULL,NULL,'United States','NCT01714193','A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of an Oral Contraceptive in Healthy Volunteers','Healthy',NULL,'Drug: Oral contraceptive|Drug: Canagliflozin (JNJ-28431754)','null','Johnson & Johnson Pharmaceutical Research & Development, L.L.C.','Interventional','30','Industry',1,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','DIA1002','2012-10-23','2008-02-01','2008-03-01','2012-11-16','2012-11-01','N',NULL,'N','2008-03-01','NP',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25345427','2015-01-01',NULL,NULL,NULL,NULL,1,'Healthy',NULL,NULL,'N','N','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Invokamet','DIA1003','2015-02-03','2014-08-08',NULL,1,'PK Study',NULL,NULL,NULL,NULL,NULL,'United States','NCT01759576','A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function','Renal Insufficiency|Healthy',NULL,'Drug: Canagliflozin (JNJ-28431754)','null','Johnson & Johnson Pharmaceutical Research & Development, L.L.C.','Interventional','40','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','DIA1003','2012-12-24','2008-03-01','2008-11-01','2013-05-27','2013-05-01','N',NULL,'N','2008-11-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25659911','2015-03-01',NULL,NULL,'open-label, single-dose, multi-center, parallel-group, phase 1 study','40',1,'Renal Impairment','United States',NULL,'N','Y','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'N','N','N','N','N','N','Y','Y','Y','Y','Y','Y','N','Y','N','N','N','Y','N','N','N'),('Invokamet','DIA1007','2012-02-08','2014-08-08',NULL,1,'PK Study','Patients',29,NULL,NULL,NULL,'United States','NCT01177163','A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus','Diabetes Mellitus, Type 2',NULL,'Drug: Placebo|Drug: JNJ 28431754 300 mg/placebo|Drug: JNJ 28431754 100 mg/placebo','null','Johnson & Johnson Pharmaceutical Research & Development, L.L.C.','Interventional','29','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment','CR014881','2010-08-05','2008-05-01','2009-03-01','2013-05-27','2013-05-01','N',NULL,'N',NULL,NULL,'http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=787&filename=CR014881_CSR.pdf',NULL,NULL,NULL,NULL,'2012-06-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','N','Y','Y'),('Invokamet','DIA1008','2015-12-11','2014-08-08',NULL,1,'PK Study',NULL,NULL,NULL,NULL,NULL,'United States','NCT01748526','A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers','Healthy',NULL,'Drug: Canagliflozin (JNJ-28431754) 200 mg|Drug: Canagliflozin (JNJ-28431754) 300 mg','null','Johnson & Johnson Pharmaceutical Research & Development, L.L.C.','Interventional','16','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label','DIA1008','2012-12-10','2008-08-01','2008-09-01','2013-01-08','2013-01-01','N',NULL,'N','2008-09-01','NP',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26687552','2016-01-01',NULL,NULL,NULL,'15',1,'Healthy','India',NULL,'N','Y','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'N','N','N','N','N','N','Y','Y','Y','Y','Y','Y','N','N','N','N','N','N','N','N','N'),('Invokamet','DIA1019',NULL,'2014-08-08',NULL,1,'PK Study',NULL,NULL,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Invokamet','DIA1023','2013-05-14','2014-08-08',NULL,1,'PK Study',NULL,NULL,NULL,'Phase 1, PCD is probably pre February 1, 2015',NULL,'United States','NCT01128985','A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus','Diabetes Mellitus, Type 2',NULL,'Drug: Canagliflozin 50 mg|Drug: Canagliflozin 100 mg|Drug: Canagliflozin 300 mg|Drug: Placebo','null','Johnson & Johnson Pharmaceutical Research & Development, L.L.C.','Interventional','39','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','DIA1023','2010-05-20','2010-03-01','2010-07-01','2013-05-27','2013-05-01','N',NULL,'N',NULL,'United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23670707','2013-06-01',NULL,NULL,'double-blind, placebo-controlled, randomized, parallel-group, multi-center','36',1,'Type 2 Diabetes','United States ',NULL,'N','Y','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','N','Y','Y'),('Invokamet','DIA1028',NULL,'2014-08-08',NULL,1,NULL,NULL,NULL,NULL,'Phase 1, PCD is probably pre February 1, 2015',NULL,'United States','NCT01273571','A Pharmacokinetic and Pharmacodynamic Study of Metformin and Canagliflozin in Healthy Adult Volunteers','Healthy',NULL,'Drug: Canagliflozin/Metformin','null','Johnson & Johnson Pharmaceutical Research & Development, L.L.C.','Interventional','18','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','DIA1028','2010-12-23','2010-12-01','2011-02-01','2013-07-26','2013-07-01','N',NULL,'N',NULL,'United States ',NULL,NULL,NULL,NULL,'http://onlinelibrary.wiley.com.ezproxy.cul.columbia.edu/doi/10.1002/cpdd.166/epdf, \"Effect of Canagliflozin on the\nPharmacokinetics of Glyburide, Metformin,  2014, The American\nand Simvastatin in Healthy Participants\"','2014-08-29',NULL,NULL,'open-label, fixed-sequence, single center study','18',1,'healthy participants','US',NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'','','N','N','N','N','N','Y','Y','N','Y','N','N','N','N','N','N','N','N','N','N'),('Invokamet','DIA1030',NULL,'2014-08-08',NULL,1,'PK Study',NULL,NULL,NULL,NULL,NULL,'United States','NCT01281579','A Single and Multiple Dose Study of Canagliflozin in Healthy Volunteers','Healthy',NULL,'Drug: Canagliflozin 100 mg|Drug: Canagliflozin 50 mg|Drug: Canagliflozin 300 mg','null','Johnson & Johnson Pharmaceutical Research & Development, L.L.C.','Interventional','27','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','DIA1030','2011-01-20','2011-01-01','2011-04-01','2012-11-29','2012-11-01','N',NULL,'N','2011-04-01','Belgium',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25500487','2015-02-01',NULL,NULL,'open-label, single-(day 1) and multiple-dose (days 4-9), parallel-group','27',1,'Healthy ',NULL,NULL,'N','N','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Invokamet','DIA1032',NULL,'2014-08-08',NULL,1,'PK Study','Healthy',34,NULL,'Phase 1, PCD is probably pre February 1, 2015',NULL,'United States','NCT01286103','A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult Volunteers','Healthy',NULL,'Drug: Canagliflozin 300 mg once daily and 150 mg twice daily|Drug: Canagliflozin 100 mg once daily and 50 mg twice daily','null','Johnson & Johnson Pharmaceutical Research & Development, L.L.C.','Interventional','34','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label','DIA1032','2011-01-13','2011-01-01','2011-05-01','2012-03-12','2012-03-01','N',NULL,'N',NULL,'Removed: US',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25907176','2015-06-01',NULL,NULL,NULL,'34',1,'Healthy',NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','N','N','N','N','N','N','N','N','N','N'),('Invokamet','DIA1036',NULL,'2014-08-08',NULL,1,'Bioavailability','Healthy',85,NULL,NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Invokamet','DIA1037',NULL,'2014-08-08',NULL,1,'Food Effect','Healthy',24,NULL,NULL,NULL,'United States','NCT01459094','Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers','Healthy',NULL,'Drug: A (CANA/MET IR FDC tablet - fasting state) / B (CANA/MET IR FDC tablet - fed state)|Drug: B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state)','null','Janssen Research & Development, LLC','Interventional','24','Industry',1,'Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label','DIA1037','2011-10-21','2011-10-01','2011-12-01','2013-02-18','2013-02-01','N',NULL,'N','2011-12-01','NP',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25546166','2015-03-01',NULL,NULL,NULL,NULL,1,'Healthy',NULL,NULL,'N','N','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Invokamet','DIA1038',NULL,'2014-08-08',NULL,1,'Bioequivalence','Healthy',83,NULL,NULL,NULL,'United States','NCT01463228','A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers','Healthy',NULL,'Drug: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Drug: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)','null','Janssen Research & Development, LLC','Interventional','83','Industry',1,'Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label','DIA1038','2011-10-07','2011-09-01','2012-01-01','2012-08-21','2012-08-01','N',NULL,'N','2012-01-01','United States',NULL,NULL,NULL,NULL,'http://www.omicsonline.org/open-access/bioequivalence-of-canagliflozinmetformin-immediate-release-fixed-dose-combination-tablets-compared-with-concomitant-administration-of-single-components-jbb.10000199.pdf','2014-10-11',NULL,NULL,'open-label, single-center, single-dose, 2-treatment, 2-period crossover trial','64',1,NULL,NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Invokamet','DIA1045','2014-07-09','2014-08-08',NULL,1,'Food effect',NULL,NULL,NULL,NULL,NULL,'United States','NCT01381887','A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus','Diabetes Mellitus, Type 2',NULL,'Drug: Placebo|Drug: Canagliflozin 300mg/Placebo|Drug: Canagliflozin 300mg/Canagliflozin 150mg|Drug: Canagliflozin 300mg','null','Johnson & Johnson Pharmaceutical Research & Development, L.L.C.','Interventional','37','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','DIA1045','2011-06-09','2011-06-01','2011-11-01','2013-04-19','2013-04-01','N',NULL,'N','2011-11-01','United States ',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25110280','2014-10-01',NULL,NULL,'double-blind, placebo-controlled, randomized-sequence, four-period crossover study','37',1,'Type 2 Diabetes','United States',NULL,'N','Y','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Invokamet','DIA1046',NULL,'2014-08-08',NULL,1,'Bioequivalence','Healthy',64,NULL,NULL,NULL,'United States','NCT01508195','A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers','Healthy',NULL,'Drug: Canagliflozin tablets|Drug: Metformin IR tablets|Drug: Canagliflozin/metformin IR FDC tablets|Drug: Canagliflozin/metformin IR FDC tablets|Drug: Canagliflozin tablets|Drug: Metformin IR tablets','null','Janssen Research & Development, LLC','Interventional','64','Industry',1,'Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label','DIA1046','2012-01-09','2012-01-01','2012-03-01','2013-01-30','2013-01-01','N',NULL,'N','2012-03-01','United States',NULL,NULL,NULL,NULL,'http://www.omicsonline.org/open-access/bioequivalence-of-canagliflozinmetformin-immediate-release-fixed-dose-combination-tablets-compared-with-concomitant-administration-of-single-components-jbb.10000199.pdf','2014-10-11',NULL,NULL,'open-label, single-center, single-dose, 2-treatment, 2-period crossover trial','64',1,NULL,NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Invokamet','DIA1047','2014-06-08','2014-08-08',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01483781','A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus','Diabetes Mellitus, Type 2|Plasma Volume',NULL,'Drug: Canagliflozin|Drug: Placebo','null','Janssen Research & Development, LLC','Interventional','36','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','DIA1047','2011-11-30','2011-12-01','2012-08-01','2014-08-19','2014-08-01','N',NULL,'N','2012-08-01','Germany ',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24939043','2014-11-01',NULL,NULL,'randomized, double-blind, placebo-controlled','36',1,'Type 2 Diabetes','Germany',NULL,'N','Y','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Invokamet','DIA1050',NULL,'2014-08-08',NULL,1,'Bioequivalence','Healthy',64,NULL,NULL,NULL,'United States','NCT01508182','A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers','Healthy',NULL,'Drug: Canagliflozin tablets|Drug: Metformin IR tablets|Drug: Canagliflozin/metformin IR FDC tablets|Drug: Canagliflozin tablets|Drug: Metformin IR tablets|Drug: Canagliflozin/metformin IR FDC tablets','null','Janssen Research & Development, LLC','Interventional','64','Industry',1,'Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label','DIA1050','2012-01-09','2012-01-01','2012-03-01','2013-01-15','2013-01-01','N',NULL,'N','2012-03-01','United States',NULL,NULL,NULL,NULL,'http://www.omicsonline.org/open-access/bioequivalence-of-canagliflozinmetformin-immediate-release-fixed-dose-combination-tablets-compared-with-concomitant-administration-of-single-components-jbb.10000199.pdf','2014-10-11',NULL,NULL,'open-label, single-center, single-dose, 2-treatment, 2-period crossover trial','64',1,NULL,NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Invokamet','DIA1051',NULL,'2014-08-08',NULL,1,'Bioequivalence','Healthy',64,NULL,NULL,NULL,'United States','NCT01454622','A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers','Healthy',NULL,'Drug: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Drug: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)','null','Johnson & Johnson Pharmaceutical Research & Development, L.L.C.','Interventional','64','Industry',1,'Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label','DIA1051','2011-10-17','2011-09-01','2011-11-01','2013-05-03','2013-05-01','N',NULL,'N','2011-11-01','United States',NULL,NULL,NULL,NULL,'http://www.omicsonline.org/open-access/bioequivalence-of-canagliflozinmetformin-immediate-release-fixed-dose-combination-tablets-compared-with-concomitant-administration-of-single-components-jbb.10000199.pdf','2014-10-11',NULL,NULL,'open-label, single-center, single-dose, 2-treatment, 2-period crossover trial','64',1,NULL,NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Invokamet','DIA1056','2015-01-05','2014-08-08',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01877889','A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers','Healthy',NULL,'Drug: Canagliflozin|Drug: Dapagliflozin','null','Janssen-Cilag International NV','Interventional','60','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','DIA1056','2013-06-12','2013-07-01','2014-03-01','2014-03-25','2014-03-01','N',NULL,'N','2014-03-01','Germany',NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25421015','2015-02-01',NULL,NULL,'randomized, double-blind, two-stage group sequentlal, two-period crossover study','54',1,'Healthy',NULL,NULL,'N','N','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','N','Y','N','N','N','Y','N','N','N'),('Invokamet','DIA2001','2012-04-09','2014-08-08',NULL,2,'Randomiszed, double-blind','HbA1c7 to 10.5%',451,NULL,NULL,NULL,'United States','NCT00642278','An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes','Diabetes Mellitus, Type II|Diabetes Mellitus, Non Insulin Dependent',NULL,'Drug: Canagliflozin (JNJ-28431754)|Drug: Sitagliptin|Drug: Placebo','null','Johnson & Johnson Pharmaceutical Research & Development, L.L.C.','Interventional','451','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','DIA2001','2008-03-21','2008-04-01','2009-01-01','2013-07-15','2013-07-01','Y','2013-04-01','Y','2009-01-01','United States,   Argentina,   Bulgaria,   Canada,   Czech Republic,   India,   Malaysia,   Mexico,   Poland,   Puerto Rico,   Romania,   Russian Federation,   United Kingdom','http://yoda.yale.edu/sites/default/files/nct00642278.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22548646, http://www.ncbi.nlm.nih.gov/pubmed/22492586','2012-06-01',NULL,NULL,'randomized, double-blind, placebo-controlled, multi-center, dose-ranging','451',2,'Type 2 Diabetes','US, Canada, Mexico, Argentina, Bulgaria, Czech Republic, UK, Poland, Romania, Russia, India, Malaysia',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Janssen Pharmaceuticals / Johnson and Johnson','Y','Y','Y','2009-07-23','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Invokamet','DIA2003',NULL,'2014-08-08',NULL,2,'Randomiszed, double-blind','HbA1c7 to 10.5%',279,NULL,NULL,NULL,'United States','NCT01340664','An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy','Diabetes Mellitus, Type 2',NULL,'Drug: Canagliflozin 50 mg|Drug: Placebo|Drug: Canagliflozin 150 mg|Drug: Metformin','null','Janssen Research & Development, LLC','Interventional','279','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','DIA2003','2011-04-21','2011-07-01','2012-04-01','2014-09-05','2014-09-01','Y','2014-08-20','Y','2012-04-01','United States,   Canada,   Czech Republic,   Mexico,   Romania,   Russian Federation,   Slovakia',NULL,NULL,NULL,NULL,'http://www.sciencedirect.com/science/article/pii/S2214623714000143','2014-06-01',NULL,NULL,'randomized, double-blind, placebo-controlled','279',2,'Type 2 Diabetes',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','Y','Y','Y','2012-03-30','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Invokamet','DIA3002','2013-10-13','2014-08-08',NULL,3,'Randomiszed, double-blind','T2DM, HbA1c7 to 10.5%',469,NULL,NULL,NULL,'United States','NCT01106625','The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)','Diabetes Mellitus, Type 2',NULL,'Drug: Canagliflozin|Drug: Placebo|Drug: Metformin|Drug: Sulphonylruea','null','Janssen Research & Development, LLC','Interventional','469','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','DIA3002','2010-04-01','2010-05-01','2012-04-01','2013-06-12','2013-06-01','Y','2013-04-10','Y','2011-09-01','United States,   Australia,   Belgium,   France,   Guatemala,   Hungary,   Israel,   Mexico,   Puerto Rico,   Russian Federation,   Spain,   United Kingdom','http://yoda.yale.edu/sites/default/files/nct01106625.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24118688','2013-12-01',NULL,NULL,'randomized, double-blind, placebo-controlled','469',3,'Type 2 Diabetes',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Janssen Pharmaceuticals / Johnson and Johnson','Y','Y','Y','2012-03-30','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Invokamet','DIA3004','2013-03-28','2014-08-08',NULL,3,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01064414','An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment','Diabetes Mellitus, Type 2|Renal Insufficiency',NULL,'Drug: Canagliflozin|Drug: Placebo','null','Janssen Research & Development, LLC','Interventional','272','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','DIA3004','2010-02-04','2010-06-01','2012-08-01','2013-08-02','2013-08-01','Y','2013-04-02','Y','2011-12-01','United States,   Australia,   Belgium,   Brazil,   Canada,   France,   Germany,   India,   Korea, Republic of,   Latvia,   Malaysia,   Mexico,   New Zealand,   Poland,   Romania,   Russian Federation,   South Africa,   Spain','http://yoda.yale.edu/sites/default/files/nct01064414.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23464594','2013-05-01',NULL,NULL,NULL,'269',3,'Type 2 Diabetes and Chronic Kidney Disease',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Janssen Pharmaceuticals / Johnson and Johnson','Y','Y','Y','2012-06-27','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Invokamet','DIA3005','2013-01-24','2014-08-08','CANTATA-M*',3,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01081834','The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial','Diabetes Mellitus, Type 2',NULL,'Drug: Canagliflozin|Drug: Placebo|Drug: Sitagliptin','null','Janssen Research & Development, LLC','Interventional','678','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','DIA3005','2010-03-04','2010-03-01','2012-03-01','2013-06-12','2013-06-01','Y','2013-04-15','Y','2011-08-01','United States,   Austria,   Colombia,   Estonia,   Guatemala,   Iceland,   India,   Korea, Republic of,   Lithuania,   Malaysia,   Mexico,   Philippines,   Poland,   Puerto Rico,   Romania,   South Africa,   Spain,   Sweden','http://yoda.yale.edu/sites/default/files/nct01081834.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23279307','2013-04-01',NULL,NULL,NULL,'678',3,'Type 2 Diabetes',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Janssen Pharmaceuticals / Johnson and Johnson','Y','Y','Y','2012-04-24','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Invokamet','DIA3006','2013-09-13','2014-08-08','CANTATA-D',3,'Randomiszed, double-blind','T2DM, HbA1c7 to 10.5%',1284,NULL,NULL,NULL,'United States','NCT01106677','The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)','Diabetes Mellitus, Type 2',NULL,'Drug: Placebo|Drug: Canagliflozin|Drug: Sitagliptin|Drug: Metformin immediate release','null','Janssen Research & Development, LLC','Interventional','1284','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','DIA3006','2010-04-01','2010-05-01','2012-05-01','2013-07-25','2013-07-01','Y','2013-04-04','Y','2011-10-01','United States,   Argentina,   Bulgaria,   Colombia,   Czech Republic,   Estonia,   Greece,   India,   Latvia,   Malaysia,   Mexico,   Peru,   Poland,   Portugal,   Puerto Rico,   Russian Federation,   Singapore,   Slovakia,   Sweden,   Thailand,   Turkey,   Ukraine','http://yoda.yale.edu/sites/default/files/nct01106677.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24026211','2013-12-01',NULL,NULL,NULL,'1284',3,'Type 2 Diabetes',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Janssen Pharmaceuticals / Johnson and Johnson','Y','Y','Y','2012-03-30','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Invokamet','DIA3008','2014-12-02','2014-08-08','CANVAS',3,'Randomiszed, double-blind','T2DM, HbA1c7 to 10.5%',432,NULL,NULL,NULL,'United States','NCT01032629','CANVAS - CANagliflozin cardioVascular Assessment Study','Diabetes Mellitus, Type 2|Cardiovascular Diseases|Risk Factors',NULL,'Drug: Canagliflozin (JNJ-28431754)|Drug: Placebo','CANVAS','Janssen Research & Development, LLC|The George Institute for Global Health, Australia','Interventional','4418','Industry|Other',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','DIA3008','2009-12-10','2009-12-01','2017-06-01','2015-12-22','2015-12-01','N',NULL,'N','2017-04-01','United States,   Argentina,   Australia,   Belgium,   Canada,   Colombia,   Czech Republic,   Estonia,   France,   Germany,   Hungary,   India,   Israel,   Luxembourg,   Malaysia,   Mexico,   Netherlands,   New Zealand,   Norway,   Poland,   Russian Federation,   Spain,   Sweden,   Ukraine,   United Kingdom',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23895803, http://www.ncbi.nlm.nih.gov/pubmed/25468945, http://www.ncbi.nlm.nih.gov/pubmed/24517339, ','2015-03-01',NULL,NULL,'randomized, double-blind, placebo-controlled, parallel group, multi-center trial','4330',3,'Type 2 Diabetes','Argentina, Australia, Belgium, Colombia, Czech Republic, Estonia, Germany, United Kingdom, Hungary, India, Malasia, Israel, Luxembourg, Mexico, Netherlands, New Zealand, Norway, Poland, Russia, Spain, Sweden, United States',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','N','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','Y','Y','N','N','Y','N','N','N','Y','N','N','N'),('Invokamet','DIA3009','2013-07-12','2014-08-08','CANTATA-SU*',3,'Randomiszed, double-blind','T2DM, HbA1c7 to 9.5%',1448,NULL,NULL,NULL,'United States','NCT00968812','CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride','Diabetes Mellitus, Type 2',NULL,'Drug: Glimepiride|Drug: Canagliflozin (JNJ-28431754)|Drug: Metformin','null','Janssen Research & Development, LLC','Interventional','1452','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','DIA3009','2009-08-28','2009-09-01','2013-01-01','2014-04-03','2014-04-01','Y','2013-04-17','Y','2011-12-01','United States,   Argentina,   Bulgaria,   Canada,   Costa Rica,   Denmark,   Finland,   Germany,   India,   Israel,   Korea, Republic of,   Mexico,   Norway,   Philippines,   Poland,   Puerto Rico,   Romania,   Russian Federation,   Slovakia,   Ukraine','http://yoda.yale.edu/sites/default/files/nct00968812.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23850055','2013-09-14',NULL,NULL,'randomized, double-blind, active-controlled, non-inferiority','1452',3,'Type 2 Diabetes',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Janssen Pharmaceuticals / Johnson and Johnson','Y','Y','Y','2012-06-27','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Invokamet','DIA3010',NULL,'2014-08-08',NULL,3,'Randomiszed, double-blind','T2DM subjects 55 - 80',714,NULL,NULL,NULL,'United States','NCT01106651','A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus','Diabetes Mellitus, Type 2',NULL,'Drug: Canagliflozin 100 mg|Drug: Canagliflozin 300 mg|Drug: Antihyperglycemic agent(s)|Drug: Placebo','null','Janssen Research & Development, LLC','Interventional','716','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','DIA3010','2010-04-01','2010-06-01','2013-05-01','2014-10-27','2014-10-01','Y','2013-04-01','Y','2011-11-01','United States,   Australia,   Canada,   Colombia,   France,   Greece,   Hong Kong,   India,   New Zealand,   Poland,   Romania,   South Africa,   Spain,   Sweden,   Switzerland,   Ukraine,   United Kingdom','http://yoda.yale.edu/sites/default/files/nct01106651.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23680739, http://www.ncbi.nlm.nih.gov/pubmed/25495720, http://www.ncbi.nlm.nih.gov/pubmed/24517339, ','2013-04-01',NULL,NULL,'randomized, double-blind, placebo-controlled','716',3,'Type 2 Diabetes',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Janssen Pharmaceuticals / Johnson and Johnson','Y','Y','Y','2012-03-30','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Invokamet','DIA3011','2016-01-19','2014-08-08',NULL,3,NULL,'T2DM',NULL,NULL,NULL,NULL,'United States','NCT01809327','A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise','Diabetes Mellitus, Type 2',NULL,'Drug: Canagliflozin 100 mg|Drug: Canagliflozin 300 mg|Drug: Metformin XR','null','Janssen Research & Development, LLC','Interventional','1185','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','DIA3011','2013-03-08','2013-06-01','2014-12-01','2015-12-01','2015-11-01','Y','2015-12-01','N','2014-12-01','United States,   Argentina,   Brazil,   Czech Republic,   Hungary,   Korea, Republic of,   Mexico,   Puerto Rico,   Romania,   Russian Federation,   Slovakia,   South Africa,   Ukraine',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26786577','2016-03-01',NULL,NULL,'double-blind, five-arm, parallel-group','1186',3,'Type 2 Diabetes',NULL,NULL,'N','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','N','N','N','N','N','N','N','N'),('Invokamet','DIA3012','2014-03-12','2014-08-08',NULL,3,'Randomiszed, double-blind','T2DM, HbA1c7 to 10.5%',342,NULL,NULL,NULL,'United States','NCT01106690','The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)','Diabetes Mellitus, Type 2',NULL,'Drug: Placebo|Drug: Canagliflozin|Drug: Sitagliptin|Drug: Metformin|Drug: Pioglitazone','null','Janssen Research & Development, LLC','Interventional','344','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','DIA3012','2010-04-01','2010-06-01','2012-07-01','2013-06-26','2013-06-01','Y','2013-04-02','Y','2011-11-01','United States,   Canada,   Finland,   France,   Germany,   Greece,   India,   Mexico,   Spain,   Thailand,   United Kingdom','http://yoda.yale.edu/sites/default/files/nct01106690.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24528605','2014-05-01',NULL,NULL,'randomized, double-blind, placebo- and active-controlled','342',3,'Type 2 Diabetes',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Janssen Pharmaceuticals / Johnson and Johnson','Y','Y','Y','2012-03-30','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Invokamet','DIA3014','2014-10-14','2014-08-08',NULL,3,'Randomiszed, double-blind','T2DM asian subjects',676,NULL,NULL,NULL,'United States','NCT01381900','A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea','Diabetes Mellitus, Type 2',NULL,'Drug: Placebo|Drug: Canagliflozin 100mg|Drug: Canagliflozin 300mg|Drug: Metformin|Drug: Sulphonylurea','null','Janssen Research & Development, LLC','Interventional','678','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver)','DIA3014','2011-06-23','2011-08-01','2012-11-01','2014-04-23','2014-04-01','Y','2013-11-21','N','2012-11-01','China,   Malaysia,   Vietnam',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25175734','2015-01-01',NULL,NULL,'18-week, randomized, double-blind, placebo-controlled, parallel-group, three-arm study','676',3,'Type 2 Diabetes','China, Malaysia, Vietnam',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y'),('Invokamet','DIA3015','2013-04-05','2014-08-08',NULL,3,'Randomiszed, double-blind','T2DM, HbA1c7 to 10.5%',755,NULL,NULL,NULL,'United States','NCT01137812','The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)','Diabetes Mellitus, Type 2',NULL,'Drug: Sitagliptin 100 mg|Drug: Canagliflozin 300 mg|Drug: Metformin|Drug: Sulphonylurea','null','Janssen Research & Development, LLC','Interventional','756','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','DIA3015','2010-06-03','2010-07-01','2012-03-01','2015-01-05','2015-01-01','Y','2013-04-02','Y','2012-03-01','United States,   Austria,   Belgium,   Brazil,   Canada,   Denmark,   France,   Germany,   India,   Israel,   Korea, Republic of,   Malaysia,   Netherlands,   New Zealand,   Poland,   Singapore,   Ukraine','http://yoda.yale.edu/sites/default/files/nct01137812.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23564919','2013-09-01',NULL,NULL,'randomized, double-blind, active-controlled, 52-week','755',3,'Type 2 Diabetes',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Janssen Pharmaceuticals / Johnson and Johnson','Y','Y','Y','2012-06-01','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Invokamet','DIA4002','2015-12-10','2014-08-08',NULL,4,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01939496','Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents','Diabetes Mellitus, Type 2|Hypertension',NULL,'Drug: Canagliflozin|Drug: Placebo','null','Janssen Scientific Affairs, LLC','Interventional','172','Industry',4,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','DIA4002','2013-09-06','2013-10-01','2015-04-01','2015-04-13','2015-04-01','N',NULL,'N','2015-04-01','United States,   Puerto Rico',NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26663712','2016-01-01',NULL,NULL,'randomized, double-blind, placebo-controlled, parallel-group, three-arm, multicenter study','171',NULL,'Hypertension',NULL,NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','N','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','Y','Y','N','N','N','N','N','N','N','N','N','N'),('Invokamet','NAP1002',NULL,'2014-08-08',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT00963768','A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus','Diabetes Mellitus, Type 2',NULL,'Drug: JNJ 28431754|Drug: Placebo','null','Johnson & Johnson Pharmaceutical Research & Development, L.L.C.','Interventional','116','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','NAP1002','2009-08-20','2007-06-01','2007-12-01','2014-04-22','2014-04-01','N',NULL,'N','2007-12-01','United States, Germany, Republic of Korea',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25268802, http://www.ncbi.nlm.nih.gov/pubmed/25166023','2014-08-28',NULL,NULL,'randomized, double-blind, placebo-controlled, single and multiple ascending-dose study','116',1,'Type 2 Diabetes','United States, Germany, Korea',NULL,'N','Y','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Invokamet','NAP1004',NULL,'2014-08-08',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01756417','A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers','Healthy',NULL,'Drug: Metformin|Drug: Canagliflozin (JNJ-28431754)','null','Johnson & Johnson Pharmaceutical Research & Development, L.L.C.','Interventional','18','Industry',1,'Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','NAP1004','2012-12-20','2007-10-01','2007-11-01','2013-02-26','2013-02-01','N',NULL,'N','2007-11-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'1','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'N','N','N','N','N','N','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Invokamet','OBE2001','2013-12-09','2014-08-08',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT00650806','A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes','Obesity',NULL,'Drug: Canagliflozin (JNJ-28431754)|Drug: Placebo','null','Johnson & Johnson Pharmaceutical Research & Development, L.L.C.','Interventional','376','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','OBE2001','2008-03-31','2008-05-01','2008-09-01','2013-04-01','2013-04-01','Y','2013-04-01','Y','2008-09-01','United States,   Puerto Rico',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24227660','2014-04-01',NULL,NULL,'randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, 12-week study','376',2,'BMI > 27','United States, Puerto Rico',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','Y','Y','Y','2009-07-23','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Invokamet','TA-7284-01',NULL,'2014-08-08',NULL,0,NULL,NULL,NULL,'Japan',NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N',NULL,NULL,NULL,NULL,'Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Invokamet','TA-7284-05',NULL,'2014-08-08',NULL,3,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01413204','Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes','Type 2 Diabetes Mellitus',NULL,'Drug: TA-7284 Low|Drug: TA-7284 High|Drug: Placebo','null','Mitsubishi Tanabe Pharma Corporation','Interventional','272','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','TA-7284-05','2011-08-04','2011-07-01','2012-08-01','2014-05-27','2014-05-01','Y','2014-03-26','N','2012-08-01','Japan',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25010793','2014-08-01',NULL,NULL,'randomized, double-blind, placebo-controlled','272',3,'Type 2 Diabetes','Japan',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Invokamet','TA-7284-06','2015-11-03','2014-08-08',NULL,3,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01387737','Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus','Type 2 Diabetes Mellitus',NULL,'Drug: TA-7284-Low|Drug: TA-7284-High','null','Mitsubishi Tanabe Pharma Corporation','Interventional','1299','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','TA-7284-06','2011-06-28','2011-05-01','2012-12-01','2014-05-27','2014-05-01','Y','2014-03-26','N','2012-11-01','Japan',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26530268','2015-11-01',NULL,NULL,'multi-center, randomized, open-label, 52-week study','1299',3,'Type 2 Diabetes','Japan',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Invokamet','TA-7284-07',NULL,'2014-08-08',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,'United States','NCT01512849','A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment','Type 2 Diabetes Mellitus',NULL,'Drug: TA-7284 Low|Drug: TA-7284 High','null','Mitsubishi Tanabe Pharma Corporation','Interventional','24','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label','TA-7284-07','2012-01-13','2012-01-01','2012-09-01','2014-05-13','2014-05-01','Y','2014-03-25','N','2012-09-01','Japan',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25200141','2014-10-01',NULL,NULL,'open-label, randomized, two-way crosover, two-sequence, single-dose','12',1,'Type 2 Diabetes','Japan',NULL,'Y','Y','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Invokamet','TA-7284-08',NULL,'2014-08-08',NULL,0,NULL,NULL,NULL,'Japan',NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Janssen Pharmaceuticals / Johnson and Johnson','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Invokamet','TA7284-02','2015-08-18','2014-08-08',NULL,1,'PK Study',NULL,NULL,NULL,NULL,NULL,'United States','NCT00707954','Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients','Type 2 Diabetes Mellitus',NULL,'Drug: TA-7284|Drug: Placebo of TA-7284','null','Mitsubishi Tanabe Pharma Corporation','Interventional','61','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment','TA-7284-02','2008-06-27','2008-06-01','2009-02-01','2014-03-26','2014-03-01','Y','2014-03-26','N','2009-02-01','Japan',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26280756','2015-08-01',NULL,NULL,'randomized, double-blind, placebo-controlled, multiple-dose','61',1,'Type 2 Diabetes','Japan',NULL,'Y','Y','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0',NULL,'N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Jublia','DPSI-IDP-108-P1-01',NULL,'2014-06-06','P1-01',1,'Dermal irritation','Healthy',55,NULL,NULL,NULL,'Canada',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Dow Pharmaceutical Sciences / Valeant','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Jublia','DPSI-IDP-108-P1-02',NULL,'2014-06-06','P1-02',1,'PK Study','Healthy',10,NULL,NULL,NULL,'Canada',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24002148','2013-09-01',NULL,NULL,'single-center, open-label studies','10',NULL,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Dow Pharmaceutical Sciences / Valeant','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Jublia','DPSI-IDP-108-P1-03',NULL,'2014-06-06','P1-03',1,'Maximal use','Severe onychomycosis',20,NULL,NULL,NULL,'Canada',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24002148','2013-09-01',NULL,NULL,'single-center, open-label studies','20',NULL,'Severe Onychomycosis',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Dow Pharmaceutical Sciences / Valeant','N','N','N',NULL,'Y','Y','N','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Jublia','DPSI-IDP-108-P1-04',NULL,'2014-06-06','P1-04',1,'Contact sensitization by repetitive application','Healthy',239,NULL,NULL,NULL,'Canada',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23556032','2013-03-01',NULL,NULL,'single center study','239',NULL,'Healthy','United States',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Dow Pharmaceutical Sciences / Valeant','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Jublia','DPSI-IDP-108-P2-01',NULL,'2014-06-06','P2-01',2,'Safety and efficacy','Mild to moderate onychomycosis',135,'Mexico',NULL,NULL,'Canada','NCT00777868','A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis','Onychomycosis',NULL,'Drug: Low Strength IDP-108|Drug: High Strength IDP-108|Drug: High Strength IDP-108 under occlusion|Drug: Vehicle','null','Dow Pharmaceutical Sciences','Interventional','135','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','DPSI-IDP-108-P2-01','2008-10-20','2007-10-01','2009-04-01','2012-06-20','2012-06-01','N',NULL,'N','2009-04-01','Mexico',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23377392','2013-02-01',NULL,NULL,'multicenter, randomized, parallel-group, double-blind, vehicle-controlled study','135',2,'Mild to Moderate DLSO','Mexico',NULL,'N','N','Y','Y','Y','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Dow Pharmaceutical Sciences / Valeant','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Jublia','DPSI-IDP-108-P3-01',NULL,'2014-06-06','P3-01',3,'Safety and efficacy','Mild to moderate onychomycosis',870,'US, Japan, Canada',NULL,NULL,'Canada','NCT01008033','Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis','Onychomycosis',NULL,'Drug: IDP-108|Drug: Vehicle','null','Dow Pharmaceutical Sciences','Interventional','870','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','DPSI-IDP-108-P3-01','2009-11-03','2009-11-01','2011-12-01','2012-06-20','2012-06-01','N',NULL,'N','2011-11-01','United States,   Canada,   Japan',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23177180','2013-04-01',NULL,NULL,'multicenter, randomized, parallel- group, double-blind, vehicle-controlled studies ','870',3,'Mild to Moderate DLSO','United States, Canada, Japan',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','Y','Y',NULL,NULL,NULL,'0','Dow Pharmaceutical Sciences / Valeant','N','Y','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Jublia','DPSI-IDP-108-P3-02',NULL,'2014-06-06','P3-02',3,'Safety and efficacy','Mild to moderate onychomycosis',781,'US, Canada',NULL,NULL,'Canada','NCT01007708','The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis','Onychomycosis',NULL,'Drug: IDP-108|Drug: Vehicle','null','Dow Pharmaceutical Sciences','Interventional','780','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','DPSI-IDP-108-P3-02','2009-11-03','2009-11-01','2011-12-01','2012-06-20','2012-06-01','N',NULL,'N','2011-12-01','United States, Canada',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23177180','2013-04-01',NULL,NULL,'multicenter, randomized, parallel- group, double-blind, vehicle-controlled studies ','785',3,'Mild to Moderate DLSO','United States, Canada, Japan',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','Y','Y',NULL,NULL,NULL,'0','Dow Pharmaceutical Sciences / Valeant','N','Y','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Jublia','KP-103-02',NULL,'2014-06-06',NULL,1,'Irritation and photosensitization','Healthy',56,'Japan',NULL,NULL,'Canada',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Dow Pharmaceutical Sciences / Valeant','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Jublia','KP-103-03',NULL,'2014-06-06',NULL,1,'Affected vs normal toenail including thickness','Diseased',41,'Japan',NULL,NULL,'Canada',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25607707','2014-11-01',NULL,NULL,'multi-center, open label study','40',NULL,'Onychomycosis','Japan',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0',NULL,'N','N','N',NULL,'Y','Y','N','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Kybella','114253',NULL,'2015-04-29','Study 07/Trial 07',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Kybella','1403740',NULL,'2015-04-29',' (confirmatory trial)',3,'',NULL,201,NULL,NULL,NULL,NULL,'NCT02052622','Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101','Subcutaneous Fat',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','201',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)',NULL,'2014-01-28','2012-02-01',NULL,NULL,NULL,'',NULL,'N','2013-12-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-06-03',NULL,'2015-04-29','1009',2,'',NULL,85,NULL,NULL,NULL,NULL,'NCT00618722','Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat','Moderate or Severe Submental Fullness',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','85',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2008-02-08','2007-08-01',NULL,NULL,NULL,'','2015-05-28','N','2008-10-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-06-04',NULL,'2015-04-29','1010',1,'',NULL,16,NULL,NULL,NULL,NULL,'NCT00422188','Deoxycholic Acid Injection for the Treatment of Superficial Lipomas','Lipoma',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','16',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2007-01-11','2007-01-01',NULL,NULL,NULL,'',NULL,'N','2007-11-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-07-05',NULL,'2015-04-29','1011',2,'',NULL,62,NULL,NULL,NULL,NULL,'NCT00608842','Phase 2 Study for the Treatment of Superficial Lipomas','Lipoma',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','62',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2008-01-23','2007-11-01',NULL,NULL,NULL,'','2015-12-08','5/30/14','2008-08-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'Y',NULL,'2014-05-30','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-07-07',NULL,'2015-04-29','1012',2,'',NULL,73,NULL,NULL,NULL,NULL,'NCT00618618','Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat','Moderate or Severe Submental Fullness',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','73',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2008-02-08','2008-04-01',NULL,NULL,NULL,'','2015-05-28','5/30/14','2008-12-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'Y',NULL,'2014-05-30','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-07-08',NULL,'2015-04-29','2012 [typo-Clin Pharm: 37]',1,'',NULL,24,NULL,NULL,NULL,NULL,'NCT00618709','Dose-Escalation Safety and Pharmacokinetic Study of ATX-101','Healthy',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','24',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label',NULL,'2008-01-23','2008-01-01',NULL,NULL,NULL,'',NULL,'N','2008-12-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-08-10',NULL,'2015-04-29','1013',1,'',NULL,14,NULL,NULL,NULL,NULL,'NCT00835952','ATX-101 Abdominoplasty','Characteristics of Subcutaneous Fat',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','14',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2009-02-03','2008-11-01',NULL,NULL,NULL,'',NULL,'N','2009-03-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-08-11',NULL,'2015-04-29','1014',2,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-08-12',NULL,'2015-04-29','1015',2,'',NULL,205,NULL,NULL,NULL,NULL,'NCT02159729','Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101','Submental Fat|Healthy',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','205',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)',NULL,'2014-06-06','2009-02-01',NULL,NULL,NULL,'',NULL,'N','2015-12-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-09-15',NULL,'2015-04-29','1016',2,'',NULL,129,NULL,NULL,NULL,NULL,'NCT01032889','Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study','Moderate or Severe Submental Fullness',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','129',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2009-12-10','2009-12-01',NULL,NULL,NULL,'','2015-05-28','5/30/14','2010-12-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'Y',NULL,'2014-05-30','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-10-16',NULL,'2015-04-29','1017',3,'',NULL,363,NULL,NULL,NULL,NULL,'NCT01305577','Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat','Moderate or Severe Submental Fullness',NULL,NULL,NULL,'Kythera Biopharmaceuticals|Bayer','Interventional','363',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2011-02-10','2010-12-01',NULL,NULL,NULL,'','2015-05-28','N','2012-01-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/24147933','2014-02-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-10-17','2014-03-08','2015-04-29','1018',3,'',NULL,360,NULL,NULL,NULL,NULL,'NCT01294644','Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat','Moderate or Severe Submental Fullness',NULL,NULL,NULL,'Kythera Biopharmaceuticals|Bayer','Interventional','360',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2011-02-10','2011-01-01',NULL,NULL,NULL,'','2015-05-28','N','2012-02-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/24605812','2014-12-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-10-18','2015-02-14','2015-04-29','1020',1,'',NULL,10,NULL,NULL,NULL,NULL,'NCT01319916','Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue','Healthy',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','10',NULL,NULL,'Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-03-18','2010-12-01',NULL,NULL,NULL,'',NULL,'N','2011-01-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25684122','2015-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-10-19',NULL,'2015-04-29','1021',1,'',NULL,24,NULL,NULL,NULL,NULL,'NCT01320761','A Study to Assess Injection Comfort of Two Formulations of ATX-101','Healthy',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','24',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2011-03-18',NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-11-22',NULL,'2015-04-29','1022',3,'',NULL,506,NULL,NULL,NULL,NULL,'NCT01542034','Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area','Moderate or Severe Submental Fullness',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','506',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2012-02-24','2012-02-01',NULL,NULL,NULL,'','2015-05-28','5/30/14','2013-05-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26673433','2016-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'Y',NULL,'2014-05-30','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-11-23',NULL,'2015-04-29','1023',3,'',NULL,516,NULL,NULL,NULL,NULL,'NCT01546142','Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area','Moderate or Severe Submental Fullness',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','516',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2012-02-24','2012-03-01',NULL,NULL,NULL,'','2015-05-28','5/30/14','2013-05-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'Y',NULL,'2014-05-30','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-11-24',NULL,'2015-04-29','1026',1,'',NULL,218,NULL,NULL,NULL,NULL,'NCT01706679','Evaluation of the Effect of ATX-101 on QT/QTc Intervals','Healthy',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','218',NULL,NULL,'Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind',NULL,'2012-10-11','2012-10-01',NULL,NULL,NULL,'',NULL,'N','2013-02-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-11-26',NULL,'2015-04-29','1036',3,'','adults with moderate to severe submental convexity ',165,NULL,NULL,NULL,NULL,'NCT01426373','Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area','Moderate or Severe Submental Fullness',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','165',NULL,NULL,'Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-08-26','2011-08-01',NULL,NULL,NULL,'','2015-12-08','5/30/14','2013-06-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'Y',NULL,'2014-05-30','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-11-30',NULL,'2015-04-29','Study 05/Trial 05',1,'',NULL,5,NULL,NULL,NULL,NULL,'NCT01462786','To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101','Healthy',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','5',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-10-17','2011-10-01',NULL,NULL,NULL,'',NULL,'N','2011-11-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-12-32',NULL,'2015-04-29','1038',1,'','adults with moderate to severe submental convexity ',24,NULL,NULL,NULL,NULL,'NCT01632917','Open-Label Pharmacokinetic Study of Final Formulations of ATX-101','Healthy',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','24',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-06-29','2012-06-01',NULL,NULL,NULL,'',NULL,'N','2012-07-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25738850','2015-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-13-27',NULL,'2015-04-29','1039',3,'',NULL,93,NULL,NULL,NULL,NULL,'NCT02035267','Safety Study of ATX-101 in Subjects With Varying Chin Sizes','Submental Fat|Safety|Efficacy|Healthy Volunteers',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','93',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2014-01-12','2013-12-01',NULL,NULL,NULL,'',NULL,'N','2015-06-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-13-28',NULL,'2015-04-29','1040',3,'',NULL,60,NULL,NULL,NULL,NULL,'NCT02123134','Safety Study of ATX-101 for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age','Submental Fat|Healthy Volunteers',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','60',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2014-04-22','2014-04-01',NULL,NULL,NULL,'',NULL,'N','2015-08-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-13-35',NULL,'2015-04-29','Study 1403740',2,'','adults with sufficient submental fat',224,NULL,NULL,NULL,NULL,'NCT02163902','Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101','Submental Fat|Healthy',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','224',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)',NULL,'2014-06-12','2013-12-01',NULL,NULL,NULL,'',NULL,'N','2016-05-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-13-36',NULL,'2015-04-29','Study 03/Trial 03',3,'',NULL,84,NULL,NULL,NULL,NULL,'NCT02007434','Patient Experience Study of Deoxycholic Acid Injection','Moderate or Severe Submental Fullness',NULL,NULL,NULL,'Kythera Biopharmaceuticals','Interventional','84',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-10-30','2013-12-01',NULL,NULL,NULL,'','2015-06-12','N','2014-06-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Kybella','ATX-101-16-509',NULL,'2015-04-29','Study 04',NULL,'','geriatric population (65-75)',75,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'75',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Kythera Biopharms / Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Lynparza','D0810C00001','2012-01-30','2014-12-19','Study 1',1,'Safety and tolerability in Japanese','Adv. Solid tumors',12,'Japan',NULL,NULL,'UK','NCT00572364','Open Label, Dose Escalation Phase I Study of AZD2281','Advanced Solid Malignancies',NULL,'Drug: KU-0059436 (AZD2281)(PARP inhibitor)','null','AstraZeneca','Interventional','18','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','D0810C00001','2007-12-12','2007-11-01','2009-06-01','2009-08-19','2009-08-01','N',NULL,'N','2009-03-01','Japan','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1668&filename=D0810C00001.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22145984','2012-03-01',NULL,NULL,'2 phases: dose-escalation and dose-expansion','12',1,'Advanced Solid Tumors','Japan',NULL,'N','Y','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Lynparza','D0810C00002','2009-06-24','2014-12-19','Study 2/Trial 2 / Study KU-36-92',1,'Safety and tolerability of KU-0059436','Adv. Solid tumors',98,' ',NULL,NULL,'UK','NCT00516373','A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)','Ovarian Neoplasms|BRCA1 Protein|BRCA2 Protein',NULL,'Drug: KU-0059436 (AZD2281)(PARP inhibitor)','null','AstraZeneca','Interventional','95','Industry',1,'Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','KU36-92|D0810C00002','2007-08-13','2005-07-01','2016-12-01','2016-03-23','2016-03-01','N',NULL,'N','2008-12-01','Belgium,   Netherlands,   Poland,   United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2678&filename=CSR_Synopsis_D0810C00002(KU36-92).pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19553641, http://www.ncbi.nlm.nih.gov/pubmed/20406929','2009-07-09',NULL,NULL,'dose-escalation study','60',1,'Advanced Solid Tumors','United Kingdom, Netherlands',NULL,'N','Y','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Lynparza','D0810C00004',NULL,'2014-12-19','Study 4  ',1,'Dose Escalation','Adv. Solid tumors',189,NULL,NULL,NULL,'UK','NCT00516724','Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel','Triple Negative Metastatic Breast Cancer|Advanced Ovarian Cancer|Carboplatin|Paclitaxel',NULL,'Drug: KU-0059436 (AZD2281)(PARP inhibitor)|Drug: Carboplatin|Drug: KU-0059436 (AZD2281)(PARP inhibitor)|Drug: Paclitaxel|Drug: KU-0059436 (AZD2281)(PARP inhibitor)|Drug: Paclitaxel + Carboplatin','null','AstraZeneca','Interventional','192','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','KU36-96|D0810C00004','2007-08-13','2007-06-01','2016-12-01','2016-03-02','2016-03-01','N',NULL,'N','2013-01-01','Belgium,   Netherlands,   United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2679&filename=CSR_Synopsis_D0810C00004(KU36-96).pdf',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'open-label randomized two-period crossover study',NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Lynparza','D0810C00005','2015-01-07','2014-12-19','Study 5',1,'PK, safety','Adv. Solid tumors, normal, mild, or moderate hepatic impairment',66,NULL,NULL,NULL,'UK','NCT00515866','Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer','Pancreatic Neoplasms',NULL,'Drug: KU-0059436 (AZD2281)(PARP inhibitor)|Drug: Gemcitabine','null','AstraZeneca','Interventional','68','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','KU36-29|D0810C00005','2007-08-13','2007-08-01','2012-07-01','2013-12-19','2013-12-01','N',NULL,'N','2011-10-01','United States,   United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1671&filename=CSR_Synopsis_D0810C00005(KU36-29).pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25573533','2015-04-01',NULL,NULL,'dose-escalation trial','66',1,'Advanced/metastatic Pancreatic Cancer, Advanced Solid Tumors',NULL,NULL,'N','Y','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Lynparza','D0810C00006','2011-05-18','2014-12-19',NULL,1,'PK, safety','Adv. Solid tumors, normal or impaired renal function',19,NULL,NULL,NULL,'UK','NCT00516438','Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan','Malignant Solid Tumors',NULL,'Drug: KU-0059436 (AZD2281)(PARP inhibitor)|Drug: Topotecan','null','AstraZeneca|KuDOS Pharmaceuticals Limited','Interventional','48','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','KU36-93|D0810C00006','2007-08-13','2007-07-01','2009-11-01','2010-12-07','2010-12-01','N',NULL,'N','2009-03-01','United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=736&filename=CSR_Synopsis_D0810C00006(KU36-93).pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21590367','2012-08-01',NULL,NULL,'multicenter open-label in combo w topotecan incl. dose-escalation phase','21',1,'Advanced Solid Tumors',NULL,NULL,'N','Y','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Lynparza','D0810C00007','2010-01-13','2014-12-19','Study 7',1,'PD','Breast cancer',60,NULL,NULL,NULL,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23315029','2013-08-01',NULL,NULL,NULL,'60',1,'Breast Cancer',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca Pharmaceuticals','N','N','N',NULL,'Y','Y','N','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Lynparza','D0810C00008','2010-07-06','2014-12-19','Study 8/Trial 8',2,'Efficacy of KU-0059436','gBRCA Breast cancer',54,NULL,NULL,NULL,'UK','NCT00494234','Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer','Breast Neoplasms',NULL,'Drug: KU-0059436 (AZD2281) (PARP inhibitor)|Drug: KU-0059436 (AZD2281) (PARP inhibitor)','ICEBERG 1','AstraZeneca|KuDOS Pharmaceuticals Limited','Interventional','81','Industry',2,'Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','KU36-44|D0810C00008','2007-06-27','2007-06-01','2016-12-01','2015-12-04','2015-11-01','Y','2015-01-16','Y','2009-02-01','United States,   Australia,   Germany,   Sweden,   United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=733&filename=CSR_Synopsis_D0810C00008(KU36-44).pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20609467','2010-07-24',NULL,NULL,'efficacy, safety, and tolerability','54',2,'BRCA1 or BRA2 mutations and recurrent Ovarian Cancer','Australia, Germany, Spain, Sweden, United Kingdom, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','Y','Y','Y','2013-09-16','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Lynparza','D0810C00009','2010-07-06','2014-12-19','Study 9/Trial 9',2,'Efficacy of KU-0059436','gBRCA Ovarian Cancer',57,NULL,NULL,NULL,'UK','NCT00494442','Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer','Ovarian Neoplasm',NULL,'Drug: KU-0059436 (AZD2281)(PARP inhibitor)|Drug: KU-0059436 (AZD2281)(PARP inhibitor)','ICEBERG 2','AstraZeneca|KuDOS Pharmaceuticals Limited','Interventional','70','Industry',2,'Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','KU36-58|D0810C00009','2007-06-27','2007-06-01','2016-12-01','2015-12-07','2015-07-01','Y','2015-01-15','Y','2009-03-01','United States,   Australia,   Germany,   Spain,   Sweden','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=734&filename=CSR_Synopsis_D0810C00009(KU36-58).pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20609468','2010-07-02',NULL,NULL,'international, multicenter, 2 sequential cohorts of women - efficacy and tolerability','70',2,'BRCA1 or BRA2 mutations and recurrent Ovarian Cancer','Australia, Germany, Spain, Sweden, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','Y','Y','Y','2013-09-17','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Lynparza','D0810C00010',NULL,'2014-12-19',NULL,1,'PK, ADME','Adv. Solid tumors',6,NULL,NULL,NULL,'UK','NCT00633269','Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours','Neoplasm Metastasis',NULL,'Drug: AZD2281','null','AstraZeneca|KuDOS Pharmaceuticals Limited','Interventional','6','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','D0810C00010|KU36-37','2008-03-05','2008-04-01','2008-10-01','2009-01-13','2009-01-01','N',NULL,'N','2008-10-01','United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1672&filename=D0810C00010.pdf',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Lynparza','D0810C00012','2011-12-27','2014-12-19','Study 12/Trial 12',2,'Efficay of AZD2281','gBRCA Ovarian Cancer',125,NULL,NULL,NULL,'UK','NCT00628251','Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer','Ovarian Neoplasms',NULL,'Drug: AZD2281|Drug: Liposomal Doxorubicin|Drug: AZD2281','ICEBERG 3','AstraZeneca','Interventional','125','Industry',2,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','D0810C00012','2008-02-26','2008-07-01','2015-12-01','2014-11-05','2014-11-01','Y','2015-01-14','Y','2009-09-01','United States,   Australia,   Belgium,   Germany,   Israel,   Poland,   Spain,   Sweden,   United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=193&filename=CSR_Synopsis_D0810C00012.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22203755','2012-02-01',NULL,NULL,'multicenter, open-label, randomized study','97',2,'BRCA1 or BRA2 mutations and recurrent Ovarian Cancer',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','Y','Y','Y','2013-07-22','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Lynparza','D0810C00019','2012-03-27','2014-12-19','Study 19/Trial 19/D08110C00019',2,'Randomized double blind','Plat-sensitive ovarian cancer',264,'Australia, Belgium, Czech Republic, Estonia, Germany, Israel, Canada, France, Netherlands, Poland, Romania, Russia, Spain, Ukraine, UK, USA',NULL,NULL,'UK','NCT00753545','Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer','Ovarian Cancer',NULL,'Drug: AZD2281|Drug: matching placebo','null','AstraZeneca','Interventional','265','Industry',2,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D0810C00019','2008-09-12','2008-08-01','2012-11-01','2013-02-06','2013-02-01','Y','2012-12-07','N','2010-06-01','United States,   Australia,   Belgium,   Canada,   Czech Republic,   Estonia,   France,   Germany,   Israel,   Netherlands,   Poland,   Romania,   Russian Federation,   Spain,   Ukraine,   United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=242&filename=CSR_Synopsis_D0810C00019.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22452356','2012-04-12',NULL,NULL,'randomized, double blind study','265',2,'Platinum-sensitive Ovarian Cancer',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Lynparza','D0810C00020','2011-08-19','2014-12-19','Trial 20/Study 20',2,'Non-randomized olaparib monotherapy','BRCAm Ovarian Cancer',90,NULL,NULL,NULL,'UK','NCT00679783','Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer','Ovarian Carcinoma|Breast Cancer',NULL,'Drug: AZD2281','null','AstraZeneca|British Columbia Cancer Agency','Interventional','112','Industry|Other',2,'Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','D0810C00020','2008-05-15','2008-07-01','2016-12-01','2016-04-11','2016-04-01','Y','2011-07-19','N','2010-03-01','Canada','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=194&filename=D0810C00020.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21862407','2011-09-01',NULL,NULL,'multicenter open-label non-randomized study','91',2,'Ovarian Carcinoma or Triple-negative Breast Cancer','Canada',NULL,'Y','Y','Y','Y','Y','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Lynparza','D0810C00021','2014-05-14','2014-12-19','Study 21',1,'Dose Escalation','Plat-sensitive ovarian cancer',54,NULL,NULL,NULL,'UK','NCT00782574','Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients','Advanced Solid Tumors',NULL,'Drug: AZD2281|Drug: Cisplatin','null','AstraZeneca','Interventional','59','Industry',1,'Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','D0810C00021','2008-10-29','2008-11-01','2016-12-01','2016-03-02','2016-03-01','N',NULL,'N','2012-02-01','United States,   Spain','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1674&filename=D0810C00021.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24827126','2014-08-01',NULL,NULL,'open-label multicenter study','59',1,'Advanced Breast, Ovarian and Other Solid Tumors',NULL,NULL,'N','Y','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Lynparza','D0810C00024',NULL,'2014-12-19','Study 24/Trial 24',1,'Comparative bioavailability','Adv. Solid tumors',134,NULL,NULL,NULL,'UK','NCT00777582','Phase I Comparative Bioavailability Study','Solid Tumors',NULL,'Drug: AZD2281','null','AstraZeneca','Interventional','228','Industry',1,'Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label','D0810C00024','2008-10-21','2008-10-01','2016-03-01','2016-03-02','2016-03-01','N',NULL,'N','2009-02-01','Australia,   Belgium,   Switzerland,   United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1676&filename=D0810C00024_Study_Synopsis.pdf',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Lynparza','D0810C00039','2015-08-17','2014-12-19','Study 39',2,'Efficacy in combo with chemo vs placebo','Adv. Gastric cancer',61,NULL,NULL,NULL,'UK','NCT01063517','Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients','Gastric Cancer',NULL,'Drug: olaparib|Drug: paclitaxel|Drug: Placebo','null','AstraZeneca','Interventional','267','Industry',2,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D0810C00039','2010-02-04','2010-02-01','2016-12-01','2016-04-18','2016-04-01','Y','2015-01-13','Y','2012-05-01','Korea','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1677&filename=D0810C00039.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26282658','2015-11-20',NULL,NULL,'prospective, randomized, double-blind, multicenter','124',2,'Gastric Cancer',NULL,NULL,'Y','Y','Y','Y','Y','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N','2013-07-12','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Lynparza','D0810C00041','2014-12-04','2014-12-19','Study 41',2,'Efficacy in combo with chemo','Plat-sensitive ovarian cancer',81,NULL,NULL,NULL,'UK','NCT01081951','Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer','Ovarian Cancer',NULL,'Drug: olaparib|Drug: paclitaxel|Drug: carboplatin|Drug: paclitaxel|Drug: Drug: carboplatin','null','AstraZeneca','Interventional','173','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','D0810C00041','2010-02-26','2010-02-01','2016-12-01','2016-03-02','2016-03-01','Y','2012-11-12','N','2011-10-01','United States,   Australia,   Belgium,   Canada,   Czech Republic,   Germany,   Italy,   Japan,   Netherlands,   Panama,   Peru,   Spain,   United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=243&filename=CSR-D0810C00041.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25481791','2015-01-01',NULL,NULL,'randomized open-label study','173',2,'Platinum-sensitive Ovarian Cancer','Canada, Czech Republic, Spain, United Kingdom, Netherlands, Italy, Belgium, Germany, Australia, United States, Japan, Panama',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Lynparza','D0810C00042','2014-11-03','2014-12-19','Study 42/Trial 42',2,'Single arm','gBRCA -mutated advanced tumors',298,NULL,NULL,NULL,'UK','NCT01078662','Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats','Ovarian|Breast|Prostate|Pancreatic|Advanced Tumours',NULL,'Drug: olaparib','null','AstraZeneca','Interventional','318','Industry',2,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','D0810C00042','2010-03-01','2010-02-01','2016-12-01','2016-03-02','2016-03-01','Y','2015-01-13','Y','2012-07-01','United States,   Australia,   Germany,   Israel,   Spain,   Sweden','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25366685','2015-01-20',NULL,NULL,'prospective, multicenter, nonrandomized study','298',2,'BRCA1/2','Isreal, Australia, Germany, Spain, Sweden, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Astrazeneca Pharmaceuticals','Y','Y','Y','2013-05-09','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Lynparza','D0810L00001','2014-07-15','2014-12-19',NULL,1,'Dose Escalation','Adv. Solid tumors',44,NULL,NULL,NULL,'UK','NCT00819221','AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours','Solid Tumors',NULL,'Drug: AZD2281|Drug: liposomal doxorubicin','null','AstraZeneca','Interventional','44','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','D0810L00001|Eudract No. 2008-007680-17','2009-01-07','2009-01-01','2016-09-01','2016-02-16','2016-02-01','N',NULL,'N','2011-11-01','Italy,   Switzerland','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1679&filename=D0810L00001.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25025963','2014-08-12',NULL,NULL,'open-label multicenter dose-finding study','44',1,'Advnaced Solid Tumors',NULL,NULL,'N','Y','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Lynparza','D0816C00002',NULL,'2014-12-19','SOLO2',3,'Efficacy','Ovarian   ',264,NULL,NULL,NULL,'UK','NCT01874353','Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy','Platinum Sensitive|BRCA Mutated|Relapsed Ovarian Cancer|Following Complete or Partial Response to Platinum Based Chemotherapy',NULL,'Drug: Olaparib 300mg tablets|Drug: Placebo to match olaparib 300mg','null','AstraZeneca|European Network of Gynaecological Oncology Trial Groups (ENGOT)|Myriad Genetic Laboratories, Inc.','Interventional','297','Industry|Other',3,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D0816C00002','2013-06-07','2013-09-01','2021-04-01','2016-04-14','2016-04-01','N',NULL,'N','2016-09-01','United States,   Australia,   Belgium,   Brazil,   Canada,   China,   France,   Germany,   Israel,   Italy,   Japan,   Korea, Republic of,   Netherlands,   Poland,   Russian Federation,   Spain,   United Kingdom','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Astrazeneca Pharmaceuticals','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Lynparza','D0816C00004','2015-08-05','2014-12-19',NULL,1,'Randomized crossover',NULL,80,NULL,NULL,NULL,'UK','NCT01921140','To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours','Solid Tumours',NULL,'Drug: Olaparib tablets|Procedure: Pharmacokinetic sampling|Other: Dietary Fasted|Other: Dietary High Fat','null','AstraZeneca','Interventional','80','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label','D0816C00004','2013-07-12','2013-09-01','2016-12-01','2016-03-25','2016-03-01','N',NULL,'N','2014-04-01','Belgium,   Denmark,   Netherlands,   United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1825&filename=D0816C00004_Study_Synopsis_Redacted.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26242220','2015-10-01',NULL,NULL,NULL,'116',1,'Advanced Solid Tumors',NULL,NULL,'N','Y','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Lynparza','D0816C00005',NULL,'2014-12-19',NULL,1,'PK, safety',NULL,NULL,NULL,NULL,NULL,'UK','NCT01894243','Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment','Solid Tumours',NULL,'Drug: Olaparib tablet dosing','null','AstraZeneca','Interventional','39','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label','D0816C00005|2013-002246-37','2013-07-04','2014-03-01','2018-01-01','2016-04-22','2016-04-01','N',NULL,'N','2017-01-01','Belgium,   France,   Netherlands,   United Kingdom','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','N','N',NULL,NULL,NULL,'0','Astrazeneca Pharmaceuticals','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Lynparza','D0816C00006',NULL,'2014-12-19',NULL,1,'PK, safety',NULL,NULL,NULL,NULL,NULL,'UK','NCT01894256','Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function','Solid Tumours',NULL,'Drug: Olaparib tablet dosing','null','AstraZeneca','Interventional','57','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label','D0816C00006|2013-002225-30','2013-07-04','2013-11-01','2016-02-01','2016-03-18','2016-03-01','Y','2016-03-18','N','2015-03-01','Belgium,   Denmark,   France,   Netherlands,   United Kingdom','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','Y','N',NULL,'N','N','N',NULL,NULL,NULL,'0','Astrazeneca Pharmaceuticals','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Lynparza','D0816C00007',NULL,'2014-12-19',NULL,1,'Non-randomized two-treatment',NULL,83,NULL,NULL,NULL,'UK','NCT01900028','To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours','Solid Tumours',NULL,'Procedure: Pharmacokinetic sampling|Drug: Olaparib tablet dosing|Drug: Itraconazole','null','AstraZeneca','Interventional','85','Industry',1,'Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label','D0816C00007|2013-001892-18','2013-07-12','2013-10-01','2016-12-01','2016-03-15','2016-03-01','N',NULL,'N','2014-04-01','Belgium,   Denmark,   Netherlands,   United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1826&filename=D0816C00007_Study_Synopsis_Redacted.pdf',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Lynparza','D0816C00008',NULL,'2014-12-19',NULL,1,'PK with rifampicin',NULL,NULL,NULL,NULL,NULL,'UK','NCT01929603','Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours','Solid Tumours',NULL,'Procedure: Pharmacokinetic sampling|Drug: Rifampicin|Drug: Olaparib tablet dosing','null','AstraZeneca','Interventional','32','Industry',1,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label','D0816C00008','2013-08-23','2013-12-01','2016-12-01','2016-04-20','2016-04-01','N',NULL,'N','2014-05-01','Belgium,   Netherlands','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1867&filename=D0816C00008_Study_Synopsis_Redacted.pdf',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Lynparza','D0816C00010',NULL,'2014-12-19','Trial 10',3,'Olaparib monotherapy versus physician\'s choice','2+ lines of plat. Chemo for gBRCAm-ovarian cancer',NULL,NULL,NULL,NULL,'UK','NCT02282020','Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments','Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity',NULL,'Drug: OLAPARIB|Drug: Single agent chemotherapy','SOLO3','AstraZeneca|Myriad Genetic Laboratories, Inc.','Interventional','411','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','D0816C00010','2014-10-20','2015-02-01','2019-12-01','2016-04-19','2016-04-01','N',NULL,'N','2017-12-01','United States,   Argentina,   Belgium,   Brazil,   Canada,   Czech Republic,   Hungary,   Israel,   Italy,   Korea, Republic of,   Mexico,   Poland,   Spain,   United Kingdom','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Astrazeneca Pharmaceuticals','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Lynparza','D0818C00002',NULL,'2014-12-19','SOLO-2 ',3,'Efficacy','Ovarian, peritoneal and/or fallopian cancer',NULL,NULL,NULL,NULL,'UK','NCT01874353',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca Pharmaceuticals','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Lynparza','D081AC00001','2015-06-06','2014-12-19',NULL,1,'Activity','Adv. Solid tumors',33,NULL,NULL,NULL,'UK','NCT01851265','D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours','Solid Tumours',NULL,'Drug: Olaparib|Other: Dietary Fasted|Other: Dietary standard|Other: Dietary High Fat','null','AstraZeneca','Interventional','35','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Outcomes Assessor)','D081AC00001|2013-001255-13','2013-05-08','2013-07-01','2016-12-01','2016-04-20','2016-04-01','N',NULL,'N','2013-10-01','Belgium,   Netherlands,   United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1820&filename=D081AC00001_Study_Synopsis.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26048134','2015-06-01',NULL,NULL,'food effect','32',1,'Advanced Solid Tumors',NULL,NULL,'N','Y','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Lynparza','D9010C00008','2016-01-19','2014-12-19','Study 8',2,'Activity','Colorectal cancer',33,NULL,NULL,NULL,'UK','NCT00912743','Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status','Colorectal Cancer',NULL,'Drug: olaparib','null','AstraZeneca','Interventional','33','Industry',2,'Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','D9010C00008|AGICC 09CRC01','2009-05-28','2009-05-01','2012-03-01','2013-05-20','2013-05-01','N','2015-01-13','Y','2012-03-01','United States','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=638&filename=D9010C00008.pdf',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26786262','2016-02-01',NULL,NULL,NULL,'33',2,'CRC','United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','N',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','Y','Y','Y','2013-05-20','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('MenHibrix','100381/004',NULL,'2012-06-14','Hib-MenCY-TT-004',2,'Dose-ranging. Controlled - extension study',NULL,47,NULL,NULL,NULL,NULL,'NCT00129116',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2005-08-10','2003-03-01',NULL,NULL,NULL,'Y','2012-06-15','N','2003-12-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20697200',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'GlaxoSmithKline Biologicals','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('MenHibrix','101858',NULL,'2012-06-14','Hib-MenCY-TT-005',2,'Immunogenicity and safety (doses 1-3). Controlled (p. 88)',NULL,287,NULL,NULL,NULL,NULL,'NCT00129129',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2005-08-10','2004-08-01',NULL,NULL,NULL,'Y','2012-06-15','N','2006-02-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20035207','2010-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'GlaxoSmithKline Biologicals','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('MenHibrix','102015',NULL,'2012-06-14','Hib-MenCY-TT-006 ',2,'Immunogenicity, and safety (4th dose). Controlled.',NULL,236,NULL,NULL,NULL,NULL,'NCT00129129',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2005-08-10','2004-08-01',NULL,NULL,NULL,'Y','2012-06-15','N','2006-02-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20035207','2010-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'GlaxoSmithKline Biologicals','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('MenHibrix','102370','2012-08-01','2012-06-14','Hib-MenCY-TT-007',2,'Immunogenicity and safety (doses 1-3)',NULL,661,NULL,NULL,NULL,NULL,'NCT00134719',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2005-08-10','2005-04-01',NULL,NULL,NULL,'Y','2012-06-15','N','2007-07-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20948453\r\nhttp://www.ncbi.nlm.nih.gov/pubmed/22617844','2011-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'GlaxoSmithKline Biologicals','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('MenHibrix','102371','2012-08-01','2012-06-14','Hib-MenCY-TT-008',2,'Immunogenicity, and safety (4th dose)',NULL,625,NULL,NULL,NULL,NULL,'NCT00134719',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2005-08-10','2005-04-01',NULL,NULL,NULL,'Y','2012-06-15','N','2007-07-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20948453\r\nhttp://www.ncbi.nlm.nih.gov/pubmed/22617844','2011-03-02',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'GlaxoSmithKline Biologicals','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('MenHibrix','103813','2012-08-01','2012-06-14','Hib-MenCY-TT -009',3,'Lot-to-lot consistency, immunogenicity, and safety (dose: 1-3)',NULL,3136,NULL,NULL,NULL,NULL,'NCT00289783',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-02-09','2006-02-01',NULL,NULL,NULL,'Y','2012-06-15','Y','2008-02-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23649970\r\nhttp://www.ncbi.nlm.nih.gov/pubmed/22617844','2012-08-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'GlaxoSmithKline Biologicals','N','N','N','2009-05-29','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','N','N'),('MenHibrix','105067','2012-08-01','2012-06-14','Hib-MenCY-TT -010',3,'Immunogenicity, and safety (4th dose)',NULL,2769,NULL,NULL,NULL,NULL,'NCT00289783',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-02-09','2006-02-01',NULL,NULL,NULL,'Y','2012-06-15','Y','2008-02-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23649970\r\nhttp://www.ncbi.nlm.nih.gov/pubmed/22617844',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'GlaxoSmithKline Biologicals','N','N','N','2009-05-29','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('MenHibrix','105987','2012-02-13','2012-06-14','Hib-MenCY-TT-011',3,'Safety (doses 1-3). Controlled.',NULL,3278,NULL,NULL,NULL,NULL,'NCT00345579',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-06-26','2006-09-01',NULL,NULL,NULL,'Y','2012-06-15','Y','2007-10-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22327493','2012-02-13',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'GlaxoSmithKline Biologicals','N','N','N','2009-04-27','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('MenHibrix','105988','2012-02-13','2012-06-14','Hib-MenCY-TT-012 ',3,'Safety (dose 4). Controlled.',NULL,3010,NULL,NULL,NULL,NULL,'NCT00345683',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-06-26','2007-07-01',NULL,NULL,NULL,'Y','2012-06-15','Y','2008-11-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22327493','2012-02-13',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'GlaxoSmithKline Biologicals','N','N','N','2009-06-08','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('MenHibrix','107824',NULL,'2012-06-14','Hib-MenCY-TT-013',2,'1-year antibody persistence. Controlled.',NULL,138,NULL,NULL,NULL,NULL,'NCT00359983',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-07-31','2006-09-01',NULL,NULL,NULL,'Y','2012-06-15','N','2007-11-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23340564','2013-06-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'GlaxoSmithKline Biologicals','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('MenHibrix','110870',NULL,'2012-06-14','MenACWY-TT-057',3,'Safety and immunogenicity',NULL,1290,NULL,NULL,NULL,NULL,'NCT00614614',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-01-31','2008-02-01',NULL,NULL,NULL,'Y','2012-06-15','Y','2009-09-01',NULL,NULL,NULL,NULL,NULL,NULL,'2014-10-08',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'GlaxoSmithKline Biologicals','N','N','N','2011-11-22','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('MenHibrix','792014/001','2007-10-25','2012-06-14','Hib-MenCY-TT-001 ',2,'Dose-ranging. Controlled',NULL,82,NULL,NULL,NULL,NULL,'NCT00127855',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2005-08-08','2003-03-01',NULL,NULL,NULL,'Y','2012-06-15','N','2004-02-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/17996996','2007-10-25',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'GlaxoSmithKline Biologicals','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('MenHibrix','792014/002','2007-10-25','2012-06-14','Hib-MenCY-TT-002',2,'Dose-ranging. Controlled',NULL,NULL,NULL,NULL,NULL,NULL,'NCT00127855',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2005-08-08','2003-03-01',NULL,NULL,NULL,'Y','2012-06-15','N','2004-02-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/17996996','2007-10-26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'GlaxoSmithKline Biologicals','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('MenHibrix','792014/003',NULL,'2012-06-14','Hib-MenCY-TT-003 ',2,'Dose-ranging. Controlled',NULL,78,NULL,NULL,NULL,NULL,'NCT00129116',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2005-08-10','2003-03-01',NULL,NULL,NULL,'Y','2012-06-15','N','2003-12-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20697200','2010-08-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'GlaxoSmithKline Biologicals','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Movantik','05-IN-OX001',NULL,'2014-09-16','SAD Study',1,'Safety, tolerability crossover','Healthy',48,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca Pharmaceuticals','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Movantik','07-IN-NX002',NULL,'2014-09-16',NULL,1,'Safety, tolerability ','Healthy',32,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca Pharmaceuticals','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Movantik','07-IN-NX003a',NULL,'2014-09-16','MAD STUDY',2,'Efficacy of NGL at various doses',NULL,208,'US, Germany, Romania, Canada',NULL,NULL,NULL,'NCT00600119','A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)','Opioid Induced Constipation (OIC)',NULL,'Drug: placebo|Drug: NKTR-118',NULL,'AstraZeneca|Nektar Therapeutics','Interventional','207','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','07-IN-NX003','2008-01-11','2007-12-01','2009-04-01','2015-05-28','2015-05-01','Y','2014-10-13','Y','2009-03-01','United States','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1143&filename=07-IN-NX003_CSR_Synopsis.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23726675','2013-09-01',NULL,NULL,'randomized double blind placebo controlled dose-escalation study','207',2,'OIC','United States, Germany, Romania, Canada',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','Y','Y','Y','2013-01-28','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Movantik','08-PNL-04',NULL,'2014-09-16',NULL,1,'Bioavailability','Healthy',20,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca Pharmaceuticals','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Movantik','D3820C00001',NULL,'2014-09-16',NULL,1,'Absorption distribution metabolism and excretion','Healthy',6,NULL,NULL,NULL,NULL,'NCT01348724','Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] NKTR-118','Healthy Volunteers',NULL,'Drug: [14C] NKTR-118',NULL,'AstraZeneca','Interventional','6','Industry',1,'Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label','D3820C00001','2011-04-21','2011-06-01','2011-09-01','2014-10-13','2014-10-01','N',NULL,'N','2011-09-01','United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1385&filename=D3820C00001_Clinical_Study_Report_Synopsis.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26329350','2015-10-01',NULL,NULL,'open-label, single-arm, noncomparative, single-dose, single-center, mass-balance study','6',1,'Healthy','United Kingdom',NULL,'N','Y','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'N','N','N','N','N','N','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Movantik','D3820C00004',NULL,'2014-09-16','Study 04, Study 004, KODIAC-04',3,'Compare response to NGL doses','Opioid-induced constipation (OIC)',652,'US, Germany, Slovakia, and Australia',NULL,NULL,NULL,'NCT01309841','Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation','Opioid-Induced Constipation (OIC)',NULL,'Drug: NKTR-118|Drug: NKTR-118|Drug: Placebo',NULL,'AstraZeneca','Interventional','652','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)','D3820C00004|2011-001987-24','2011-03-04','2011-03-01','2012-08-01','2015-05-29','2015-05-01','Y','2014-10-13','N','2012-08-01','United States,   Australia,   Germany,   Slovakia','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1853&filename=Clinical_Study_Report_Synopsis_D3820C00004.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26535126, http://www.ncbi.nlm.nih.gov/pubmed/24896818','2014-06-19',NULL,NULL,'randomized double blind parallel group placebo controlled','652',3,'OIC and LIR',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Movantik','D3820C00005',NULL,'2014-09-16','Study 05, Study 005, KODIAC-05',3,'Compare response to NGL doses','OIC',700,'US, Belgium, Croatia, Czech Republic, Hungary, Spain, Sweden, UK',NULL,NULL,NULL,'NCT01323790','Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation','Opioid-Induced Constipation (OIC)',NULL,'Drug: NKTR-118|Drug: NKTR-118|Drug: Placebo',NULL,'AstraZeneca','Interventional','700','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)','D3820C00005|2011-001986-41','2011-03-24','2011-03-01','2012-09-01','2015-06-01','2015-05-01','Y','2014-10-13','N','2012-09-01','United States,   Belgium,   Croatia,   Czech Republic,   Hungary,   Spain,   Sweden,   United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1852&filename=Clinical_Study_Report_Synopsis_D3820C00005.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26535126, http://www.ncbi.nlm.nih.gov/pubmed/24896818','2014-06-19',NULL,NULL,'randomized double blind parallel group placebo controlled','700',3,'OIC and LIR',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Movantik','D3820C00006',NULL,'2014-09-16','Study 06',3,'Compare response to NGL doses','OIC',23,'US, Poland, Czech Republic',NULL,NULL,NULL,'NCT01384292','Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain','Opioid-Induced Constipation',NULL,'Drug: NKTR-118|Drug: NKTR-118|Drug: Placebo',NULL,'AstraZeneca','Interventional','14','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D3820C00006|2011-001985-16','2011-06-28','2011-06-01','2012-09-01','2015-05-28','2015-05-01','Y','2014-10-13','N','2012-09-01','United States,   Australia,   Belgium,   Bulgaria,   Croatia,   Czech Republic,   Germany,   Poland,   Puerto Rico,   Romania,   Slovakia,   South Africa,   Spain,   United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1388&filename=Clinical_Study_Report_Synopsis_D3820C00006.pdf',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','N','Y','Y','N','Y','N',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','Y','Y','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Movantik','D3820C00007',NULL,'2014-09-16','Study 07, Study 007',3,'Compare response to NGL doses','OIC',302,'US extension of Study 04',NULL,NULL,NULL,'NCT01395524','A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation','Opioid-Induced Constipation (OIC)',NULL,'Drug: NKTR-118|Drug: NKTR-118|Drug: Placebo',NULL,'AstraZeneca','Interventional','302','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D3820C00007','2011-06-28','2011-07-01','2012-09-01','2015-06-15','2015-05-01','Y','2014-10-13','N','2012-09-01','United States','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1389&filename=Clinical_Study_Report_Synopsis_D3820C00007.pdf',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','N','Y','Y','N','Y','N',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','Y','Y','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Movantik','D3820C00008',NULL,'2014-09-16','Study 08, Study 008, KODIAC-08',3,'Safety, tolerability ','OIC',844,'US',NULL,NULL,NULL,'NCT01336205','Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation','Opioid-Induced Constipation (OIC)',NULL,'Drug: NKTR-118|Drug: Usual care',NULL,'AstraZeneca','Interventional','844','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','D3820C00008','2011-04-14','2011-04-01','2012-12-01','2014-10-13','2014-10-01','Y','2014-10-13','N','2012-12-01','United States','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1390&filename=Clinical_Study_Report_Synopsis_D3820C00008.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25112584','2014-10-01',NULL,NULL,'multicenter open label randomized parallel group','844',3,'OIC','United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Movantik','D3820C00009',NULL,'2014-09-16',NULL,1,'PK of NGL','Renal impairment',32,NULL,NULL,NULL,NULL,'NCT01372826','Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function','Renal Impairment',NULL,'Drug: NKTR118 Group1|Drug: NKTR118 Group 2|Drug: NKTR118 Group3|Drug: NKTR118',NULL,'AstraZeneca','Interventional','32','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label','D3820C00009','2011-05-25','2011-06-01','2011-11-01','2014-10-13','2014-10-01','N',NULL,'N','2011-10-01','United States','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1391&filename=D3820C00009_Clinical_Study_Report_Synopsis.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24946021','2014-12-01',NULL,NULL,'dual center open-label nonrandomized parallel group study','32',1,'Healthy and Renal Impairment','United States',NULL,'N','Y','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'N','N','N','N','N','N','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Movantik','D3820C00010',NULL,'2014-09-16',NULL,1,'PK and safety and tolerability','Hepatic impairment',24,NULL,NULL,NULL,NULL,'NCT01392807','Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function','Hepatic; Functional Disturbance',NULL,'Drug: NKTR-118',NULL,'AstraZeneca','Interventional','24','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label','D3820C00010','2011-07-08','2011-07-01','2011-11-01','2014-10-13','2014-10-01','N',NULL,'N','2011-11-01','United States','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1392&filename=D3820C00010_Clinical_Study_Report_Synopsis.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24945932','2014-12-01',NULL,NULL,'single dose, nonrandoimzed, open-label, parallel group study','24',1,'Mild or Moderate Hepatic Impairment','United States',NULL,'N','Y','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'N','N','N','N','N','N','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Movantik','D3820C00011',NULL,'2014-09-16','Quinidine DDI Study',1,'PK of NGL','Healthy',57,NULL,NULL,NULL,NULL,'NCT01533155','Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118','Drug Induced Constipation',NULL,'Drug: Nektar 118|Drug: Quinidine|Drug: Quinidine placebo|Drug: Morphine',NULL,'AstraZeneca','Interventional','214','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)','D3820C00011','2012-02-10','2012-03-01','2012-09-01','2014-10-13','2014-10-01','N',NULL,'N','2012-09-01','United States','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1393&filename=Clinical_Study_Report_Synopsis_D3820C00011.pdf',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26248047','2016-04-01',NULL,NULL,'double-blind (quinidine administration), randomized, 2-part, crossover, single-center study','38',1,'Healthy','United States',NULL,'N','Y','Y','Y','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'N','N','N','N','N','N','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Movantik','D3820C00012',NULL,'2014-09-16','Study 0012',1,'Ketoconazole DDI','Healthy',22,NULL,NULL,NULL,NULL,'NCT01520896','Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118','Bioavailability|Healthy Volunteers|Drug- Drug Interactions',NULL,'Drug: NKTR-118|Drug: Ketoconazole',NULL,'AstraZeneca','Interventional','22','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label','D3820C00012','2012-01-26','2012-02-01','2012-04-01','2014-10-13','2014-10-01','N',NULL,'N','2012-04-01','United States','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1394&filename=D3820C00012_Clinical_Study_Report_Synopsis.pdf',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26678015','2015-12-17',NULL,NULL,'open-label, nonrandomized, fixed-sequence, 3-period, 3-treatment, crossover, single-center study','22',1,'Healthy  ','United States',NULL,'N','Y','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'N','N','N','N','N','N','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Movantik','D3820C00014',NULL,'2014-09-16',NULL,1,'TQTc','Healthy ',52,NULL,NULL,NULL,NULL,'NCT01325415','A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects','Amount of NKTR-118 in Blood|Variation in the Heart\'s Electrical Cycle',NULL,'Drug: NKTR-118|Drug: moxifloxacin|Drug: Placebo',NULL,'AstraZeneca','Interventional','45','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)','D3820C00014','2011-03-28','2011-04-01','2011-07-01','2014-10-13','2014-10-01','N',NULL,'N','2011-07-01','United States','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1395&filename=D3820C00014_Clinical_Study_Report_Synopsis.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24238792','2013-12-01',NULL,NULL,'randomized, positive- and placebo-conrolled crossover study','52',1,'Healthy','United States',NULL,'N','Y','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'N','N','N','N','N','N','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Movantik','D3820C00015',NULL,'2014-09-16','Rifampin DDI Study',1,'Rifampin on PK','Healthy',22,NULL,NULL,NULL,NULL,'NCT01533870','Study in Healthy Volunteers to Investigate the Effects of Rifampin on the Pharmacokinetics of NKTR-118','Drug Induced Constipation',NULL,'Drug: NKTR-118|Drug: Rifampin',NULL,'AstraZeneca','Interventional','22','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label','D3820C00015','2012-02-13','2012-03-01','2012-05-01','2014-10-13','2014-10-01','N',NULL,'N','2012-05-01','United States','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1396&filename=D3820C00015.pdf',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26678015','2015-12-17',NULL,NULL,'open-label, nonrandomized, fixed-sequence, 3-period, 3-treatment, crossover, single-center study','22',1,'Healthy','United States',NULL,'N','Y','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'N','N','N','N','N','N','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Movantik','D3820C00018',NULL,'2014-09-16',NULL,1,'Bioequivalence','Healthy',42,NULL,NULL,NULL,NULL,'NCT01623609','Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol','Opioid Induced Constipation',NULL,'Drug: Naloxegol|Drug: Naloxegol',NULL,'AstraZeneca','Interventional','42','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label','D3820C00018','2012-06-18','2012-07-01','2012-09-01','2014-10-13','2014-10-01','N',NULL,'N','2012-09-01','United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1397&filename=Clinical_Study_Report_Synopsis_D3820C00018.pdf',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'N','N','N','N','N','N','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Movantik','D3820C00020',NULL,'2014-09-16','Study 0020/Japanese SAD and MAD',1,'Safety, tolerability ','Healthy',50,'Japan',NULL,NULL,NULL,'NCT01318655','Single and Multiple Ascending Dose Study for NKTR-118 and Cross-over Study to Investigate the Effect of Food for NKTR-118 in Japanese Healthy Subjects','Healthy',NULL,'Drug: NKTR-118|Drug: Placebo',NULL,'AstraZeneca','Interventional','50','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label','D3820C00020','2011-03-17','2011-03-01','2011-07-01','2011-08-24','2011-08-01','N',NULL,'N','2011-07-01','Japan','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1398&filename=D3820C00020_Clinical_Study_Report_Synopsis.pdf',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'N','N','N','N','N','N','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Movantik','D3820C00025',NULL,'2014-09-16',NULL,1,'Relativit bioavailability','Healthy',24,NULL,NULL,NULL,NULL,'NCT01365000','Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects','Healthy',NULL,'Drug: NKTR118 Formulation 1|Drug: NKTR118 Formulation 2|Drug: NKTR118 Formulation 3|Drug: NKTR118 Formulation 1a|Drug: NKTR118 Formulation 3a',NULL,'AstraZeneca','Interventional','21','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label','D3820C00025','2011-05-31','2011-06-01','2011-08-01','2014-10-13','2014-10-01','N',NULL,'N','2011-08-01','United States','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1399&filename=D3820C00025_Clinical_Study_Report_Synopsis.pdf',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'N','N','N','N','N','N','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Movantik','D3820C00032',NULL,'2014-09-16','Diltiazem DDI Study',1,'Diltiazem on PK','Healthy',43,NULL,NULL,NULL,NULL,'NCT01594619','Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol','Drug Induced Constipation',NULL,'Drug: Naloxegol|Drug: Diltiazem XR',NULL,'AstraZeneca','Interventional','44','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label','D3820C00032','2012-05-08','2012-05-01','2012-08-01','2014-10-13','2014-10-01','N',NULL,'N','2012-08-01','United States','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1401&filename=Clinical_Study_Report_Synopsis_D3820C00032.pdf',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26678015','2015-12-17',NULL,NULL,'open-label, nonrandomized, fixed-sequence, 3-period, 3-treatment, crossover, single-center study','43',1,'Healthy','United States',NULL,'N','Y','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca Pharmaceuticals','N','N','N',NULL,'N','N','N','N','N','N','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Odomzo','CAMN107Y2101',NULL,'2015-07-24','Study 08',1,'',NULL,11,NULL,NULL,NULL,NULL,'NCT01456676','Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy','Philadelphia Chromosome Positive Chronic Myelogenous Leukemia',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','11',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-10-14','2012-01-01',NULL,NULL,NULL,'',NULL,'N','2014-02-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Odomzo','CAMN107Y2102',NULL,'2015-07-24','Study 27',NULL,'',NULL,13,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'13',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225A1102','2016-04-01','2015-07-24','Study 10',NULL,'',NULL,36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'36',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26898300','2016-02-22',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225A2108 ',NULL,'2015-07-24','Study 11',1,'',NULL,50,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'50',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225A2110 ',NULL,'2015-07-24','Study 12',NULL,'',NULL,6,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'6',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225A2112',NULL,'2015-07-24','Study 15/Trial 15',1,'','healthy',100,NULL,NULL,NULL,NULL,'NCT01769768','Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients','Advanced Solid Tumor',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','100',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-01-15','2013-04-01',NULL,NULL,NULL,'',NULL,'N','2016-11-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225A2114','2016-04-01','2015-07-24','Study 16',NULL,'','healthy',49,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'49',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26898300','2016-02-22',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225A2201','2015-06-01','2015-07-24','Study 17/Trial 17',2,'','Healthy',230,NULL,NULL,NULL,NULL,'NCT01327053','A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma','Basal Cell Carcinoma',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','230',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2011-03-30','2011-06-01',NULL,NULL,NULL,'','2015-08-24','N','2013-06-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25981810','2015-05-14',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225B2209',NULL,'2015-07-24','Study 18',2,'',NULL,10,NULL,NULL,NULL,NULL,'NCT01350115','Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)','Basal Cell Carcinoma|Gorlin Syndrome|Nevoid Basal Cell Carcinoma Syndrome',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','10',NULL,NULL,'Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2011-05-06','2011-04-01',NULL,NULL,NULL,'','2015-08-18','N','2012-10-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225C2301',NULL,'2015-07-24','Study 19',2,'','healthy',22,NULL,NULL,NULL,NULL,'NCT01708174','A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)','Medulloblastoma',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','22',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-10-11','2013-05-01',NULL,NULL,NULL,'',NULL,'N','2016-07-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225X1101','2016-04-01','2015-07-24','Study 22/Trial 22',1,'','randomized double-blind study of two dose levels;',45,NULL,NULL,NULL,NULL,'NCT01208831','An East Asian Study of LDE225','Advanced Solid Tumor Cancers|Medulloblastoma|Basal Cell Carcinoma',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','45',NULL,NULL,'Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-09-21','2010-10-01',NULL,NULL,NULL,'',NULL,'N','2013-10-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26898300','2016-02-22',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225X2101','2014-04-01','2015-07-24','ATX-101-10-22 (Clin: 6)',1,'','patients with locally advanced or metastatic basal cell carcinoma',103,NULL,NULL,NULL,NULL,'NCT00880308','Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors','Advanced Solid Tumor Cancers|Medulloblastoma|Basal Cell Carcinoma',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','103',NULL,NULL,'Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2009-04-09','2009-03-01',NULL,NULL,NULL,'',NULL,'N','2013-07-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/24523439','2014-02-12',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225X2103',NULL,'2015-07-24','REFINE-2 Study',1,'','nevoid BCC syndrome',18,NULL,NULL,NULL,NULL,'NCT01487785','Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients','Pancreatic Cancer',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','18',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-12-05','2012-03-01',NULL,NULL,NULL,'',NULL,'N','2014-07-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225X2104',NULL,'2015-07-24','Study 23/Trial 23',2,'',NULL,76,NULL,NULL,NULL,NULL,'NCT01125800','A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB','Medulloblastoma,|Rhabdomyosarcoma,|Neuroblastoma,|Hepatoblastoma,|Glioma,|Astrocytoma',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','76',NULL,NULL,'Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-05-12','2011-02-01',NULL,NULL,NULL,'','2015-09-29','N','2014-10-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225X2114',NULL,'2015-07-24','ATX-101-10-23 (Clin: 6)',1,'','advanced solid tumors; japanese patients',120,NULL,NULL,NULL,NULL,'NCT01576666','Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors','Dose Escalation|Safety|Preliminary Efficacy|Advanced Solid Tumors|Metastatic Breast Cancer|Advanced Pancreatic Adenocarcinoma|Metastatic Colorectal Cancer|Recurrent Glioblastoma Multiforme|Gastric Cancer|Gastroesophageal Junction Cancer|Triple Negative Metastatic Breast Cancer|Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','120',NULL,NULL,'Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label',NULL,'2012-04-10','2012-07-01',NULL,NULL,NULL,'',NULL,'N','2015-04-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225X2116',NULL,'2015-07-24','REFINE-2 Study',2,'','advanced solid tumors',50,NULL,NULL,NULL,NULL,'NCT01787552','A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF','Primary Myelofibrosis|Thrombocythemia, Essential|Thrombocytosis|Myeloproliferative Disorders|Bone Marrow Diseases|Hematologic Diseases|Blood Coagulation Disorders|Blood Platelet Disorders|Hemorrhagic Disorders',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','50',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-02-06','2013-05-01',NULL,NULL,NULL,'',NULL,'N','2016-12-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225X2203',NULL,'2015-07-24','Study 24/Trial 24',2,'',NULL,70,NULL,NULL,NULL,NULL,'NCT01826214','Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia','Acute Leukemias',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','70',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-03-25','2013-05-01',NULL,NULL,NULL,'','2016-04-14','N','2015-05-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225XUS02T',NULL,'2015-07-24','Study 26',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225XUS03T',NULL,'2015-07-24','Study 32',NULL,'','healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Odomzo','CLDE225XUS20',NULL,'2015-07-24','Study 28',2,'',NULL,10,NULL,NULL,NULL,NULL,'NCT02002689','LDE225 for Patients With PTCH1 or SMO Mutated Tumors','PTCH1 or SMO Activated Solid and Hematologic Tumors',NULL,NULL,NULL,'Novartis Pharmaceuticals|Novartis','Interventional','10',NULL,NULL,'Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-12-01','2014-02-01',NULL,NULL,NULL,'','2016-03-23','N','2015-03-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novartis Pharms Corp',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Otezla','ASTH-001',NULL,'2014-09-23',NULL,2,'%FI','Mild asthma',73,NULL,NULL,NULL,NULL,'NCT',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2050-01-01',NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'http://www.celgene.com/content/uploads/CC-10004-ASTH-001-Synopsis_Redacted.pdf',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'1','Celgene Corp','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Otezla','BCT-001',NULL,'2014-09-23',NULL,2,'Oral Ulcers','Behcet\'s disease',111,NULL,NULL,NULL,NULL,'NCT00866359','A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behet Disease','Behcet Syndrome',NULL,'Drug: Apremilast (CC-10004)|Drug: Placebo',NULL,'Celgene Corporation','Interventional','111','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','CC-10004-BCT-001|EudraCT#: 2008-002722-11','2009-03-18','2009-10-01','2013-07-01','2014-08-26','2014-08-01','Y','2014-04-22','Y','2012-05-01','United States,   Turkey','http://www.celgene.com/content/uploads/CC-10004-BCT-001-Synopsis-_Redacted.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25875256','2015-04-16',NULL,NULL,'double-blind, placebo-controlled, parallel-group ','111',2,'Behcet\'s syndrome','Turkey, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Celgene Corp','Y','Y','Y','2013-05-29','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Otezla','CC-10004-BA-001',NULL,'2014-09-23',NULL,1,NULL,'Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Celgene Corp','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-BA-002',NULL,'2014-09-23',NULL,1,NULL,'Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Celgene Corp','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-CP-011',NULL,'2014-09-23',NULL,1,'PK','Hepatic impairment',32,'US',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.researchgate.net/publication/264836860_Pharmacokinetics_and_safety_of_apremilast_CC-10004_in_subjects_with_hepatic_impairment','2014-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Celgene Corp','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-CP-012',NULL,'2014-09-23',NULL,1,'Bioavailability','Healthy male',12,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Celgene Corp','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-CP-018',NULL,'2014-09-23',NULL,1,'PK','Healthy male',36,'US',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Celgene Corp','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-CP-019',NULL,'2014-09-23',NULL,1,'PK','Renal impairment',16,'US',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Celgene Corp','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-CP-020',NULL,'2014-09-23',NULL,1,'PK with contraceptive','Healthy female',40,'US',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Celgene Corp','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-CP-022',NULL,'2014-09-23',NULL,1,'Food Effect','Healthy',46,'US',NULL,NULL,NULL,'NCT01634178','Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Subjects','Healthy Volunteer',NULL,'Drug: Apremilast|Drug: Apremilast',NULL,'Celgene Corporation','Interventional','46','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label','CC-10004-CP-022','2012-07-03','2012-02-01','2012-03-01','2012-07-05','2012-06-01','N',NULL,'N','2012-03-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Celgene Corp','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-CP-024',NULL,'2014-09-23',NULL,1,'PK, demographic','Healthy',36,'US',NULL,NULL,NULL,'NCT01634191','Pharmacokinetics of Apremilast (CC-10004) in Healthy Elderly Subjects','Healthy Volunteer',NULL,'Drug: Apremilast',NULL,'Celgene Corporation','Interventional','36','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label','CC-10004-CP-024','2012-07-03','2012-02-01','2012-04-01','2012-07-05','2012-06-01','N',NULL,'N','2012-03-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Celgene Corp','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-CP-025',NULL,'2014-09-23',NULL,1,'PK with rifampin','Healthy',21,'US',NULL,NULL,NULL,'NCT01561963','A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast','Healthy',NULL,'Drug: Apremilast|Drug: Rifampin',NULL,'Celgene Corporation','Interventional','21','Industry',1,'Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label','CC-10004-CP-025','2012-03-21','2012-02-01','2012-04-01','2012-10-16','2012-10-01','N',NULL,'N','2012-04-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24962564','2014-11-01',NULL,NULL,'single center, open-label, sequential treatment trial w 3 treatment periods','21',1,'Healthy Female','United States',NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Celgene Corp','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-PK-001',NULL,'2014-09-23','Study 1398/317',1,'Dose','Healthy males, sterile females',40,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Celgene Corp','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-PK-002','2011-08-23','2014-09-23',NULL,1,'ADME','Healthy male',6,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21859393','2011-12-01',NULL,NULL,'open-label, single-dose study re metabolites etc.','6',1,'Healthy Male','United States',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Celgene Corp','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-PK-005',NULL,'2014-09-23',NULL,1,'Ketoconazole effect','Healthy male',18,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24962564','2014-11-01',NULL,NULL,'single center, open-label, sequential treatment trial w 2 treatment periods','18',1,'Healthy Male','United States',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Celgene Corp','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-PK-007',NULL,'2014-09-23',NULL,1,'Dose','Healthy male',55,'UK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Celgene Corp','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-PK-008',NULL,'2014-09-23',NULL,1,'QTc','Healthy male',60,'US',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Celgene Corp','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-PK-010','2014-05-08','2014-09-23',NULL,1,'PK with methotrexate','RA or PSA',15,'US',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26097790','2014-11-01',NULL,NULL,'open-label, multicenter, 3-treatment period squential study','15',1,'Psoriati arthritis','United States',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Celgene Corp','N','N','N',NULL,'Y','Y','N','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-PSA-001',NULL,'2014-09-23','PSA-001, Study 1',2,'ACR20','Psoriatic Arthritis',204,NULL,NULL,NULL,'United States','NCT00456092','Phase II Study With CC-10004 in Psoriatic Arthritis','Psoriatic Arthritis',NULL,'Drug: CC-10004|Drug: CC-10004|Drug: Matching Placebo',NULL,'Celgene Corporation','Interventional','204','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','CC-10004-PSA-001','2007-04-02','2009-01-01','2009-05-01','2013-11-22','2013-11-01','N',NULL,'Y','2009-05-01','Belgium,   Canada,   Germany,   Netherlands,   United Kingdom','http://www.celgene.com/content/uploads/CC-10004-PSA-001-Synopsis_Redacted.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22806399','2012-10-01',NULL,NULL,'randomized, double-blind, placebo-controlled','204',2,'Active Psoriatic Arthritis','Canada, Belgium, Germany, Netherlands, United Kingdom',NULL,'N','Y','Y','Y','Y','Y','Y','N','Y','N','N','Y','Y',NULL,NULL,NULL,'1','Celgene Corp','N','Y','N','2013-03-28','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-PSA-002','2014-03-04','2014-09-23','PSA-002, \"Palace 1\", Study 2',3,'ACR20','Psoriatic Arthritis',504,NULL,NULL,NULL,NULL,'NCT01172938','Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis','Psoriatic Arthritis',NULL,'Drug: Apremilast 20mg|Drug: Apremilast 30mg|Drug: Placebo + 20 mg Apremilast|Drug: Placebo + 30 mg Apremilast',NULL,'Celgene Corporation','Interventional','504','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','CC-10004-PSA-002','2010-07-06','2010-06-01','2016-11-01','2015-10-19','2015-10-01','Y','2014-04-22','Y','2012-04-01','United States,   Australia,   Austria,   Canada,   France,   Germany,   Hungary,   New Zealand,   Poland,   Russian Federation,   South Africa,   Spain,   United Kingdom','http://www.celgene.com/content/uploads/CC-10004-PSA-002-Synopsis_Redacted.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24595547','2014-06-01',NULL,NULL,'placebo-controlled phase of PALACE 1','504',3,'Psoriatic Arthritis',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Celgene Corp','Y','Y','Y','2013-05-29','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Otezla','CC-10004-PSA-003',NULL,'2014-09-23','PSA-003, \"Palace 2\", Study 3',3,'ACR20','Psoriatic Arthritis',488,NULL,NULL,NULL,NULL,'NCT01212757','PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis','Psoriatic Arthritis',NULL,'Drug: Apremilast 20mg|Drug: Apremilast 30mg|Drug: Placebo + 20 mg Apremilast|Drug: Placebo + 30 mg Apremilast',NULL,'Celgene Corporation','Interventional','488','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','CC-10004-PSA-003|2010-018386-32','2010-09-29','2010-09-01','2017-01-01','2015-12-22','2015-12-01','Y','2014-04-21','Y','2012-07-01','United States,   Belgium,   Bulgaria,   Canada,   Czech Republic,   Estonia,   France,   Germany,   Hungary,   Italy,   Poland,   Russian Federation,   South Africa,   Spain,   Taiwan,   United Kingdom','http://www.celgene.com/content/uploads/CC-10004-PSA-003-Synopsis_Redacted.pdf',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','N','Y','Y','Y','Y','N',NULL,NULL,NULL,'1','Celgene Corp','Y','Y','Y','2013-05-29','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Otezla','CC-10004-PSA-004',NULL,'2014-09-23','PSA-004, \"Palace 3\", Study 4',3,'ACR20','Psoriatic Arthritis',505,NULL,NULL,NULL,NULL,'NCT01212770','PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis','Psoriatic Arthritis',NULL,'Drug: Apremilast 20mg|Drug: Apremilast 30mg|Drug: Placebo + 20 mg Apremilast|Drug: Placebo + 30 mg Apremilast',NULL,'Celgene Corporation','Interventional','505','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','CC-10004-PSA-004','2010-09-29','2010-09-01','2017-02-01','2015-11-12','2015-11-01','Y','2014-04-22','Y','2012-07-01','United States,   Australia,   Canada,   Finland,   France,   Germany,   Italy,   Korea, Republic of,   Lithuania,   Poland,   Romania,   Russian Federation,   Slovakia,   Spain,   Switzerland,   United Kingdom','http://www.celgene.com/content/uploads/CC-10004-PSA-004-Synopsis_Redacted.pdf',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26792812','2016-01-20',NULL,NULL,'randomized, placebo-controlled, double-blind phase','505',3,'Psoriati arthritis',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Celgene Corp','Y','Y','Y','2013-07-23','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Otezla','CC-10004-PSA-005',NULL,'2014-09-23','PSA-005',3,'ACR20','Psoriatic Arthritis',428,NULL,NULL,NULL,NULL,'NCT01307423','Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)','Psoriatic Arthritis',NULL,'Drug: Apremilast 20mg|Drug: Apremilast 30mg|Drug: Placebo',NULL,'Celgene Corporation','Interventional','529','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','CC-10004-PSA-005|2010-020324-22','2010-11-29','2010-12-01','2017-06-01','2015-09-28','2015-09-01','Y','2014-05-16','Y','2013-01-01','United States,   Australia,   Belgium,   Bulgaria,   Canada,   Czech Republic,   Estonia,   France,   Hungary,   Italy,   Korea, Republic of,   Lithuania,   New Zealand,   Poland,   Romania,   Russian Federation,   Taiwan,   United Kingdom','http://www.celgene.com/content/uploads/CC-10004-PSA-005-Synopsis_Redacted.pdf',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','N','Y','Y','Y','Y','N',NULL,NULL,NULL,'1','Celgene Corp','Y','Y','Y','2013-07-26','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Otezla','CC-10004-PSOR-001','2008-04-16','2014-09-23','PSOR-001',2,'PASI','Severe plaque psoriasis',19,NULL,NULL,NULL,NULL,'NCT00604682','Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis','Psoriasis',NULL,'Drug: CC10004',NULL,'Celgene Corporation','Interventional','19','Industry',2,'Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','CC-10004-PSOR-001','2008-01-17','2005-01-01','2005-12-01','2012-10-09','2008-01-01','N',NULL,'N','2005-10-01','United States','http://www.celgene.com/content/uploads/CC-10004-PSOR-001-Synopsis_Redacted.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/18419879','2008-05-01',NULL,NULL,'open label single-arm','19',2,'Severe Plaque-type Psoriasis','United States',NULL,'N','Y','Y','Y','Y','Y','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Celgene Corp','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-PSOR-003',NULL,'2014-09-23','PSOR-003',2,'PASI','Moderate to severe psoriasis',260,NULL,NULL,NULL,NULL,'NCT00606450','Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis','Psoriasis',NULL,'Drug: CC-10004|Drug: CC-10004|Drug: Placebo',NULL,'Celgene Corporation','Interventional','260','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','CC-10004-PSOR-003','2008-01-22','2006-04-01','2007-05-01','2013-05-29','2013-05-01','N',NULL,'N','2007-02-01','Canada,   Czech Republic,   Germany','http://www.celgene.com/content/uploads/CC-10004-PSOR-003-Synopsis_Redacted.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23030767','2013-03-01',NULL,NULL,'randomized double-blind placebo-controlled parallel-group dose-comparison','259',2,'Moderate to Severe Plaque Psoriasis','Canada, Czech Republic, Germany, ',NULL,'N','Y','Y','Y','Y','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Celgene Corp','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Otezla','CC-10004-PSOR-004',NULL,'2014-09-23','PSOR-004',2,'PASI','Moderate to severe psoriasis',352,NULL,NULL,NULL,NULL,'NCT00521339','Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis','Psoriasis-Type Psoriasis|Plaque-Type Psoriasis',NULL,'Drug: Apremilast',NULL,'Celgene Corporation','Interventional','31','Industry',2,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','CC-10004-PSOR-004','2007-08-24','2007-08-01','2009-05-01','2015-11-09','2015-11-01','Y','2014-10-14','Y','2009-04-01','United States','http://www.celgene.com/content/uploads/CC-10004-PSOR-004-Synopsis-Redacted.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23986162','2013-08-01',NULL,NULL,'open-label study evaluating efficacy, tolerability, safety, and PK','30',2,'Recalcitrant Plaque Psoriasis','United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Celgene Corp','Y','Y','Y','2010-08-24','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Otezla','CC-10004-PSOR-005','2012-06-29','2014-09-23','PSOR-005, PSOR-005-E-LTE, PSOR-005-E',2,'PASI-75','Moderate to severe plaque psoriasis',352,NULL,NULL,NULL,NULL,'NCT00773734','Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)','Psoriasis|Plaque-type Psoriasis',NULL,'Drug: Apremilast 10mg|Drug: Apremilast 20mg|Drug: Apremilast 30 mg|Drug: Placebo|Drug: Apremilast 30mg|Drug: Apremilast 20mg',NULL,'Celgene Corporation','Interventional','352','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','CC-10004-PSOR-005','2008-10-14','2008-09-01','2015-05-01','2015-09-11','2015-09-01','Y','2014-10-22','Y','2009-08-01','United States, Canada','http://www.celgene.com/content/uploads/CC-10004-PSOR-005-Synopsis-Redacted.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22748702','2012-08-25',NULL,NULL,'multicenter, randomized, placebo-controlled, dose-ranging study','89',2,'Moderate to severe Plaque Psoriasis','Canada, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Celgene Corp','Y','Y','Y','2013-07-26','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Otezla','CC-10004-PSOR-008',NULL,'2014-09-23','PSOR-008, ESTEEM-1',3,'PASI-75','Moderate to severe plaque psoriasis',844,'US, Canada, Europe, Australia',NULL,NULL,NULL,'NCT01194219','Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis','Plaque Psoriasis',NULL,'Drug: Apremilast|Drug: Placebo|Drug: Topical treatments or phototherapy',NULL,'Celgene Corporation','Interventional','844','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','CC-10004-PSOR-008','2010-08-31','2010-09-01','2016-10-01','2016-03-25','2016-03-01','Y','2014-10-22','Y','2012-12-01','United States,   Australia,   Belgium,   Canada,   France,   Germany,   Italy,   United Kingdom','http://www.celgene.com/content/uploads/CC-10004-PSOR-008-Synopsis_Redacted.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26089047','2015-07-01',NULL,NULL,NULL,'844',3,'Moderate to severe Plaque Psoriasis','randomized, double-blind, placebo-controlled',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Celgene Corp','Y','Y','Y','2013-05-24','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Otezla','CC-10004-PSOR-009','2015-11-07','2014-09-23','PSOR-009',3,'PASI-75','Moderate to severe plaque psoriasis',413,'US, Canada, Europe  ',NULL,NULL,NULL,'NCT01232283','Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.','Plaque Psoriasis',NULL,'Drug: Apremilast|Drug: Placebo|Other: Topical or Phototherapy Therapy',NULL,'Celgene Corporation','Interventional','413','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','CC-10004-PSOR-009','2010-10-29','2010-11-01','2016-11-01','2015-10-19','2015-10-01','Y','2014-10-22','Y','2012-12-01','United States,   Austria,   Canada,   Denmark,   France,   Germany,   Italy,   Spain,   Switzerland','http://www.celgene.com/content/uploads/CC-10004-PSOR-009-Synopsis_Redacted.pdf',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/?term=Efficacy+and+safety+of+apremilast%2C+an+oral+phosphodiesterase+4+inhibitor%2C+in+patients+with+moderate-to-severe+plaque+psoriasis+over+52+weeks%3A+a+phase+III%2C+randomized+controlled+trial+(ESTEEM+2)','2015-12-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Celgene Corp','Y','Y','Y','2013-05-24','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Otezla','RA-002',NULL,'2014-09-23',NULL,2,'ACR20','Rheumatoid Arthritis',237,NULL,NULL,NULL,NULL,'NCT01285310','Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis','Rheumatoid Arthritis',NULL,'Drug: Apremilast 30 mg|Drug: Apremilast 20 mg|Drug: Placebo',NULL,'Celgene Corporation','Interventional','237','Industry',2,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','CC-10004-RA-002|2010-019926-15','2010-11-19','2010-12-01','2012-09-01','2014-08-13','2014-08-01','Y','2014-04-22','Y','2012-02-01','United States,   Czech Republic,   Poland,   Spain','http://www.celgene.com/content/uploads/CC-10004-RA-002-Synopsis_Redacted.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25779750','2015-07-01',NULL,NULL,'pilot, multicenter, randomized, double-blind, placebo-controlled, parallel-group','237',2,'Rheumatoid Arthritis','Czech Republic, Poland, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Celgene Corp','Y','Y','Y','2013-05-28','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Perjeta','BO16934',NULL,'2012-06-08',NULL,2,' Interventional, open Label, parallel, safety/efficacy study',NULL,79,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2003-02-01',NULL,NULL,NULL,'N',NULL,'N','2004-12-01',NULL,NULL,NULL,NULL,NULL,NULL,'2010-02-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Perjeta','BO17003',NULL,'2012-06-08',NULL,1,' Interventional,  open-label, safety, PK',NULL,19,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2004-01-01',NULL,NULL,NULL,'N',NULL,'N','2004-05-01',NULL,NULL,NULL,NULL,NULL,NULL,'2008-05-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'0','0','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Perjeta','BO17004',NULL,'2012-06-08',NULL,2,'Interventional, Open Label, Single group, PK',NULL,68,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2003-09-01',NULL,NULL,NULL,'N',NULL,'N','2005-05-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'0','0','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Perjeta','BO17021',NULL,'2012-06-08',NULL,1,' Interventional, open-label, safety, PK',NULL,19,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2004-04-01',NULL,NULL,NULL,'N',NULL,'N','2006-01-01',NULL,NULL,NULL,NULL,NULL,NULL,'2007-11-13',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'0','0','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Perjeta','BO17929',NULL,'2012-06-08',NULL,2,NULL,'Patients [3]',95,NULL,NULL,NULL,NULL,'NCT01674062',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2012-08-24','2006-05-01',NULL,NULL,NULL,NULL,NULL,NULL,'2017-12-01',NULL,NULL,NULL,NULL,NULL,NULL,'2010-02-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,'N','N','N','N','N','N','N',NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N'),('Perjeta','BO17931',NULL,'2012-06-08',NULL,2,'Interventional, randomized, safety/efficacy, parallel assgnment, open label',NULL,149,NULL,NULL,NULL,NULL,'NCT02004093',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2013-12-03','2005-12-01',NULL,NULL,NULL,'Y','2014-07-31','N','2008-09-01',NULL,NULL,NULL,NULL,NULL,NULL,'2012-09-20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Perjeta','BO22280',NULL,'2012-06-08','TRYPHAENA',2,'Safety',NULL,225,NULL,NULL,NULL,NULL,'NCT00976989',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-09-14','2009-12-01',NULL,NULL,NULL,'N',NULL,'N','2016-08-01',NULL,NULL,NULL,NULL,NULL,NULL,'2013-05-22',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','N','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Perjeta','JO17076',NULL,'2012-06-08',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Perjeta','TOC2572g',NULL,'2012-06-08',NULL,2,'Interventional, non randomized, safety/efficacy, single group, open label, PK',NULL,60,NULL,NULL,NULL,NULL,'NCT00063154',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2003-06-20','2014-07-03',NULL,NULL,NULL,'N',NULL,'N','2004-04-05',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Perjeta','TOC2682g',NULL,'2012-06-08',NULL,2,'Interventional, non randomized, safety/efficacy, single group, open label, PK',NULL,45,NULL,NULL,NULL,NULL,'NCT00058539',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2003-04-08','2014-04-03',NULL,NULL,NULL,'N',NULL,'N','2004-10-04',NULL,NULL,NULL,NULL,NULL,NULL,'2007-02-20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Perjeta','TOC2689g',NULL,'2012-06-08',NULL,2,'Interventional, open label, efficacy',NULL,129,NULL,NULL,NULL,NULL,'NCT00058552',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2003-04-08','2003-03-01',NULL,NULL,NULL,'N',NULL,'N','2004-07-04',NULL,NULL,NULL,NULL,NULL,NULL,'2006-08-08',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Perjeta','TOC3258g',NULL,'2012-06-08',NULL,2,'Interventional, Placebo-Controlled, Double-Blind, PK',NULL,131,NULL,NULL,NULL,NULL,'NCT00096993',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2004-11-17','2014-01-05',NULL,NULL,NULL,'N',NULL,'N','2004-09-07',NULL,NULL,NULL,NULL,NULL,NULL,'2009-11-09',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Perjeta','WO20024',NULL,'2012-06-08',NULL,1,'Interventional, Non-randomized, Open Label, Single group, Safety/efficacy study ',NULL,15,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-09-01',NULL,NULL,NULL,'N',NULL,'N','2008-12-01',NULL,NULL,NULL,NULL,NULL,NULL,'2012-05-19',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'0','0','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Perjeta','WO20697',NULL,'2012-06-08','NEOSPHERE',2,'pCR',NULL,417,NULL,NULL,NULL,NULL,'NCT00545688',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2007-10-16','2007-12-01',NULL,NULL,NULL,'N',NULL,'N','2014-09-01',NULL,NULL,NULL,NULL,NULL,NULL,'2011-12-06',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Perjeta','WO20698/ TOC4129g',NULL,'2012-06-08','CLEOPATRA',3,'Interventional, randomized, safety/efficacy, parallel assgnment, doube blind',NULL,808,NULL,NULL,NULL,NULL,'NCT00567190',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2007-12-03','2008-02-01',NULL,NULL,NULL,'Y','2012-08-14','N','2011-05-01',NULL,NULL,NULL,NULL,NULL,NULL,'2010-12-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Genentech','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Signifor','B2101','2012-04-19','2012-12-14',NULL,1,'Ascending Single LAR Dose (tolerability/safety, PK & PD)','Healthy',72,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22573933','2012-04-19',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Signifor','B2102','2012-04-21','2012-12-14',NULL,1,'tolerability/safety, PK & PD','Healthy',33,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22527887','2012-04-21',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Signifor','B2103','2012-03-01','2012-12-14',NULL,2,'used for safety data; compare efficacy of SOM230 and sandostatin',NULL,12,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2002-12-05',NULL,NULL,'N',NULL,'N','2002-12-05',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22383336, http://www.ncbi.nlm.nih.gov/pubmed/16060911, http://www.ncbi.nlm.nih.gov/pubmed/16003295, http://www.ncbi.nlm.nih.gov/pubmed/14764775','2012-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'0','0','N','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Signifor','B2106','2012-02-24','2012-12-14',NULL,1,'ascending dose study (tolerability/safety, PK & PD)','Healthy',17,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22364824','2012-02-24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Signifor','B2107',NULL,'2012-12-14',NULL,2,'tolerability/safety & PD','Healthy',66,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22713526','2014-05-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Signifor','B2108','2011-06-14','2012-12-14',NULL,1,'safety of subcutaneous infusion of pasireotide','Healthy',44,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21673137','2011-06-14',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Signifor','B2110',NULL,'2012-12-14',NULL,1,'Cancelled with no Patients (HV)','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Signifor','B2112','2013-05-17','2012-12-14',NULL,1,'human ADME study','Healthy',4,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23680921','2013-05-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','Y','N','N','N','Y','N','N','N'),('Signifor','B2113',NULL,'2012-12-14',NULL,1,'ascending dose study to assess MTD','Healthy',55,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Signifor','B2114','2012-01-26','2012-12-14',NULL,1,'Hepatitic impairment study','Patients',34,NULL,NULL,NULL,NULL,'NCT00698464',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-06-11','2016-07-15','2009-04-01',NULL,NULL,'N',NULL,'N','2009-04-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22282526','2012-01-26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Signifor','B2124','2013-12-25','2012-12-14',NULL,1,'effect of anti-diabetic medications on pasireotide-induced hyperglycemia','Healthy',90,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24461109','2014-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Signifor','B2125',NULL,'2012-12-14',NULL,1,'QT study','Healthy',112,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24242903','2014-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Signifor','B2201','2010-04-21','2012-12-14',NULL,2,'used for safety data (efficacy, safety, PK/PD)','Patients',60,NULL,NULL,NULL,NULL,'NCT00088582',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2004-07-30','2016-03-15','2005-10-01',NULL,NULL,'N',NULL,'N','2005-10-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20410233','2010-04-21',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Signifor','B2201E1',NULL,'2012-12-14',NULL,2,'used for safety data (extension study)','Patients',30,NULL,NULL,NULL,NULL,'NCT00171730',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2005-09-13','2016-08-15','2013-07-01',NULL,NULL,'N',NULL,'N','2013-07-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23529827',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Signifor','B2202','2012-09-14','2012-12-14',NULL,2,'used for safety data (safety, efficacy, QoL, and PK)','Patients',45,NULL,NULL,NULL,NULL,'NCT00088595',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2004-07-30','2016-01-15','2008-07-01',NULL,NULL,'N',NULL,'N','2008-07-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22807497','2012-09-14',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Signifor','B2208','2008-10-28','2012-12-14',NULL,2,'safety, efficacy, PK','Patients',39,NULL,NULL,NULL,NULL,'NCT00088608',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2004-07-30','2016-04-15','2006-06-01',NULL,NULL,'N',NULL,'N','2006-06-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/18957506','2008-10-28',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Signifor','B2208E1',NULL,'2012-12-14',NULL,2,'extension to B2208','Patients',19,NULL,NULL,NULL,NULL,'NCT00171951',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2005-09-13','2016-08-15','2013-12-06',NULL,NULL,'N',NULL,'N','2013-12-06',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23943009','2014-08-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Signifor','B2216','2013-06-03','2012-12-14',NULL,2,'Investigator-initiated trial','Healthy',45,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2010-04-23',NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23733372','2013-06-03',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','Y','N','N','N','Y','N','N','N'),('Signifor','B2305',NULL,'2012-12-14',NULL,3,'efficacy - pivotal trial','Patients',162,NULL,NULL,NULL,NULL,'NCT00434148',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2007-02-09','2006-12-01','2010-03-17',NULL,NULL,'N',NULL,'N','2010-03-17',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22397653, http://www.ncbi.nlm.nih.gov/pubmed/23575965','2012-03-08',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Novartis','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Signifor','C2101','2012-03-01','2012-12-14',NULL,1,'ascending dose study (tolerability/safety, PK & PD)','Healthy',78,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-12-28',NULL,NULL,'N',NULL,'N','2006-12-28',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22383336','2012-05-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,NULL,'N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Sirturo','BAC1003',NULL,'2012-12-28',NULL,1,'DDI with RMP','Healthy',16,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Healthy',NULL,NULL,NULL,NULL,NULL,NULL,'2004-10-01',NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2014-05-26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y','N','N','N',NULL,'Janssen','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','N','N','N','N','N','N','N','N','N','N'),('Sirturo','C104',NULL,'2012-12-28',NULL,1,'DDI with INH and PZA','Healthy',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Healthy',NULL,NULL,NULL,NULL,NULL,NULL,'2005-05-01',NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2014-05-26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y','N','N','N',NULL,'Janssen','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','N','N','N','N','N','N','N','N','N','N'),('Sirturo','C108',NULL,'2012-12-28',NULL,1,'bioavailability','Healthy',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Healthy',NULL,NULL,NULL,NULL,NULL,NULL,'2005-01-01',NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2014-05-26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y','N','N','N',NULL,'Janssen','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','N','N','N','N','N','N','N','N','N','N'),('Sirturo','C109',NULL,'2012-12-28',NULL,1,'DDI with ketoconazole','Healthy',16,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Healthy',NULL,NULL,NULL,NULL,NULL,NULL,'2005-06-01',NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2014-05-26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y','N','N','N',NULL,'Janssen','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','N','N','N','N','N','N','N','N','N','N'),('Sirturo','C110',NULL,'2012-12-28',NULL,1,'DDI with lopinavir/ritonavir','Healthy',12,NULL,NULL,NULL,NULL,'NCT00828529',NULL,NULL,'Completed',NULL,NULL,NULL,'Healthy','16',NULL,1,NULL,NULL,'2009-01-22','2009-02-01',NULL,NULL,NULL,'N',NULL,'N','2009-05-01',NULL,NULL,NULL,NULL,NULL,NULL,'2014-05-26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y','N','N','N',NULL,'Janssen','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Sirturo','C111',NULL,'2012-12-28',NULL,1,'bioavailability','Healthy',28,NULL,NULL,NULL,NULL,'NCT00946842',NULL,NULL,'Completed',NULL,NULL,NULL,'Healthy','28',NULL,1,NULL,NULL,'2009-07-23','2009-08-01',NULL,NULL,NULL,'N',NULL,'N','2010-03-01',NULL,NULL,NULL,NULL,NULL,NULL,'2014-05-26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y','N','N','N',NULL,'Janssen','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Sirturo','C112',NULL,'2012-12-28',NULL,1,'hepatitic impairment study','Patients',16,NULL,NULL,NULL,NULL,'NCT01012284',NULL,NULL,'Completed',NULL,NULL,NULL,'Patients','16',NULL,1,NULL,NULL,'2009-11-12','2010-01-01',NULL,NULL,NULL,'N',NULL,'N','2011-01-01',NULL,NULL,NULL,NULL,NULL,NULL,'2014-05-26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y','N','N','N',NULL,'Janssen','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Sirturo','C117',NULL,'2012-12-28',NULL,1,'DDI with nevirapine in HIV infected','Patients',16,NULL,NULL,NULL,NULL,'NCT00910806',NULL,NULL,NULL,NULL,NULL,NULL,'Healthy',NULL,NULL,NULL,NULL,NULL,NULL,'2009-06-01',NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2014-05-26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y','N','N','N',NULL,'Janssen','N','N','N',NULL,'Y','Y','N','N','Y','Y','N','Y','Y','N','Y','N','N','N','N','N','N','N','N','N','N'),('Sirturo','C210',NULL,'2012-12-28',NULL,3,'confirmatory trial','Study withdrawn prior to enrollment',NULL,NULL,NULL,NULL,NULL,'NCT01600963',NULL,NULL,NULL,NULL,NULL,NULL,'Patients','0',NULL,3,NULL,NULL,'2012-04-24','2014-03-01',NULL,NULL,NULL,'N',NULL,'N','2016-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','N','N','N','N','N',NULL,'Janssen','N','N','N',NULL,'N','?','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Sirturo','CDE-101',NULL,'2012-12-28',NULL,1,'Pt 1: ascending dose; Pt 2: food interaction','Healthy',54,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Healthy',NULL,NULL,NULL,NULL,NULL,NULL,'2004-02-01',NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2014-05-26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y','N','N','N',NULL,'Janssen','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','N','N','N','N','N','N','N','N','N','N'),('Sirturo','CDE-102',NULL,'2012-12-28',NULL,1,'multiple ascending dose','Healthy',27,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Healthy',NULL,NULL,NULL,NULL,NULL,NULL,'2004-03-01',NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2014-05-26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y','N','N','N',NULL,'Janssen','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','N','N','N','N','N','N','N','N','N','N'),('Sirturo','TBC1003',NULL,'2012-12-28',NULL,1,'QT study','Healthy',88,NULL,NULL,NULL,NULL,'NCT01291563',NULL,NULL,'Completed',NULL,NULL,NULL,'Healthy','88',NULL,1,NULL,NULL,'2011-02-01','2011-02-01',NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2014-05-26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','Y','N','N','N','N',NULL,'N','Y','Y','N','N','N',NULL,'Janssen','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','N','N','N','N','N','N','N','N','N','N'),('Sirturo','TMC207-C202','2008-05-27','2012-12-28',NULL,2,'Degree of reduction in sputum viable count over 7-day period','Patients',75,NULL,NULL,NULL,NULL,'NCT00523926,  NCT00910806',NULL,NULL,'Completed',NULL,NULL,NULL,'Patients','75',NULL,2,NULL,NULL,'2007-08-30','2005-05-01',NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/18505852','2008-05-27',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Janssen','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','N','Y','Y','N','N','Y','Y','N','Y','Y'),('Sirturo','TMC207-C208','2012-03-05','2012-12-28',NULL,2,'Stage 1: PK, antibacterial activity, safety & tolerability; Stage 2: Superiority compared to placebo (efficacy)','Patients',47,NULL,NULL,NULL,NULL,'NCT00449644',NULL,NULL,'Completed',NULL,NULL,NULL,'Patients','208',NULL,2,NULL,NULL,'2007-03-16','2007-06-01',NULL,NULL,NULL,'Y','2013-01-29','Y','2010-03-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19494215, http://www.ncbi.nlm.nih.gov/pubmed/22391540','2009-06-04',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Janssen','N','N','N','2011-06-20','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Sirturo','TMC207-C209',NULL,'2012-12-28',NULL,2,'Safety, tolerability, efficacy','Patients',233,NULL,NULL,NULL,NULL,'NCT00910871',NULL,NULL,'Completed',NULL,NULL,NULL,'Patients','241',NULL,2,NULL,NULL,'2009-05-28','2009-09-01',NULL,NULL,NULL,'Y','2013-01-30','N','2011-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Janssen','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Sivextro','16101',NULL,'2014-10-29',NULL,1,'Bioavailability',NULL,36,'Japan',NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Sivextro','16102',NULL,'2014-10-29',NULL,1,'Intestinal flora evaluation',NULL,24,'Japan',NULL,NULL,'United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Sivextro','TR701-101',NULL,'2014-10-29','Study 101',1,'Safety PK','Healthy',80,NULL,NULL,NULL,'United States','NCT00671814','Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults','Healthy Subjects',NULL,'Drug: TR-701|Drug: linezolid|Drug: placebo','SAD/MAD','Trius Therapeutics LLC','Interventional','90','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','TR701-101','2008-05-01','2008-01-01','2008-05-01','2012-06-01','2011-10-01','N',NULL,'N','2008-05-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23926058','2014-03-01',NULL,NULL,'two-part, nine-cohort, double-blind; single- and multiple-ascending dose','80',1,'Healthy','United States',NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Sivextro','TR701-102',NULL,'2014-10-29',NULL,1,'Microdialysis','Healthy',12,NULL,NULL,NULL,'United States','NCT00666601','Microdialysis and Pharmacokinetic Study of TR-701','Healthy',NULL,'Drug: TR-700 (active moiety)|Drug: TR-701 (pro-drug)','null','Trius Therapeutics LLC','Interventional','15','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label','TR701-102','2008-04-23','2008-04-01','2009-03-01','2011-10-12','2011-10-01','N',NULL,'N','2008-06-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Sivextro','TR701-103',NULL,'2014-10-29',NULL,1,'Food effect','Healthy fasted',12,NULL,NULL,NULL,'United States','NCT00671359','Food Effects of Single Oral Dose of 600mg TR-701','Healthy',NULL,'Drug: TR-701 600mg','null','Trius Therapeutics LLC','Interventional','12','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label','TR701-103','2008-05-01','2008-04-01','2008-05-01','2011-10-12','2011-10-01','N',NULL,'N','2008-05-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23926058','2014-03-01',NULL,NULL,'food effect, open-label randomized, 2-sequence, 2-treatment, 2-period crossover ','12',1,'Healthy','United States',NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Sivextro','TR701-104',NULL,'2014-10-29',NULL,2,'Clinical and microbiological response, PopPK','Patients with cSSSI',192,NULL,NULL,NULL,'United States','NCT00761215','Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections','Skin Diseases, Infectious|Skin Diseases, Bacterial',NULL,'Drug: TR-701 200 mg|Drug: TR-701 300 mg|Drug: TR-701 400 mg','null','Trius Therapeutics LLC','Interventional','192','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','TR701-104','2008-09-25','2008-09-01','2009-05-01','2014-08-08','2014-08-01','Y','2014-07-15','Y','2009-05-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21115795','2011-02-01',NULL,NULL,'ose-ranging, randomized, double-blind, noncontrolled study','192',2,'cSSSI','United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','Y','Y','Y','2014-04-02','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Sivextro','TR701-105',NULL,'2014-10-29',NULL,1,'Safety PK with tyramine','Healthy',39,NULL,NULL,NULL,'United States','NCT01539473','A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge','Healthy Volunteers',NULL,'Drug: TR-701 FA with Tyramine|Drug: Placebo-controlled withTyramine','null','Trius Therapeutics LLC','Interventional','30','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)','TR701-105','2012-02-21','2012-02-01','2012-05-01','2012-06-12','2012-05-01','N',NULL,'N','2012-05-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23612197','2013-07-01',NULL,NULL,'randomized, double-blind, placebo-controlled crossover','30',1,'Healthy',NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Sivextro','TR701-106',NULL,'2014-10-29',NULL,1,'Safety PK of excretion','Healthy male',6,NULL,NULL,NULL,'United States','NCT01442831','Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects','Healthy',NULL,'Drug: Human ADME','null','Trius Therapeutics LLC','Interventional','6','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','TR701-106','2011-06-06','2010-09-01','2010-09-01','2011-10-12','2011-10-01','N',NULL,'N','2010-09-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24875463','2014-08-01',NULL,NULL,'metabolism of drug','6',1,'Healthy',NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Sivextro','TR701-107',NULL,'2014-10-29',NULL,1,'Safety PK of venous','Healthy',90,NULL,NULL,NULL,'United States','NCT00983255','Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)','Bacterial Infections',NULL,'Drug: TR-701 FA for injection, 200 mg/vial|Drug: TR-701 FA tablets','IV/SAD/MAD','Trius Therapeutics LLC','Interventional','90','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Factorial Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','TR701-107','2009-09-22','2009-09-01','2010-01-01','2014-07-18','2010-07-01','N',NULL,'N','2010-01-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24989138','2014-09-01',NULL,NULL,'double-blind, single- and multiple-ascending dose PK study, tolerability and open-label crossover studies','90',1,'Healthy','United States',NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Sivextro','TR701-108',NULL,'2014-10-29',NULL,1,'Bioavailability','Healthy',12,NULL,NULL,NULL,'United States','NCT00876655','Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate','Healthy',NULL,'Drug: TR-701 di-sodium phosphate salt|Drug: TR-701 free acid phosphate','null','Trius Therapeutics LLC','Interventional','12','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label','TR701-108','2009-04-03','2009-02-01','2009-03-01','2011-10-12','2011-10-01','N',NULL,'N','2009-03-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23926058','2014-03-01',NULL,NULL,'relative bioavailability, open-label randomized, 2-sequence, 2-treatment, 2-period, crossover ','12',1,'Healthy','United States',NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Sivextro','TR701-109',NULL,'2014-10-29',NULL,1,'Safety PK','Elderly',28,NULL,NULL,NULL,'United States','NCT01496677','Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects','Healthy Subjects',NULL,'Drug: TR-701 FA 200 mg|Drug: TR-701 FA 200 mg','null','Trius Therapeutics LLC','Interventional','28','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label','TR701-109','2011-12-19','2011-12-01','2012-02-01','2015-03-17','2015-03-01','N',NULL,'N','2012-02-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Sivextro','TR701-110',NULL,'2014-10-29','Study 110',1,'Safety and opthalmic',NULL,72,NULL,NULL,NULL,'United States','NCT01623401','A Phase 1, Open-Label, 10 Day Safety Study','Healthy Subjects',NULL,'Drug: TR-701 FA','null','Trius Therapeutics LLC','Interventional','72','Industry',1,'Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label','TR701-110','2012-06-06','2012-05-01','2012-08-01','2012-12-05','2012-04-01','N',NULL,'N','2012-08-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Sivextro','TR701-111',NULL,'2014-10-29',NULL,1,'Safety PK','Adolescents',20,NULL,NULL,NULL,'United States','NCT01156077','Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients','Bacterial Infection',NULL,'Drug: TR-701 FA|Drug: TR-701 FA','null','Trius Therapeutics LLC','Interventional','20','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label','TR701-111','2010-06-11','2010-06-01','2011-09-01','2011-09-26','2011-09-01','N',NULL,'N','2011-09-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'multicenter, open-label, single-dose','20',1,'Receiving antibacterial',NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Sivextro','TR701-112',NULL,'2014-10-29','Study 112, ESTABLISH-1',3,'ABSSSI, PopPK','Patients with ABSSSI',667,'North America, Europe, Latin America',NULL,NULL,'United States','NCT01170221','TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.','Skin and Subcutaneous Tissue Bacterial Infections',NULL,'Drug: TR-701 FA|Drug: Linezolid','ABSSSI','Trius Therapeutics LLC','Interventional','667','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','TR701-112','2010-07-23','2010-08-01','2011-09-01','2014-08-31','2014-08-01','Y','2014-07-15','Y','2011-09-01','United States,   Argentina,   Brazil,   Canada,   Czech Republic,   Germany,   Hungary,   Latvia,   Peru,   Slovakia,   Ukraine',NULL,NULL,NULL,NULL,' http://www.ncbi.nlm.nih.gov/pubmed/23403680','2013-02-13',NULL,NULL,'randomized, double-blind, noninferiority trial','667',3,'ABSSSI','United States, Canada, Germany, Czech Republic, Hungary, Slovakia, Latvia, Ukraine, Argentina, Brazil, Peru',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','Y','Y','Y','2014-04-02','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Sivextro','TR701-113',NULL,'2014-10-29','Study 113',3,'ABSSSI , IV to oral','Adults and adolescents with ABSSSI',666,'US, Europ, South Africa, Australia, New Zealand Argentina',NULL,NULL,'United States','NCT01421511','TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections','Skin and Subcutaneous Tissue Bacterial Infections',NULL,'Drug: TR-701 FA|Drug: Linezolid','null','Trius Therapeutics LLC','Interventional','666','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','TR701-113','2011-08-19','2011-09-01','2013-01-01','2014-08-31','2014-08-01','Y','2014-07-15','Y','2013-01-01','United States,   Argentina,   Australia,   Brazil,   Germany,   Mexico,   New Zealand,   Poland,   Russian Federation,   South Africa,   Spain',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24909499','2014-08-01',NULL,NULL,'randomized, double-blind, phase 3, non-inferiority trial','666',3,'ABSSSI','Argentina, Australia, germany, New Zealand, Poland, Russia, South Africa, Spain, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','Y','Y','Y','2014-04-02','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Sivextro','TR701-114',NULL,'2014-10-29',NULL,1,'Safety and blood pressure','Healthy',18,NULL,NULL,NULL,'United States','NCT01577459','A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response','Healthy Subjects',NULL,'Drug: TR-701 FA with PSE|Other: TR-701 FA Placebo with PSE','null','Trius Therapeutics LLC','Interventional','18','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)','TR701-114','2012-04-11','2012-04-01','2012-05-01','2012-06-06','2012-04-01','N',NULL,'N','2012-05-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23612197','2013-07-01',NULL,NULL,'randomized, double-blind, placebo-controlled crossover','18',1,'Healthy',NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Sivextro','TR701-115',NULL,'2014-10-29',NULL,1,'QTcF','Healthy',48,NULL,NULL,NULL,'United States','NCT01461460','A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects','Healthy Volunteer',NULL,'Drug: TR-701 FA 1200 mg|Drug: Moxifloxacin 400 mg|Drug: TR-701 FA 200 mg plus Placebo|Drug: Placebo','null','Trius Therapeutics LLC','Interventional','48','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver)','TR701-115','2011-10-26','2011-11-01','2011-12-01','2015-03-17','2015-03-01','N',NULL,'N','2011-12-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Sivextro','TR701-119',NULL,'2014-10-29',NULL,1,'Safety and pulmonary epithelial lining fluid',NULL,20,NULL,NULL,NULL,'United States','NCT01271998','Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg','Bacterial Infection',NULL,'Drug: TR-701 FA','null','Trius Therapeutics LLC','Interventional','20','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label','TR701-119','2010-12-07','2010-12-01','2010-12-01','2011-09-15','2011-08-01','N',NULL,'N','2010-12-01','United States',NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/22330925','2012-05-01',NULL,NULL,NULL,'20',NULL,'Healthy',NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Sivextro','TR701-123',NULL,'2014-10-29',NULL,1,'Safety PK','Renal impairment',24,NULL,NULL,NULL,'United States','NCT01452828','A Pharmacokinetics and Safety Study in Subjects With Renal Impairment','Renal Impairment',NULL,'Drug: TR-701 FA single infusion|Drug: TR-701 FA|Drug: TR-701 FA','null','Trius Therapeutics LLC','Interventional','24','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','TR701-123','2011-09-21','2011-10-01','2012-03-01','2012-06-07','2011-10-01','N',NULL,'N','2012-03-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25136024','2014-11-01',NULL,NULL,'open-label single-dose parallel-group','24',1,'Renal Impairment','United States',NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Sivextro','TR701-124',NULL,'2014-10-29',NULL,1,'Safety PK','Hepatic impairment',32,NULL,NULL,NULL,'United States','NCT01431833','A PK and Safety Study in Subjects With Hepatic Impairment','Hepatic Impairment',NULL,'Drug: TR-701 FA','null','Trius Therapeutics LLC','Interventional','32','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label','TR701-124','2011-08-05','2011-08-01','2012-05-01','2012-06-06','2011-09-01','N',NULL,'N','2012-05-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25136024','2014-11-01',NULL,NULL,'open-label single-dose parallel-group','32',1,'Hepatic Impairment','United States',NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Sivextro','TR701-126',NULL,'2014-10-29',NULL,2,'Exploratory skin lesion','Patients with major cutaneous abscess',200,NULL,NULL,NULL,'United States','NCT01519778','A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study','Major Cutaneous Abscess|Cellulitis|Erysipelas',NULL,'Drug: TR701 FA','null','Trius Therapeutics LLC|Bayer','Interventional','200','Industry',2,'Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label','TR701-126','2012-01-24','2012-02-01','2012-08-01','2015-03-12','2015-03-01','Y','2015-02-27','Y','2012-08-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','Y','Y','N','Y','N','N','Y','N',NULL,NULL,NULL,'0','Cubist Pharmaceuticals / Merck and Co.','N','Y','N','2014-04-02','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','N','N','Y','N','N','N'),('Stivarga','11650',NULL,'2012-09-27','PH-36733',1,'Patient PK and Initial Tolerability','Patients',76,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2012-03-15',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bayer','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stivarga','11651',NULL,'2012-09-27','PH-36742, PH-36741',1,'Dose escalation','Patients',84,NULL,NULL,NULL,NULL,' ',NULL,NULL,'Active, not recruiting',NULL,NULL,NULL,NULL,'84',NULL,1,NULL,NULL,'2010-02-11','2007-02-01','2013-08-01','2013-07-02',NULL,'N',NULL,'N','2013-08-01',NULL,NULL,NULL,NULL,NULL,'http://www.clinicaltrials.gov/ct2/show/NCT01117623?term=regorafenib+11651&rank=1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bayer','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stivarga','11656',NULL,'2012-09-27','PH-36735',NULL,'Open label','Patients',45,NULL,NULL,NULL,NULL,'NCT00934882',NULL,NULL,'Completed',NULL,NULL,NULL,NULL,'45',NULL,1,NULL,NULL,'2009-07-03','2009-08-01',NULL,NULL,NULL,'N',NULL,'N','2012-04-01',NULL,NULL,NULL,NULL,NULL,'http://www.clinicaltrials.gov/ct2/show/NCT00934882?term=regorafenib+bayer&rank=22','2013-03-13',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bayer','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stivarga','11726',NULL,'2012-09-27','A46572, A55873',2,'Uncontrolled Phase II','Patients',49,NULL,NULL,NULL,NULL,'NCT00664326',NULL,NULL,'Active, not recruiting',NULL,NULL,NULL,NULL,'49',NULL,2,NULL,NULL,'2008-04-17','2008-04-01',NULL,'2013-07-11',NULL,'Y','2012-10-28','N','2009-05-01',NULL,NULL,NULL,NULL,NULL,'http://www.clinicaltrials.gov/ct2/show/NCT00664326?term=regorafenib+bayer&rank=20','2012-09-06',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bayer','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Stivarga','12434',NULL,'2012-09-27','PH-36721',NULL,'Extrinsic Factor PK, Open label','Patients',16,NULL,NULL,NULL,NULL,'NCT01287598',NULL,NULL,'Active, not recruiting',NULL,NULL,NULL,NULL,'40',NULL,1,NULL,NULL,'2011-01-31','2011-08-01','2013-10-01','2013-07-05',NULL,'N',NULL,'N','2013-10-01',NULL,NULL,NULL,NULL,NULL,'http://www.clinicaltrials.gov/ct2/show/NCT01287598?term=12434&rank=1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bayer','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stivarga','12435',NULL,'2012-09-27','PH-36717',NULL,'Human PK Study/ Extrinsic Factor PK','Healthy',24,NULL,NULL,NULL,NULL,'NCT01318265',NULL,NULL,'Completed',NULL,NULL,NULL,NULL,'24',NULL,1,NULL,NULL,'2011-02-18','2011-03-01',NULL,'2012-10-18',NULL,'N',NULL,'N','2011-07-01',NULL,NULL,NULL,NULL,NULL,'http://www.clinicaltrials.gov/ct2/show/NCT01318265?term=regorafenib+12435&rank=1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bayer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stivarga','12436',NULL,'2012-09-27','PH-36734',NULL,'Healthy subject PK, open label','Healthy',4,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bayer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stivarga','12437',NULL,'2012-09-27','PH-36595',NULL,'Biopharmaceutic, relative bioavailability','Healthy',48,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bayer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stivarga','13172',NULL,'2012-09-27','A51164',2,'Uncontrolled Phase II, open label','Patients',16,NULL,NULL,NULL,NULL,'NCT00960258',NULL,NULL,'Ongoing',NULL,NULL,NULL,NULL,'15',NULL,1,NULL,NULL,'2009-07-03','2009-07-01',NULL,'2013-09-02',NULL,'N',NULL,'N','2010-04-01',NULL,NULL,NULL,NULL,NULL,'http://www.clinicaltrials.gov/ct2/show/NCT00960258?term=regorafenib+bayer&rank=26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bayer','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stivarga','14387',NULL,'2012-09-27','A53306',NULL,'RCT, double-blinded, placebo-controlled','Patients',760,NULL,NULL,NULL,NULL,'NCT01103323',NULL,NULL,'Active, not recruiting',NULL,NULL,NULL,NULL,'760',NULL,3,NULL,NULL,'2010-04-08','2010-04-01',NULL,'2013-07-18',NULL,'Y','2012-10-19','N','2011-07-01',NULL,NULL,NULL,NULL,NULL,'http://www.clinicaltrials.gov/ct2/show/NCT01103323?term=bayer+Regorafenib&rank=18','2012-11-22',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bayer','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Stivarga','14596',NULL,'2012-09-27','A51601',2,'Uncontrolled Phase II','Patients',36,NULL,NULL,NULL,NULL,'NCT01003015',NULL,NULL,'Completed',NULL,NULL,NULL,NULL,'36',NULL,2,NULL,NULL,'2009-10-02','2009-09-01','2013-03-01',NULL,NULL,'N',NULL,'N','2010-11-01',NULL,NULL,NULL,NULL,NULL,'http://www.clinicaltrials.gov/ct2/show/NCT01003015?term=regorafenib+bayer&rank=25','2013-06-25',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bayer','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stivarga','14656',NULL,'2012-09-27','PH-36525',NULL,'Bioavailability, Open label, randomized, crossover','Healthy',24,NULL,NULL,NULL,NULL,'NCT01002378',NULL,NULL,'Completed',NULL,NULL,NULL,NULL,'24',NULL,1,NULL,NULL,'2009-10-26','2009-10-01','2010-02-01','2013-05-21',NULL,'N',NULL,'N','2010-02-01',NULL,NULL,NULL,NULL,NULL,'http://www.clinicaltrials.gov/ct2/show/NCT01002378?term=regorafenib+14656&rank=1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bayer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stivarga','14814',NULL,'2012-09-27','PH-36720',NULL,'Patient PD and PK/PD ; Open label','Patients',54,NULL,NULL,NULL,NULL,'NCT01339104',NULL,NULL,'Completed',NULL,NULL,NULL,NULL,'53',NULL,1,NULL,NULL,'2011-04-19','2011-04-01','2013-08-01','2013-09-13',NULL,'N',NULL,'N','2013-08-01',NULL,NULL,NULL,NULL,NULL,'http://www.clinicaltrials.gov/ct2/show/NCT01339104?term=regorafenib+%22phase+I%22+bayer&rank=5','2012-03-15',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bayer','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stivarga','14996',NULL,'2012-09-27','A51600',2,'Uncontrolled Phase II','Patients',12,NULL,NULL,NULL,NULL,'NCT01096030',NULL,NULL,'Completed',NULL,NULL,NULL,NULL,'33',NULL,1,NULL,NULL,'2010-03-29','2010-07-01',NULL,'2013-01-21',NULL,'N',NULL,'N','2012-11-01',NULL,NULL,NULL,NULL,NULL,'http://www.clinicaltrials.gov/ct2/show/NCT01096030?term=regorafenib+bayer&rank=16',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Bayer','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stivarga','15524',NULL,'2012-09-27','PH-36716',NULL,'Human PK Study/ Extrinsic Factor PK','Healthy',24,NULL,NULL,NULL,NULL,'NCT01322438',NULL,NULL,'Completed',NULL,NULL,NULL,NULL,'24',NULL,1,NULL,NULL,'2011-03-23','2011-03-01','2011-05-01','2013-07-02',NULL,'N',NULL,'N','2011-05-01',NULL,NULL,NULL,NULL,NULL,'http://www.clinicaltrials.gov/ct2/show/NCT01322438?term=regorafenib+15524&rank=1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,NULL,'N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-183-0101',NULL,'2012-08-27',NULL,1,'Elvitegravir safety, PK, antiviral activity','Patients',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-183-0102',NULL,'2012-08-27',NULL,1,'Elvitegravir pilot PK study','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-183-0103',NULL,'2012-08-27',NULL,NULL,'drug interaction study - no other info',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-183-0105',NULL,'2012-08-27',NULL,2,'Elvitegravir compared to comparator PI','Patients',NULL,NULL,NULL,NULL,NULL,'NCT00298350',NULL,NULL,NULL,NULL,NULL,NULL,'Patients','278',NULL,2,NULL,NULL,'2006-02-28','2006-02-01',NULL,NULL,NULL,'N',NULL,'N','2007-06-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20146631','2010-03-15',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-183-0113',NULL,'2012-08-27',NULL,1,'Elvitegravir effect of RTV doses on PK','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-183-0119',NULL,'2012-08-27',NULL,1,'Elvitegravir PK interaction','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-183-0121',NULL,'2012-08-27',NULL,1,'relative bioavailability',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-183-0126',NULL,'2012-08-27',NULL,1,'Elvitegravir PK, metabolism, and excretion','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-183-0128',NULL,'2012-08-27',NULL,1,'Effect of doses on the QT/QTc Interval in healthy subjects','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-183-0130',NULL,'2012-08-27',NULL,2,'Used for high-level safety data',NULL,NULL,NULL,NULL,NULL,NULL,'NCT00445146',NULL,NULL,NULL,NULL,NULL,NULL,'Healthy','122',NULL,2,NULL,NULL,'2007-02-28','2007-03-01',NULL,NULL,NULL,'N',NULL,'N','2014-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','?','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-183-0133',NULL,'2012-08-27',NULL,1,'Elvitegravir and Cobicistat PK','normal & impaired hepatitic function',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-183-0140',NULL,'2012-08-27',NULL,1,'Elvitegravir multiple dose relative availability','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-183-0145','2011-10-18','2012-08-27',NULL,3,'used for high-level safety data',NULL,NULL,NULL,NULL,NULL,NULL,'NCT00708162',NULL,NULL,NULL,NULL,NULL,NULL,'Patients','712',NULL,3,NULL,NULL,'2008-06-30','2008-09-01',NULL,NULL,NULL,'N',NULL,'Y','2010-12-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22015077','2011-10-18',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N','2011-08-23','Y','Y','Y','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Stribild','GS-US-183-0146',NULL,'2012-08-27',NULL,1,'Elvitegravir multiple dose PK interaction','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-216-0105',NULL,'2012-08-27',NULL,2,'used for high-level safety data',NULL,NULL,NULL,NULL,NULL,NULL,'NCT00892437',NULL,NULL,NULL,NULL,NULL,NULL,'Patients','85',NULL,2,NULL,NULL,'2009-04-30','2009-06-01',NULL,NULL,NULL,'N',NULL,'Y','2009-12-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N','2011-08-23','?','?','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-216-0106',NULL,'2012-08-27',NULL,NULL,'DDI Trial of FDC with Oral Contraceptives',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'?','?','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-216-0107',NULL,'2012-08-27',NULL,1,'Effect on the QT/QTc Interval in healthy subjects','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-216-0114','2013-03-26','2012-08-27',NULL,3,'used for high-level safety data',NULL,NULL,NULL,NULL,NULL,NULL,'NCT01108510',NULL,NULL,NULL,NULL,NULL,NULL,'Patients','692',NULL,3,NULL,NULL,'2010-04-20','2010-04-01',NULL,NULL,NULL,'N',NULL,'Y','2011-11-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23532097','2013-03-26',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N','2011-08-23','Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-216-101',NULL,'2012-08-27',NULL,1,'Cobicistat safety, tolerability, PK & PD','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-216-111',NULL,'2012-08-27',NULL,1,'Cobicistat PK, metabolism, excretion','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-216-112',NULL,'2012-08-27',NULL,1,'Cobicistat effect on enzymes','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-216-113',NULL,'2012-08-27',NULL,1,'Cobicistat PK, safety and tolerability','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-216-116',NULL,'2012-08-27',NULL,1,'Cobicistat tablet formulation and PK','normal & renal impairment',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-216-120',NULL,'2012-08-27',NULL,1,'Elvitegravir and Cobicistat relative bioavailability and PK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-216-121',NULL,'2012-08-27',NULL,1,'Cobicistat effect on renal function','normal & renal impairment',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-216-122',NULL,'2012-08-27',NULL,1,'Elvitegravir and Cobicistat relative bioavailability and PK','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-216-123',NULL,'2012-08-27',NULL,1,'Elvitegravir and Cobicistat drug interaction',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-216-124',NULL,'2012-08-27',NULL,1,'Elvitegravir and Cobicistat PK','renal impairment',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-236-0101',NULL,'2012-08-27',NULL,1,'Fixed Dose Combination Tablet - relative bioavailability',NULL,44,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20683270','2010-11-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-236-0102','2012-07-31','2012-08-27',NULL,3,'safety/efficacy of E/C/F/T formulation vs ATR','Patients',700,NULL,NULL,NULL,NULL,'NCT01095796',NULL,NULL,NULL,NULL,NULL,NULL,'Patients','700',NULL,3,NULL,NULL,'2010-03-17','2010-03-01',NULL,NULL,NULL,'N',NULL,'Y','2011-07-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22748591, http://www.ncbi.nlm.nih.gov/pubmed/23392460, http://www.ncbi.nlm.nih.gov/pubmed/23337366, http://www.ncbi.nlm.nih.gov/pubmed/22849516','2012-06-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N','2011-08-23','Y','Y','Y','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Stribild','GS-US-236-0103','2012-07-31','2012-08-27',NULL,3,'safety/efficacy of E/C/F/T formulation vs ATV/r + TVD','Patients',708,NULL,NULL,NULL,NULL,'NCT01106586',NULL,NULL,NULL,NULL,NULL,NULL,'Patients','708',NULL,3,NULL,NULL,'2010-04-14','2010-04-01',NULL,NULL,NULL,'N',NULL,'Y','2011-09-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22748590, http://www.ncbi.nlm.nih.gov/pubmed/22849516','2012-06-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N','2011-08-23','Y','Y','Y','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Stribild','GS-US-236-0104','2012-07-31','2012-08-27',NULL,2,'safety/efficacy of E/C/F/T formulation vs ATR','Patients',71,NULL,NULL,NULL,NULL,'NCT00869557',NULL,NULL,NULL,NULL,NULL,NULL,'Patients','71',NULL,2,NULL,NULL,'2009-03-24','2009-04-01',NULL,NULL,NULL,'N',NULL,'Y','2009-11-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22849516, http://www.ncbi.nlm.nih.gov/pubmed/21412057','2011-03-27',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N','2011-08-23','Y','Y','Y','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Stribild','GS-US-236-0105',NULL,'2012-08-27',NULL,1,'Fixed Dose Combination Tablet - effect of food on PK',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-236-0106',NULL,'2012-08-27',NULL,1,'Fixed Dose Combination Tablet - drug interaction',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-236-0110',NULL,'2012-08-27',NULL,1,'Fixed Dose Combination Tablet - relative bioavailability',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Gilead Sciences INC','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Stribild','GS-US-236-0118',NULL,'2012-08-27',NULL,3,'safety','Patients',NULL,NULL,NULL,NULL,NULL,'NCT01363011',NULL,NULL,NULL,NULL,NULL,NULL,'Patients','100',NULL,3,NULL,NULL,'2011-05-11','2011-05-01',NULL,NULL,NULL,'N',NULL,'Y','2013-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,NULL,'N','N','N','2014-01-10','Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Tagrisso','D5160C00001 (comprised of AURA and AURA Extension)','2015-04-30','2015-11-13','Study 35',1,'',NULL,974,NULL,NULL,NULL,NULL,'NCT01802632','AZD9291 First Time In Patients Ascending Dose Study','Advanced Non-Small Cell Lung Cancer; Advanced (Inoperable) Non-Small Cell Lung Cancer',NULL,NULL,NULL,'AstraZeneca','Interventional','974',NULL,NULL,'safety/efficacy study, single-group assignmnet, open-label, treatment',NULL,'2013-02-25','2017-03-17',NULL,NULL,NULL,'',NULL,'N','2017-05-17','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25923549','2015-04-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Astrazeneca Pharms',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Tagrisso','D5160C00002',NULL,'2015-11-13','Study 36',2,'',NULL,472,NULL,NULL,NULL,NULL,'NCT02094261','Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours','Non-Small Cell Lung Cancer',NULL,NULL,NULL,'AstraZeneca','Interventional','472',NULL,NULL,'safety/efficacy study, single-group assignment, open-label, treatment',NULL,'2014-03-17','2017-04-17',NULL,NULL,NULL,'','2016-04-28','N','2017-05-17','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Astrazeneca Pharms',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,NULL,NULL),('Tagrisso','D5160C00003',NULL,'2015-11-13','Q2201 (Summ 15)',3,'',NULL,410,NULL,NULL,NULL,NULL,'NCT02151981','AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer','Anticancer Treatment',NULL,NULL,NULL,'AstraZeneca','Interventional','410',NULL,NULL,'randomized, safety/efficacy study, parallel assignment, open-label, treatment',NULL,'2014-05-15','2017-08-17',NULL,NULL,NULL,'',NULL,'N','2017-04-17','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Astrazeneca Pharms',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tagrisso','D5160C00005','2016-04-01','2015-11-13',NULL,1,'',NULL,35,NULL,NULL,NULL,NULL,'NCT01951599','To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food','Healthy',NULL,NULL,NULL,'AstraZeneca','Interventional','35',NULL,NULL,'non-randomized, bioavailability, single-group assignment, open-label, basic science',NULL,'2013-09-24','2017-10-17',NULL,NULL,NULL,'',NULL,'N','2017-06-17','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/27198274','2016-02-02',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Astrazeneca Pharms',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Tagrisso','D5160C00006','2016-04-01','2015-11-13','Study 30',1,'',NULL,198,NULL,NULL,NULL,NULL,'NCT02143466','AZD9291 in Combination With Ascending Doses of Novel Therapeutics','Advanced Non-Small Cell Lung Cancer',NULL,NULL,NULL,'AstraZeneca','Interventional','198',NULL,NULL,'non-randomized, safety/efficacy study, parallel assignment, open-label, treatment',NULL,'2014-05-09','2017-08-17',NULL,NULL,NULL,'',NULL,'N','2017-12-17','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/27198274','2016-04-15',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Astrazeneca Pharms',NULL,'N',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Tagrisso','D5160C00007',NULL,'2015-11-13',NULL,3,'',NULL,650,NULL,NULL,NULL,NULL,'NCT02296125','AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer','Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-Small Cell Lung Cancer',NULL,NULL,NULL,'AstraZeneca/Parexel','Interventional','650',NULL,NULL,'randomized, safety/efficacy study, parallel assignment, double-blind, treatment',NULL,'2014-10-22','2017-12-17',NULL,NULL,NULL,'',NULL,'N','2017-05-17','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Astrazeneca Pharms',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tagrisso','D5160C00008',NULL,'2015-11-13',NULL,1,'','patients w/ locally advanced or metastatic NSCLC (Stage IIIB-IV)',39,NULL,NULL,NULL,NULL,'NCT02161770','An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD9291 Following a Single Oral Dose to Patients With Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment','Solid Tumours',NULL,NULL,NULL,'AstraZeneca','Interventional','39',NULL,NULL,'non-randomized, PK study, parallel assignment, open-label',NULL,'2014-05-29','2017-12-17',NULL,NULL,NULL,'',NULL,'N','2017-08-17','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Astrazeneca Pharms',NULL,'N',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tagrisso','D5160C00009',NULL,'2015-11-13','A1102',1,'','healthy subjects',43,NULL,NULL,NULL,NULL,'NCT02163733','Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment','Advanced Non-Small Cell Lung Cancer, Advanced (Inoperable) Non-Small Cell Lung Cancer',NULL,NULL,NULL,'AstraZeneca','Interventional','43',NULL,NULL,'randomized, PK, crossover assignment, open-label',NULL,'2014-05-29','2017-11-17',NULL,NULL,NULL,'','2016-03-03','N','2017-03-17','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Astrazeneca Pharms',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,NULL,NULL),('Tagrisso','D5160C00010',NULL,'2015-11-13','A2108',1,'',NULL,136,NULL,NULL,NULL,NULL,'NCT02224053','Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers','Healthy',NULL,NULL,NULL,'AstraZeneca','Interventional','136',NULL,NULL,'PK, single-group assignment, open-label, treatment',NULL,'2014-08-20','2017-09-17',NULL,NULL,NULL,'','2015-11-26','N','2017-01-17','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Astrazeneca Pharms',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tagrisso','D5160C00011',NULL,'2015-11-13','A2001 (typo)',1,'',NULL,8,NULL,NULL,NULL,NULL,'NCT02096679','Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD9291 in Volunteers','Healthy',NULL,NULL,NULL,'AstraZeneca','Interventional','8',NULL,NULL,'non-randomized, PK, single-group assignment, open-label, basic science',NULL,'2014-03-24','2017-05-17',NULL,NULL,NULL,'','2015-07-02','N','2017-08-17','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Astrazeneca Pharms',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tagrisso','D5160C00012',NULL,'2015-11-13','A2110',1,'','patients w/ locally advanced or metastatic EGFR mutation-positive NSCLC who are treatment-na?ve',47,NULL,NULL,NULL,NULL,'NCT02157883','Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)','Advanced Non-Small Cell Lung Cancer, Advanced (Inoperable) Non-Small Cell Lung Cancer',NULL,NULL,NULL,'AstraZeneca','Interventional','47',NULL,NULL,'non-randomized, PK, crossover assignment, open-label',NULL,'2014-06-05','2017-11-17',NULL,NULL,NULL,'','2016-03-15','N','2017-04-17','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Astrazeneca Pharms',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,NULL,NULL),('Tagrisso','D5160C00013',NULL,'2015-11-13',NULL,1,'',NULL,51,NULL,NULL,NULL,NULL,'NCT02197247','Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC','Non-Small Cell Lung Cancer',NULL,NULL,NULL,'AstraZeneca','Interventional','51',NULL,NULL,'PK, single-group assignment, open-label',NULL,'2014-07-21','2017-12-17',NULL,NULL,NULL,'',NULL,'N','2017-07-17','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Astrazeneca Pharms',NULL,'N',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tagrisso','D5160C00014',NULL,'2015-11-13','A2214',1,'',NULL,57,NULL,NULL,NULL,NULL,'NCT02197234','Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC','Non-Small Cell Lung Cancer',NULL,NULL,NULL,'AstraZeneca','Interventional','57',NULL,NULL,'non-randomized, PK, factorial assignment, open-label, treatment',NULL,'2014-07-21','2017-12-17',NULL,NULL,NULL,'','2016-04-08','N','2017-04-17','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Astrazeneca Pharms',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,NULL,NULL),('Tagrisso','D5160C00019',NULL,'2015-11-13','LDE225A2201',1,'','healthy subjects',55,NULL,NULL,NULL,NULL,'NCT02317016','Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer','Non-Small Cell Lung Cancer',NULL,NULL,NULL,'AstraZeneca','Interventional','55',NULL,NULL,'PK study, single-group assignment, open-label, treatment',NULL,'2014-12-11','2017-03-17',NULL,NULL,NULL,'','2016-06-06','N','2017-07-17','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Astrazeneca Pharms',NULL,'N',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tagrisso','D5160C00021',NULL,'2015-11-13','A2201',NULL,'',NULL,NULL,NULL,NULL,NULL,NULL,'NCT02451852','AZD9291 US Expanded Access Program','EGFR T790M Mutation Positive NSCLC',NULL,NULL,NULL,'AstraZeneca','Expanded Access',NULL,NULL,NULL,'Not Provided',NULL,'2015-05-20',NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Astrazeneca Pharms',NULL,'N',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','EX1250-4080',NULL,'2015-09-25','1982',3,'',NULL,7638,NULL,NULL,NULL,NULL,'NCT01959529','A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','7638',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-10-08','2013-10-01',NULL,NULL,NULL,'',NULL,'N','2016-09-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1045-3834',NULL,'2015-09-25','LDE225B2209',1,'',NULL,32,NULL,NULL,NULL,NULL,'NCT01455142','A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','32',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2011-10-17','2011-10-01',NULL,NULL,NULL,'',NULL,'N','2012-01-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1050-4008',NULL,'2015-09-25','B2209',1,'',NULL,33,NULL,NULL,NULL,NULL,'NCT01773798','A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','33',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-01-18','2013-01-01',NULL,NULL,NULL,'',NULL,'N','2013-08-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-1835','2011-01-26','2015-09-25',NULL,2,'','patients w/ resistant disease',178,NULL,NULL,NULL,NULL,'NCT00612040','Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','178',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2008-01-25','2008-01-01',NULL,NULL,NULL,'','2015-10-16','11/9/09','2008-06-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21270174','2017-03-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2009-11-09','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-1836',NULL,'2015-09-25','X1101',2,'',NULL,245,NULL,NULL,NULL,NULL,'NCT00611884','Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','245',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2008-01-29','2008-01-01',NULL,NULL,NULL,'','2015-10-16','11/9/09','2008-08-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21396703','2011-03-12',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2009-11-09','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-1876',NULL,'2015-09-25','X2101',2,'','T1DM',63,NULL,NULL,NULL,NULL,'NCT01868529','Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','63',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-05-30','2008-01-01',NULL,NULL,NULL,'',NULL,'N','2008-06-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-1987','2012-07-10','2015-09-25',NULL,1,'','T1DM',49,NULL,NULL,NULL,NULL,'NCT01154881','A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','49',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2010-06-30','2010-06-01',NULL,NULL,NULL,'',NULL,'N','2010-11-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22726241','2017-10-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-1988',NULL,'2015-09-25',NULL,1,'','T1DM',27,NULL,NULL,NULL,NULL,'NCT00966368','Comparison of Two NN1250 Formulations in Healthy Volunteers','Diabetes|Healthy',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','27',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2009-08-25','2009-08-01',NULL,NULL,NULL,'',NULL,'N','2009-10-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-1989',NULL,'2015-09-25',NULL,1,'','T2DM on metformin',24,NULL,NULL,NULL,NULL,'NCT00976326','A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function','Diabetes|Healthy',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','24',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2009-09-11','2009-08-01',NULL,NULL,NULL,'',NULL,'N','2010-03-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24277680','2017-02-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-1990',NULL,'2015-09-25',NULL,1,'','T1DM  ',32,NULL,NULL,NULL,NULL,'NCT01006057','A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function','Diabetes|Healthy',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','32',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2009-10-30','2009-11-01',NULL,NULL,NULL,'',NULL,'N','2010-05-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24163264','2017-02-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-1991','2012-06-07','2015-09-25',NULL,1,'','T2DM',54,NULL,NULL,NULL,NULL,'NCT00961324','A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','54',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2009-08-17','2009-07-01',NULL,NULL,NULL,'',NULL,'N','2009-10-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22594461','2017-09-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-1992',NULL,'2015-09-25',NULL,1,'','healthy volunteers',20,NULL,NULL,NULL,NULL,'NCT01151072','A Trial Comparing the Effect of NN1250 After Different Routes of Injection in Healthy Subjects','Diabetes|Healthy',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','20',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-06-24','2010-06-01',NULL,NULL,NULL,'',NULL,'N','2010-10-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25124362','2017-09-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-1993',NULL,'2015-09-25',NULL,1,'','hepatic impairment',66,NULL,NULL,NULL,NULL,'NCT01114542','A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','66',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2010-04-29','2010-05-01',NULL,NULL,NULL,'',NULL,'N','2010-08-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26086190','2015-06-18',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-1994',NULL,'2015-09-25',NULL,1,'','renal impairment',27,NULL,NULL,NULL,NULL,'NCT00964418','A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','27',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2009-08-24','2009-08-01',NULL,NULL,NULL,'',NULL,'N','2009-11-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24263619','2017-01-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-1995',NULL,'2015-09-25',NULL,1,'','T1DM',37,NULL,NULL,NULL,NULL,'NCT01030926','A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','37',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2009-12-11','2009-12-01',NULL,NULL,NULL,'',NULL,'N','2010-05-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24467565','2017-02-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-1996','2015-08-27','2015-09-25','AURA, AURA1, D1560C00001, D5160C0001B (Phase 1), D5160C0001C (Phase 2)',1,'','healthy adults',22,NULL,NULL,NULL,NULL,'NCT01135927','A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','22',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2010-05-31','2010-06-01',NULL,NULL,NULL,'',NULL,'N','2010-10-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/27042281','2017-03-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-1999',NULL,'2015-09-25','AURA2; D1560C00002 (Chem. Review, p. 148)',1,'','T1DM',24,NULL,NULL,NULL,NULL,'NCT01437592','Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects','Diabetes|Healthy',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','24',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-09-09','2011-09-01',NULL,NULL,NULL,'',NULL,'N','2011-11-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3538','2013-09-22','2015-09-25','3846',1,'','geriatric and young adults w/T1DM',28,NULL,NULL,NULL,NULL,'NCT01002768','Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','28',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2009-10-26','2017-10-17',NULL,NULL,NULL,'',NULL,'N','2017-03-17','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24057153','2017-01-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3561',NULL,'2015-09-25','D1560C00005, Study 5',3,'','young adults and geriatric subjects',350,NULL,NULL,NULL,NULL,'NCT01513473','A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','350',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-01-16','2012-01-01',NULL,NULL,NULL,'','2015-10-12','11/7/13','2013-07-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25683037','2017-05-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2013-11-07','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3569','2012-09-14','2015-09-25',NULL,2,'','children, adolescent, and adult w/T1DM  ',65,NULL,NULL,NULL,NULL,'NCT00841087','Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','65',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2009-02-10','2009-01-01',NULL,NULL,NULL,'','2015-10-16','11/9/09','2009-05-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24843632','2013-01-29',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,'2009-11-09','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3579',NULL,'2015-09-25','FLAURA',3,'','Japanese T1DM  ',1030,NULL,NULL,NULL,NULL,'NCT00982644','Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','1030',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2009-09-22','2009-09-01',NULL,NULL,NULL,'','2015-10-14','2/23/11','2010-12-01','','1',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/24170235','2017-12-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2011-02-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3580','2013-05-06','2015-09-25',NULL,3,'','healthy adults',458,NULL,NULL,NULL,NULL,'NCT01046110','Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','458',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-01-08','2010-01-01',NULL,NULL,NULL,'','2015-10-19','2/24/11','2010-11-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23577643','2017-08-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2011-02-24','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3582',NULL,'2015-09-25',NULL,3,'','pediatric trial',1006,NULL,NULL,NULL,NULL,'NCT00972283','Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','1006',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2009-09-03','2009-09-01',NULL,NULL,NULL,'','2015-10-14','12/1/11','2010-10-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22521072','2012-04-21',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2011-12-01','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3583',NULL,'2015-09-25','D1560C00010, Study 10',3,'','T1DM',629,NULL,NULL,NULL,NULL,'NCT00982228','Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','629',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2009-09-22','2009-09-01',NULL,NULL,NULL,'','2015-10-14','2/24/11','2010-11-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22521071','2012-04-21',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2011-02-24','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3585','2014-05-08','2015-09-25',NULL,3,'','Type 2 diabetes mellitus',456,NULL,NULL,NULL,NULL,'NCT01074268','Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','456',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-02-22','2010-02-01',NULL,NULL,NULL,'','2015-10-15','2/25/11','2010-12-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24702700','2017-10-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,'2011-02-25','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3586','2013-06-03','2015-09-25',NULL,3,'','Type 2 diabetes mellitus',435,NULL,NULL,NULL,NULL,'NCT01059799','Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','435',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-01-29','2010-02-01',NULL,NULL,NULL,'','2015-10-12','2/23/11','2010-12-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24843715','2017-11-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,'2011-02-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3587',NULL,'2015-09-25',NULL,3,'','Type 2 diabetes mellitus',833,NULL,NULL,NULL,NULL,'NCT01849289','A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin na??ve Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','833',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-05-06','2013-06-01',NULL,NULL,NULL,'','2015-10-16','N','2014-05-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/27098525','2017-06-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3643',NULL,'2015-09-25',NULL,3,'','Type 1 diabetes mellitus',566,NULL,NULL,NULL,NULL,'EUCTR2009-015754-38-FR',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'566',NULL,NULL,NULL,NULL,NULL,'2010-04-08',NULL,NULL,NULL,'','2016-01-31','N','2011-12-20','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3644',NULL,'2015-09-25',NULL,3,'','type 1 diabetes mellitus, Japanese pax',396,NULL,NULL,NULL,NULL,'EUCTR2009-015755-24-FR',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'396',NULL,NULL,NULL,NULL,NULL,'2010-04-08',NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3667',NULL,'2015-09-25','AURA3, AURA P3',3,'','Type 2 diabetes mellitus, Japanese pax',566,NULL,NULL,NULL,NULL,'EUCTR2009-015816-17-IE',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'566',NULL,NULL,NULL,NULL,NULL,'2010-07-20',NULL,NULL,NULL,'','2016-01-31','N','2011-05-10','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3668','2013-01-22','2015-09-25','Study 11',3,'','Type 2 diabetes mellitus',687,NULL,NULL,NULL,NULL,'NCT01006291','Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','687',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2009-10-30','2009-11-01',NULL,NULL,NULL,'','2015-10-12','11/5/10','2010-09-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23340894','2017-04-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2010-11-05','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3672','2013-05-28','2015-09-25',NULL,3,'','Type 2 diabetes mellitus',460,NULL,NULL,NULL,NULL,'NCT01068665','Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','460',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-02-12','2010-03-01',NULL,NULL,NULL,'','2015-10-12','2/23/11','2010-11-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23715753','2017-09-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2011-02-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3678',NULL,'2015-09-25','4000',1,'','Type 2 diabetes mellitus, insulin treated',33,NULL,NULL,NULL,NULL,'NCT01076634','Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','33',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2010-02-24','2017-02-17',NULL,NULL,NULL,'',NULL,'N','2017-07-17','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23749405','2013-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3718','2013-07-09','2015-09-25',NULL,3,'','T1DM',467,NULL,NULL,NULL,NULL,'NCT01076647','Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','467',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-02-25','2010-03-01',NULL,NULL,NULL,'','2015-10-13','2/23/11','2010-12-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24622318','2017-10-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2011-02-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3724','2013-07-09','2015-09-25','1835',3,'','Type 2 diabetes mellitus',460,NULL,NULL,NULL,NULL,'NCT01068678','Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','460',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-02-12','2010-02-01',NULL,NULL,NULL,'','2015-10-12','2/24/11','2010-11-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24622318','2017-10-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2011-02-24','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3725',NULL,'2015-09-25','1836',3,'','Type 2 diabetes mellitus',324,NULL,NULL,NULL,NULL,'EUCTR2009-015721-36-FI',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'324',NULL,NULL,NULL,NULL,NULL,'2010-04-26',NULL,NULL,NULL,'','2016-01-31','N','2011-06-16','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3762','2014-02-05','2015-09-25','1876',1,'','Type 2 diabetes mellitus',63,NULL,NULL,NULL,NULL,'NCT01043510','The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','63',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2010-01-05','2010-01-01',NULL,NULL,NULL,'',NULL,'N','2010-10-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24508419','2014-04-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3763',NULL,'2015-09-25','1987',1,'','Type 2 insulin naive',1,NULL,NULL,NULL,NULL,'NCT01467414','A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','1',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-10-31','2011-10-01',NULL,NULL,NULL,'',NULL,'N','2011-12-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3765',NULL,'2015-09-25','1988',1,'','Type 2 insulin na?ve',18,NULL,NULL,NULL,NULL,'NCT00964964','A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','18',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2009-08-24','2009-08-01',NULL,NULL,NULL,'',NULL,'N','2009-09-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3769',NULL,'2015-09-25','1989',1,'','T1DM',26,NULL,NULL,NULL,NULL,'NCT01193387','Comparison of Two Identical NN1250 Formulations in Healthy Volunteers','Diabetes|Healthy',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','26',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2010-08-31','2010-08-01',NULL,NULL,NULL,'',NULL,'N','2010-11-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3770','2013-02-07','2015-09-25','1990',3,'','T2DM in African American, Hispanic, Caucasian',493,NULL,NULL,NULL,NULL,'NCT01079234','Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','493',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-03-02','2010-03-01',NULL,NULL,NULL,'','2015-10-12','12/8/11','2010-11-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23393185','2017-03-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2011-12-08','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3829',NULL,'2015-09-25','1991',3,'','T2DM',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3839',NULL,'2015-09-25','1992',3,'','T1DM',143,NULL,NULL,NULL,NULL,'NCT01135992','Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN_??)','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','143',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-05-31','2010-06-01',NULL,NULL,NULL,'','2015-10-16','2/24/11','2010-11-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2011-02-24','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3846','2013-06-29','2015-09-25','1993',3,'',NULL,222,NULL,NULL,NULL,NULL,'NCT01326026','Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin na??ve Subjects With Type 2 Diabetes Mellitus','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','222',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-03-29','2011-03-01',NULL,NULL,NULL,'','2015-10-16','1/17/12','2011-12-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23812875','2017-06-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2012-01-17','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3874',NULL,'2015-09-25','1994',3,'','type 1 diabetes mellitus',24,NULL,NULL,NULL,NULL,'NCT01569841','A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','24',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-03-30','2012-04-01',NULL,NULL,NULL,'','2015-10-16','12/19/12','2012-11-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2012-12-19','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3923',NULL,'2015-09-25','1995',3,'',NULL,373,NULL,NULL,NULL,NULL,'NCT01364428','Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','373',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-05-31','2011-06-01',NULL,NULL,NULL,'','2015-10-16','5/9/12','2012-01-01','','1',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/24518180','2017-08-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2012-05-09','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3943',NULL,'2015-09-25','1996',3,'','T2DM',145,NULL,NULL,NULL,NULL,'NCT01570751','A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','145',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-04-02','2012-04-01',NULL,NULL,NULL,'','2015-10-16','1/24/14','2014-01-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2014-01-24','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3944','2016-05-02','2015-09-25','1999',3,'','Type 2 diabetes mellitus',346,NULL,NULL,NULL,NULL,'NCT01664247','The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','346',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2012-08-10','2012-10-01',NULL,NULL,NULL,'','2015-10-23','1/24/14','2013-12-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26990378','2017-07-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2014-01-24','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3948','2014-02-11','2015-09-25','3561 (main + extension)',3,'',NULL,413,NULL,NULL,NULL,NULL,'NCT01388361','Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','413',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-07-04','2011-09-01',NULL,NULL,NULL,'','2015-10-23','11/28/13','2012-07-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24443830','2017-07-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2013-11-28','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3995',NULL,'2015-09-25','3569',3,'','Type 2 diabetes mellitus',501,NULL,NULL,NULL,NULL,'NCT02034513','A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','501',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2014-01-07','2014-01-01',NULL,NULL,NULL,'',NULL,'N','2016-01-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3998',NULL,'2015-09-25','3579',3,'','T2DM',724,NULL,NULL,NULL,NULL,'NCT02030600','A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','724',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2014-01-07','2014-01-01',NULL,NULL,NULL,'',NULL,'N','2015-12-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-3999','2015-11-27','2015-09-25','3580',1,'','Type 2 diabetes mellitus',40,NULL,NULL,NULL,NULL,'NCT01704417','A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','40',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-10-08','2012-10-01',NULL,NULL,NULL,'',NULL,'N','2013-03-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26450456','2017-02-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-4000',NULL,'2015-09-25','3582',1,'','Type 2 diabetes mellitus',18,NULL,NULL,NULL,NULL,'NCT01623375','A Trial Investigating the Absolute Bioavailability of Insulin Degludec in Healthy Subjects','Diabetes|Healthy',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','18',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-06-04','2012-06-01',NULL,NULL,NULL,'',NULL,'N','2012-08-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-4060',NULL,'2015-09-25','3583',3,'','Type 1 diabetes mellitus',458,NULL,NULL,NULL,NULL,'NCT01880736','A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','458',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-06-14','2013-06-01',NULL,NULL,NULL,'','2015-10-16','N','2014-04-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/27182031','2016-02-22',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN1250-4061',NULL,'2015-09-25','3585',NULL,'','Type 2 diabetes mellitus',6000,NULL,NULL,NULL,NULL,'NCT01984372','Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba??','Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Observational','6000',NULL,NULL,'Observational Model: Cohort|Time Perspective: Prospective',NULL,'2013-11-07','2013-11-01',NULL,NULL,NULL,'',NULL,'N','2019-04-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-1718',NULL,'2015-09-25','3586',1,'',NULL,64,NULL,NULL,NULL,NULL,'NCT01865279','Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec','Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','64',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-05-27','2005-12-01',NULL,NULL,NULL,'',NULL,'N','2006-04-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-1719',NULL,'2015-09-25','3587',1,'','healthy adults',40,NULL,NULL,NULL,NULL,'NCT01865292','Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','40',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-05-27','2006-08-01',NULL,NULL,NULL,'',NULL,'N','2006-11-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-1738',NULL,'2015-09-25','extension of 3579',1,'','Type 2 diabetes mellitus, Japanese pax',59,NULL,NULL,NULL,NULL,'NCT01865305','Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes','Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','59',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-05-27','2006-09-01',NULL,NULL,NULL,'',NULL,'N','2007-02-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-1740',NULL,'2015-09-25','extension of 3583',1,'','Diabetes mellitus, Japan',36,NULL,NULL,NULL,NULL,'NCT01865318','Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','36',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-05-27','2006-09-01',NULL,NULL,NULL,'',NULL,'N','2007-01-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-1788',NULL,'2015-09-25','extension of 3582',1,'','healthy subjects, T1DM and T2DM',32,NULL,NULL,NULL,NULL,'NCT01865331','Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects','Diabetes|Healthy',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','32',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-05-27','2006-12-01',NULL,NULL,NULL,'',NULL,'N','2007-03-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-1790',NULL,'2015-09-25','3668',1,'','T1DM and T2DM',32,NULL,NULL,NULL,NULL,'NCT01868555','Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese Subjects','Diabetes|Healthy',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','32',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-05-30','2007-12-01',NULL,NULL,NULL,'',NULL,'N','2008-02-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-1791','2011-02-01','2015-09-25','3672',2,'','T1DM and T2DM,  Ideg & IDegAsp',178,NULL,NULL,NULL,NULL,'NCT00614055','Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','178',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2008-01-30','2008-01-01',NULL,NULL,NULL,'','2015-10-16','11/9/09','2008-07-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21285389','2017-03-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,'2009-11-09','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-1792','2012-06-01','2015-09-25',NULL,2,'','T1DM  ',182,NULL,NULL,NULL,NULL,'NCT00613951','Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','182',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2008-01-30','2008-01-01',NULL,NULL,NULL,'','2015-10-16','11/9/09','2008-08-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22660026','2017-08-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,'2009-11-09','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-1959',NULL,'2015-09-25',NULL,1,'','healthy Japanese subjects, Ideg & IDegAsp',119,NULL,NULL,NULL,NULL,'NCT01868568','Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','119',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-05-30','2008-04-01',NULL,NULL,NULL,'',NULL,'N','2008-08-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-1977',NULL,'2015-09-25','extension of 3585',1,'','healthy Japanese subjects, Ideg & IDegAsp',27,NULL,NULL,NULL,NULL,'NCT00992537','Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','27',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2009-10-08','2009-10-01',NULL,NULL,NULL,'',NULL,'N','2010-01-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-1978',NULL,'2015-09-25','3762',1,'','T2Dm, insulin na?ve, on metformin',39,NULL,NULL,NULL,NULL,'NCT01134224','A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','39',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2010-05-27','2010-05-01',NULL,NULL,NULL,'',NULL,'N','2010-11-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-1979','2014-06-03','2015-09-25','3763',1,'','T2Dm, insulin na?ve, on metformin',22,NULL,NULL,NULL,NULL,'NCT01590836','A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','22',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-04-30','2012-04-01',NULL,NULL,NULL,'',NULL,'N','2012-06-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24888255','2017-06-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-1980',NULL,'2015-09-25','3765',1,'','T1DM,  Ideg & IDegAsp ',26,NULL,NULL,NULL,NULL,'NCT01125553','A Comparison Between Two Formulations of NN5401 in Healthy Subjects','Diabetes|Healthy',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','26',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2010-05-07','2010-05-01',NULL,NULL,NULL,'',NULL,'N','2010-08-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-1981',NULL,'2015-09-25','3769',1,'','T1DM,  Ideg & IDegAsp ',28,NULL,NULL,NULL,NULL,'NCT01174303','A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','28',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2010-08-02','2010-08-01',NULL,NULL,NULL,'',NULL,'N','2010-11-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26088815','2017-07-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-1982',NULL,'2015-09-25','3770',1,'',NULL,38,NULL,NULL,NULL,NULL,'NCT01138488','A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','38',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-06-04','2010-06-01',NULL,NULL,NULL,'',NULL,'N','2010-11-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26782928','2016-01-18',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-1983','2016-02-04','2015-09-25','extension of 3770',1,'','T1DM',21,NULL,NULL,NULL,NULL,'NCT01051102','Effect of NN5401 in Japanese Subjects With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','21',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2010-01-15','2010-01-01',NULL,NULL,NULL,'',NULL,'N','2010-04-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/27181070','2016-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-1985',NULL,'2015-09-25','3839',1,'','healthy subjects',116,NULL,NULL,NULL,NULL,'NCT01868581','Bioequivalence Between Two Explorative Insulin Degludec Formulations and Between Two Explorative IDegAsp Formulations in Healthy Subjects','Diabetes|Healthy',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','116',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-05-30','2008-05-01',NULL,NULL,NULL,'',NULL,'N','2008-08-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-3539','2015-05-01','2015-09-25','3874',1,'','T1DM in children, adolescents, and adults',33,NULL,NULL,NULL,NULL,'NCT00993096','Investigation of the Response Relationship of NN5401 in Type 1 Diabetics','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','33',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2009-10-08','2009-09-01',NULL,NULL,NULL,'',NULL,'N','2009-12-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25772444','2017-07-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-3570',NULL,'2015-09-25','3923',2,'','Japanese subjects w/T1DM',66,NULL,NULL,NULL,NULL,'NCT00842361','Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','66',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2009-02-11','2009-01-01',NULL,NULL,NULL,'','2015-10-19','11/9/09','2009-06-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,'2009-11-09','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-3590',NULL,'2015-09-25','3943',3,'','healthy subjects, Ideg & IDegAsp',530,NULL,NULL,NULL,NULL,'NCT01045707','Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','530',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-01-08','2010-01-01',NULL,NULL,NULL,'','2015-10-19','2/24/11','2010-10-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2011-02-24','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-3592','2014-05-08','2015-09-25','3944',3,'','T1DM  ',446,NULL,NULL,NULL,NULL,'NCT01009580','Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','446',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2009-11-05','2009-11-01',NULL,NULL,NULL,'','2015-10-19','11/9/10','2010-08-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24812432','2014-08-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,'2010-11-09','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-3593',NULL,'2015-09-25','3948',3,'','T1DM',465,NULL,NULL,NULL,NULL,'NCT01045447','Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','465',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-01-08','2010-01-01',NULL,NULL,NULL,'','2015-10-19','2/24/11','2010-10-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/27027878','2016-03-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2011-02-24','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-3594','2012-08-28','2015-09-25','3995',3,'','Japanese w/T2DM, insulin treated',548,NULL,NULL,NULL,NULL,'NCT00978627','Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','548',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2009-09-16','2009-08-01',NULL,NULL,NULL,'','2015-10-19','11/9/10','2010-05-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22933438','2012-11-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2010-11-09','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-3597','2014-10-14','2015-09-25','3998',3,'','Type 2 diabetes mellitus',424,NULL,NULL,NULL,NULL,'NCT01059812','A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','424',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-01-29','2010-02-01',NULL,NULL,NULL,'','2015-10-19','2/23/11','2010-12-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25498130','2015-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,'2011-02-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-3645',NULL,'2015-09-25','3999',3,'','Type 2 diabetes mellitus',NULL,NULL,NULL,NULL,NULL,'EUCTR2009-013412-13-GB',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-12-02',NULL,NULL,NULL,'','2016-01-30','N','2010-12-02','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-3726',NULL,'2015-09-25','4060',3,'','Type 1 diabetes mellitus',526,NULL,NULL,NULL,NULL,'EUCTR2009-015839-33',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'526',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-3816',NULL,'2015-09-25','4061',3,'','Type 2 diabetes mellitus, Japanese pax',362,NULL,NULL,NULL,NULL,'NCT01835431','A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','362',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-04-16','2013-10-01',NULL,NULL,NULL,'','2015-10-13','N','2014-11-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-3844',NULL,'2015-09-25','1718',3,'','T1DM',276,NULL,NULL,NULL,NULL,'NCT01365507','Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-na??ve Subjects With Type 2 Diabetes Using Two Dosing Regimens','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','276',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-05-31','2011-06-01',NULL,NULL,NULL,'','2015-10-19','5/9/12','2012-04-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26773557','2016-01-16',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2012-05-09','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-3857',NULL,'2015-09-25','1719',1,'','T1DM  ',27,NULL,NULL,NULL,NULL,'NCT01173926','Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes','Diabetes|Diabetes Mellitus, Type 1',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','27',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-07-30','2010-07-01',NULL,NULL,NULL,'',NULL,'N','2010-11-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-3896','2013-04-05','2015-09-25','1738',3,'','Type 2 diabetes mellitus',296,NULL,NULL,NULL,NULL,'NCT01272193','Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','296',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-01-06','2011-01-01',NULL,NULL,NULL,'','2015-10-21','1/17/12','2011-09-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23557077','2015-09-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2012-01-17','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-3940','2015-11-17','2015-09-25','1740',3,'','pediatric, T1DM, IDegAsp OD',394,NULL,NULL,NULL,NULL,'NCT01513590','A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin na??ve Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','394',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-01-16','2012-01-01',NULL,NULL,NULL,'','2015-10-19','N','2012-11-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26435365','2016-04-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-3941','2015-12-31','2015-09-25','1788',3,'','T2DM, insuline na?ve',272,NULL,NULL,NULL,NULL,'NCT01680341','Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','272',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-08-31','2012-08-01',NULL,NULL,NULL,'','2015-10-16','11/7/13','2013-08-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26720250','2016-05-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2013-11-07','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-3996','2016-01-11','2015-09-25','1790',3,'','T2DM',274,NULL,NULL,NULL,NULL,'NCT01713530','A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','274',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-10-22','2013-02-01',NULL,NULL,NULL,'','2015-10-16','1/24/14','2014-01-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26592732','2016-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2014-01-24','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN5401-4003',NULL,'2015-09-25','1791',3,'','Japan, Type 2 diabetes mellitus',40,NULL,NULL,NULL,NULL,'NCT01814137','A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','40',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-03-15','2013-03-01',NULL,NULL,NULL,'','2015-10-14','11/20/14','2014-03-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2014-11-20','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN9068-3632','2015-07-14','2015-09-25','1792',1,'','IDegAsp BID insulin na?ve',24,NULL,NULL,NULL,NULL,'NCT00983021','Safety and Tolerability of NN9068 in Healthy Male Volunteers','Diabetes|Healthy',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','24',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2009-09-22','2009-09-01',NULL,NULL,NULL,'',NULL,'N','2009-12-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25998481','2015-12-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN9068-3697','2014-09-01','2015-09-25','Trial 1959',3,'','IDegAsp BID insulin treated',1663,NULL,NULL,NULL,NULL,'NCT01336023','Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','1663',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-04-13','2011-05-01',NULL,NULL,NULL,'',NULL,'12/19/12','2012-05-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25190523','2014-11-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2012-12-19','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN9068-3851',NULL,'2015-09-25','1977',3,'','T2DM',438,NULL,NULL,NULL,NULL,'NCT01676116','The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','438',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-08-28','2012-08-01',NULL,NULL,NULL,'',NULL,'11/20/14','2014-03-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2014-11-20','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN9068-3912','2014-08-11','2015-09-25','1978',3,'','T2DM',414,NULL,NULL,NULL,NULL,'NCT01392573','A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','414',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2011-07-07','2011-11-01',NULL,NULL,NULL,'',NULL,'12/19/12','2012-10-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25114296','2014-11-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2012-12-19','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN9068-3951',NULL,'2015-09-25','1979',3,'','healthy male subjects',435,NULL,NULL,NULL,NULL,'NCT01618162','The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','435',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2012-06-11','2012-08-01',NULL,NULL,NULL,'',NULL,'11/7/13','2013-10-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,'2013-11-07','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN9068-3952',NULL,'2015-09-25','1980',3,'','T2DM insulin na?ve',557,NULL,NULL,NULL,NULL,'NCT01952145','A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','557',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2013-09-24','2013-09-01',NULL,NULL,NULL,'',NULL,'N','2014-11-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26934259','2016-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Tresiba/Ryzodeg','NN9068-4119',NULL,'2015-09-25','1981',3,'','T2DM insulin na?ve, switch from GLP-1',31,NULL,NULL,NULL,NULL,'NCT02100475','A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification','Diabetes|Diabetes Mellitus, Type 2',NULL,NULL,NULL,'Novo Nordisk A/S','Interventional','31',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2014-03-27','2014-04-01',NULL,NULL,NULL,'',NULL,'N','2015-04-01','','1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Novo Nordisk Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Viberzi','CPS1005',NULL,'2015-05-27','3593',1,'','Healthy',30,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Tosara Ltd/ Furiex Pharmaceuticals Inc/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Viberzi','CPS1006',NULL,'2015-05-27','extension of 3590; NN5401-3726',1,'','Healthy',40,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'40',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Tosara Ltd/ Furiex Pharmaceuticals Inc/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Viberzi','CPS1007',NULL,'2015-05-27','3594',1,'','Healthy',53,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'53',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Tosara Ltd/ Furiex Pharmaceuticals Inc/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Viberzi','CPS1008',NULL,'2015-05-27','3678',1,'','Hepatic impairment',64,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'64',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Tosara Ltd/ Furiex Pharmaceuticals Inc/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Viberzi','CPS1009',NULL,'2015-05-27','3570',1,'','IBS-d',28,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'28',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Tosara Ltd/ Furiex Pharmaceuticals Inc/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Viberzi','CPS1010',NULL,'2015-05-27','3816',1,'','Healthy',36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'36',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Tosara Ltd/ Furiex Pharmaceuticals Inc/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Viberzi','CPS1011','2017-05-17','2015-05-27','3597',1,'','Healthy',30,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25491493','2015-01-14',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Tosara Ltd/ Furiex Pharmaceuticals Inc/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Viberzi','CPS1012',NULL,'2015-05-27','extension of 3594',1,'','Healthy',28,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'28',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Tosara Ltd/ Furiex Pharmaceuticals Inc/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Viberzi','EDI1001',NULL,'2015-05-27','3590',1,'','IBS-d',74,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'74',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Tosara Ltd/ Furiex Pharmaceuticals Inc/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Viberzi','EDI1002',NULL,'2015-05-27','3539',1,'','pax w type 2 diabetes inadequately controlled on insulin',18,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'18',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Tosara Ltd/ Furiex Pharmaceuticals Inc/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Viberzi','EDI1003',NULL,'2015-05-27','3592',1,'','IBS-d',8,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'8',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Tosara Ltd/ Furiex Pharmaceuticals Inc/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Viberzi','IBS2001','2013-04-09','2015-05-27','3538',2,'','T2DM insulin treated',807,NULL,NULL,NULL,NULL,'NCT01130272','Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea','Irritable Bowel Syndrome',NULL,NULL,NULL,'Furiex Pharmaceuticals, Inc','Interventional','807',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2010-05-24','2010-05-01',NULL,NULL,NULL,'',NULL,'9/9/11','2011-07-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/23583433','2013-08-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Tosara Ltd/ Furiex Pharmaceuticals Inc/ Allergan Inc',NULL,'Y',NULL,'2011-09-09','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Viberzi','IBS3001',NULL,'2015-05-27','1983',3,'','T2DM, insulin na?ve, add on to SU',1281,NULL,NULL,NULL,NULL,'NCT01553591','Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)','Irritable Bowel Syndrome',NULL,NULL,NULL,'Furiex Pharmaceuticals, Inc','Interventional','1281',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)',NULL,'2012-03-08','2012-05-01',NULL,NULL,NULL,'',NULL,'3/25/14','2014-01-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26789872','2016-01-21',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Tosara Ltd/ Furiex Pharmaceuticals Inc/ Allergan Inc',NULL,'Y',NULL,'2014-03-25','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Viberzi','IBS3002',NULL,'2015-05-27','1985',3,'','T2DM, insulin treated',1146,NULL,NULL,NULL,NULL,'NCT01553747','Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)','Irritable Bowel Syndrome',NULL,NULL,NULL,'Furiex Pharmaceuticals, Inc','Interventional','1146',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)',NULL,'2012-03-08','2012-05-01',NULL,NULL,NULL,'',NULL,'3/25/14','2014-01-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26789872','2016-01-21',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Tosara Ltd/ Furiex Pharmaceuticals Inc/ Allergan Inc',NULL,'Y',NULL,'2014-03-25','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Viekira Pak','Human factor study',NULL,'2014-12-19',NULL,1,'Viekira Pak wallet',NULL,39,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M10-687',NULL,'2014-12-19',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'NCT00768690','A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333','HCV Infection',NULL,'Drug: ABT-333|Drug: ketoconazole|Drug: placebo',NULL,'Abbott','Interventional','45','Industry',1,'Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)','M10-687','2008-10-07','2008-10-01',NULL,'2010-10-11','2010-09-01','N',NULL,'N','2009-02-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M10-749',NULL,'2014-12-19',NULL,1,'Safety PK','Healthy',24,NULL,NULL,NULL,NULL,'NCT00850044','Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1','HCV Infection',NULL,'Drug: ABT-450|Drug: ritonavir|Drug: placebo for ABT-450|Drug: Placebo for ritonavir',NULL,'Abbott','Interventional','87','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','M10-749','2009-02-20','2009-02-01',NULL,'2010-10-14','2010-09-01','N',NULL,'N','2009-07-01','United States',NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26710243',NULL,NULL,NULL,NULL,'87',1,'healthy',NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M10-798',NULL,'2014-12-19',NULL,1,'ADME, ABT-450/r','Healthy',4,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M11-030',NULL,'2014-12-19',NULL,1,'Microdose PK','Healthy',8,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M11-388',NULL,'2014-12-19',NULL,1,'ABT-450/ritonvair co-formulation study',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M11-389',NULL,'2014-12-19',NULL,1,'Food Effect','Heathy',21,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M11-602',NULL,'2014-12-19',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'NCT01074008','A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072','Hepatitis C|HCV|Chronic Hepatitis C Infection|Hepatitis C Genotype 1',NULL,'Drug: ABT-450|Drug: ABT-072|Drug: ABT-333|Drug: Ritonavir|Drug: Peginterferon alpha-2a|Drug: Ribavirin|Other: Placebo','Champion2','AbbVie (prior sponsor, Abbott)|AbbVie','Interventional','74','Industry',2,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','M11-602','2010-02-22','2010-03-01','2012-01-01','2014-12-29','2014-12-01','Y','2014-12-29','Y','2011-06-01','United States,   Puerto Rico',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25451053','2015-02-01',NULL,NULL,NULL,'75',2,'HCV Infected','United States, Puerto Rico',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','Y','Y','Y','2012-06-25','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Viekira Pak','M11-603',NULL,'2014-12-19',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M11-646',NULL,'2014-12-19','SAPPHIRE-I',3,'RBV v PBO','GT1, non-cirrhotic',631,NULL,NULL,NULL,NULL,'NCT01716585','A Study to Evaluate Chronic Hepatitis C Infection','Chronic Hepatitis C Infection',NULL,'Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin|Drug: Placebo for ABT-450/r/ABT-267|Drug: Placebo for ABT-333|Drug: Placebo for ribavirin',NULL,'AbbVie (prior sponsor, Abbott)|AbbVie','Interventional','636','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','M11-646|2012-002019-25','2012-10-18','2012-11-01','2014-10-01','2015-10-09','2015-10-01','Y','2014-12-23','N','2013-10-01','Australia,   Austria,   Canada,   France,   Germany,   Hungary,   Italy,   New Zealand,   Spain,   Sweden,   Switzerland,   United Kingdom,   United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24720703','2014-04-24',NULL,NULL,NULL,'631',3,'HCV Infection','France, Germany, Hungary, Italy, Spain, Sweden, United Kingdom, Australia, New Zealand, Switzerland, United States, Canada',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Viekira Pak','M11-652',NULL,'2014-12-19','AVIATOR',2,'RBV X 8, 12, 24','GT1, non-cirrhotic',571,NULL,NULL,NULL,NULL,'NCT01464827','ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients','Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1',NULL,'Drug: ABT-450|Drug: ABT-333|Drug: ABT-267|Drug: Ribavirin|Drug: Ritonavir',NULL,'AbbVie (prior sponsor, Abbott)|AbbVie','Interventional','580','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','M11-652|2010-022455-31','2011-09-28','2011-10-01','2013-09-01','2015-04-02','2015-04-01','Y','2014-12-23','Y','2013-03-01','United States,   Australia,   Canada,   France,   Germany,   New Zealand,   Puerto Rico,   Spain,   United Kingdom',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24428468','2014-01-16',NULL,NULL,NULL,'571',2,'Genotype 1, Hepatitis C','United States, United Kingdom, Spain, Germany, New Zealand, France, Australia, Canada',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','Y','Y','Y','2014-03-25','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Viekira Pak','M12-116',NULL,'2014-12-19',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'NCT01181427','Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects','HCV Infection',NULL,'Drug: ABT-267|Drug: Placebo|Procedure: Blood Sample Collection|Drug: Cytochrome P450 inhibitor',NULL,'Abbott','Interventional','137','Industry',1,'Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','M12-116','2010-08-12','2010-08-01','2012-01-01','2012-01-20','2012-01-01','N',NULL,'N','2011-03-01','United States',NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25451055','2014-12-01',NULL,NULL,NULL,'18',NULL,'HCV genotype 1a -infected',NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M12-186',NULL,'2014-12-19',NULL,1,'ADME, ABT-267','Healthy',4,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M12-187',NULL,'2014-12-19',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M12-189',NULL,'2014-12-19',NULL,1,'Safety PK with Ketoconazole','Healthy',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M12-193',NULL,'2014-12-19',NULL,1,'Safety PK, with and without ABT-333','Normal to severe hepatic impairment',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M12-196',NULL,'2014-12-19',NULL,1,'Safety PK with CYP2C8 inhibitor','Healthy',12,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25646891','2015-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M12-198',NULL,'2014-12-19',NULL,1,'Safety PK with warfarin','Healthy',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25646891','2015-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M12-199',NULL,'2014-12-19',NULL,1,'Safety PK with omeprazole','Healthy',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25646891','2015-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M12-200','2015-01-01','2014-12-19',NULL,1,'Safety PK with rosuvastatin or pravastatin','Healthy',48,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25646891','2015-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','N','N'),('Viekira Pak','M12-201','2015-01-01','2014-12-19',NULL,1,'Safety PK with digoxin','Healthy',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25646891','2015-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','N','N'),('Viekira Pak','M12-202',NULL,'2014-12-19',NULL,1,'Safety PK with darunavir','Healthy',43,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26740513','2016-01-05',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M12-204',NULL,'2014-12-19',NULL,1,'drug-drug interaction trial w/ escitalopram or duloxetine; single-center, multiple-dose, open-label study','healthy adult male and female subjects',48,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26459906','2015-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M12-205',NULL,'2014-12-19',NULL,1,'Safety PK, with contraceptive','Healthy',34,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25646891','2015-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M12-215','2015-06-10','2014-12-19',NULL,1,'Safety PK','Normal to severe hepatic impairment',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26070406','2015-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','N','Y','N','N','N','Y','N','N','N'),('Viekira Pak','M12-221',NULL,'2014-12-19',NULL,1,'Safety PK','Healthy Han Chinese, Japanese, Caucasian',18,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M12-536',NULL,'2014-12-19',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'NCT01672983','A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection','Chronic Hepatitis C Infection',NULL,'Drug: ABT-450/ritonavir, ABT-267',NULL,'AbbVie (prior sponsor, Abbott)|AbbVie','Interventional','110','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','M12-536','2012-07-27','2012-07-01','2014-05-01','2015-10-27','2015-10-01','Y','2015-10-27','N','2014-05-01','Japan',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25644279','2015-05-01',NULL,NULL,NULL,'110',2,'Hepatitis C','Japan',NULL,'N','Y','Y','Y','Y','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M12-680',NULL,'2014-12-19',NULL,1,'double-blind, 4-period, placebo and active-controlled, randomized; potential for cardiac repolarization effects; designed to evaluate potential for QTc prolongation due to ABT-450, ritonavir, ABT-267, and ABT-333 in combination in healthy adults','healthy adults, male and female, 18 - 55 y/o',60,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M12-683',NULL,'2014-12-19',NULL,1,'Bioavailability, 4 dose ','Healthy',40,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M12-746',NULL,'2014-12-19',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'NCT01306617','A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Nave and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection','Chronic Hepatitis C Infection|Hepatitis C|Hepatitis C Virus',NULL,'Drug: ABT-450|Drug: ABT-333|Drug: ribavirin|Drug: ritonavir',NULL,'AbbVie (prior sponsor, Abbott)|AbbVie','Interventional','50','Industry',2,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','M12-746','2011-02-28','2011-02-01','2012-10-01','2014-12-29','2014-12-01','Y','2014-12-29','Y','2011-11-01','United States  ',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23439262','2013-07-01',NULL,NULL,NULL,'11',2,'Chronic Hepatitis C','United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','Y','Y','Y','2012-11-16','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Viekira Pak','M12-997',NULL,'2014-12-19',NULL,1,'Safety PK with methadone','Stable subjects',38,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26459906','2015-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M12-998',NULL,'2014-12-19',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'NCT01458535','A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-267 and With and Without Ribavirin (RBV) in Treatment-Nave Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)','Hepatitis C Virus',NULL,'Drug: ABT-450/r|Drug: ABT-267|Drug: ribavirin','Navigator','AbbVie (prior sponsor, Abbott)|AbbVie','Interventional','61','Industry',2,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','M12-998','2011-09-23','2011-10-01','2013-05-01','2014-05-30','2014-05-01','N',NULL,'Y','2013-05-01','United States,   Puerto Rico',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25246359','2015-02-01',NULL,NULL,NULL,'61',2,'HCV Genotype 1, 2, and 3','United States',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','Y','N','2014-05-30','Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M12-999',NULL,'2014-12-19','CORAL-I*',2,'RBV X 24','GT1 with recurrent HCV',34,NULL,NULL,NULL,NULL,'NCT01782495','A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients','Chronic Hepatitis C Infection',NULL,'Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: ribavirin (RBV)','CORAL-I','AbbVie','Interventional','195','Industry',2,'Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','M12-999|2012-004792-39','2013-01-22','2013-02-01','2017-08-01','2016-01-23','2016-01-01','N',NULL,'N','2016-12-01','United States,   Australia,   France,   Germany,   Spain,   United Kingdom',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25386767','2014-12-18',NULL,NULL,NULL,'34',3,'HCV Infection','United States, Spain',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','N','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M13-013',NULL,'2014-12-19',NULL,1,'drug-drug interaction w/ lopinavir/ritonavir; single-center, randomized, multiple-dose, non-fasting, open-label','healthy adult male and female subjects',48,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M13-098',NULL,'2014-12-19','SAPPHIRE-II',3,'RBV v PBO','GT1, non-cirrhotic',394,NULL,NULL,NULL,NULL,'NCT01715415','A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults','Chronic Hepatitis C Infection',NULL,'Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin|Drug: Placebo for ABT-450/r/ABT-267|Drug: Placebo for ABT-333|Drug: Placebo for ribavirin',NULL,'AbbVie (prior sponsor, Abbott)|AbbVie','Interventional','395','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','M13-098|2012-002035-29','2012-10-25','2012-11-01','2014-10-01','2015-10-23','2015-10-01','Y','2014-12-23','N','2013-11-01','Australia,   Canada,   Czech Republic,   Denmark,   France,   Germany,   Ireland,   Italy,   Mexico,   Netherlands,   Portugal,   Puerto Rico,   Russian Federation,   Spain,   United Kingdom,   United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24720679','2014-04-24',NULL,NULL,NULL,'394',3,'HCV Infection','United States, Ireland, Portugal, Italy, Spain, United Kingdom, Netherlands, Germany, Canada, France, Puerto Rico, Russia, Czech Republic, Denmark, Australia',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Viekira Pak','M13-099',NULL,'2014-12-19','TURQUOISE-II',3,'RBV X 12, 24','GT1, with compensated cirrhosis',380,NULL,NULL,NULL,NULL,'NCT01704755','A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis','Chronic Hepatitis C Infection|Compensated Cirrhosis',NULL,'Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin (RBV)','TURQUOISE-II','AbbVie (prior sponsor, Abbott)|AbbVie','Interventional','381','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','M13-099|2012-003088-23','2012-09-28','2012-10-01','2014-09-01','2015-09-24','2015-09-01','Y','2014-12-23','N','2014-01-01','Belgium,   Canada,   France,   Germany,   Italy,   Puerto Rico,   Spain,   United Kingdom,   United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24725237','2014-05-22',NULL,NULL,NULL,'380',3,'Hepatitis C with cirrhosis','Belgium, Canada, France, Germany, Italy, Puerto Rico, Spain, United Kingdom, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Viekira Pak','M13-100',NULL,'2014-12-19',NULL,1,'Safety PK with Buprenorphine/Naloxone','Stable subjects',36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26459906','2015-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M13-102',NULL,'2014-12-19',NULL,3,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'NCT01773070','A Follow up Study Designed to Obtain Long Term Data on Subjects Who Either Achieved a Sustained Virologic Response or or Did Not Achieve a Sustained Virologic Response in an Abbott Sponsored Hepatitis C Study','Hepatitis C',NULL,'Drug: ABT-450/ritonavir|Drug: ABT-333|Drug: ABT-267',NULL,'AbbVie (prior sponsor, Abbott)|AbbVie','Interventional','500','Industry',3,'Intervention Model: Single Group Assignment|Masking: Open Label','M13-102|2012-003073-26','2012-11-19','2013-06-01','2016-10-01','2016-01-13','2016-01-01','N',NULL,'N','2016-10-01','United States,   Australia,   Belgium,   Canada,   Denmark,   Germany,   New Zealand,   Puerto Rico,   Spain,   United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Abbvie Inc','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M13-103',NULL,'2014-12-19',NULL,1,'Safety PK with cyclosporine','Healthy',36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25708713','2015-05-01',NULL,NULL,NULL,'12',1,'Healthy','United States',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M13-104',NULL,'2014-12-19',NULL,1,'Safety PK with atripla','Healthy',16,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M13-329',NULL,'2014-12-19',NULL,1,'ADME, ABT-333','Healthy',4,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M13-330',NULL,'2014-12-19',NULL,1,'Food Effect','Healthy',18,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M13-331',NULL,'2014-12-19',NULL,1,'Bioavailability ','Healthy',32,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M13-386',NULL,'2014-12-19',NULL,2,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'NCT01563536','Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects','Chronic Hepatitis C Infection',NULL,'Drug: ABT-267|Drug: ABT-450|Drug: ABT-333|Drug: Ritonavir|Drug: Ribavirin','null','AbbVie (prior sponsor, Abbott)|AbbVie','Interventional','12','Industry',2,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','M13-386','2012-01-27','2012-02-01','2013-06-01','2014-12-29','2014-12-01','Y','2014-12-29','Y','2012-04-01','United States',NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26597291','2016-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','Y','Y','Y','2013-04-25','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Viekira Pak','M13-389',NULL,'2014-12-19','PEARL-II',3,'RBV X 12','GT1, non-cirrhotic',186,NULL,NULL,NULL,NULL,'NCT01674725','A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C','Chronic Hepatitis C Infection',NULL,'Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin','PEARL-II','AbbVie (prior sponsor, Abbott)|AbbVie','Interventional','187','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','M13-389|2011-005740-95','2012-07-27','2012-08-01','2014-10-01','2015-10-13','2015-10-01','Y','2014-12-23','N','2014-01-01','Austria,   Belgium,   Italy,   Netherlands,   Portugal,   Puerto Rico,   Sweden,   Switzerland,   Turkey,   United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24818763','2014-08-01',NULL,NULL,NULL,'179',3,'Genotype 1b, Hepatitis C','Austria, Belgium, Italy, Netherlands, Portugal, Puerto Rico, Sweden, Switzerland, Turkey, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Viekira Pak','M13-391',NULL,'2014-12-19',NULL,1,'Bioavailability, 2 dose','Healthy',42,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M13-392',NULL,'2014-12-19',NULL,1,'Safety PK with ritonavir','Healthy',36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M13-393',NULL,'2014-12-19','PEARL I*',2,'SVR','GT4 INFECTED',320,NULL,NULL,NULL,NULL,'NCT01685203','A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection','Hepatitis C, Chronic',NULL,'Drug: ABT-450/r|Drug: ABT-267|Drug: Ribavirin (RBV)','PEARL-I','AbbVie (prior sponsor, Abbott)|AbbVie','Interventional','316','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','M13-393|2011-005762-38','2012-09-12','2012-08-01','2015-02-01','2015-08-03','2015-08-01','Y','2015-06-09','N','2014-06-01','France,   Hungary,   Italy,   Poland,   Puerto Rico,   Romania,   Spain,   Turkey,   United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25837829, http://www.ncbi.nlm.nih.gov/pubmed/26170136','2015-10-01',NULL,NULL,NULL,'181',2,'Genotype 1b Chronic Hepatitis C with and without cirrhosis','France, Hungary, Italy, Poland, Puerto Rico, Romania, Spain, Turkey, United States',NULL,'N','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','N','N','Y','N','N','N'),('Viekira Pak','M13-394',NULL,'2014-12-19',NULL,1,'Safety PK with atazanavir','Healthy',72,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26740513','2016-01-05',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M13-491',NULL,'2014-12-19',NULL,1,'Safety PK with tacrolimus','Healthy',36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25708713','2015-05-01',NULL,NULL,NULL,'12',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M13-492',NULL,'2014-12-19',NULL,1,'Safety PK with lopinavir/ritonavir','Healthy',60,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26740513','2016-01-05',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M13-506',NULL,'2014-12-19',NULL,1,'Safety PK with darunavir','Healthy',72,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26740513','2016-01-05',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M13-782',NULL,'2014-12-19',NULL,1,'Safety PK with rilpivirine','Healthy',20,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M13-783',NULL,'2014-12-19',NULL,1,'Safety PK with emtricitabine','Healthy',36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M13-961',NULL,'2014-12-19','PEARL-III /M13-96',3,'RBV X 12','GT1, non-cirrhotic',419,NULL,NULL,NULL,NULL,'NCT01767116','A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection','Chronic Hepatitis C Infection',NULL,'Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin|Drug: Placebo for ribavirin','PEARL-III','AbbVie (prior sponsor, Abbott)|AbbVie','Interventional','419','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','M13-961|2012-003687-52','2012-11-30','2012-12-01','2014-08-01','2015-08-19','2015-08-01','Y','2014-12-23','N','2013-12-01','Austria,   Belgium,   Hungary,   Israel,   Italy,   Poland,   Portugal,   Romania,   Russian Federation,   Spain,   United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24795200','2014-05-22',NULL,NULL,NULL,'419',3,'Genotype 1b, Hepatitis C','Austria, Belgium, Hungary, Israel, Italy, Poland, Portugal, Romania, Russian Federation, Spain, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Viekira Pak','M14-002',NULL,'2014-12-19','PEARL-IV',3,'RBV X 12','GT1, non-cirrhotic',305,NULL,NULL,NULL,NULL,'NCT01833533','A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection','Chronic Hepatitis C Infection',NULL,'Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin|Drug: Placebo for Ribavirin','PEARL-IV','AbbVie','Interventional','305','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','M14-002|2012-005522-29','2013-02-27','2013-03-01','2014-09-01','2015-09-04','2015-09-01','Y','2014-12-23','N','2013-12-01','Canada,   United Kingdom,   United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24795200','2014-05-22',NULL,NULL,NULL,'305',3,'Genotype 1a, Hepatitis C','Canada, United Kingdom, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Viekira Pak','M14-004',NULL,'2014-12-19','TURQUOISE-1',2,'RBV X 12, 24','GT1 WITH HIV',62,NULL,NULL,NULL,NULL,'NCT01939197','A Two Part, Open-label Study to Evaluate the Safety and Effectiveness of ABT-450/r/ABT-267 or ABT-450/r/ABT-267 and ABT-333 Given With or Without a Drug Called Ribavirin in People With Both Hepatitis C Virus Genotype 1 or 4 Infection and Human Immunodeficiency Virus, Type 1 Infection','Hepatitis C Virus Infection|Human Immunodeficiency Virus Infection|Chronic Hepatitis C|Compensated Cirrhosis and Non-cirrhotics',NULL,'Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: Ribavirin (RBV)','TURQUOISE-I','AbbVie','Interventional','320','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','M14-004|2012-005143-24','2013-09-06','2013-08-01','2016-10-01','2016-01-20','2016-01-01','N',NULL,'N','2016-07-01','United States,   Australia,   Canada,   France,   Germany,   Italy,   New Zealand,   Puerto Rico,   Russian Federation,   Spain,   United Kingdom',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25706092','2015-03-24',NULL,NULL,NULL,'63',3,'Hepatitis co-infected with HIV-1','United States, Puerto Rico',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','N','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M14-027',NULL,'2014-12-19',NULL,1,'Safety PK','Healthy',12,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25646891','2015-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M14-103',NULL,'2014-12-19',NULL,2,'RBV X 12','GT1, non-cirrhotic',38,NULL,NULL,NULL,NULL,'NCT01911845','An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine','Chronic Hepatitis C Infection|Chronic Hepatitis C',NULL,'Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: Ribavirin (RBV)','null','AbbVie','Interventional','38','Industry',2,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','M14-103','2013-05-13','2013-04-01','2014-09-01','2015-09-16','2015-08-01','Y','2014-12-23','N','2013-12-01','United States',NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25839406','2015-04-01',NULL,NULL,NULL,'38',2,'chronic HCV genotype 1 infection, absence of cirrhosis, treatment-naive or peginterferon|ribavirin treatment-experienced, on stable opioid replacement therapy of methadone or buprenorphine|naloxone','US',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Viekira Pak','M14-196',NULL,'2014-12-19',NULL,1,'Bioequivalence','Healthy',32,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M14-226',NULL,'2014-12-19',NULL,3,'evaulation of safety and efficacy of ombitasvir/ABT-450/Ritonavir and Dasabuvir w/ or w/o ribavirin (RBV)','treatment-naive adults w/ genotype 1 chronic hepatitis C Virus (HCV) infection, with severe renal impairment or end-stage renal disease',NULL,NULL,NULL,NULL,NULL,'NCT02207088','Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease','Chronic Hepatitis C|Hepatitis C Virus|Compensated Cirrhosis|Severe Renal Impairment|End-stage Renal Disease',NULL,'Drug: ombitasvir/paritaprevir/ritonavir|Drug: dasabuvir|Drug: Ribavirin','null','AbbVie','Interventional','70','Industry',3,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','M14-226|2014-001527-77','2014-07-31','2014-09-01','2016-12-01','2016-01-20','2016-01-01','N',NULL,'N','2016-12-01','United States',NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26976799','2016-03-11',NULL,NULL,NULL,'20',NULL,'HCV genotype 1 infection in treatment-naive adults w/o cirrhosis','US',NULL,'N','N','Y','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Abbvie Inc','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M14-227',NULL,'2014-12-19',NULL,3,'evaluation of safety and efficacy of ABT-450/Ritonavir/ABT-267 and ABT-333 w/ Ribavirin','adults w/ genotype 1 chronic hepatitis C virus infection and decompensated cirrhosis',NULL,NULL,NULL,NULL,NULL,'NCT02219477','A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis','Chronic Hepatitis C|Decompensated Cirrhosis|Hepatitis C Virus',NULL,'Drug: ABT-450/ritonavir/ABT-267|Drug: ABT-333|Drug: Ribavirin','TURQUOISE-CPB','AbbVie','Interventional','60','Industry',3,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','M14-227|2014-001477-13','2014-08-15','2014-11-01','2017-02-01','2016-01-13','2016-01-01','N',NULL,'N','2016-06-01','United States,   Canada,   Germany',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Abbvie Inc','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M14-324',NULL,'2014-12-19',NULL,1,'Safety PK with Alprazolam or Zolpidem Tartrate','Healthy',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25646891','2015-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Viekira Pak','M14-325','2015-01-01','2014-12-19',NULL,1,'Safety PK with Furosemide or Amlodipine Besylate','Healthy',26,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25646891','2015-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Abbvie Inc','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','N','N'),('Viekira Pak','M14-490',NULL,'2014-12-19','TURQUOISE-III',3,'open-label, single-arm study to evaluate safety and efficacy of ombitasvir/ABT-450/ritonavir and dasabuvir','adults w/ genotype 1b chronic hepatitis C virus (HCV) infection and cirrhosis',NULL,NULL,NULL,NULL,NULL,'NCT02219503','A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis','Chronic Hepatitis C Infection|Compensated Cirrhosis|Hepatitis C Virus',NULL,'Drug: ombitasvir/ABT-450/ritonavir|Drug: dasabuvir','TURQUOISE-III','AbbVie','Interventional','60','Industry',3,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','M14-490|2014-001953-18','2014-08-15','2014-09-01','2015-09-01','2015-10-09','2015-10-01','N',NULL,'N','2015-06-01','Belgium,   Canada,   United States',NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26476290','2015-10-22',NULL,NULL,NULL,'60',3,'HCV genotype 1b infection, cirrhosis','US, Canada, Belgium',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','N','Y',NULL,NULL,NULL,'0',NULL,'N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N','N'),('Vraylar','A002-A1',NULL,'2015-09-17','3844',1,'','Healthy',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','A002-A10',NULL,'2015-09-17','3857',NULL,'','Healthy',44,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'44',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','A002-A11',NULL,'2015-09-17','3896',3,'','Recreational opioid users',38,NULL,NULL,NULL,NULL,'NCT01626859','A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia','Schizophrenia',NULL,NULL,NULL,'Mitsubishi Tanabe Pharma Corporation','Interventional','38',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-06-19','2017-05-17',NULL,NULL,NULL,'',NULL,'N','2017-08-17','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','A002-A2',NULL,'2015-09-17','3940',1,'','Recreational opioid users',20,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','A002-A3',NULL,'2015-09-17','3941',2,'','healthy Japanese males',35,NULL,NULL,NULL,NULL,'NCT00862992','Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia','Schizophrenia',NULL,NULL,NULL,'Mitsubishi Tanabe Pharma Corporation','Interventional','35',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2009-03-15','2008-04-01',NULL,NULL,NULL,'',NULL,'N','2009-09-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','A002-A4',NULL,'2015-09-17','3996',3,'','healthy volunteers',480,NULL,NULL,NULL,NULL,'NCT01625000','Safety and Efficacy of MP-214 in Patients With Schizophrenia','Schizophrenia',NULL,NULL,NULL,'Mitsubishi Tanabe Pharma Corporation','Interventional','480',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2012-06-19','2012-05-01',NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','A002-A5',NULL,'2015-09-17','4003',3,'','Japanese patients with schizophrenia',480,NULL,NULL,NULL,NULL,'NCT01626872','Long-Term Study of MP-214 in Patients With Schizophrenia','Schizophrenia',NULL,NULL,NULL,'Mitsubishi Tanabe Pharma Corporation','Interventional','480',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2012-06-19','2012-06-01',NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','A002-A6',NULL,'2015-09-17',NULL,2,'','healthy Japanese males',50,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'50',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','A002-A7',NULL,'2015-09-17','3697',3,'','patients with schizophrenia ',125,NULL,NULL,NULL,NULL,'NCT01625897','A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia','Schizophrenia',NULL,NULL,NULL,'Mitsubishi Tanabe Pharma Corporation','Interventional','125',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-06-19','2012-05-01',NULL,NULL,NULL,'',NULL,'N','2015-03-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','A002-A8',NULL,'2015-09-17','3851',3,'','patients with schizophrenia',42,NULL,NULL,NULL,NULL,'NCT01626885','A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia','Schizophrenia',NULL,NULL,NULL,'Mitsubishi Tanabe Pharma Corporation','Interventional','42',NULL,NULL,'Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-06-19','2012-05-01',NULL,NULL,NULL,'',NULL,'N','2014-06-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-188-001',NULL,'2015-09-17','3912',1,'','patients with schizophrenia',40,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'40',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-188-002',NULL,'2015-09-17','3951',1,'','healthy Japanese, South Korean, Taiwanese, Caucasian males',32,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'32',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-188-003',NULL,'2015-09-17','3952',1,'','Patients with chronic phase/elderly schizophrenia ',5,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'5',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-01',NULL,'2015-09-17','4119',1,'','schizophrenia receiving multiple psychotropic drugs',62,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'62',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-02',NULL,'2015-09-17','DEVOTE',1,'','healthy males',129,NULL,NULL,NULL,NULL,'NCT01376076','Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia','Schizophrenia',NULL,NULL,NULL,'Forest Laboratories','Interventional','129',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)',NULL,'2011-06-16','2011-06-01',NULL,NULL,NULL,'',NULL,'N','2012-02-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-03',NULL,'2015-09-17','Study 1',2,'','healthy males',392,NULL,NULL,NULL,NULL,'NCT00404573','Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia','Schizophrenia',NULL,NULL,NULL,'Forest Laboratories','Interventional','392',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind',NULL,'2006-11-27','2006-11-01',NULL,NULL,NULL,'',NULL,'N','2007-08-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26655732','2016-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-04',NULL,'2015-09-17','Study 2',3,'','healthy',617,NULL,NULL,NULL,NULL,'NCT01104766','Safety and Efficacy of Cariprazine in Patients With Schizophrenia','Schizophrenia',NULL,NULL,NULL,'Forest Laboratories|Gedeon Richter Ltd.','Interventional','617',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)',NULL,'2010-04-09','2017-04-17',NULL,NULL,NULL,'',NULL,'12/30/11','2017-12-17','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26717533','2017-12-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,'2011-12-30','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-05',NULL,'2015-09-17',NULL,3,'','patients with schizophrenia or schizoaffective disorder',459,NULL,NULL,NULL,NULL,'NCT01104779','Safety and Efficacy of Cariprazine in Schizophrenia','Schizophrenia',NULL,NULL,NULL,'Forest Laboratories|Gedeon Richter Ltd.','Interventional','459',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)',NULL,'2010-04-14','2010-04-01',NULL,NULL,NULL,'',NULL,'12/6/12','2011-12-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26075487','2015-08-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,'2012-12-06','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-06',NULL,'2015-09-17',NULL,3,'','mania and schizophrenia (schizoaffective)',766,NULL,NULL,NULL,NULL,'NCT01412060','Cariprazine Relative to Placebo in the Prevention of Relapse of Symptoms in Patients With Schizophrenia','Schizophrenia',NULL,NULL,NULL,'Forest Laboratories|Gedeon Richter Ltd.','Interventional','766',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2011-08-04','2011-08-01',NULL,NULL,NULL,'',NULL,'9/25/15','2014-08-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,'2015-09-25','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-11',NULL,'2015-09-17',NULL,3,'','controlled schizophrenia',588,NULL,NULL,NULL,NULL,'NCT01104792','Long-term Study of Cariprazine in Patients With Schizophrenia','Schizophrenia',NULL,NULL,NULL,'Forest Laboratories|Gedeon Richter Ltd.','Interventional','588',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-04-12','2010-04-01',NULL,NULL,NULL,'',NULL,'3/28/14','2013-01-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,'2014-03-28','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-14',NULL,'2015-09-17',NULL,2,'','adults with schizophrenia ',8,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'8',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-16','2014-01-10','2015-09-17',NULL,2,'','adults with schizophrenia, acute exacerbation',732,NULL,NULL,NULL,NULL,'NCT00694707','Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia','Schizophrenia',NULL,NULL,NULL,'Forest Laboratories|Gedeon Richter Ltd.','Interventional','732',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2008-06-06','2008-06-01',NULL,NULL,NULL,'',NULL,'3/2/12','2009-08-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/24412468','2014-02-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,'2012-03-02','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-17',NULL,'2015-09-17',NULL,2,'','patients with schizophrenia',93,NULL,NULL,NULL,NULL,'NCT00839852','The Purpose of the Study is to Determine Whether Cariprazine is a Safe and Tolerated Long-term Treatment in Patients With Chronic Stable Schizophrenia','Schizophrenia',NULL,NULL,NULL,'Forest Laboratories|Gedeon Richter Ltd.','Interventional','93',NULL,NULL,'Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2009-02-05','2009-05-01',NULL,NULL,NULL,'',NULL,'9/13/11','2010-08-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,'2011-09-13','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-18',NULL,'2015-09-17',NULL,1,'','controlled schizophrenia',36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'36',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-31','2014-07-24','2015-09-17',NULL,2,'','schizophrenia for at least 1 year',238,NULL,NULL,NULL,NULL,'NCT00488618','Study Evaluating RGH-188 in the Treatment of Patients With Acute Mania','Bipolar Disorder',NULL,NULL,NULL,'Forest Laboratories|Gedeon Richter Ltd.','Interventional','238',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)',NULL,'2007-06-19','2007-04-01',NULL,NULL,NULL,'',NULL,'3/2/12','2008-07-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25056368','2015-02-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,'2012-03-02','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-32','2014-11-24','2015-09-17',NULL,3,'','adults with schizophrenia ',312,NULL,NULL,NULL,NULL,'NCT01058096','Safety and Efficacy of Cariprazine for Mania','Bipolar Disorder|Mania',NULL,NULL,NULL,'Forest Laboratories|Gedeon Richter Ltd.','Interventional','312',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)',NULL,'2010-01-27','2010-01-01',NULL,NULL,NULL,'',NULL,'8/2/11','2011-07-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25532076','2015-03-15',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,'2011-08-02','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-33',NULL,'2015-09-17',NULL,3,'','schizophrenia',497,NULL,NULL,NULL,NULL,'NCT01058668','Safety and Efficacy of Cariprazine for Bipolar I Disorder','Mania|Bipolar I Disorder',NULL,NULL,NULL,'Forest Laboratories|Gedeon Richter Ltd.','Interventional','497',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)',NULL,'2010-01-27','2010-01-01',NULL,NULL,NULL,'',NULL,'12/30/11','2011-12-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/25562205','2015-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,'2011-12-30','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-36',NULL,'2015-09-17',NULL,3,'','patients with schizophrenia or schizoaffective disorder',403,NULL,NULL,NULL,NULL,'NCT01059539','Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder','Bipolar I Disorder',NULL,NULL,NULL,'Forest Laboratories|Gedeon Richter Ltd.','Interventional','403',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-01-27','2010-01-01',NULL,NULL,NULL,'',NULL,'12/6/12','2012-03-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,'2012-12-06','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-52',NULL,'2015-09-17',NULL,2,'','adults with acute manic or mixed episodes of Bipolar 1 Disorder (acute mania)',234,NULL,NULL,NULL,NULL,'NCT00852202','Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression','Bipolar Depression',NULL,NULL,NULL,'Forest Laboratories|Gedeon Richter Ltd.','Interventional','234',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2009-02-25','2009-06-01',NULL,NULL,NULL,'',NULL,'7/6/11','2010-06-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,'2011-07-06','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-56','2015-11-06','2015-09-17',NULL,2,'','adults with acute manic or mixed episodes of Bipolar 1 Disorder (acute mania)',584,NULL,NULL,NULL,NULL,'NCT01396447','Safety, Tolerability, and Efficacy of Cariprazine in Patients With Bipolar Depression','Depression, Bipolar',NULL,NULL,NULL,'Forest Laboratories|Gedeon Richter Ltd.','Interventional','584',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2011-07-15','2011-07-01',NULL,NULL,NULL,'',NULL,'2/27/15','2014-01-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26541814','2016-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,'2015-02-27','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-71',NULL,'2015-09-17',NULL,2,'','adults with acute manic or mixed episodes of Bipolar 1 Disorder (acute mania)',232,NULL,NULL,NULL,NULL,'NCT00854100','Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder','Major Depressive Disorder',NULL,NULL,NULL,'Forest Laboratories|Gedeon Richter Ltd.','Interventional','232',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2009-02-26','2009-06-01',NULL,NULL,NULL,'',NULL,'2/6/12','2010-12-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,'2012-02-06','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-MD-75',NULL,'2015-09-17',NULL,2,'','bipolar mania',819,NULL,NULL,NULL,NULL,'NCT01469377','Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder','Major Depressive Disorder',NULL,NULL,NULL,'Forest Laboratories|Gedeon Richter Ltd.','Interventional','819',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2011-11-08','2011-12-01',NULL,NULL,NULL,'',NULL,'N','2013-12-01','','0',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/27046309','2016-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-PK-04',NULL,'2015-09-17',NULL,NULL,'','patients with bipolar depression',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-PK-07',NULL,'2015-09-17',NULL,1,'','bipolar depression',36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'36',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-PK-10',NULL,'2015-09-17',NULL,NULL,'','patients with MDD',42,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'42',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-PK-14',NULL,'2015-09-17',NULL,NULL,'','adjunctive therapy in MDD',50,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'50',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-PK-15',NULL,'2015-09-17',NULL,1,'','healthy vs patients with hepatic impairment',2,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Vraylar','RGH-PK-17',NULL,'2015-09-17',NULL,NULL,'','healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Forest Res Inst In/ Actavis/ Allergan Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Xeljanz','A3921002',NULL,'2012-11-06',NULL,1,'Single rising dose (oral)','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2014-12-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921003','2009-02-19','2012-11-06',NULL,1,'Multiple rising dose (12 days)','Patients',59,NULL,NULL,NULL,NULL,'NCT01736696',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2012-11-26','2002-11-01',NULL,NULL,NULL,'Y','2012-12-06','N','2004-04-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19225543','2009-02-19',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Xeljanz','A3921004',NULL,'2012-11-06',NULL,1,'PK in end-stage renal disease','Patients',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','2012-11-19','N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/?term=Pharmacokinetics+of+tofacitinib%2C+a+janus+kinase+inhibitor%2C+in+patients+with+impaired+renal+function+and+end','2013-09-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'Y','Y','N','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Xeljanz','A3921005',NULL,'2012-11-06',NULL,1,'Relative bioavailability and food effects','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921006',NULL,'2012-11-06',NULL,1,'PK (Renal impairment)','Patients',NULL,NULL,NULL,NULL,NULL,'NCT01740362',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/?term=Pharmacokinetics+of+tofacitinib%2C+a+janus+kinase+inhibitor%2C+in+patients+with+impaired+renal+function+and+end','2013-09-30',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'0','0','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921010',NULL,'2012-11-06',NULL,NULL,'PK mass balance study','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/?term=The+Pharmacokinetics%2C+Metabolism%2C+and+Clearance+Mechanisms+of+Tofacitinib%2C+a+Janus+Kinase+Inhibitor%2C+in+Humans','2014-01-24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921013',NULL,'2012-11-06',NULL,1,'DDI with methotrexate','Patients',12,NULL,NULL,NULL,NULL,'NCT01745055',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2012-12-04','2005-04-01',NULL,NULL,NULL,'Y','2012-12-06','N','2006-06-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20233177','2010-02-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Xeljanz','A3921014',NULL,'2012-11-06',NULL,1,'DDI with fluconazole','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'Gupta P, Chow V, Wang R et al. Evaluation of the effect of fluconazole and ketoconazole on the pharmacokinetics of tofacitinob in healthy adult subjects. Clinical Pharmacolgy in Drug Development 2013; 3(1): 72-77','2013-10-08',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921015',NULL,'2012-11-06',NULL,1,'PK, safety & tolerability - hepatitic impairment','Patients',18,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2014-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921019','2009-10-30','2012-11-06',NULL,2,'Used for safety data','Patients',264,NULL,NULL,NULL,NULL,'NCT00147498',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2005-09-02','2005-01-01',NULL,NULL,NULL,'Y','2012-11-19','Y','2006-06-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19565475 \nhttp://www.ncbi.nlm.nih.gov/pubmed/19880676 \nhttp://www.ncbi.nlm.nih.gov/pubmed/19587388','2009-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N','2012-11-07','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Xeljanz','A3921020',NULL,'2012-11-06',NULL,1,'DDI with tacrolimus & cyclosporine','Healthy',NULL,NULL,NULL,NULL,NULL,'NCT00860496',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921024',NULL,'2012-11-06',NULL,NULL,'Extension study','Patients',4000,NULL,NULL,NULL,NULL,'NCT00413699',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-12-18','2007-02-01',NULL,NULL,NULL,'N',NULL,'N','2015-01-01',NULL,NULL,NULL,NULL,NULL,NULL,'2014-04-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921025','2011-10-17','2012-11-06',NULL,2,'ACR20 response at Month 3','Patients',507,NULL,NULL,NULL,NULL,'NCT00413660',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-12-18','2007-01-01',NULL,NULL,NULL,'Y','2012-12-04','Y','2008-08-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22006202','2011-10-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N','2009-04-06','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Xeljanz','A3921028',NULL,'2012-11-06',NULL,1,NULL,'Healthy',60,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/?term=A+supra-therapeutic+dose+of+the+janus+kinase+inhibitor+tasocitinib+(CP-690%2C550)+does+not+prolong+Qtc+interval+in+healthy+subjects','2010-12-08',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921032','2013-01-05','2012-11-06',NULL,3,'CR20 response, changes in HAQ-DI and proportion with DAS28-4(ESR) less than 2.6','Patients',399,NULL,NULL,NULL,NULL,'NCT00960440',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-08-14','2009-10-01',NULL,NULL,NULL,'Y','2012-12-06','Y','2011-03-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23294500','2013-01-05',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N','2012-11-05','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','N','N'),('Xeljanz','A3921033',NULL,'2012-11-06',NULL,1,'Effect of multi-dose on Glomerular Filtration Rate','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921035',NULL,'2012-11-06',NULL,2,'ACR20 response at Month 3','Patients',384,NULL,NULL,NULL,NULL,'NCT00550446',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2007-10-25','2007-09-01',NULL,NULL,NULL,'Y','2012-11-29','Y','2009-01-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21952978','2012-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N','2009-04-24','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Xeljanz','A3921036',NULL,'2012-11-06',NULL,1,'PK, safety & tolerability in Japanese and Western subjects','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921039',NULL,'2012-11-06',NULL,2,'ACR20 response at Month 3','Patients',136,NULL,NULL,NULL,NULL,'NCT00603512',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-01-17','2008-01-01',NULL,NULL,NULL,'Y','2012-11-14','Y','2008-09-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21584942 \nhttp://www.ncbi.nlm.nih.gov/pubmed/22460142','2011-08-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N','2009-04-06','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Xeljanz','A3921040',NULL,'2012-11-06',NULL,2,'ACR20 response at Month 3','Patients',384,NULL,NULL,NULL,NULL,'NCT00687193',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-05-22','2009-03-01',NULL,NULL,NULL,'Y','2012-11-26','Y','2010-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N','2010-11-19','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Xeljanz','A3921041',NULL,'2012-11-06',NULL,3,'Extension study','Patients',480,NULL,NULL,NULL,NULL,'NCT00661661',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-02-07','2008-04-01',NULL,NULL,NULL,'N',NULL,'N','2013-12-01',NULL,NULL,NULL,NULL,NULL,NULL,'2014-04-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921044',NULL,'2012-11-06',NULL,3,'CR20 response, changes in HAQ-DI and proportion with DAS28-4(ESR) less than 2.6','Patients',797,NULL,NULL,NULL,NULL,'NCT00847613',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-02-17','2009-03-01',NULL,NULL,NULL,'Y','2012-12-05','Y','2011-04-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23348607','2013-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N','2012-11-05','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Xeljanz','A3921045',NULL,'2012-11-06',NULL,3,'ACR20 response, changes in HAQ- DI, and rates of DAS28-4(ESR) <2.6','Patients',610,NULL,NULL,NULL,NULL,'NCT00814307',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-12-22','2009-02-01',NULL,NULL,NULL,'Y','2012-12-05','Y','2010-06-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22873530','2012-08-09',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N','2010-11-18','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Xeljanz','A3921046',NULL,'2012-11-06',NULL,3,'CR20 response, changes in HAQ-DI and proportion with DAS28-4(ESR) less than 2.6','Patients',792,NULL,NULL,NULL,NULL,'NCT00856544',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-03-03','2009-05-01',NULL,NULL,NULL,'Y','2012-12-06','Y','2011-01-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24026258','2013-08-20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N','2012-11-05','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Xeljanz','A3921054',NULL,'2012-11-06',NULL,1,'Effect of ketoconazole on PK','Healthy',12,NULL,NULL,NULL,NULL,'NCT01202240',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2010-09-13','2010-09-01',NULL,NULL,NULL,'N',NULL,'N','2010-09-01',NULL,NULL,NULL,NULL,NULL,'Gupta P, Chow V, Wang R et al. Evaluation of the effect of fluconazole and ketoconazole on the pharmacokinetics of tofacitinob in healthy adult subjects. Clinical Pharmacolgy in Drug Development 2013; 3(1): 72-77','2013-10-08',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921056',NULL,'2012-11-06',NULL,1,'DDI with rifampin','Healthy',12,NULL,NULL,NULL,NULL,'NCT01204112',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2010-09-15','2010-09-01',NULL,NULL,NULL,'N',NULL,'N','2010-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921059',NULL,'2012-11-06',NULL,1,'DDI with midazolam','Healthy',24,NULL,NULL,NULL,NULL,'NCT00902460',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-05-14','2009-06-01',NULL,NULL,NULL,'N',NULL,'N','2009-07-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22233204','2012-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921064',NULL,'2012-11-06',NULL,3,'CR20 response, changes in HAQ-DI and proportion with DAS28-4(ESR) less than 2.6','Patients',717,NULL,NULL,NULL,NULL,'NCT00853385',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-02-27','2009-05-01',NULL,NULL,NULL,'Y','2012-12-04','Y','2011-03-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22873531','2012-08-09',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N','2012-11-05','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Xeljanz','A3921065',NULL,'2012-11-06',NULL,1,'PK, safety & tolerability in Chinese subjects','Healthy',NULL,NULL,NULL,NULL,NULL,'NCT01101919',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921068',NULL,'2012-11-06',NULL,2,'Used for safety data','Patients',110,NULL,NULL,NULL,NULL,'NCT01164579',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2010-07-15','2010-10-01',NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921071',NULL,'2012-11-06',NULL,1,'DDI with oral contraceptives','Healthy',20,NULL,NULL,NULL,NULL,'NCT01137708',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921073',NULL,'2012-11-06',NULL,2,'Used for safety data','Patients',29,NULL,NULL,NULL,NULL,'NCT00976599',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-09-11','2009-11-01',NULL,NULL,NULL,'Y','2012-12-04','Y','2011-07-01',NULL,NULL,NULL,NULL,NULL,NULL,'2014-11-14',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N','2012-11-05','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Xeljanz','A3921075',NULL,'2012-11-06',NULL,1,'bioequivalence','Healthy',24,NULL,NULL,NULL,NULL,'NCT01184092',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2010-08-16','2010-08-01',NULL,NULL,NULL,'N',NULL,'N','2010-09-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921076',NULL,'2012-11-06',NULL,1,'food effect on final formulation','Healthy',16,NULL,NULL,NULL,NULL,'NCT01184001',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2010-08-17','2010-09-01',NULL,NULL,NULL,'N',NULL,'N','2010-09-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921077',NULL,'2012-11-06',NULL,1,'Absolute bioavailabiliyu','Healthy',12,NULL,NULL,NULL,NULL,'NCT01143805',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2010-06-09','2010-07-01',NULL,NULL,NULL,'N',NULL,'N','2010-08-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xeljanz','A3921109','2013-03-12','2012-11-06',NULL,2,'Used for safety data','Patients',111,NULL,NULL,NULL,NULL,'NCT01059864',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2010-01-28','2010-02-01',NULL,NULL,NULL,'Y','2012-11-14','Y','2010-11-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23482473','2013-03-12',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Pfizer','N','N','N','2012-11-05','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','Y','Y','Y','Y','Y','N','N','N'),('Xeljanz','A3921152',NULL,'2012-11-06',NULL,1,'planned for evaluation of effect on mGFR in patients with active RA ','Patients',147,NULL,NULL,NULL,NULL,'NCT01484561',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2011-11-30','2012-04-01',NULL,NULL,NULL,'Y','2014-01-11','N','2013-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','N','N','Y','N',NULL,'N','Y','N','N','N','Y',NULL,NULL,'N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xigduo','CV181168','2015-08-31','2014-10-29',NULL,3,'Add-on to dapagliflozin and metformin','T2DM',280,NULL,NULL,NULL,NULL,'NCT01619059','Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes','Type 2 Diabetes',NULL,'Drug: Saxagliptin|Drug: Dapagliflozin|Drug: Metformin IR|Drug: Placebo matching with Saxagliptin',NULL,'AstraZeneca','Interventional','317','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','CV181-168|2011-006323-37','2012-06-12','2012-06-01','2015-01-01','2016-02-18','2016-02-01','Y','2016-02-18','N','2014-06-01','United States,   Canada,   Czech Republic,   Hungary,   Mexico,   Poland,   Puerto Rico,   Romania,   Russian Federation','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26324329','2015-11-01',NULL,NULL,NULL,'857',3,'Type 2 Diabetes','United States, Puerto Rico, Canada, Romania, Russian Federation, Poland, Czech Republic, Mexico, Hungary',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','Y','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','Y','Y','Y','N','N','N','N','N','N','N','N','N'),('Xigduo','CV181169','2014-10-28','2014-10-29',NULL,3,'Add on to metformin XR','T2DM',516,NULL,NULL,NULL,NULL,'NCT01606007','Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes','Type 2 Diabetes',NULL,'Drug: Saxagliptin|Drug: Metformin XR|Drug: Dapagliflozin|Drug: Placebo matching with Dapagliflozin|Drug: Placebo matching with Saxagliptin',NULL,'AstraZeneca','Interventional','1282','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','CV181-169|2012-000679-18','2012-05-23','2012-07-01','2014-01-01','2015-12-22','2015-12-01','Y','2014-12-19','N','2014-01-01','United States,   Canada,   Korea, Republic of,   Mexico,   Poland,   Puerto Rico,   Romania,   South Africa','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3665&filename=CV181169_Synopsis.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25352655','2015-03-01',NULL,NULL,'multicenter, randomized, double-blind, active-controlled, parallel-group','1282',3,'Type 2 Diabetes',NULL,NULL,'N','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Xigduo','D1690C00004','2011-08-04','2014-10-29',NULL,3,'Add-on to metformin','Patients on metformin with HBA1c 6.5-10%',814,NULL,NULL,NULL,NULL,'NCT00660907','Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients','Type 2 Diabetes',NULL,'Drug: dapagliflozin|Drug: glipizide|Drug: metformin hydrochloride',NULL,'AstraZeneca|Bristol-Myers Squibb','Interventional','1217','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1690C00004','2008-04-15','2008-03-01','2013-01-01','2015-03-10','2015-03-01','Y','2013-01-21','N','2009-12-01','Argentina,   France,   Germany,   Italy,   Mexico,   Netherlands,   South Africa,   Spain,   Sweden,   United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=289&filename=CSR-D1690C00004.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21816980, http://www.ncbi.nlm.nih.gov/pubmed/23529570, http://www.ncbi.nlm.nih.gov/pubmed/24919526, *http://www.ncbi.nlm.nih.gov/pubmed/25735400','2011-09-01',NULL,NULL,'randomized, double- blind, parallel-group, active-controlled, noninferiority trial ','814',3,'Type 2 Diabetes','Argentina, France, germany, United Kingdom, Italy, Mexioc, Ntherlands, South Africa, Spain, Sweden',NULL,'Y','Y','Y','Y','Y','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Xigduo','D1690C00006',NULL,'2014-10-29',NULL,3,'Add-on to insulin','Patients with HBA1c 6.5-10.5%',243,NULL,NULL,NULL,NULL,'NCT00673231','Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Placebo|Drug: Dapagliflozin|Drug: Dapagliflozin',NULL,'AstraZeneca|Bristol-Myers Squibb','Interventional','1240','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1690C00006','2008-05-06','2008-04-01','2011-01-01','2013-09-25','2013-09-01','Y','2013-01-21','N','2009-05-01','United States,   Austria,   Bulgaria,   Canada,   Finland,   Germany,   Hungary,   Netherlands,   Romania,   Russian Federation,   Slovakia,   Spain,   United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=291&filename=CSR-D1690C00006.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23911013, http://www.ncbi.nlm.nih.gov/pubmed/23529568, http://www.ncbi.nlm.nih.gov/pubmed/22431673','2012-03-20',NULL,NULL,'randomized, placebo-controlled, multicenter trial plus extension','808',3,'Type 2 Diabetes','Austria, Bulgaria, Canada, Finland, United Kingdom, Hungary, Ntherlands, Romania, Russian Federation, Slovakia, Spain, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Xigduo','D1690C00010',NULL,'2014-10-29',NULL,3,'Add-on to sitagliptin','Patients with HBA1c 7-10%',228,NULL,NULL,NULL,NULL,'NCT00984867','Dapagliflozin DPPIV Inhibitor add-on Study','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Placebo',NULL,'AstraZeneca|Bristol-Myers Squibb','Interventional','833','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1690C00010','2009-09-23','2009-10-01','2011-09-01','2014-06-09','2014-06-01','Y','2013-01-21','N','2011-03-01','United States,   Argentina,   Germany,   Mexico,   Poland,   United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=292&filename=D1690C00010_Study_Synopsis_1Mar2012.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24144654','2013-10-21',NULL,NULL,' multicenter, randomized, double-blind, placebo-controlled, parallel-group w/ blinded extension','432',3,'Type 2 Diabetes','Argentina, Germany, Mexico, Poland, UK, US',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Xigduo','D1690C00012','2012-01-11','2014-10-29',NULL,3,'Superiority','Patients on metformin with HBA1c 6.5-8.5%',182,NULL,NULL,NULL,NULL,'NCT00855166','Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes','Type 2 Diabetes Mellitus',NULL,'Drug: Dapagliflozin|Drug: Metformin|Drug: Sitagliptin|Drug: Placebo',NULL,'AstraZeneca|Bristol-Myers Squibb','Interventional','182','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','D1690C00012','2009-03-03','2009-02-01','2011-12-01','2013-08-09','2013-08-01','Y','2013-01-21','N','2010-06-01','Bulgaria,   Czech Republic,   Hungary,   Poland,   Sweden','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=293&filename=D1690C00012%2050-week%20Study%20Synopsis%20final%20revised.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22238392, http://www.ncbi.nlm.nih.gov/pubmed/23906445, http://www.ncbi.nlm.nih.gov/pubmed/22651373','2012-03-01',NULL,NULL,'international, multicenter, randomized, parallel-group, double-blind, placebo-controlled - See more at: http://press.endocrine.org.ezproxy.med.nyu.edu/doi/full/10.1210/jc.2011-2260#sthash.d1jbq9UV.dpuf','182',3,'Type 2 Diabetes','Bulgaria, Czech Republic, Hungary, Poland, Sweden',NULL,'Y','Y','Y','Y','Y','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Xigduo','D1690C00018','2015-04-07','2014-10-29',NULL,3,'Superiority','T2DM',324,NULL,NULL,NULL,NULL,'NCT01031680','Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension','Type 2 Diabetes Mellitus|Cardiovascular Disease|Hypertension|Inadequate Glycaemic Control',NULL,'Drug: Dapagliflozin|Drug: Placebo',NULL,'AstraZeneca|Bristol-Myers Squibb','Interventional','922','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1690C00018','2009-12-10','2010-02-01','2012-12-01','2013-09-24','2013-09-01','Y','2013-01-21','N','2011-05-01','United States,   Argentina,   Canada,   Germany,   Romania,   Slovakia,   Spain,   Taiwan,   Vietnam','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=294&filename=CSR-D1690C00018.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25852208','2015-07-01',NULL,NULL,'multicenter, randomized, double-blind, placebo-controlled, international','922',3,'Type 2 Diabetes',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y','Y','N','Y'),('Xigduo','D1690C00019','2014-06-02','2014-10-29',NULL,3,'Superiority','T2DM',378,NULL,NULL,NULL,NULL,'NCT01042977','Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease','Type 2 Diabetes Mellitus|Cardiovascular Disease|Inadequate Glycaemic Control',NULL,'Drug: Dapagliflozin|Drug: Placebo',NULL,'AstraZeneca|Bristol-Myers Squibb','Interventional','964','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1690C00019','2010-01-05','2010-03-01','2012-12-01','2013-12-18','2013-12-01','Y','2013-01-21','N','2011-05-01','United States,   Argentina,   Australia,   Austria,   Bulgaria,   Canada,   Chile,   Germany,   Hungary,   Poland','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=295&filename=CSR-D1690C00019.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24890683','2014-07-01',NULL,NULL,'multicen- ter, randomized, double-blind, age-stratified, placebo-con- trolled ','964',3,'Type 2 Diabetes','United States, Canada, Australia, Chile, Argentina, 5 Centers in Europe',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Xigduo','D1691C00007',NULL,'2014-10-29',NULL,1,'Crossover bioequivalence','Healthy',40,NULL,NULL,NULL,NULL,'NCT01535677','To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately','Type 2 Diabetes Mellitus',NULL,'Drug: Dapagliflozin + Glucophage tablet fasted|Drug: Dapagliflozin/metformin IR FDC tablet fasted|Drug: Dapagliflozin + Glucophage tablet fed|Drug: Dapagliflozin/metformin IR FDC tablet fed',NULL,'AstraZeneca|Bristol-Myers Squibb','Interventional','71','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label','D1691C00007','2012-01-13','2013-04-01','2013-07-01','2015-07-08','2015-07-01','N',NULL,'N','2013-07-01','United Kingdom','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1195&filename=D1691C00007_CSR_Synopsis.pdf',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'1','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xigduo','D1693C00001',NULL,'2014-10-29',NULL,3,'CV, death, MI or ischemic stroke ','T2DM under 40',17150,NULL,NULL,NULL,NULL,'NCT01730534','Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events','Diabetes Mellitus, Non-Insulin-Dependent|High Risk for Cardiovascular Event',NULL,'Drug: Dapagliflozin 10 mg|Drug: Placebo tablet','DECLARE-TIMI58','AstraZeneca|Bristol-Myers Squibb|The TIMI Study Group|Hadassah Medical Organization','Interventional','17276','Industry|Other',3,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1693C00001','2012-11-15','2013-04-01','2019-04-01','2015-12-10','2015-12-01','N',NULL,'N','2019-04-01','United States,   Argentina,   Australia,   Belgium,   Brazil,   Bulgaria,   Canada,   China,   Czech Republic,   France,   Germany,   Hong Kong,   Hungary,   India,   Israel,   Italy,   Japan,   Korea, Republic of,   Mexico,   Netherlands,   Philippines,   Poland,   Romania,   Russian Federation,   Slovakia,   South Africa,   Spain,   Sweden,   Taiwan,   Thailand,   Turkey,   Ukraine,   United Kingdom,   Vietnam','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Xigduo','D1693C00005','2015-01-15','2014-10-29',NULL,3,'Add-on to metformin','T2DM',218,NULL,NULL,NULL,NULL,'NCT01392677','Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea','Type 2 Diabetes Mellitus|High HbA1c Level|Inadequate Glycaemic Control',NULL,'Drug: dapagliflozin|Drug: placebo',NULL,'AstraZeneca|Bristol-Myers Squibb','Interventional','311','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','D1693C00005','2011-07-11','2011-10-01','2013-08-01','2014-02-11','2014-02-01','Y','2013-11-05','N','2013-01-01','Canada,   Czech Republic,   Germany,   Poland,   Slovakia,   Spain','http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1200&filename=D1693C00005.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25592197','2015-03-01',NULL,NULL,'international, multicenter, randomized, double-blind, parallel-group, placebo-controlled,','219',3,'Type 2 Diabetes','Canada, Czech Republic, Germany, Poland, Slovak Republic, Spain',NULL,'Y','Y','Y','Y','Y','N','Y','Y','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y');
INSERT INTO `master` VALUES ('Xigduo','MB102-065',NULL,'2014-10-29',NULL,1,'Bioavailability','Healthy BMI 18 - 32',44,NULL,NULL,NULL,NULL,'NCT01002807','Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State','Type 2 Diabetes Mellitus (T2DM)',NULL,'Drug: Dapagliflozin|Drug: Metformin XR|Drug: Glucophage',NULL,'AstraZeneca','Interventional','15','Industry',1,'Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Crossover Assignment|Masking: Open Label','MB102-065','2009-10-26','2009-11-01','2010-01-01','2015-03-20','2015-03-01','N',NULL,'N','2009-12-01','United States','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,NULL,'Astrazeneca AB','N','N','N',NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xigduo','MB102013','2010-06-21','2014-10-29',NULL,3,'Superiority','Treatment naive with HBA1c 7.5-10%',278,NULL,NULL,NULL,NULL,'NCT00528372','A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Dapagliflozin placebo|Drug: Metformin',NULL,'AstraZeneca|Bristol-Myers Squibb','Interventional','1067','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','MB102-013 LT','2007-09-11','2007-09-01','2010-07-01','2015-09-30','2015-09-01','Y','2014-02-06','N','2009-02-01','United States,   Canada,   Mexico,   Russian Federation',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20566676, http://www.ncbi.nlm.nih.gov/pubmed/25381876','2010-10-01',NULL,NULL,'24-week randomized, par- allel-group, double-blind, placebo- controlled ','485',3,'Type 2 Diabetes','United States, Canada, Mexico, Russia',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Xigduo','MB102014',NULL,'2014-10-29',NULL,3,'Add-on to metformin','Patients on metformin with HBA1c 7-10%',546,NULL,NULL,NULL,NULL,'NCT00528879','A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Placebo|Drug: Metformin',NULL,'AstraZeneca|Bristol-Myers Squibb','Interventional','915','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','MB102-014 LT|MB102-014','2007-09-11','2007-09-01','2010-05-01','2015-09-30','2015-09-01','Y','2014-02-06','N','2008-11-01','United States,   Argentina,   Brazil,   Canada,   Mexico',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20609968, http://www.ncbi.nlm.nih.gov/pubmed/23425012','2010-06-26',NULL,NULL,'randomised, double-blind, parallel-group, placebo-controlled ','534',3,'Type 2 Diabetes','United States, Canada, Argentina, Mexico, Brazil',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Xigduo','MB102021','2012-03-13','2014-10-29','Study 2021',3,'Change in HbA1c','Treatment naive with HBA1c 7.5-12%',598,NULL,NULL,NULL,NULL,'NCT00643851','An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Metformin XR',NULL,'AstraZeneca','Interventional','600','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','MB102-021','2008-03-20','2008-06-01','2009-08-01','2015-03-20','2015-03-01','N',NULL,'N','2009-08-01','United States,   Korea, Republic of,   Mexico,   Philippines,   Puerto Rico,   Russian Federation,   Ukraine','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22413962','2012-05-01',NULL,NULL,'randomised, double-blind active-controlled ','591',3,'Type 2 Diabetes',NULL,NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','Y','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Xigduo','MB102026',NULL,'2014-10-29',NULL,1,'Drug interaction','Healthy',15,NULL,NULL,NULL,NULL,'NCT00546741','Drug Interaction With Metformin','Diabetes',NULL,'Drug: Dapagliflozin|Drug: Metformin|Drug: Dapagliflozin + Metformin',NULL,'AstraZeneca','Interventional','18','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label','MB102-026','2007-10-18','2007-11-01','2008-02-01','2015-03-24','2015-03-01','N',NULL,'N','2008-02-01','United States','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xigduo','MB102034','2012-03-13','2014-10-29','Study 2034',3,'Change in HbA1c','Treatment naive with HBA1c 7.5-12%',630,NULL,NULL,NULL,NULL,'NCT00859898','Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes','Type 2 Diabetes Mellitus',NULL,'Drug: Dapagliflozin|Drug: Metformin XR|Drug: Metformin XR|Drug: dapagliflozin matching Placebo|Drug: metformin HCl Modified Release matching Placebo',NULL,'Bristol-Myers Squibb|AstraZeneca','Interventional','1093','Industry',3,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','MB102-034|Eudract #: 2008-007548-33','2009-03-10','2009-04-01','2010-05-01','2014-02-04','2014-02-01','Y','2014-02-04','N','2010-05-01','United States,   India,   Korea, Republic of,   Mexico,   Puerto Rico,   Russian Federation','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22413962','2012-05-01',NULL,NULL,NULL,'638',3,'Type 2 Diabetes',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Xigduo','MB102055',NULL,'2014-10-29',NULL,3,'Add-on to metformin','T2DM',444,NULL,NULL,NULL,NULL,'NCT01095666','A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Metformin|Drug: Dapagliflozin Placebo|Drug: Pioglitazone',NULL,'AstraZeneca','Interventional','445','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','MB102-055','2010-03-26','2010-06-01','2013-03-01','2015-03-20','2015-03-01','N',NULL,'N','2013-03-01','China,   India,   Korea, Republic of','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26589253','2015-11-20',NULL,NULL,'randomized, double-blind, placebo-controlled, parallel-group','444',3,'Type 2 Diabetes','China, India, South Korea',NULL,'N','N','Y','Y','Y','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Xigduo','MB102060',NULL,'2014-10-29',NULL,1,'Bioavailability','Healthy BMI 18 - 32',15,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xigduo','MB102071',NULL,'2014-10-29',NULL,1,'Bioavailability','Healthy BMI 18 - 32',15,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xigduo','MB102073',NULL,'2014-10-29',NULL,3,'Superiority','T2DM with hypertension',558,NULL,NULL,NULL,NULL,'NCT01137474','A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Placebo-matching dapagliflozin|Drug: Oral antidiabetic agent|Drug: Angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB)|Drug: With or without insulin',NULL,'Bristol-Myers Squibb|AstraZeneca','Interventional','2996','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','MB102-073 ST|2010-019797-32','2010-06-03','2010-07-01','2013-02-01','2014-04-01','2014-04-01','Y','2014-02-07','N','2013-02-01','United States,   Canada,   Colombia,   Czech Republic,   Denmark,   Finland,   Germany,   Hungary,   India,   Mexico,   Peru,   Poland,   Puerto Rico,   Romania,   Russian Federation,   Spain','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','Y','Y','Y','Y','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','Y','Y','Y',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Xigduo','MB102077','2015-11-27','2014-10-29',NULL,3,'Superiority','T2DM with hypertension',857,NULL,NULL,NULL,NULL,'NCT01195662','A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Placebo matching Dapagliflozin',NULL,'AstraZeneca|Bristol-Myers Squibb','Interventional','2245','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','MB102-077 ST|2010-019798-13','2010-09-03','2010-10-01','2013-02-01','2015-12-02','2015-12-01','Y','2014-02-07','N','2013-02-01','United States,   Australia,   Canada,   Colombia,   Czech Republic,   Denmark,   Finland,   Germany,   Hungary,   India,   Ireland,   Mexico,   Poland,   Puerto Rico,   Romania,   United Kingdom','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26620248','2016-03-01',NULL,NULL,'double-blind, placebo-controlled','1213',3,'Type 2 Diabetes','Australia, Canada, Colombia, Czech Republic, Denmark, Finland, germany, Hungary, India, Ireland, Mexico, Poland, Puerto Rico, Romania, United Kingdom, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Xigduo','MB102091',NULL,'2014-10-29',NULL,1,'Safety PK','Pediatric T2DM (children age 10-17)',24,NULL,NULL,NULL,NULL,'NCT01525238','PK Study of Dapagliflozin in Pediatric Subjects With T2DM','Type 2 Diabetes Mellitus',NULL,'Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Dapagliflozin',NULL,'Bristol-Myers Squibb|AstraZeneca','Interventional','24','Industry',1,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label','MB102-091|2011-005225-40','2012-01-31','2012-07-01','2014-09-01','2015-02-06','2014-11-01','N',NULL,'N','2014-09-01','United States,   Mexico',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xigduo','MB102092',NULL,'2014-10-29',NULL,1,'Bioequivalence with IC tables','Healthy',36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xigduo','MB102100',NULL,'2014-10-29',NULL,1,'Bioequivalence   ','Healthy',36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Astrazeneca AB','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xigduo','MB102129','2015-08-05','2014-10-29',NULL,3,'Add-on to saxagliptin and metformin','T2DM',280,NULL,NULL,NULL,NULL,'NCT01646320','Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes','Type 2 Diabetes',NULL,'Drug: Dapagliflozin|Drug: Placebo matching with Dapagliflozin|Drug: Saxagliptin|Drug: Metformin immediate release (IR)',NULL,'Bristol-Myers Squibb|AstraZeneca','Interventional','320','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','MB102-129|2011-006324-20','2012-07-18','2012-09-01','2015-02-01','2015-09-16','2014-10-01','Y','2016-03-09','N','2014-08-01','United States,   Czech Republic,   Mexico,   Poland,   Puerto Rico,   Romania,   Russian Federation,   United Kingdom','N',NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/26246458','2015-11-01',NULL,NULL,NULL,'320',3,'Type 2 Diabetes','United States, Puerto Rico, Romania, Poland, Mexico, United Kingdom',NULL,'N','N','Y','Y','Y','Y','Y','N','Y','N','N','Y','Y',NULL,NULL,NULL,'0',NULL,'N','Y','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','Y','Y','Y','N','N','N','N','N','N','N','N','N'),('Xtoro','C-10-007',NULL,'2014-12-17',NULL,1,'PK','Healthy',41,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Alcon Research Ltd / Novartis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Xtoro','C-10-018',NULL,'2014-12-17',NULL,3,'Efficacy and safety','Patients 6 months or older with AOE of less than 4 weeks',693,'US, Canada, Puerto Rico',NULL,NULL,NULL,'NCT01535599','Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa','Acute Otitis Externa',NULL,'Drug: AL-60371, 0.3% Otic Suspension|Other: AL-60371 Vehicle',NULL,'Alcon Research','Interventional','768','Industry',3,'Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','C-10-018','2012-02-15','2012-03-01','2013-05-01','2014-06-24','2014-06-01','Y','2014-05-19','N','2013-05-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','Y','Y','Y','Y','Y','N',NULL,NULL,NULL,'0','Alcon Research Ltd / Novartis','Y','Y','Y',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Xtoro','C-10-019',NULL,'2014-12-17',NULL,3,'Efficacy and safety','Patients 6 months or older with AOE of less than 4 weeks',549,'US, Canada, Puerto Rico',NULL,NULL,NULL,'NCT01535560','Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa','Acute Otitis Externa',NULL,'Drug: AL-60371, 0.3% otic suspension|Drug: AL-60371 Vehicle',NULL,'Alcon Research','Interventional','589','Industry',3,'Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)','C-10-019','2012-02-15','2012-04-01','2012-10-01','2013-10-18','2013-10-01','Y','2013-10-18','N','2012-10-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','Y','Y','Y','Y','Y','N',NULL,NULL,NULL,'0','Alcon Research Ltd / Novartis','Y','Y','Y',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Xtoro','C-10-022',NULL,'2014-12-17',NULL,1,'PK','Patients with acute otitis externa',36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Alcon Research Ltd / Novartis','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Yondelis','10045020',NULL,'2015-10-23',NULL,1,'','uterine carcinoma',9,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'9',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','10045030','2015-03-18','2015-10-23',NULL,1,'',NULL,73,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'73',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25795406','2015-04-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','EORTC-62091','2015-04-23','2015-10-23','extension trial',2,'','Japanese sarcoma patients',133,NULL,NULL,NULL,NULL,'NCT01189253','Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma','Sarcoma',NULL,NULL,NULL,'European Organisation for Research and Treatment of Cancer - EORTC|Sarcoma Alliance for Research through Collaboration','Interventional','133',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-08-25','2011-05-01',NULL,NULL,NULL,'',NULL,'N','2013-06-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25912752','2015-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET-A-002-95',NULL,'2015-10-23',NULL,NULL,'','locally advanced or metatstatic liposarcoma or leiomyosarcoma',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET-A-006-00','2011-06-10','2015-10-23',NULL,1,'','patients w solid tumors',33,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'33',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21660618','2017-09-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET-A-010-01',NULL,'2015-10-23',NULL,1,'','malignant pleural mesothelioma',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET-A-013-01',NULL,'2015-10-23',NULL,NULL,'','healthy',8,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'8',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/16133794','2005-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET-B-005-98',NULL,'2015-10-23',NULL,2,'',NULL,99,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'99',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET-B-008-98',NULL,'2015-10-23','MD-04',2,'',NULL,50,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'50',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/?term=14990645','2005-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET-B-010-99',NULL,'2015-10-23',NULL,2,'',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET-B-011-00',NULL,'2015-10-23','MD-31',NULL,'','untreated, localized, myxoid/round cell liposarcoma',1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'1',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET-B-016-99',NULL,'2015-10-23','extension study',2,'','unselected STS',36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'36',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/15084621','2004-04-15',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET-B-017-99',NULL,'2015-10-23','MD-05',2,'','pax w locally advance metastatic tumor',34,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'34',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET-B-020-99',NULL,'2015-10-23','MD-32',2,'','translocation-related sarcomas',4,NULL,NULL,NULL,NULL,'NCT00027508','Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma','Malignant Mesothelioma',NULL,NULL,NULL,'PharmaMar|National Cancer Institute (NCI)','Interventional','4',NULL,NULL,'Primary Purpose: Treatment',NULL,'2001-12-07','2001-07-01',NULL,NULL,NULL,'',NULL,'N','2002-02-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET-B-028-06','2011-06-03','2015-10-23',NULL,2,'','unselected STS',29,NULL,NULL,NULL,NULL,'NCT00579501','Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma','Liposarcoma,Myxoid',NULL,NULL,NULL,'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PharmaMar','Interventional','29',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2007-12-20','2007-04-01',NULL,NULL,NULL,'','2014-01-28','2/14/13','2010-01-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21642514','2012-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'Y',NULL,'2013-02-14','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET-C-002-07','2014-02-07','2015-10-23','MD-16',3,'','unselected STS',121,NULL,NULL,NULL,NULL,'NCT00796120','An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)','Sarcoma',NULL,NULL,NULL,'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PharmaMar','Interventional','121',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2008-11-20','2008-11-01',NULL,NULL,NULL,'','2014-03-25','4/18/13','2012-08-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24512981','2014-04-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'Y',NULL,'2013-04-18','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET743-OVA-1002',NULL,'2015-10-23',NULL,NULL,'',NULL,8,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'8',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET743-OVA-1003',NULL,'2015-10-23',NULL,NULL,'','Japanese sarcoma patients',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET743-OVC-1001','2011-07-08','2015-10-23',NULL,2,'','patients w unresectable or metastatic leiomyosarcoma or liposarcoma',75,NULL,NULL,NULL,NULL,'NCT00786838','A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram','Solid Tumor',NULL,NULL,NULL,'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PharmaMar','Interventional','75',NULL,NULL,'Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)',NULL,'2008-11-04','2008-10-01',NULL,NULL,NULL,'','2013-03-29','N','2009-12-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21739119','2012-02-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET743-OVC-1002','2014-08-07','2015-10-23',NULL,1,'','patients w liposarcoma or leiomyosarcoma',12,NULL,NULL,NULL,NULL,'NCT01273480','A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies','Neoplasm Metastases',NULL,NULL,NULL,'Janssen Research & Development, LLC','Interventional','12',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-12-23','2010-12-01',NULL,NULL,NULL,'',NULL,'N','2012-10-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25100135','2014-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET743-OVC-1003','2014-08-07','2015-10-23','long-term extension study in mania',1,'','recurrent, pediatric rhabdomyosarcoma, Ewing sarcoma, or non-rhabdomyosarcomatous soft tissue sarcomas',12,NULL,NULL,NULL,NULL,'NCT01267084','A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies','Neoplasm Metastases',NULL,NULL,NULL,'Janssen Research & Development, LLC|PharmaMar','Interventional','12',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2010-12-23','2011-02-01',NULL,NULL,NULL,'',NULL,'N','2012-11-01','','1',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25100135','2014-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET743-SAR-2005','2011-11-14','2015-10-23',NULL,2,'','untreated advanced and or metastatic STS',50,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'50',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22088484','2012-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET743-SAR-3002','2013-02-05','2015-10-23','RGH-188-02, RGM-MD-02 (typo, Med:35), RGH-PK-02 (typo, Med: 35)',3,'','schizophrenia for at least 1 year',1803,NULL,NULL,NULL,NULL,'NCT00210665','A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment','Sarcoma',NULL,NULL,NULL,'Janssen Research & Development, LLC','Expanded Access','1803',NULL,NULL,'0',NULL,'2005-09-13',NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23385197','2013-06-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET743-SAR-3006',NULL,'2015-10-23',NULL,3,'','advanced or metastatic untreated soft-tissue sarcoma',171,NULL,NULL,NULL,NULL,'NCT01692678','A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma','Advanced or Metastatic Liposarcoma or Leiomyosarcoma',NULL,NULL,NULL,'Xian-Janssen Pharmaceutical Ltd.','Interventional','171',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-08-06','2012-08-01',NULL,NULL,NULL,'',NULL,'N','2018-03-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET743-SAR-3007','2015-09-14','2015-10-23',NULL,3,'','healthy',518,NULL,NULL,NULL,NULL,'NCT01343277','A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma','Advanced Liposarcoma or Leiomyosarcoma',NULL,NULL,NULL,'Janssen Research & Development, LLC|PharmaMar','Interventional','518',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2011-04-26','2011-06-01',NULL,NULL,NULL,'','2015-12-22','N','2015-01-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26371143','2016-03-10',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'Y',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET743-STS-201','2009-08-03','2015-10-23',NULL,2,'','healthy',270,NULL,NULL,NULL,NULL,'NCT00060944','A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer','Liposarcoma|Leiomyosarcoma',NULL,NULL,NULL,'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PharmaMar','Interventional','270',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2003-05-16','2003-05-01',NULL,NULL,NULL,'','2014-01-14','8/12/11','2008-05-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19652065','2009-09-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'Y',NULL,'2011-08-12','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Yondelis','ET743-USA-11',NULL,'2015-10-23',NULL,1,'','patients w advanced malignancies',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Yondelis','OVA-301','2010-07-19','2015-10-23',NULL,3,'','patients w advanced malignancies',672,NULL,NULL,NULL,NULL,'NCT00113607','An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer','Ovarian Cancer',NULL,NULL,NULL,'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PharmaMar','Interventional','672',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment',NULL,'2005-06-09','2017-04-17',NULL,NULL,NULL,'','2013-06-18','4/10/12','2017-11-17','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20643863','2017-01-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Janssen Prods',NULL,'Y',NULL,'2012-04-10','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,NULL,NULL),('Zaltrap','ARD6122','2013-10-11','2012-08-03',NULL,2,'Monotherapy; safety in advanced ovarian cancer','Patients',215,NULL,NULL,NULL,NULL,'NCT00327171',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-05-16','2006-05-01',NULL,NULL,NULL,'Y','2012-08-17','Y','2008-04-01','United States,   Australia,   Canada,   France,   Germany,   Italy,   Netherlands,   Portugal,   Spain,   Sweden,   Switzerland',NULL,NULL,NULL,NULL,' http://www.ncbi.nlm.nih.gov/pubmed/24127346','2013-10-11',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N','2011-08-08','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Zaltrap','ARD6123',NULL,'2012-08-03',NULL,2,'Monotherapy; safety in locally advanced lung cancer','Patients',96,NULL,NULL,NULL,NULL,'NCT00284141',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-01-30','2006-01-01',NULL,NULL,NULL,'Y','2012-08-17','Y','2008-07-01','United States, Canada, France',NULL,NULL,NULL,NULL,' http://www.ncbi.nlm.nih.gov/pubmed/20593550','2010-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N','2011-07-21','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Zaltrap','ARD6772','2011-11-21','2012-08-03',NULL,2,'Monotherapy; response rate in advanced ovarian cancer','Patients',16,NULL,NULL,NULL,NULL,'NCT00396591',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-11-06','2006-10-01',NULL,NULL,NULL,'Y','2012-08-17','Y','2008-11-01','United States, Italy, Sweden',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22112608','2011-11-21',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N','2011-07-21','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Zaltrap','EFC10261','2012-01-20','2012-08-03','VITAL',3,'Combination; PK in metastic lung cancer (previously failed)','Patients',905,NULL,NULL,NULL,NULL,'NCT00532155',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2007-09-19','2007-09-01',NULL,NULL,NULL,'Y','2012-08-17','Y','2011-01-01','Turkey,   Korea, Republic of,   Taiwan,   Austria,   Brazil,   Bulgaria,   Canada,   Chile,   China,   Czech Republic,   Argentina,   Finland,   France,   Germany,   Greece,   Hong Kong,   Hungary,   India,   Italy,   United States,   Malaysia,   Netherlands,   Poland,   Portugal,   Romania,   Russian Federation,   Singapore,   Spain,   Sweden,   Estonia,   United Kingdom,   Australia',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22264850, http://www.ncbi.nlm.nih.gov/pubmed/22965962','2012-01-20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N','2012-02-17','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Zaltrap','EFC10262','2012-01-20','2012-08-03','VELOUR',3,'Combination; PK in metastic colorectal cancer (previously failed)','Patients',1216,NULL,NULL,NULL,NULL,' NCT00561470',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2007-11-20','2007-11-01',NULL,NULL,NULL,'Y','2012-08-17','N','2011-02-01','Argentina,   Australia,   Austria,   Belgium,   Brazil,   Chile,   Czech Republic,   Denmark,   Estonia,   France,   Germany,   Greece,   Italy,   Korea, Republic of,   Netherlands,   New Zealand,   Norway,   Poland,   Puerto Rico,   Romania,   Russian Federation,   South Africa,   Spain,   Sweden,   Turkey,   Ukraine,   United Kingdom,   United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22264850, http://www.ncbi.nlm.nih.gov/pubmed/22949147','2012-01-20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Zaltrap','EFC10547','2012-01-20','2012-08-03','VANILLA',3,'Combination;  Compared to Gemcitabine for Metastatic Pancreatic Cancer','Patients',541,NULL,NULL,NULL,NULL,'NCT00574275',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2007-12-14','2007-12-01',NULL,NULL,NULL,'Y','2012-08-17','Y','2010-11-01','Germany,   Argentina,   Austria,   Belgium,   Bulgaria,   Canada,   Chile,   Colombia,   Cyprus,   Czech Republic,   France,   Switzerland,   Greece,   Hungary,   India,   Italy,   Mexico,   Poland,   Puerto Rico,   Romania,   Russian Federation,   Slovakia,   Spain,   United States(UM), India (LM), Italy, Mexico (UM), Poland, Puerto Rico, Romania (UM), Russian Federation, Slovakia,  Spain,  Switzerland',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22264850, http://www.ncbi.nlm.nih.gov/pubmed/23642329','2012-01-20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N','2011-07-21','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Zaltrap','EFC10668',NULL,'2012-08-03',NULL,2,NULL,NULL,168,NULL,NULL,NULL,NULL,'NCT00851084',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-02-24','2009-02-01',NULL,NULL,NULL,'Y','2013-02-19','N','2011-04-01','Australia,   Germany,   Italy,   Korea, Republic of,   Russian Federation,   Spain,   United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','Y','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','EFC10688',NULL,'2012-08-03','AFFIRM',2,'randomized, Phase 2 study in first-line mCRC of the combination of mFOLFOX6 vs.\r\naflibercept/mFOLFOX6.',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','EFC6125','2011-12-20','2012-08-03',NULL,2,'Monotherapy; PK and safety in advanced ovarian cancer','Patients',58,NULL,NULL,NULL,NULL,'NCT00327444',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2006-05-16','2006-07-01',NULL,NULL,NULL,'Y','2012-08-17','Y','2009-10-01','India,   Austria,   Belgium,   Canada,   Hungary,   United Kingdom,   Israel,   Spain,   United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22192729, http://www.ncbi.nlm.nih.gov/pubmed/21606416','2011-12-20',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N','2011-07-21','Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','N','Y','Y'),('Zaltrap','EFC6546',NULL,'2012-08-03','VENICE',3,NULL,'Patients',1224,NULL,NULL,NULL,NULL,'NCT00519285',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2007-08-21','2007-08-01',NULL,NULL,NULL,'Y','2013-04-25','N','2012-02-01','United States, Argentina (UM), Australia, Belgium, Brazil (UM), Canada, Chile, Croatia, Czech Republic, Denmark, Estonia, France, Germany, Hong Kong, Hungary (UM), Israel, Italy, Korea, Republic of, Netherlands, Poland, Portugal, Russian Federation, Singapore, South Africa (UM), Spain, Sweden, Switzerland, Taiwan, Turkey (UM), Ukraine (LM), United Kingdom',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23742877','2013-06-04',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','Y','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','PDY 6655',NULL,'2012-08-03',NULL,1,'Monotherapy; bioavailability','Healthy',40,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','PDY6656',NULL,'2012-08-03',NULL,1,'Monotherapy; PK','Healthy',48,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','POH0251',NULL,'2012-08-03',NULL,NULL,'population analysis',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','POH0253',NULL,'2012-08-03',NULL,NULL,'population analysis',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','POH0262',NULL,'2012-08-03',NULL,NULL,'population analysis',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','POH0263',NULL,'2012-08-03',NULL,NULL,'population analysis',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','POH0265',NULL,'2012-08-03',NULL,NULL,'population analysis',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','POH0274',NULL,'2012-08-03',NULL,NULL,'population analysis',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','TCD10173',NULL,'2012-08-03',NULL,1,'Combination; DLT and safety in Hodgkin\'s B-cell lymphoma ','Patients',28,NULL,NULL,NULL,NULL,'NCT00644124',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2008-03-21','2008-03-01',NULL,NULL,NULL,'N',NULL,'N','2011-10-01','France',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','TCD6117',NULL,'2012-08-03',NULL,1,'Combination; safety, tolerability and PK DLT and RP2D','Patients',32,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','TCD6118',NULL,'2012-08-03',NULL,1,'Combination; safety and antitumor response','Patients',65,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','TCD6119',NULL,'2012-08-03',NULL,1,'Combination; safety; tolerability and PK DLT and R2PD','Patients',44,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','TCD6120',NULL,'2012-08-03',NULL,1,'Combination; DLT and R2DP with docetaxel','Patients',134,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','TCD6121',NULL,'2012-08-03',NULL,1,'Combination; DLT and R2DPwith gemcitabine','Patients',61,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','TED10089',NULL,'2012-08-03',NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'NCT00479076',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2007-05-24','2007-03-01','2016-01-11',NULL,NULL,'N',NULL,'N','2011-01-01','Japan',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','TED6113','2009-12-22','2012-08-03',NULL,1,'Monotherapy; safety and tolerability','Patients',38,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,'United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20028764, http://www.ncbi.nlm.nih.gov/pubmed/22921183','2009-12-22',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','Y','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Zaltrap','TED6114','2012-07-17','2012-08-03',NULL,1,'Monotherapy; long-term safety and tolerabiility','Patients',18,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22805331   ','2012-06-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','Y','Y','N','N','Y','Y','N','Y','Y'),('Zaltrap','TED6115',NULL,'2012-08-03',NULL,1,'Monotherapy; safety and tolerability ','Patients',57,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','TED6116',NULL,'2012-08-03',NULL,1,'Monotherapy; long-term safety and and tolerability','Patients',44,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zaltrap','TES10897',NULL,'2012-08-03',NULL,1,'Combination; effect of aflibercept on QTcF interval','Patients',87,NULL,NULL,NULL,NULL,'NCT00876044',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-04-03','2009-04-01','2016-02-10',NULL,NULL,'N',NULL,'N','2010-02-01','United States, Belgium,  Denmark,  Germany,  Italy,  Romania,  Turkey',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/23429593','2013-06-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Sanofi Aventis','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zerbaxa','CXA-101-01',NULL,'2014-12-19',NULL,1,'Safety PK ','Healthy',68,'Europe, North America, South America, Israel, India, South Korea, Australia, South Africa',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20457817','2010-08-01',NULL,NULL,'single-center, prospective, randomized, double-blind, placebo-controlled','64',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals LLC / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zerbaxa','CXA-101-02',NULL,'2014-12-19',NULL,1,'Safety PK ','Normal and renal impairment',12,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25196976','2015-02-01',NULL,NULL,'open-label, single dose ','12',1,'Healthy and Renal Impairmnt',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals LLC / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zerbaxa','CXA-101-03',NULL,'2014-12-19',NULL,2,'Safety, PopPK','cUTI Subjects',127,NULL,NULL,NULL,NULL,'NCT00921024','Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections','Complicated Urinary Tract Infection',NULL,'Drug: CXA-101|Drug: Ceftazidime',NULL,'Cubist Pharmaceuticals LLC','Interventional','129','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','7625-001|CXA 101-03','2009-06-12','2009-07-01','2010-04-01','2016-01-06','2016-01-01','Y','2015-01-09','N','2010-03-01','United States,   Germany,   Poland',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25196976','2015-02-01',NULL,NULL,'multicenter, prospective, randomized, double- blind, active comparator/ placebo- controlled ','77',2,'cUTI',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals LLC / Merck and Co.','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Zerbaxa','CXA-201-01',NULL,'2014-12-19',NULL,1,'Safety PK, crossover ','Healthy',58,'Europe, North America, South America, Israel, India, South Korea, Thailand, South Africa',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22450972','2012-06-01',NULL,NULL,'single-center, prospective, randomized, double-blind study of single and multiple ascending doses','48',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals LLC / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zerbaxa','CXA-201-02',NULL,'2014-12-19',NULL,1,'Safety PK ','Normal to moderate renal impairment',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25196976','2015-02-01',NULL,NULL,'open-label, single dose ','24',1,'Healthy and Renal Impairmnt',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals LLC / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zerbaxa','CXA-cIAI-10-08  ',NULL,'2014-12-19',NULL,3,NULL,'cIAI Subjects',NULL,NULL,NULL,NULL,NULL,'NCT01445678','Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections','Complicated Intra-abdominal Infection',NULL,NULL,NULL,NULL,'Interventional',NULL,NULL,NULL,NULL,NULL,'2011-09-26','2011-12-01',NULL,NULL,NULL,NULL,'2015-01-09','N','2013-10-01','United States,   Argentina,   Bulgaria,   Chile,   Croatia,   Estonia,   Germany,   Hungary,   Israel,   Korea, Republic of,   Latvia,   Lithuania,   Moldova, Republic of,   Poland,   Serbia',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25670823','2015-05-15',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,NULL,'Cubist Pharmaceuticals LLC / Merck and Co.','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Zerbaxa','CXA-cIAI-10-09',NULL,'2014-12-19','CXA-cIAI-10-08  ',3,'Efficacy and safety','cIAI Subjects',979,NULL,NULL,NULL,NULL,'NCT01445678','Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections','Complicated Intra-abdominal Infection',NULL,'Drug: CXA-201 and metronidazole|Drug: Meropenem',NULL,'Cubist Pharmaceuticals LLC','Interventional','494','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','7625A-004|CXA-cIAI-10-09','2011-09-26','2011-12-01','2013-10-01','2016-01-06','2016-01-01','Y','2015-01-09','N','2013-10-01','United States,   Argentina,   Bulgaria,   Chile,   Croatia,   Estonia,   Germany,   Hungary,   Israel,   Korea, Republic of,   Latvia,   Lithuania,   Moldova, Republic of,   Poland,   Serbia',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25670823','2015-05-15',NULL,NULL,'prospective, randomized, double-blind','993',3,'cIAI',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals LLC / Merck and Co.','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Zerbaxa','CXA-cUTI-10-04',NULL,'2014-12-19','CXA-cUTI-10-05',3,'Efficacy and safety','cIAI Subjects',1068,NULL,NULL,NULL,NULL,'NCT01345929','Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis','Complicated Urinary Tract Infection|Pyelonephritis',NULL,'Drug: CXA-201|Drug: Levofloxacin',NULL,'Cubist Pharmaceuticals LLC','Interventional','558','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','7625A-005|CXA-cUTI-10-04','2011-04-28','2011-06-01','2013-09-01','2016-01-06','2016-01-01','Y','2015-01-09','N','2013-08-01','United States,   Brazil,   Colombia,   Estonia,   Georgia,   Germany,   Hungary,   Israel,   Latvia,   Mexico,   Moldova, Republic of,   Romania,   Russian Federation,   Serbia,   Slovakia,   South Africa,   Thailand',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25931244','2015-05-16',NULL,NULL,'randomized, double-blind, double-dummy, non-inferiority trial','1083',3,'cUTI',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals LLC / Merck and Co.','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Zerbaxa','CXA-cUTI-10-05',NULL,'2014-12-19',NULL,3,NULL,'cIAI Subjects',NULL,NULL,NULL,NULL,NULL,'NCT01345929','Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis','Complicated Urinary Tract Infection|Pyelonephritis',NULL,NULL,NULL,NULL,'Interventional',NULL,NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2011-04-28','2011-06-01',NULL,NULL,NULL,NULL,'2015-01-09','N','2013-08-01','United States,   Brazil,   Colombia,   Estonia,   Georgia,   Germany,   Hungary,   Israel,   Latvia,   Mexico,   Moldova, Republic of,   Romania,   Russian Federation,   Serbia,   Slovakia,   South Africa,   Thailand',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25931244','2015-05-16',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,NULL,'Cubist Pharmaceuticals LLC / Merck and Co.','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Zerbaxa','CXA-DDI-12-10',NULL,'2014-12-19',NULL,1,'Safety PK ','Healthy',16,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Cubist Pharmaceuticals LLC / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zerbaxa','CXA-ELF-10-03',NULL,'2014-12-19',NULL,1,'Safety PK, ELF penetration','Healthy',51,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22773741','2012-10-01',NULL,NULL,'open-label, comparator-controlled, randomized study','51',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals LLC / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zerbaxa','CXA-IAI-10-01',NULL,'2014-12-19',NULL,2,'Safety, PopPK','cIAI Subjects',122,NULL,NULL,NULL,NULL,'NCT01147640','Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections','Complicated Intra-abdominal Infection',NULL,'Drug: CXA-101/ tazobactam and metronidazole|Drug: meropenem plus saline placebo',NULL,'Cubist Pharmaceuticals LLC','Interventional','122','Industry',2,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','7625A-012|CXA-IAI-10-01','2010-06-17','2010-06-01','2011-03-01','2016-01-06','2016-01-01','Y','2015-01-09','N','2011-02-01','United States,   Argentina,   Georgia,   Russian Federation,   Serbia',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24982069','2014-09-01',NULL,NULL,'prospective, double-blind, randomized, multi-center','122',2,'cIAI',NULL,NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals LLC / Merck and Co.','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Zerbaxa','CXA-MD-11-07',NULL,'2014-12-19',NULL,1,'Safety PK ','Healthy',16,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25196976','2015-02-01',NULL,NULL,'randomized, double-blind, multidose, placebo-controlled','12',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals LLC / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zerbaxa','CXA-NP-11-08',NULL,'2014-12-19',NULL,3,'Efficacy and safety','VAP Subjects',4,NULL,NULL,NULL,NULL,'NCT01853982','Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia','Ventilator-Associated Pneumonia (VAP)',NULL,'Drug: Ceftolozane/Tazobactam|Drug: Piperacillin/Tazobactam',NULL,'Cubist Pharmaceuticals LLC','Interventional','4','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','7625A-009|CXA-NP-11-08','2013-05-13','2013-07-01','2013-12-01','2016-01-06','2016-01-01','Y','2015-04-19','N','2013-12-01','United States,   Australia,   New Zealand',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Cubist Pharmaceuticals LLC / Merck and Co.','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','Y','N','N','Y','N','N','N'),('Zerbaxa','CXA-QT-10-02',NULL,'2014-12-19',NULL,1,'Safety, QTc','Healthy',51,NULL,NULL,NULL,NULL,'NCT02508753','Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects','Healthy',NULL,'Drug: CXA-101/tazobactam|Drug: CXA-101/tazobactam|Drug: Moxifloxacin|Drug: placebo',NULL,'Cubist Pharmaceuticals LLC','Interventional','52','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)','CXA-QT-10-02','2010-06-17','2010-06-01','2010-07-01','2015-07-24','2015-07-01','N',NULL,'N','2010-07-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25196976','2015-02-01',NULL,NULL,'randomized, double- blind,\ndouble- dummy, placebo- and active- controlled 4- way crossover','51',1,'cUTI',NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals LLC / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zerbaxa','CXA-REN-11-01',NULL,'2014-12-19',NULL,1,'Safety PK ','Severe renal impairment',12,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/25196976','2015-02-01',NULL,NULL,'open label, prospective, multicenter ','6',1,'Severe Renal Impairment',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Cubist Pharmaceuticals LLC / Merck and Co.','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zioptan','15001',NULL,'2012-02-10','15-001',2,'dose-response','Patients',152,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Merck Sharpe Dohme','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zioptan','15002',NULL,'2012-02-10',NULL,2,'dose-response','Patients',144,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Merck Sharpe Dohme','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zioptan','15003',NULL,'2012-02-10',NULL,3,NULL,NULL,458,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Merck Sharpe Dohme','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zioptan','15005',NULL,'2012-02-10',NULL,1,'Open-label; PK & safety','Healthy',19,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Merck Sharpe Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zioptan','74450',NULL,'2012-02-10',NULL,1,'dose-escalation',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Merck Sharpe Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zioptan','74451',NULL,'2012-02-10',NULL,1,'dose-escalation',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Merck Sharpe Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zioptan','74452',NULL,'2012-02-10',NULL,1,'dose-escalation',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Merck Sharpe Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zioptan','74453',NULL,'2012-02-10',NULL,1,'dose-escalation',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Merck Sharpe Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zioptan','74457',NULL,'2012-02-10',NULL,2,'safety/efficacy','Patients',38,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20148656','2010-02-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Merck Sharpe Dohme','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zioptan','74458',NULL,'2012-02-10',NULL,3,NULL,NULL,533,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20420586','2010-02-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Merck Sharpe Dohme','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zioptan','74460',NULL,'2012-02-10',NULL,3,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Merck Sharpe Dohme','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zioptan','77550',NULL,'2012-02-10',NULL,3,'PD','Patients',43,NULL,NULL,NULL,NULL,'NCT00918346',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-06-09','2005-09-14',NULL,NULL,NULL,'Y','2009-08-04','N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/18752510','2008-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Merck Sharpe Dohme','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','Y','N','Y'),('Zioptan','77551',NULL,'2012-02-10',NULL,1,'PK','Healthy',16,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/18752509','2008-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Merck Sharpe Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zioptan','77552',NULL,'2012-02-10',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2010-04-27',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N','N','N','N',NULL,'Merck Sharpe Dohme','N','N','N',NULL,'0','0','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zioptan','77553',NULL,'2012-02-10',NULL,3,NULL,'Patients',185,NULL,NULL,NULL,NULL,'NCT01087671',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2010-03-03','2010-04-01',NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19253237','2009-03-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','Y','N','N',NULL,'N','Y','N','N','N','N',NULL,'Merck Sharpe Dohme','N','N','N',NULL,'Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zioptan','MK-2452-001','2012-02-04','2012-02-10',NULL,3,'safety/efficacy','Patients',643,NULL,NULL,NULL,NULL,'NCT01026831',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2009-12-02','2010-01-01',NULL,NULL,NULL,'Y','2011-08-09','N','2010-09-01',NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22310086','2012-02-04',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','N','Y','Y','N',NULL,'N','Y','N','N','N','Y',NULL,'Merck Sharpe Dohme','N','N','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y'),('Zioptan','MK-2452-002',NULL,'2012-02-10',NULL,3,'safety/efficacy','Patients  ',190,NULL,NULL,NULL,NULL,'NCT01254604',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'2010-12-03','2015-12-11',NULL,NULL,NULL,'Y','2014-04-09','N','2015-05-13',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','N','Y','Y','N',NULL,'N','N','N','N','N','Y',NULL,NULL,'N','N','N',NULL,'?','?','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P03445',NULL,'2014-05-08',NULL,1,'Food effect table v capsule',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/27121935','2013-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P03447',NULL,'2014-05-08',NULL,1,'Food and antacid,  PK of vorapaxar following vorapaxar sulfate',NULL,123,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/27121783','2013-07-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P03448',NULL,'2014-05-08',NULL,1,'PK and effect of race','Healthy Japanse and Caucasion',111,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21969227','2012-03-01',NULL,NULL,NULL,'111',1,'Healthy','United States',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P03449',NULL,'2014-05-08',NULL,1,'PK, rising single','Healthy  ',54,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21935705','2012-03-01',NULL,NULL,'single ascending dose','50',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P03450',NULL,'2014-05-08',NULL,1,'PK, rising multiple','Healthy',48,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/21935705','2012-03-01',NULL,NULL,'multiple doses','48',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P03454',NULL,'2014-05-08',NULL,1,'C-vorapaxar absorption','Healthy',6,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P03458',NULL,'2014-05-08',NULL,1,'PK with digoxin','Healthy',22,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/27121563','2013-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P03462',NULL,'2014-05-08','TQT Study',1,'TQT ',NULL,123,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/27128226','2014-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P03464',NULL,'2014-05-08',NULL,1,'PK for patients with renal disease','Renal disease',15,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22315147','2012-07-01',NULL,NULL,'two-stage, open-label clinical trial','15',1,'ESRD and Healthy','United States',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P03465',NULL,'2014-05-08',NULL,1,'PK for hepatic impairment','Patients with hepatic impairment',32,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22527342','2012-11-01',NULL,NULL,'open-label, single-dose, parallel-group','32',1,'Hepatic Impairment','United States',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P03573',NULL,'2014-05-08','TRA-PCI',2,'Loading and maintenance doses','Non-emergent PCI',1030,NULL,NULL,NULL,NULL,'NCT00132912','Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573AM1) (COMPLETED)','Arterial Obstructive Diseases|Coronary Disease',NULL,'Drug: SCH 530348',NULL,'Merck Sharp & Dohme Corp.','Interventional','1030','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double-Blind','P03573','2005-08-19','2005-08-01','2007-01-01','2015-10-19','2015-10-01','N',NULL,'N','2007-01-01','Belgium,   Canada,   Germany,   Italy,   New Zealand,   United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/19286091','2009-03-14',NULL,NULL,'multicenter, placebo-controlled','1030',2,'Non-urgent PCI, Coronary Angiography',NULL,NULL,'N','N','Y','Y','Y','Y','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P03629',NULL,'2014-05-08',NULL,1,'PK with CYP3A4 inhibitor','Healthy',38,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/23426761','2013-05-01',NULL,NULL,'DDI - randomized, open-label, parallel-group','35',1,'Healthy',NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P04132',NULL,'2014-05-08',NULL,1,'PK with warfarin','Healthy',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22476387','2012-11-01',NULL,NULL,'open-label, non-randomized, two period study','12',1,'Healthy','United States',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P04736',NULL,'2014-05-08','TRACER',3,'Prevention of CV events','Patients with ACS',12944,NULL,NULL,NULL,NULL,'NCT00527943','Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA.CER) (Study P04736)','Atherosclerosis|Myocardial Ischemia|Myocardial Infarction',NULL,'Drug: Vorapaxar|Drug: Placebo',NULL,'Merck Sharp & Dohme Corp.|Duke Clinical Research Institute','Interventional','12944','Industry|Other',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)','P04736|TRACER|2006-002809-31|MK-5348-014','2007-09-07','2007-12-01','2011-07-01','2015-10-08','2015-10-01','Y','2014-05-09','N','2011-07-01','Argentina,   Australia,   Austria,   Belgium,   Brazil,   Canada,   Chile,   China,   Colombia,   Czech Republic,   Denmark,   Finland,   France,   Germany,   Hong Kong,   Hungary,   Israel,   Italy,   Japan,   Korea, Republic of,   Malaysia,   Netherlands,   Norway,   Peru,   Poland,   Portugal,   Puerto Rico,   Singapore,   South Africa,   Spain,   Sweden,   Switzerland,   Taiwan,   Turkey,   United Kingdom,   United States','N',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22077816','2012-01-05',NULL,NULL,'multinational, double blind, randomized trial','12944',3,'Acute Coronary Syndromes without ST-segment elevation','Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Malaysia, Netherlands, New Zealand, Norway, Peru, Poland, Portugal, Puerto Rico, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'0','Merck Sharp Dohme','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Zontivity','P04737',NULL,'2014-05-08','TRA 2P / TRA 2P -TIMI 50',3,'Prevention of CV ','Patients with prior MI, prior stroke or PAD',26449,NULL,NULL,NULL,NULL,'NCT00526474','Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2P - TIMI 50) (P04737)','Atherosclerosis|Ischemia|Myocardial Infarction|Cerebrovascular Accident|Peripheral Arterial Disease',NULL,'Drug: Vorapaxar|Drug: Placebo',NULL,'Merck Sharp & Dohme Corp.|The Thrombolysis in Myocardial Infarction Study (TIMI) Group','Interventional','26449','Industry|Other',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)','P04737|TRA 2P - TIMI 50|2006-002942-12|MK-5348-015','2007-09-06','2007-09-01','2011-12-01','2015-04-24','2015-04-01','Y','2014-05-16','N','2011-12-01','Argentina,   Australia,   Austria,   Belgium,   Brazil,   Canada,   Chile,   Colombia,   Czech Republic,   Denmark,   Finland,   France,   Germany,   Hong Kong,   Hungary,   Israel,   Italy,   Japan,   Malaysia,   Netherlands,   New Zealand,   Norway,   Poland,   Portugal,   Puerto Rico,   Singapore,   South Africa,   Spain,   Sweden,   Switzerland,   United Kingdom,   United States','http://198.61.244.207/Upload/37_Applied%20Redaction%205348%20P015%20CSR%20Synopsis.pdf; http://198.61.244.207/Upload/71_Applied%20Redaction%205348%20P015%20CSR%20Synopsis.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/22443427','2012-04-12',NULL,NULL,'multinational, double-blind, placebo-controlled trial','26449',3,'Prior Myocardial Infarction, Peripheral Arterial Disease, Stroke','Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Malaysia, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, Switzerland, United Kingdom, United States',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','Y','Y',NULL,NULL,NULL,'1','Merck Sharp Dohme','Y','Y','N',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Zontivity','P04772',NULL,'2014-05-08',NULL,2,NULL,NULL,117,NULL,NULL,NULL,NULL,'NCT00684203','Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)','Atherosclerosis|Myocardial Ischemia|Myocardial Infarction',NULL,'Drug: Vorapaxar|Drug: Placebo|Drug: Aspirin|Drug: Clopidogrel',NULL,'Merck Sharp & Dohme Corp.','Interventional','120','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','P04772','2008-05-22','2006-12-01','2007-10-01','2015-07-20','2015-07-01','Y','2014-05-09','Y','2007-10-01',NULL,'http://198.61.244.207/Upload/118_Applied%20Redaction%205348%20P016%20CSR%20Synopsis.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20124733','2010-02-26',NULL,NULL,'multicenter, randomized, double-blind, placebo-controlled, sequential and parallel group trial','117',2,'Ischemic Chest Discomfort','Japan',NULL,'Y','Y','Y','Y','Y','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Merck Sharp Dohme','N','N','N','2008-10-09','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Zontivity','P05005',NULL,'2014-05-08',NULL,2,'Dose-ranging study','Japanese undgoing PCI',90,NULL,NULL,NULL,NULL,'NCT00684515','Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)','Cerebral Infarction',NULL,'Drug: Vorapaxar 2.5 mg|Drug: Vorapaxar 1 mg|Drug: Placebo|Drug: Aspirin 75-150 mg',NULL,'Merck Sharp & Dohme Corp.','Interventional','90','Industry',2,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','P05005','2008-05-22','2006-09-01','2007-11-01','2015-10-15','2015-10-01','Y','2014-05-09','Y','2007-11-01',NULL,'http://198.61.244.207/Upload/117_Applied%20Redaction%205348%20P017%20CSR%20Synopsis.pdf',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/20947374','2012-05-01',NULL,NULL,'multicenter, randomized, double-blind, parallel-group, placebo controlled','90',2,'Ischemic Stroke','Japan',NULL,'Y','Y','Y','Y','Y','N','Y','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'1','Merck Sharp Dohme','N','N','N','2008-10-09','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Zontivity','P05183',NULL,'2014-05-08',NULL,3,'Vacuolation of the retinal INL','SD-OCT',102,NULL,NULL,NULL,NULL,'NCT00617123','Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)','Atherosclerosis|Ischemia|Myocardial Infarction|Cerebrovascular Accident',NULL,'Drug: Vorapaxar 2.5 mg|Drug: Placebo',NULL,'Merck Sharp & Dohme Corp.|The TIMI (Thrombolysis in Myocardial Infarction) Study Group|Duke Clinical Research Institute','Interventional','258','Industry|Other',3,'Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)','P05183|MK-5348-018','2008-02-04','2008-07-01','2010-10-01','2015-06-23','2015-06-01','Y','2014-05-09','N','2010-10-01','Canada,   Colombia,   Hungary,   Israel,   Netherlands,   Sweden,   United States','http://198.61.244.207/Upload/116_Applied%20Redaction%205348%20P018%20CSR%20Synopsis.pdf',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','Y','Y','Y','Y','N','Y','Y','N','Y','N',NULL,NULL,NULL,'1','Merck Sharp Dohme','Y','Y','N',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','Y','Y','Y','Y','N','N','N'),('Zontivity','P05185',NULL,'2014-05-08',NULL,1,'Vacuolation of the retinal INL','Healthy and patients with atherosclerotic disease',137,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'Y','Y','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P05361',NULL,'2014-05-08',NULL,1,'PK with rosiglitazone','Healthy',18,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/27128003','2015-01-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P06452',NULL,'2014-05-08',NULL,1,'Bioavailability','Healthy',126,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P06453',NULL,'2014-05-08',NULL,1,'PK in Chinese subjects','Healthy Chinese',28,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.researchgate.net/publication/264901880_Pharmacokinetics_of_vorapaxar_and_its_metabolite_following_oral_administration_in_healthy_Chinese_and_American_subjects','2014-08-01',NULL,NULL,NULL,'14',1,NULL,'United States',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P06558',NULL,'2014-05-08',NULL,1,'BE study of tables','Healthy',NULL,NULL,NULL,NULL,NULL,'NCT01358344','A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558)','Acute Coronary Syndrome',NULL,'Drug: Pantoprazole|Drug: SCH 530348 (high percentage)|Drug: SCH 530348 (standard percentage)',NULL,'Merck Sharp & Dohme Corp.','Interventional','173','Industry',1,'Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label','P06558','2011-05-19','2010-08-01','2010-12-01','2015-09-28','2015-09-01','N',NULL,'N','2010-12-01',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P06559',NULL,'2014-05-08',NULL,1,'PK with M20','Healthy',37,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.researchgate.net/publication/264901880_Pharmacokinetics_of_vorapaxar_and_its_metabolite_following_oral_administration_in_healthy_Chinese_and_American_subjects','2014-08-01',NULL,NULL,NULL,'14',1,'Healthy','United States',NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P06560',NULL,'2014-05-08',NULL,1,'PK with prasugrel','Healthy',54,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P07045',NULL,'2014-05-08',NULL,1,'Absolute BA and mass balance','Healthy',6,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zontivity','P07969',NULL,'2014-05-08',NULL,1,'Food Effect','Healthy',16,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,'https://www.ncbi.nlm.nih.gov/pubmed/27121935','2013-10-01',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y','N','N','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Merck Sharp Dohme','N','N','N',NULL,'N','N','N','N','N','N','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zurampic','RDEA549-114',NULL,'2015-12-22',NULL,1,'','hyperuricemic gout subjects',14,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'14',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-101',NULL,'2015-12-22','not initiated by 8/13/13',1,'','STS patients',34,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'34',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26170627','2017-07-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-102',NULL,'2015-12-22','Trial 3007',1,'','hepatic impairment',64,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'64',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26170627','2017-07-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-103',NULL,'2015-12-22','Trial 201',1,'',NULL,27,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'27',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-104',NULL,'2015-12-22',NULL,1,'',NULL,24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-105',NULL,'2015-12-22',NULL,1,'','healthy male subjects',36,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'36',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-106',NULL,'2015-12-22',NULL,1,'','healthy male subjects',8,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'8',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-107',NULL,'2015-12-22',NULL,1,'','healthy male subjects',8,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'8',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-108',NULL,'2015-12-22',NULL,1,'','healthy male and female w renal insufficiency excluding subjects requiring dialysis',45,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'45',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-109',NULL,'2015-12-22','ET-B-008S',1,'','healthy male and female subjects',23,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'23',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-110',NULL,'2015-12-22',NULL,1,'','healthy male subjects',21,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'21',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-111','2014-02-08','2015-12-22',NULL,1,'','healthy male subjects',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24509406','2017-12-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-112',NULL,'2015-12-22',NULL,1,'','healthy male subjects',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-113',NULL,'2015-12-22',NULL,1,'','healthy male subjects',28,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'28',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-115',NULL,'2015-12-22','ET-D-006-09',1,'','hyperuricemic gout subjects',14,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'14',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-116',NULL,'2015-12-22',NULL,1,'','hyperuricemic gout subjects',14,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'14',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-117',NULL,'2015-12-22',NULL,1,'','healthy male subjects',89,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'89',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-118',NULL,'2015-12-22',NULL,1,'','healthy male subjects',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'24',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-120',NULL,'2015-12-22',NULL,1,'','healthy male and female subjects',18,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'18',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-121',NULL,'2015-12-22',NULL,1,'','healthy male and female subjects',16,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'16',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-122',NULL,'2015-12-22',NULL,1,'','healthy male and female subjects',27,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'27',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-123',NULL,'2015-12-22',NULL,1,'','healthy males or males with mild/moderate hepatic impairment',18,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'18',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-125',NULL,'2015-12-22',NULL,1,'','healthy male subjects',40,NULL,NULL,NULL,NULL,'NCT01744379','Single and Multiple Dose Study in Japanese','Gout',NULL,NULL,NULL,'Ardea Biosciences, Inc.','Interventional','40',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)',NULL,'2012-11-29','2012-12-01',NULL,NULL,NULL,'',NULL,'N','2013-03-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-126',NULL,'2015-12-22',NULL,1,'','healthy male subjects',21,NULL,NULL,NULL,NULL,'NCT01884272','NSAID Drug Interaction Study','Gout',NULL,NULL,NULL,'Ardea Biosciences, Inc.','Interventional','21',NULL,NULL,'Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2013-06-18','2013-06-01',NULL,NULL,NULL,'',NULL,'N','2013-08-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-127',NULL,'2015-12-22',NULL,1,'','healthy male subjects',16,NULL,NULL,NULL,NULL,'NCT01908257','Lesinurad Interaction Study With Ranitidine','Healthy',NULL,NULL,NULL,'Ardea Biosciences, Inc.','Interventional','16',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2013-07-23','2013-07-01',NULL,NULL,NULL,'',NULL,'N','2013-09-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-128',NULL,'2015-12-22',NULL,1,'','healthy male subjects',23,NULL,NULL,NULL,NULL,'NCT02028689','Metformin and Furosemide Drug-Drug Interaction Study','Healthy',NULL,NULL,NULL,'Ardea Biosciences, Inc.','Interventional','23',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2013-10-17','2013-10-01',NULL,NULL,NULL,'',NULL,'N','2013-11-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26951201','2017-06-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-129',NULL,'2015-12-22',NULL,1,'','healthy Japanese male subjects',73,NULL,NULL,NULL,NULL,'NCT01986556','Lesinurad Tablet Relative Bioavailability','Healthy',NULL,NULL,NULL,'Ardea Biosciences, Inc.','Interventional','73',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2013-11-12','2013-11-01',NULL,NULL,NULL,'',NULL,'N','2014-04-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-130',NULL,'2015-12-22',NULL,1,'','healthy male subjects',24,NULL,NULL,NULL,NULL,'NCT01982201','Antacid Interaction Study','Healthy',NULL,NULL,NULL,'Ardea Biosciences, Inc.','Interventional','24',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2013-11-08','2013-11-01',NULL,NULL,NULL,'',NULL,'N','2013-12-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-131',NULL,'2015-12-22',NULL,1,'','healthy male subjects',10,NULL,NULL,NULL,NULL,'NCT02039700','Bioavailability of Lesinurad and Intravenous [14C]Lesinurad','Healthy',NULL,NULL,NULL,'Ardea Biosciences, Inc.','Interventional','10',NULL,NULL,'Endpoint Classification: Bio-availability Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2014-01-16','2014-01-01',NULL,NULL,NULL,'',NULL,'N','2014-02-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-132',NULL,'2015-12-22',NULL,1,'','healthy male subjects',54,NULL,NULL,NULL,NULL,'NCT02127775','Lesinurad Tablet Bioequivalence','Healthy',NULL,NULL,NULL,'Ardea Biosciences, Inc.','Interventional','54',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label',NULL,'2014-04-28','2014-04-01',NULL,NULL,NULL,'',NULL,'N','2014-06-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'N','N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-201',NULL,'2015-12-22',NULL,2,'','healthy male subjects',21,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'21',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-202',NULL,'2015-12-22',NULL,2,'','healthy male subjects',123,NULL,NULL,NULL,NULL,'NCT00955981','Gout Dose Response Study','Hyperuricemia',NULL,NULL,NULL,'Ardea Biosciences, Inc.','Interventional','123',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)',NULL,'2009-08-07','2009-07-01',NULL,NULL,NULL,'',NULL,'1/7/14','2010-03-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'Y',NULL,'2014-01-07','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-203','2016-01-07','2015-12-22',NULL,2,'','healthy male subjects',208,NULL,NULL,NULL,NULL,'NCT01001338','Allopurinol Combination Study','Gout',NULL,NULL,NULL,'Ardea Biosciences, Inc.','Interventional','208',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)',NULL,'2009-10-22','2009-10-01',NULL,NULL,NULL,'',NULL,'1/7/14','2011-01-01','','0',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/26742777','2017-06-17',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'Y',NULL,'2014-01-07','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'Y','Y','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-203 (DB extension)',NULL,'2015-12-22',NULL,2,'','healthy male subjects',126,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'126',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-203 (OLE)',NULL,'2015-12-22',NULL,2,'','gout',87,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'87',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-204',NULL,'2015-12-22',NULL,2,'','subjects w gout and hyperuricemia',4,NULL,NULL,NULL,NULL,'EUCTR2009-014762-26-BE',NULL,NULL,NULL,NULL,NULL,NULL,NULL,'4',NULL,NULL,NULL,NULL,NULL,'2009-10-27',NULL,NULL,NULL,'',NULL,'N',NULL,'','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','N',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'N',NULL,NULL,'Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-301',NULL,'2015-12-22',NULL,3,'','subjects w gout and an inadequate hypouricemic response to standard of care allopurinol',603,NULL,NULL,NULL,NULL,'NCT01510158','Combining Lesinurad With Allopurinol in Inadequate Responders','Gout',NULL,NULL,NULL,'Ardea Biosciences, Inc.','Interventional','603',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver)',NULL,'2012-01-11','2012-01-01',NULL,NULL,NULL,'',NULL,'4/9/15','2014-07-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'Y',NULL,'2015-04-09','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-302',NULL,'2015-12-22',NULL,3,'','males and females with gout and an inadequate hypouricemic response to standard of care allo',610,NULL,NULL,NULL,NULL,'NCT01493531','Combining Lesinurad With Allopurinol in Inadequate Responders','Gout',NULL,NULL,NULL,'Ardea Biosciences, Inc.','Interventional','610',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)',NULL,'2011-12-13','2011-12-01',NULL,NULL,NULL,'','2016-01-14','3/23/15','2014-05-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'Y',NULL,'2015-03-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-303',NULL,'2015-12-22',NULL,3,'','subjects w gout and an inadequate hypouricemic response to standard of care allopurinol',214,NULL,NULL,NULL,NULL,'NCT01508702','Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors','Gout',NULL,NULL,NULL,'Ardea Biosciences, Inc.','Interventional','214',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)',NULL,'2012-01-10','2012-01-01',NULL,NULL,NULL,'','2016-01-14','4/28/14','2013-10-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'Y',NULL,'2014-04-28','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-304',NULL,'2015-12-22',NULL,3,'','subjects with moderate renal insufficiency not on dialysis',324,NULL,NULL,NULL,NULL,'NCT01510769','Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat','Tophaceous Gout',NULL,NULL,NULL,'Ardea Biosciences, Inc.','Interventional','324',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)',NULL,'2012-01-12','2012-01-01',NULL,NULL,NULL,'','2016-01-14','3/23/15','2014-06-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'Y',NULL,'2015-03-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-305',NULL,'2015-12-22',NULL,3,'','subjects w gout with an inadequate hypouricemic response to standard of care allopurinol; patients taking at least 300mg/day allopurinol and still had high serum uric acid and gout flares',143,NULL,NULL,NULL,NULL,'NCT01650246','Open-Label Lesinurad Monotherapy Extension Study in Gout','Gout',NULL,NULL,NULL,'Ardea Biosciences, Inc.','Interventional','143',NULL,NULL,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label',NULL,'2012-07-24','2012-08-01',NULL,NULL,NULL,'','2016-01-14','3/23/15','2014-04-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','Y','Y',NULL,NULL,NULL,'Y','Y','Y',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'Y',NULL,'2015-03-23','Y','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-306',NULL,'2015-12-22',NULL,3,'','subjects w gout with an inadequate hypouricemic response to standard of care allopurinol; patients taking at least 300mg/day allopurinol and still had high serum uric acid and gout flares',714,NULL,NULL,NULL,NULL,'NCT01808131','Lesinurad and Allopurinol Combination Extension Study in Gout','Gout',NULL,NULL,NULL,'Ardea Biosciences, Inc.','Interventional','714',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-03-07','2013-02-01',NULL,NULL,NULL,'',NULL,'N','2017-05-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zurampic','RDEA594-307',NULL,'2015-12-22',NULL,3,'','subjects w gout and intolerance or contraindication to a XOI',196,NULL,NULL,NULL,NULL,'NCT01808144','Lesinurad and Febuxostat Combination Extension Study in Gout','Gout',NULL,NULL,NULL,'Ardea Biosciences, Inc.','Interventional','196',NULL,NULL,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)',NULL,'2013-03-07','2013-03-01',NULL,NULL,NULL,'',NULL,'N','2017-05-01','','0',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','Y','Y',NULL,NULL,NULL,'N','N','N',NULL,NULL,NULL,NULL,NULL,'Ardea Biosciences / Astrazeneca Inc',NULL,'Y',NULL,NULL,'N','Y',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N',NULL,NULL,NULL,NULL,NULL),('Zydelig','101-01',NULL,'2014-07-23',NULL,1,'Safety / PK','Healthy',64,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zydelig','101-02',NULL,'2014-07-23',NULL,1,'Dose escalation','Refractory or relapsed NHL',191,NULL,NULL,NULL,NULL,'NCT00710528','Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies','Chronic Lymphocytic Leukemia (CLL)|Lymphoma, Non-Hodgkin (NHL)|Acute Myeloid Leukemia (AML)|Multiple Myeloma (MM)',NULL,'Drug: CAL-101',NULL,'Gilead Sciences','Interventional','192','Industry',1,'Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','101-02','2008-07-01','2008-06-01','2012-08-01','2012-08-29','2012-08-01','N',NULL,'N','2011-12-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24615778, http://www.ncbi.nlm.nih.gov/pubmed/24615776','2014-05-29',NULL,NULL,'2 phases: dose-escalation and cohort expansion',NULL,1,'Mantle Cell Lymphoma',NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'Y','Y','Y','N','Y','Y','N','Y','Y','N','Y','Y','N','N','N','N','N','N','N','N','N'),('Zydelig','101-04',NULL,'2014-07-23',NULL,1,'Safety, without nasal symptoms','Subjets with allergic rhinitis',41,NULL,NULL,NULL,NULL,'NCT00836914','Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber','Allergic Rhinitis',NULL,'Drug: CAL-101|Drug: Placebo',NULL,'Gilead Sciences','Interventional','41','Industry',1,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)','101-04','2009-02-02','2009-02-01','2009-03-01','2013-01-04','2013-01-01','N',NULL,'N','2009-03-01','Austria',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zydelig','101-05',NULL,'2014-07-23',NULL,1,'Food effect','Healthy',12,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zydelig','101-06',NULL,'2014-07-23',NULL,1,'Bioavailability','Healthy',15,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zydelig','101-07',NULL,'2014-07-23',NULL,1,'With riuximab','Refractory or relapsed NHL',226,NULL,NULL,NULL,NULL,'NCT01088048','Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin\'s Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia','Indolent Non-Hodgkin\'s Lymphoma|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma',NULL,'Drug: Idelalisib|Drug: Rituximab|Drug: Bendamustine|Drug: Ofatumumab|Drug: Fludarabine|Drug: Everolimus|Drug: Bortezomib|Drug: Chlorambucil|Drug: Lenalidomide',NULL,'Gilead Sciences','Interventional','241','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','101-07','2010-03-12','2010-04-01','2015-04-01','2015-05-11','2015-05-01','N',NULL,'N','2015-04-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','N','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Zydelig','101-08',NULL,'2014-07-23',NULL,2,'BID with rituximab v placebo','Untreated CLL',64,NULL,NULL,NULL,NULL,'NCT01203930','A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL','Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)',NULL,'Drug: Idelalisib|Drug: Rituximab',NULL,'Gilead Sciences','Interventional','105','Industry',2,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','101-08','2010-09-15','2010-10-01','2017-09-01','2015-08-19','2015-08-01','N',NULL,'N','2015-08-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Zydelig','101-09',NULL,'2014-07-23','PILLAR; DELTA',2,'Efficacy and safety','FL, SLL, LPL',125,'France, Germany, Italy, Poland, UK, US',NULL,NULL,NULL,'NCT01282424','Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma','Follicular Lymphoma|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma|Marginal Zone Lymphoma',NULL,'Drug: Idelalisib','DELTA','Gilead Sciences','Interventional','125','Industry',2,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','101-09|2010-022155-33','2011-01-21','2011-05-01','2016-03-01','2015-11-20','2015-11-01','Y','2014-08-22','Y','2013-06-01','United States,   France,   Germany,   Italy,   Poland,   United Kingdom',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24450858','2014-03-13',NULL,NULL,'single-group, open-label','125',2,'Relapsed Indolent Lymphoma','United States, Germany, Poland, United Kingdom, Italy, France',NULL,'Y','Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y','2014-03-20','Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Zydelig','101-10',NULL,'2014-07-23',NULL,1,'BIDx28days','Low-grade B-cell NHL',11,NULL,NULL,NULL,NULL,'NCT01306643','Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma','Indolent Non-Hodgkin\'s Lymphoma|Follicular Lymphoma|Small Lymphocytic Lymphoma|Marginal Zone Lymphoma',NULL,'Drug: Idelalisib',NULL,'Gilead Sciences','Interventional','18','Industry',1,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','101-10','2011-02-25','2011-02-01','2015-08-01','2015-10-14','2015-10-01','N',NULL,'N','2015-08-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','N','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Zydelig','101-11',NULL,'2014-07-23',NULL,2,'BID until toxicity','Refractory or relapsed NHL',25,NULL,NULL,NULL,NULL,'NCT01393106','Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma','Hodgkin Lymphoma',NULL,'Drug: Idelalisib',NULL,'Gilead Sciences','Interventional','25','Industry',2,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','101-11','2011-07-11','2011-09-01','2014-08-01','2015-11-20','2015-11-01','Y','2015-08-28','N','2014-08-01','United States',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','Y','N','Y','Y','Y','Y','Y','Y','Y','Y','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y',NULL,'Y','Y','Y','Y','N','Y','Y','N','Y','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zydelig','101-99',NULL,'2014-07-23',NULL,1,'Extension','Lymphoid malignancies',171,NULL,NULL,NULL,NULL,'NCT01090414','An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study','Chronic Lymphocytic Leukemia|Lymphoma, Non-Hodgkin',NULL,'Drug: Idelalisib',NULL,'Gilead Sciences','Interventional','202','Industry',1,'Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','101-99','2010-03-17','2010-03-01','2017-03-01','2015-10-14','2015-10-01','N',NULL,'N','2017-03-01','United States',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24615777, http://www.ncbi.nlm.nih.gov/pubmed/24615776','2014-05-29',NULL,NULL,NULL,NULL,1,'non-Hodgkin Lymphoma',NULL,NULL,'N','N','Y','Y','Y','Y','N','N','N',NULL,'N','N','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N','N'),('Zydelig','312-0115',NULL,'2014-07-23',NULL,3,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'NCT01569295','A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)','Chronic Lymphocytic Leukemia',NULL,'Drug: Idelalisib|Drug: Rituximab|Drug: Bendamustine|Drug: Placebo to match idelalisib',NULL,'Gilead Sciences','Interventional','390','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','GS-US-312-0115|2011-006292-20','2012-03-27','2012-06-01','2017-12-01','2016-01-20','2016-01-01','N',NULL,'N','2015-06-01','United States,   Australia,   Belgium,   Canada,   Croatia,   Czech Republic,   France,   Greece,   Hungary,   Ireland,   Italy,   New Zealand,   Poland,   Portugal,   Romania,   Russian Federation,   Spain,   Turkey,   United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Zydelig','312-0116',NULL,'2014-07-23','GS-US-312-0116',3,'BID with rituximab v placebo','Previously treated CLL',225,'USA, UK, Germany, Italy, France',NULL,NULL,NULL,'NCT01539512','A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)','Chronic Lymphocytic Leukemia',NULL,'Drug: Idelalisib|Drug: Rituximab|Drug: Placebo to match idelalisib',NULL,'Gilead Sciences','Interventional','220','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','GS-US-312-0116|2011-005180-24','2012-02-12','2012-04-01','2014-04-01','2015-04-20','2015-04-01','Y','2014-10-09','N','2013-10-01','United States,   France,   Germany,   Italy,   United Kingdom',NULL,NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24450857','2014-03-13',NULL,NULL,'multicenter, randomized, double-blind, placebo-controlled study','220',3,'Chronic Lymphocytic Leukemia','France, United Kingdom, Italy, Spain, Germany, United States',NULL,'N','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'0','Gilead Sciences Inc.','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Zydelig','312-0117',NULL,'2014-07-23',NULL,3,'BID two doses','Previously treated CLL',160,NULL,NULL,NULL,NULL,'NCT01539291','Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116','Chronic Lymphocytic Leukemia',NULL,'Drug: Idelalisib',NULL,'Gilead Sciences','Interventional','160','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','GS-US-312-0117|2011-006293-72','2012-02-12','2012-10-01','2016-12-01','2015-12-17','2015-12-01','N',NULL,'N','2016-12-01','United States,   France,   Germany,   Italy,   United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Zydelig','312-0119',NULL,'2014-07-23',NULL,3,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'NCT01659021','Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia','Chronic Lymphocytic Leukemia',NULL,'Drug: Idelalisib|Drug: Ofatumumab',NULL,'Gilead Sciences','Interventional','261','Industry',3,'Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','GS-US-312-0119|2012-001236-65','2012-08-03','2012-12-01','2017-03-01','2015-11-05','2015-11-01','N',NULL,'Y','2015-01-01','United States,   Australia,   Belgium,   Canada,   Denmark,   France,   Ireland,   Poland,   Spain,   Sweden,   United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N','2015-11-05','Y','Y','Y','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zydelig','313-0111',NULL,'2014-07-23',NULL,1,'Mass blance','Healthy',8,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zydelig','313-0112',NULL,'2014-07-23',NULL,1,'Safety / PK','Hepatic impairment',32,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zydelig','313-0117',NULL,'2014-07-23',NULL,1,'QTc','Healthy',48,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zydelig','313-0118',NULL,'2014-07-23',NULL,1,'Safety / PK','Renal impairment',12,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zydelig','313-0124',NULL,'2014-07-23','GS-US-313-0124',3,'2-arm randomized double-blind placebo-controlled parallel-group','Hematological malignancies',354,NULL,NULL,NULL,NULL,'NCT01732913','Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas','Indolent Non-Hodgkin\'s Lymphomas',NULL,'Drug: Idelalisib|Drug: Rituximab|Drug: Placebo to match idelalisib',NULL,'Gilead Sciences','Interventional','375','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','GS-US-313-0124','2012-11-14','2013-01-01','2022-06-01','2016-01-27','2016-01-01','N',NULL,'N','2019-06-01','United States,   Australia,   Bulgaria,   Czech Republic,   France,   Germany,   Hungary,   Israel,   Italy,   Japan,   Korea, Republic of,   Poland,   Portugal,   Romania,   Russian Federation,   Singapore,   Spain,   Sweden,   Taiwan,   United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Zydelig','313-0125',NULL,'2014-07-23',NULL,3,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'NCT01732926','Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas','Indolent Non-Hodgkin\'s Lymphomas',NULL,'Drug: Idelalisib|Drug: Rituximab|Drug: Bendamustine|Drug: Placebo to match idelalisib',NULL,'Gilead Sciences','Interventional','475','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)','GS-US-313-0125|2012-004034-42','2012-11-14','2013-01-01','2022-08-01','2015-10-23','2015-10-01','N',NULL,'N','2019-08-01','United States,   Australia,   Canada,   Czech Republic,   France,   Germany,   Israel,   Italy,   Korea, Republic of,   Poland,   Russian Federation,   Singapore,   Spain,   Sweden,   Taiwan,   United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Zydelig','313-0126',NULL,'2014-07-23',NULL,1,'Safety / PK','Healthy Japanses and caucasian',20,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zydelig','313-0130',NULL,'2014-07-23',NULL,1,'Drug interaction','Healthy',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zydelig','339-0101',NULL,'2014-07-23',NULL,1,'Safety / PK','Healthy female',24,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Gilead Sciences Inc.','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zykadia','A2101',NULL,'2014-04-29','LDK378A2101',1,'Food effect with FMI capsule','Healthy',28,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Novartis Pharmaceutical Corp','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zykadia','A2104',NULL,'2014-04-29','LDK378A2104',1,'DDI 450mg','Healthy',19,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Novartis Pharmaceutical Corp','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zykadia','A2105',NULL,'2014-04-29','LDK378A2105',1,'ADME','Healthy',6,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Novartis Pharmaceutical Corp','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zykadia','A2106',NULL,'2014-04-29','LDK378A2106',1,'DDI ','Healthy',19,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N',NULL,'N',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','N','N','N','N','N',NULL,'N','Y','N',NULL,NULL,NULL,'0','Novartis Pharmaceutical Corp','N','N','N',NULL,'N','N','N','N','N','N','N','N','N','N','N','Y','N','N','N','N','N','N','N','N','N'),('Zykadia','A2201',NULL,'2014-04-29',NULL,2,'Single arm','Patients with ALK-activated NSCLC',140,NULL,NULL,NULL,NULL,'NCT01685060','LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib','Non-Small Cell Lung Cancer',NULL,'Drug: LDK378',NULL,'Novartis Pharmaceuticals|Novartis','Interventional','141','Industry',2,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','CLDK378A2201|2012-003432-24','2012-09-04','2012-11-01','2016-01-01','2016-04-09','2016-04-01','N',NULL,'N','2016-01-01','United States,   Canada,   France,   Germany,   Hong Kong,   Italy,   Japan,   Korea, Republic of,   Netherlands,   Singapore,   Spain,   United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Novartis Pharmaceutical Corp','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Zykadia','A2203',NULL,'2014-04-29',NULL,2,'Single arm','Crizotinib naive patients',82,NULL,NULL,NULL,NULL,'NCT01685138','LDK378 in Crizotinib nave Adult Patients With ALK-activated Non-small Cell Lung Cancer','Non-Small Cell Lung Cancer',NULL,'Drug: LDK378',NULL,'Novartis Pharmaceuticals|Novartis','Interventional','126','Industry',2,'Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','CLDK378A2203|2012-003474-36','2012-09-04','2012-12-01','2016-11-01','2015-10-12','2015-10-01','N',NULL,'N','2016-11-01','United States,   Australia,   Belgium,   Canada,   France,   Hong Kong,   Italy,   Japan,   Korea, Republic of,   Norway,   Russian Federation,   Singapore,   Spain,   Sweden,   Taiwan,   Thailand,   United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Novartis Pharmaceutical Corp','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Zykadia','A2301',NULL,'2014-04-29','CLDK378A2301 / X2301',3,'Vs standard chemo','Patients ALK-rearranged, stage IIIB or IV',348,NULL,NULL,NULL,NULL,'NCT01828099','LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer','Non-Small Cell Lung Cancer',NULL,'Drug: LDK378|Drug: Pemetrexed + cisplatin or pemetrexed + carboplatin',NULL,'Novartis Pharmaceuticals|Novartis','Interventional','348','Industry',3,'Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','CLDK378A2301|2013-000319-26','2013-04-03','2013-07-01','2018-06-01','2016-01-22','2016-01-01','N',NULL,'N','2018-06-01','Argentina,   Australia,   Austria,   Brazil,   China,   Colombia,   Denmark,   France,   Germany,   Greece,   Hungary,   India,   Ireland,   Italy,   Japan,   Korea, Republic of,   Lebanon,   Mexico,   Netherlands,   Norway,   Poland,   Portugal,   Russian Federation,   Singapore,   Spain,   Sweden,   Taiwan,   Thailand,   Turkey,   United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Novartis Pharmaceutical Corp','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Zykadia','A2303',NULL,'2014-04-29','(X2303)',3,'Vs standard chemo','Patients ALK-rearranged or metastatic NSCLC',14,NULL,NULL,NULL,NULL,'NCT01828112','LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib','Non-Small Cell Lung Cancer',NULL,'Drug: LDK378|Drug: pemetrexed|Drug: docetaxel',NULL,'Novartis Pharmaceuticals|Novartis','Interventional','236','Industry',3,'Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','CLDK378A2303|2012-005637-36','2013-04-02','2013-06-01','2018-08-01','2016-01-24','2016-01-01','N',NULL,'N','2018-08-01','United States,   Belgium,   Canada,   France,   Germany,   Hong Kong,   Ireland,   Israel,   Italy,   Japan,   Korea, Republic of,   Lebanon,   Netherlands,   Portugal,   Russian Federation,   Singapore,   Spain,   Switzerland,   Turkey,   United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','Y','N','Y','N','N','N','N',NULL,NULL,NULL,'0','Novartis Pharmaceutical Corp','N','Y','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Zykadia','A2402',NULL,'2014-04-29','CLDK378A2402',NULL,'Expanded treatment protocol',NULL,4,NULL,NULL,NULL,NULL,'NCT01947608','Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC','Non-small Cell Lung Cancer (NSCLC)',NULL,'Drug: LDK378',NULL,'Novartis Pharmaceuticals|Novartis','Expanded Access',NULL,'Industry',0,'0','CLDK378A2402','2013-09-17',NULL,NULL,'2016-03-29','2016-03-01','N',NULL,'N',NULL,'United States,   Argentina,   Colombia,   Hong Kong,   India,   Jordan,   Korea, Republic of,   Mexico,   Philippines,   Thailand',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','N','N',NULL,NULL,NULL,'0','Novartis Pharmaceutical Corp','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Zykadia','X1101',NULL,'2014-04-29','LDK378X1101',1,'Dose escalation study','Japanse patients with tumors char. Genetic alterations in ALK',19,'Japan',NULL,NULL,NULL,'NCT01634763','Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)','Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)',NULL,'Drug: LDK378',NULL,'Novartis Pharmaceuticals|Novartis','Interventional','22','Industry',1,'Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label','CLDK378X1101','2012-07-03','2012-06-01','2016-01-01','2016-03-04','2016-03-01','N',NULL,'N','2016-01-01','Japan',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','N','N','N','N',NULL,'N','N','N',NULL,NULL,NULL,'0','Novartis Pharmaceutical Corp','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Zykadia','X2101',NULL,'2014-04-29','CLDK378X2101',2,'Dose escalation study','Patients with tumors char. Genetic abnomalities in ALK',304,'South Korea',NULL,NULL,NULL,'NCT01283516','A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase','Tumors Characterized by Genetic Abnormalities of ALK',NULL,'Drug: LDK378',NULL,'Novartis Pharmaceuticals|Novartis','Interventional','304','Industry',2,'Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label','CLDK378X2101|2010-019827-70','2011-01-24','2011-01-01','2016-03-01','2016-02-08','2016-02-01','Y','2014-05-29','N','2013-10-01','United States,   Australia,   Belgium,   Canada,   Germany,   Italy,   Korea, Republic of,   Netherlands,   Singapore,   Spain,   United Kingdom','https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=12003',NULL,NULL,NULL,'http://www.ncbi.nlm.nih.gov/pubmed/24670165','2014-03-27',NULL,NULL,'Dose esclation','130',1,'NSCLC',NULL,NULL,'Y','Y','Y','Y','Y','Y','N','Y','Y','Y','Y','Y','Y',NULL,NULL,NULL,'1','Novartis Pharmaceutical Corp','Y','Y','Y',NULL,'Y','Y','Y','Y','Y','Y','Y','Y','Y','N','Y','Y','N','N','Y','Y','Y','Y','N','N','N'),('Zykadia','X2102',NULL,'2014-04-29',NULL,1,'Dose escalation with AUY922','Patients with ALK rearranged NSCLC',6,NULL,NULL,NULL,NULL,'NCT01772797','Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer','Anaplastic Lymphoma Kinase (ALK)|Non-small Cell Lung Cancer',NULL,'Drug: LDK378|Drug: AUY922',NULL,'Novartis Pharmaceuticals|Novartis','Interventional','22','Industry',1,'Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','CLDK378X2102|2012-004632-29','2013-01-17','2013-06-01','2017-03-01','2016-01-24','2016-01-01','N',NULL,'N','2017-03-01','United States,   Australia,   Italy,   Singapore,   Spain',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','N','N',NULL,NULL,NULL,'0','Novartis Pharmaceutical Corp','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N'),('Zykadia','X2103',NULL,'2014-04-29',NULL,1,'Escalation study','Patients with malignancies with genetic alteration in ALK',5,NULL,NULL,NULL,NULL,'NCT01742286','Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)','Anaplastic Lymphoma Kinase (ALK)',NULL,'Drug: LDK378',NULL,'Novartis Pharmaceuticals|Novartis','Interventional','105','Industry',1,'Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label','CLDK378X2103|2012-002074-31','2012-11-30','2013-02-01','2018-08-01','2016-04-12','2016-04-01','N',NULL,'N','2018-08-01','United States,   Australia,   Canada,   France,   Germany,   Italy,   Korea, Republic of,   Netherlands,   Spain,   United Kingdom',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,'N','N','N','N','Y','Y','N','N','N',NULL,'N','N','N',NULL,NULL,NULL,'0','Novartis Pharmaceutical Corp','N','N','N',NULL,'N','Y','Y','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N','N');
/*!40000 ALTER TABLE `master` ENABLE KEYS */;
UNLOCK TABLES;
/*!40103 SET TIME_ZONE=@OLD_TIME_ZONE */;

/*!40101 SET SQL_MODE=@OLD_SQL_MODE */;
/*!40014 SET FOREIGN_KEY_CHECKS=@OLD_FOREIGN_KEY_CHECKS */;
/*!40014 SET UNIQUE_CHECKS=@OLD_UNIQUE_CHECKS */;
/*!40101 SET CHARACTER_SET_CLIENT=@OLD_CHARACTER_SET_CLIENT */;
/*!40101 SET CHARACTER_SET_RESULTS=@OLD_CHARACTER_SET_RESULTS */;
/*!40101 SET COLLATION_CONNECTION=@OLD_COLLATION_CONNECTION */;
/*!40111 SET SQL_NOTES=@OLD_SQL_NOTES */;

-- Dump completed on 2017-10-13 15:16:44
